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CHAPTER I 
INTRODUCTION 
1. PEPTIDES 
Peptides can be considered as a separate drug category, situated between the classic small organic 
molecules and the large proteins. Given their small size, i.e. generally defined as up to 50 amino acid 
(AA) residues, peptides are able to penetrate deeper into the target tissue than proteins. Moreover, 
therapeutic peptides are generally less immunogenic and are more cost-efficient to consistently 
manufacture according to the required quality parameters than recombinant proteins and 
antibodies. Peptides also offer several advantages over small organic molecules, as they have a 
greater efficacy, selectivity and specificity [1-3]. Moreover, as peptides consist of individual amino 
acids, they offer enhanced possibilities for drug discovery using combinatorial peptide libraries [4,5]. 
These libraries can be combined with specific targets, often proteins, which are at the core of many 
physiological processes. The knowledge of these protein-protein interactions continues to increase, 
resulting in an increasing diversity of targets [6-8]. Furthermore, as traditional peptides will 
eventually degrade into one of the 20 endogenous amino acids, toxicity due to metabolites is 
expected to be reduced [1-3]. 
Currently, more and more non-proteinogenic amino acids, i.e. amino acids not encoded in the human 
genetic code, are being incorporated into the sequence of peptide drug candidates [9,10]. These 
non-proteinogenic amino acids can be (unnaturally) synthesized in the lab or can be found in nature. 
Already approximately 500 non-proteinogenic amino acids have currently been identified in 
microbial organisms and plants. The synthetic inclusion of non-proteinogenic amino acids is done to 
improve peptide stability, e.g. inclusion of D-amino acids, and to obtain (more) potent peptide drugs 
by altering their tissue distribution characteristics or pharmacodynamic properties [10-12]. Given the 
vast structural diversity of non-proteinogenic amino acids, these peptide building blocks offer great 
opportunities to protein/peptide engineers and medicinal chemists for the development of new 
peptide drugs. However, as these individual non-proteinogenic amino acids are not endogenous to 
humans, metabolite-related toxicity issues might arise [13,14]. An overview of the current major 
therapeutic peptide classes with their targets and clinical use is given in Table 1 [15]. 
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Table 1. Overview of current peptide drug classes 
Target Indication / Activity Peptide example 
26S proteasome Multiple myeloma Bortezomib 
ACTH r Diagnostic agent for cortisol disorder Cosyntropin 
Angiotensin II r Anti-hypertension Saralasin 
Bacterial cell wall synthesis Antibiotic (Gram-positive) Vancomycin 
Bradykinin B2 r Hereditary angioedema Icatibant 
Calcitonin r Osteoporosis Salmon calcitonin 
Cholecystokinin-B r Diagnostic agent of gastic function Pentagastrin 
Corticotropin releasing hormone r Diagnostic agent for cushing's or ectopic ACTH syndrome Corticorelin 
Cyclophilin protein Immunosuppressant Cyclosporin 
Follicle-stimulating hormone r Fertility treatment Urofollitropin 
Glucagon r Hypoglycemia Glucagon 
Glucagon-like peptide 1 r Diabetes mellitus type 2 Exenatide 
Glucagon-like peptide 2 r Short bowel syndrome Teduglutide 
Glycoprotein (GP) IIb/IIIa Risk reducing of myocardial infarction Eptifibatide 
Gonadotropin-releasing hormone r Sex hormone-responsive cancers Buserelin 
Gp41 HIV enveloppe protein Anti-HIV Enfuvirtide 
Growth-hormone-releasing hormone r Diagnostic agent for growth hormone deficiency Somatorelin 
Guanylate cyclase 2C Irritable bowel syndrome (IBS) Linaclotide 
Histone deacetylase T-cell lymphone Romidepsin 
Neurokinin 1 r Esophageal variceal bleeding Vapreotide 
N-type calcium channels Chronic pain Ziconotide 
Nucleotide-binding oligomerization domain-containing 2 (NOD2) Osteosarcoma Mifamurtide 
Oxytocin r Postpartum bleeding Carbetocin 
Parathyroid hormone r Osteoporosis Teriparatide 
Secretine r Diagnostic aid for pancreatic exocrine dysfunction and gastrinoma Secretin (human) 
Somatostatin r Neuroendocrine tumours Somatostatin 
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Over the last 30 years, the interest of the scientific community for peptide drugs has been 
continuously growing, evidenced by the steady rise in publications focusing on various aspects of 
peptide research. The number of publications listing peptide as a topic term in the Web of Science 
database has risen from 8,081 (1980-1984) to 103,426 (2010-2014) [16]. This increased scientific 
interest has also translated into an increased peptide drug market as evidenced by the USA peptide 
market value, which is currently estimated at approximately $15 billion per year [17-19]. More than 
85% of these sales are derived from synthetic peptides, with projected individual sales of certain 
blockbuster peptide drugs, e.g. liraglutide and leuprolide, expected to surpass $1 billion in 2015 [19]. 
Moreover, the peptide market value is growing much faster than for other pharmaceuticals with an 
average peptide CAGR (Compound Annual Growth Rate) of 10% between 2006 and 2010. 
Furthermore, the success rates for bringing them to market are now approximately twice that of 
small organic molecule drugs [19]. In 2012, several new peptide drugs targeting a variety of disorders 
were approved. These included Linzess® (linaclotide) for the treatment of chronic constipation and 
irritable bowel syndrome (IBS) with constipation in adults, Surfaxin® (lucinactant) for treatment of 
infant respiratory distress syndrome (IRDS), Kyprolis® (carfilzomib) as a proteasome inhibitor to treat 
multiple myeloma, Gattex® (teduglutide) to treat adults with short bowel syndrome (SBS), 
Bydureon® (an extended-release version of Byetta, with the active ingredient exenatide) for patients 
with type 2 diabetes and Signifor® (pasireotide) for the treatment of Cushing’s disease [18,20]. A 
global overview of currently marketed peptide drugs is given in Table 2. 
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Table 2. List of marketed peptide drugs 
Peptide name Brand name Indication Administration
1
 
USA
2
 EU
3,4
 
Date No. Date No. 
Abarelix Plenaxis Prostate cancer Intramuscular 25/11/2003* (NDA)21320 1/02/2011 BE384465 
Anidulafungin 
Eraxis / Ecalta Antifungal action 
Injection 17/02/2006 (NDA)21632 - - 
Anidulafungin IV Infusion 17/02/2006 (NDA)21948 20/09/2007 EU/1/07/416/001 
Atosiban Tractocile / Antocin / 
Atosiban SUN 
Premature birth 
Injection - - 20/01/2000 EU/1/99/124/001 
Atosiban IV Infusion - - 20/01/2000 EU/1/99/124/002 
Bacitracin Bacitracin / Baciim / 
Baciguent / Baci-RX 
Gram positive skin and 
eye infection 
Injection 29/07/1948 (ANDA)060733 - - 
Bacitracin Ophthalmic 9/11/1971 (ANDA)061212 29/03/2004 BE260811 
Bentiromide Chymex 
Exocrine pancreatic 
insufficiency diagnostic 
Oral 29/12/1983* (NDA)18366 - - 
Bivalirudin Angiomax / Angiox Anticoagulant Intravenous 15/12/2000 (NDA)20873 20/09/2004 EU/1/04/289/001 
Bleomycin Blenoxane Cancer Injection 31/7/1973* (NDA)050443 11/12/1970 BE058116 
Bortezomib Velcade Multiple myeloma 
Intravenous, 
subcutaneous 
13/05/2003 (NDA)21602 26/04/2004 EU/1/04/274/001 
Buserelin Suprecur 
Prostate cancer 
Endometriosis 
Nasal - - 13/06/1985 BE131826 
Capreomycin Capastat Antibiotic Injection 2/07/1971 (NDA)50095 - - 
Carbetocin 
Duratocin / Lonactene / 
Pabal 
Postpartum bleeding injection - - 2/04/2007 BE293185 
Carfilzomib Kyprolis Multiple myeloma Intravenous 20/07/2012 (NDA)202714 3/06/2008 EU/3/08/548 
Carfilzomib Kyprolis Multiple myeloma IV infusion 20/07/2012 (NDA)202714 3/06/2008 EU/3/08/548 
Caspofungin Cancidas Antifungal action IV infusion 26/01/2001 (NDA)21227 24/10/2001 EU/1/01/196/001 
Ceruletide Tymtran Paralytic ileus Injection <1/1/1982* (NDA)18296 - - 
Cetrorelix Cetrotide Ovulation Induction Injection 11/08/2000 (NDA)21197 13/04/1999 EU/1/99/100/001 
Cobicistat Stribild HIV infection Oral 27/08/2012 (NDA)203100 24/05/2013 EU/1/13/830/001 
Colistin Coly-mycin S Antibiotic Oral, ophthalmic 17/05/1962 (NDA)050356 - - 
*
Discontinued 
1
 as indicated in Summary of Product Characteristics (SPC) 
2
 http://www.accessdata.fda.gov/scripts/cder/drugsatfda/ (- : not found in database) 
3
 http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landing_page.jsp&mid= (- : not found in database) 
4
 http://www.fagg-afmps.be/nl/items-HOME/gegevensbanken/ (- : not found in database)  
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Table 2. List of marketed peptide drugs (continued) 
Peptide name Brand name Indication Administration
1
 
USA
2
 EU
3,4
 
Date No. Date No. 
Corticorelin Acthrel Diagnostic agent Injection 23/05/1996 (NDA)20162 - - 
Corticotropin H.P. Acthar Gel Diagnostic agent Injection 29/04/1952 (NDA)08372 - - 
Cosyntropin Cortrosyn Diagnostic agent Injection 22/04/1970 (NDA)16750 - - 
Cyclosporin 
Neoral Immunosuppressant 
Oral 14/07/1995 (NDA)50715 - - 
Cyclosporin Oral 14/07/1995 (NDA)50716 - - 
Dactinomycin Cosmegen Antibiotic Injection 10/12/1964 (NDA)50682 - - 
Daptomycin Cubicin Antibiotic IV infusion 12/09/2003 (NDA)21572 19/01/2006 EU/1/05/328/001 
Degarelix Firmagon Prostate cancer Subcutaneous 24/09/2008 (NDA)22201 17/02/2009 EU/1/08/504/002 
Depreotide Neo Tect Kit Diagnostic agent Injection 3/8/1999* (NDA)21012 - - 
Depreotide NeoSpect Diagnostic agent Injection - - 29/11/2000 EMEA/H/C/000263 
Desmopressin DDAVP / Minirin Diabetes insipidus Nasal 21/02/1978 (NDA)17922 1/07/1975 BE095706 
Desmopressin DDAVP / Minirin Diabetes insipidus Injection 30/03/1984 (NDA)18938 8/04/1986 BE133874 
Desmopressin DDAVP / Minirin Diabetes insipidus Oral 6/09/1995 (NDA)19955 11/03/1997 BE181386 
Edotreotide Octreother Neuroendocrine tumor Injection - - 4/12/2008 EU/3/08/589 
Enfuvirtide Fuzeon HIV infection Subcutaneous 13/03/2003 (NDA)21481 27/05/2003 EU/1/03/252/001 
Eptifibatide Integrilin Antiplatelet drug Injection 18/05/1998 (NDA)20718 1/07/1999 EU/1/99/109/001 
Exenatide Byetta Diabetes type 2 Subcutaneous 28/04/2005 (NDA)21773 20/11/2006 EU/1/06/362/001 
Exenatide Bydureon Diabetes type 2 Subcutaneous 27/01/2012 (NDA)22200 17/06/2011 EU/1/11/696/001 
Ganirelix Orgalutran Ovulation Induction Injection 29/07/1999 (NDA)21057 17/05/2000 EU/1/00/130/001 
Glucagon Glucagon Hypoglycemia Injection 11/09/1998 (NDA)20928 20/04/1995 BE169145 
Glutathion BSS Plus 
Inborn Errors of 
Metabolism of 
Glutathione, Cystic 
Fibrosis 
Irrigation 28/10/1981 (NDA)18469 - - 
*
Discontinued 
1
 as indicated in Summary of Product Characteristics (SPC) 
2
 http://www.accessdata.fda.gov/scripts/cder/drugsatfda/ (- : not found in database) 
3
 http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landing_page.jsp&mid= (- : not found in database) 
4
 http://www.fagg-afmps.be/nl/items-HOME/gegevensbanken/ (- : not found in database)  
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Table 2. List of marketed peptide drugs (continued) 
Peptide name Brand name Indication Administration
1
 
USA
2
 EU
3,4
 
Date No. Date No. 
Glutathion Endosol Extra Ophtalimic irrigation Intraocular 27/11/1991 (NDA)20079 - - 
Gonadorelin Factrel Ovulation Induction Injection 30/09/1982* (NDA)18123 - - 
Goserelin Zoladex Prostate cancer Implantation 29/12/1989 (NDA)19726 7/09/1987 BE138731 
Gramicidin Neosporin Bacterial infections Ophthalmic 3/07/1968 (ANDA)60582 1/04/1962 BE049061 
Histrelin Vantas 
Prostate cancer 
Subcutaneous 12/10/2004 (NDA)21732 11/02/2010 BE362293 
Histrelin Supprelin LA Subcutaneous 3/05/2007 (NDA)22058 - - 
Icatibant Firazyr Hereditary angioedema Subcutaneous 25/08/2011 (NDA)22150 11/07/2008 EU/1/08/461/001 
Lanreotide Somatulin depot Acromegaly Subcutaneous 30/08/2007 (NDA)22074 11/10/1996 BE179006 
Leuprolide Lupron Prostate cancer Injection 30/03/1985 (NDA)19943 - - 
Linaclotide Linzess Irritable Bowel Syndrome Oral 30/08/2012 (NDA)202811 26/11/2012 EU/1/12/801/001 
Liraglutide Victoza Diabetes type 2 Subcutaneous 25/01/2010 (NDA)22341 30/06/2009 EMEA/H/C/001026 
Lixisenatide Lyxumia Diabetes type 2 Subcutaneous - - 1/02/2013 EU/1/12/811/001 
Lucinactant Surfaxin 
Infant Respiratory 
Distress Syndrome 
Intrathecal 6/03/2012 (NDA)21746 - - 
Lypressin Diapid Diabetes insipidus Nasal * (NDA)15755 - - 
Micafungin Mycamine Antifungal action Injection 16/03/2005 (NDA)21754 25/04/2008 EU/1/08/448/001 
Mifamurtide Mepact Osteosarcoma IV infusion - - 6/03/2009 EU/1/08/502/001 
Nafarelin Synarel Endometriosis Nasal 13/02/1990 (NDA)19886 - - 
Nesiritide Natrecor Heart failure IV infusion 10/08/2001 (NDA)20920 - - 
Octreotide Sandostatin Acromegaly Injection 21/10/1988 (NDA)19667 24/02/1998 BE191685 
Oxytocin Oxytocin Labor induction Injection 29/04/1980 (NDA)18243 1/07/1961 BE031823 
Oxytocin Pitocin Labor induction Injection 19/11/1980 (NDA)18261 - - 
*
Discontinued 
1
 as indicated in Summary of Product Characteristics (SPC) 
2
 http://www.accessdata.fda.gov/scripts/cder/drugsatfda/ (- : not found in database) 
3
 http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landing_page.jsp&mid= (- : not found in database) 
4
 http://www.fagg-afmps.be/nl/items-HOME/gegevensbanken/ (- : not found in database) 
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Table 2. List of marketed peptide drugs (continued) 
Peptide name Brand name Indication Administration
1
 
USA
2
 EU
3,4
 
Date No. Date No. 
Pasireotide Signifor Cushing's disease Subcutaneous 14/12/2012 (NDA)200677 24/04/2012 EU/1/12/753/001 
Pentagastrin Peptavlon Diagnostic agent Injection 26/07/1974* (NDA)17048 - - 
Pentetreotide Octreoscan Diagnostic agent Injection 2/06/1994 (NDA)20314 - - 
Polymyxin B 
Cortisporin Antibiotic 
Topical 26/03/1957 (NDA)50168 - - 
Polymyxin B Topical 16/04/1963 (NDA)50218 1/07/1961 BE056585 
Polymyxin B Ophthalmic 9/12/1975 (NDA)50479 1/01/1965 0241IS0118F13/7 
Pramlintide Symlin Diabetes type 1 and 2 Subcutaneous 16/03/2005 (NDA)21332 - - 
Protirelin Thypinone Diagnostic agent Injection 5/11/1976 (NDA)17638 - - 
Romidepsin Istodax T-Cell lymphoma IV infusion 5/11/2009 (NDA)22393 - - 
Salmon calcitonin Miacalcin Osteoporosis Injection 3/07/1986 (NDA)17808 25/01/1977 BE173031 
Salmon calcitonin Miacalcin Osteoporosis Nasal 17/08/1995 (NDA)20313 - - 
Saralasin Sarenin Hypertension Injection * (NDA)18009 - - 
Secretin human Chirhostim Diagnostic agent IV infusion 9/04/2004 (NDA)21256 - - 
Secretin porcine Secroflo Diagnostic agent IV infusion 4/04/2002 (NDA)21209 - - 
Sermorelin Geref 
Growth hormone 
deficiency 
Injection 28/12/1990* (NDA)19863 - - 
Sincalide Kinevac Diagnostic agent Injection 21/07/1976 (NDA)17697 - - 
Somatorelin GHRH Diagnostic agent Injection - - 26/01/1993 BE160133 
Somatostatin Somatostatin Oesophageal varices Injection - - 20/01/1986 BE133375 
Teduglutide Gattex Short bowel syndrome Subcutaneous 21/12/2012 (NDA)203441 30/08/2012 EU/1/12/787/001 
Teicoplanin Targocid Antibiotic Injection - - 8/03/1989 BE147034 
Telavancin Vibativ Antibiotic IV infusion 11/09/2009 (NDA)22110 - - 
Teriparatide Forteo Osteoporosis Subcutaneous 26/11/2002 (NDA)21318 10/06/2003 EU/1/03/247/001 
*
Discontinued 
1
 as indicated in Summary of Product Characteristics (SPC) 
2
 http://www.accessdata.fda.gov/scripts/cder/drugsatfda/ (- : not found in database) 
3
 http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landing_page.jsp&mid= (- : not found in database) 
4
 http://www.fagg-afmps.be/nl/items-HOME/gegevensbanken/ (- : not found in database)  
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Table 2. List of marketed peptide drugs (continued) 
Peptide name Brand name Indication Administration
1
 
USA
2
 EU
3,4
 
Date No. Date No. 
Terlipressin Glypressin Oesophageal varices Injection - - 11/04/1990 BE150717 
Tesamorelin Egrifta 
HIV-associated 
lipodystrophy 
Subcutaneous 10/11/2010 (NDA)22505 25/01/2011 
EMEA-001029-
PIP01-10 
Thymalfasin Zadaxin Hepatocellular carcinoma - - - 30/07/2002 EU/3/02/110 
Triptorelin Trelstar 
hormone-responsive 
cancers 
Intramuscular 15/06/2010 (NDA)20715 14/04/1997 BE182454 
Urofollitropin Bravelle Ovulation Induction Subcutaneous 19/12/2002 (NDA)21484 10/09/2007 BE302687 
Vancomycin Vancocin Antibiotic Oral 15/04/1986 (NDA)50606 5/10/1982 BE121125 
Vasopressin Pitressin diabetes insipidus Injection * (NDA)03402 - - 
Ziconotide Prialt Pain Intrathecal 28/12/2004 (NDA)21060 21/02/2005 EU/1/04/302/001 
*
Discontinued 
1
 as indicated in Summary of Product Characteristics (SPC) 
2
 http://www.accessdata.fda.gov/scripts/cder/drugsatfda/ (- : not found in database) 
3
 http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landing_page.jsp&mid= (- : not found in database) 
4
 http://www.fagg-afmps.be/nl/items-HOME/gegevensbanken/ (- : not found in database) 
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Besides their pharmaceutical applications, peptides are also used as functional food additives [21]. 
Functional foods are being enriched or enforced with a health-promoting or disease-preventing 
additive. Several bioactive peptides have been identified in milk, soy, rice ovalbumin and egg 
ovalbumin proteins [22,23]. The predominant protein in milk is casein, which consists of four 
different protein chains, i.e. αS1-casein, αS2-casein, β-casein and κ-casein [24,25]. The biological 
activities of casein-derived peptides has recently attracted much interest: evidence of 
antihypertensive, antioxidative, opioid, immunomodulatory, antimicrobial, anticariogenic, and 
mineral binding [26-36] properties of casein-derived peptides has become available, opening up a 
wide range of potential peptide drug candidates. These bioactive peptides could be produced in large 
quantities by the proteolysis of milk-derived caseins. 
Peptides are also topically used in cosmetics without or with cosmeceutical claims like the treatment 
of skin aging. Four distinct peptide groups are used for this purpose [37,38]. The first group 
comprises signal peptides, which stimulate matrix protein production in general and specifically the 
collagen production, firming up the skin. Signal peptides can also increase elastin, proteoglycan, 
glycosamineglycans and fibronectin proliferation. The second group contains enzyme inhibiting 
peptides, of which some peptides, derived from rice-proteins, down-regulate the matrix 
metalloproteinase enzymes [39]. Other peptides inhibit collagen glycosylation, increasing skin 
elasticity. Neurotransmitter inhibiting peptides inhibit the release of acetylcholine at the 
neuromuscular junction and have curare-like effects, reducing wrinkles. Next to this anti-aging and 
other direct cosmeceutical claims inherent to the incorporated peptide, also so-called carrier 
peptides are used in cosmeceuticals, facilitating the transportation of other bioactive molecules into 
the skin. These peptides, often belonging to the cell penetrating peptides or membrane transduction 
peptides, generally have a basic, arginine-rich amino acid region, facilitating the transport over 
biological membranes [40-42]. 
 
2. PEPTIDE STABILITY 
An excellent review by Manning et al. demonstrated the fragile stability profile of peptide 
therapeutics [43]. Once in solution, peptides are prone to a variety of degradation mechanisms: (i) 
deamidation and isomerization, (ii) back-bone hydrolysis of the peptide bond, (iii) beta-elimination 
and subsequent racemization, (iv) diketopiperazine and pyroglutamate formation, (v) oxidation and 
(vi) dimerization. These possible degradation routes are further discussed in Chapter VIII. However, 
the general belief that peptides are labile molecules is derived from the available stability data in 
solution. Only fragmentary and limited information about their stability in solid-state is currently 
available [44]. 
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3. PEPTIDE ADMINISTRATION 
Given their general proteolytic instability and inability to cross physiological barriers including the 
intestinal mucosa, the majority of the currently marketed peptide drugs are administered through 
parenteral routes, i.e. IV infusion, subcutaneous or intramuscular injection, as can be seen from 
Table 2. The main drawbacks of parenteral administration is the risk of non-compliance by the 
patient, which can be linked to the pain experienced during administration or needle phobia. One of 
the “holy grails” of peptide medicines, i.e. oral administration, is still under investigation but has 
already resulted in some orally active peptide drugs such as cyclosporine [45,46]. Moreover, 
considerable research has been conducted designing new peptide formulations allowing for 
alternative administration routes [47], e.g. nasal [48], pulmonary [49] and buccal [50] administration 
routes. However, as some diseases require continuous peptide therapy, e.g. osteoporosis or diabetes 
mellitus type 2, extended release formulation of those peptide therapeutics have been developed, 
e.g. Bydureon®, a prolonged-release suspension for injection of exenatide [51]. Reducing the 
administration frequency will also reduce the risk of patient incompliance and provide a stable 
therapeutic peptide drug concentration.  
Several approaches have been used to obtain sustained or extended release of peptide therapeutics. 
A popular formulation approach involves the use of biodegradable polymers. Naturally occurring 
chitosan and hyaluronic acid, as well as the synthetic polymers, e.g. poly(lactide-co-glycolide) (PLGA), 
polylactic acid (PLA) and polyglycolic acid (PGA), were used. These polymers are degraded in-vivo 
enzymatically or non-enzymatically, producing biocompatible, toxicological safe by-products and 
resulting in the release of the peptide therapeutic. Several peptide-loaded PLGA formulations have 
been reported in the literature, ranging from microparticles to nanoparticles, to implant devices as 
well as in-situ formed devices [52,53]. A major drawback of using biodegradable polymers is the 
inability of removing the formulation once it has been administered, and thus the inability of 
stopping the therapy when e.g. side-effects are detected. By using a non-biodegradable polymer, this 
can be overcome. Peptide drugs which would benefit of such an extended release formulation and 
their action mechanisms are discussed below. 
 
4. PEPTIDES WITH EXTENDED RELEASE POTENTIAL 
Buserelin acetate (trade name: Suprefact®) is a synthetic gonadotropin-releasing hormone (GnRH) 
agonist peptide drug, comprising a nine amino acid sequence (pGlu-His-Trp-Ser-Tyr-D-Ser(tBu)-Leu-
Arg-Pro-NH-Et). It is therapeutically used as an antitumor drug in hormone dependent prostate and 
  
  
breast cancers [54-58]. Naturally occurring 
and binds with its GnRH receptor in the anterior pituitary to regulate production and release of the 
gonadotropins luteinizing hormone (LH) and follicle
stimulate sex steroid hormone synthesis and gametogenesis in the gonads to ensure reproductive 
competence. Continuous GnRH 
GnRH receptor and suppression of LH and FSH release and subsequent sex hormones 
Extended-release formulations of buserelin will
hormones, thus offer an extended palliative cancer
risk of patient non-compliance. 
Enfuvirtide (T20; trade name: Fuzeon
HIV drugs called the HIV fusion inhibitors. 
HIV fusion with the human CD4+
gp160 is cleaved post-translational 
glycoprotein gp41, which are joined non
membrane as a trimeric structure
a hydrophobic fusion peptide and (iii) an extra
envelope domain is made up out of two heptad repeat sequences
which are complementary to each other
 
Figure 1. A. Gp41 structural overview and amino acid sequences of C
norleucine). B. Schematic view of a helical turn in a heptad repeat.
(Naito et al. Antimicrob. Agents Chemother. 2009; 53: 1013
 
Viral infection is initiated by binding of gp120 to the CD4 protein located on the human host cells
T-helper lymphocytes and certain monocytes and macrophages.
 
GnRH is secreted intermittently from the hypothalamus 
-stimulating hormone (FSH). In turn, these 
receptor stimulation by buserelin results in down
 result in the prolonged down-regulation
 treatment, whilst almost completely reducing the 
®), C34 and SC34EK all belong to a relatively new class of anti
The HIV envelope glycoproteins play a central role during 
 host cells, and subsequent cellular infection. The viral glycoprotein 
into a surface glycoprotein gp120 and in a transmembrane 
-covalently into a heterodimer, and are present on the viral 
. Gp41 consists of three domains: (i) a transmembrane domain, (ii) 
-envelope domain (Figure 1A
 (Figure 1A), 
 [62-67]. 
-HR derived fusion inhi
-1018)
 This first receptor 
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-regulation of the 
[59-61]. 
 of the sex 
-
). This latter extra-
i.e. N-HR and C-HR, 
 
biting peptides (Z= 
 
 
, i.e. 
binding triggers a 
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conformational change in gp120, resulting i
subsequent second receptor binding to the CXCR4 or CC
The twofold receptor interaction 
unfolding and extension of its hydrophobic fusion peptide sequence towards the human host cell
which is ultimately inserted into the 
gp41 re-orientate itself, bringing the two complementary heptad repeat sequences, N
together in a hairpin-like structure. As a result, gp41 folds itself in a st
configuration, effectively bringing the membranes of the viral particle and of the host cell in close 
proximity, allowing for fusion and infection to occur (Figure 
 
Figure 2. A. Native state of gp120 
unexposed. B. Gp120 binds with CD4 antigen and chemokine co
conformational changes and the fusion peptide is extended and inserted into the host membran
orientates itself into a 6-helix coiled
hereby pulling viral and host membranes together allowing for membrane fusion and viral infection to occur. D. 
Fusion inhibiting peptide (e.g. enfuvirtide, C34 or SC34EK) interacts with N
(Kilby et al. Nat. Med. 1998; 4: 1302
Enfuvirtide and C34 are both derive
action by interacting with the complementary viral N
n the exposure of a chemokine receptor binding site and 
R5 chemokine receptor (Figure 
of gp120 causes a conformational change in gp41, resulting
host cell membrane (Figure 2B). In this extended conformation, 
able 6
2C) [68-73]. 
and gp41. Gp41 is in a tightly packed formation, with the fusion peptide is 
-receptor. As a results gp41 undergoes 
-coil structure by bringing together the complementary N
-HR, preventing formation of 6
bundles and thus viral infection. 
-1307) 
 
d from the C-HR sequence and exert their HIV fusion inhibiting 
-HR sequences of the extended gp41 (Figure 
 
 
2B) [62-67]. 
 in its 
, 
-HR and C-HR, 
-helix or coiled-coil 
 
e. C. Gp41 re-
-HR and C-HR, 
-helix 
CHAPTER I – INTRODUCTION 
 
 
   29 
1A). This blocks the formation of the 6-helix bundle formation, ultimately inhibiting the membrane 
fusion [68-75], hence their drug class name: “HIV fusion inhibiting peptides” (Figure 2D). It has been 
reported that the α-helicity of the complexes formed between the fusion inhibiting peptides and viral 
N-HR sequences correlates with the anti-HIV activity of the fusion inhibiting peptide, suggesting that 
enhancement of C34 α-helicity would result in a more potent anti-HIV activity. In an α-helical heptad 
repeat sequence, amino acid residues which are three positions apart are located on the same side 
of the helix (Figure 1B). Therefore, the amino acids present at the solvent-accessible site of the C34 
helical bundle were replaced with glutamate (E) at position i, and lysine (K) residues at position i+4, 
whilst preserving the amino residues at the interactive site to ensure N-HR interaction. This 
derivative, named SC34EK showed enhanced anti-HIV activity when compared to the original C34 
peptide [76,77]. Given their high anti-HIV potencies (IC50 values in ng/mL ranges), this group of HIV-
fusion inhibitors are ideal drug candidates to be used in the development of a polymeric medical 
device, which would be administered locally, i.e. vaginal or cervical, having extended release 
properties to provide a prolonged microbicide activity.  
A third group of peptides with potential for extended release formulations are the antibiotic 
peptides, of which the lipopeptides are a subdivision. As can be derived from the name, lipopeptides 
differ from ordinary peptides by their connection of an acyl chain to a linear or cyclic (oligo)peptide 
structure, resulting in overall amphiphilic properties. Natural lipopeptides originate mainly from 
bacterial or fungal origin, in which Pseudomonas and Bacillus species have been studied extensively. 
Certain lipopeptide compounds exert an antibacterial function through pore formation in 
membranes, resulting in bacterial death. Other lipopeptides block the 1-3-β-glucan synthase enzyme, 
which results in a fungicidal activity due to loss of cell wall integrity. [78-81]. Biodegradable extended 
release formulations, alone or as part of medical device implants, have potential applications in 
orthopedic surgery, as the extended, local release of these antibiotic compounds will reduce the risk 
of post-operative infections. 
 
5. PEPTIDE PROCESSING 
During food processing, food products often experience thermal stress during short time intervals, 
which can be voluntary or involuntary. Voluntary exposure to high temperatures is performed for a 
wide variety of reasons, e.g. to prolong the expiration date or to improve protein digestibility [82-85].  
Unwanted exposure to heat can occur during grinding, milling, mixing, compression and compaction 
of powders. When dry powders are mixed or compressed, local temperature increases can occur due 
to friction between individual powders and friction between the powders and the walls of the mixing 
and compression apparatus [86]. Furthermore, tablet coating, performed in both food and 
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pharmaceutical industry, improves visual appearance or masks bad taste of the tablet. However, this 
technique requires extensive curing or drying steps, e.g. aqueous film coating requires drying at 
temperatures of 100 °C, to remove water from the coating [87].  
Biodegradable peptide-PLGA microparticles can be produced by solvent evaporation and solvent 
extraction, as well as by coacervation. The same microparticles can also be produced by spray-drying, 
which will expose the peptide to some degree of thermal stress. Alternatively, larger biodegradable 
implants are mainly manufactured by solvent casting of polymer-peptide mixtures, dissolved in 
organic solvent, or by hot-melt extrusion [52,53]. In hot-melt extrusion, a homogeneous extrudate is 
formed by forcing a solvent-free polymer-API mixture through a die under controlled temperature 
and pressure conditions. Unfortunately, due to the general assumption of peptide instability at 
elevated temperatures, this technique has up till now shown very limited applications involving 
peptides [88].  
 
6. STUDY OBJECTIVES 
Based upon overwhelming evidence of peptide instability in solution, it is generally believed that 
peptides are unstable at elevated temperatures. Furthermore, based upon these general 
assumptions, certain pharmaceutical processing techniques involving short-term heat exposure are 
believed to be peptide-incompatible. However, very limited research has actually been conducted 
towards their thermal stability in dry powder state. Therefore, the central goal of our research is the 
exploration of the solid-state peptide stability under dry heat conditions and their potential of hot-
melt processing into a polymeric implant. The importance lies not only in a fundamentally scientific 
point of view (i.e. “Do peptides degrade upon exposure to dry heat, and if so, which degradants are 
formed?”), but also for the applied pharmaceutical and related fields (i.e. “Can peptides be processed 
at elevated temperatures?”). Obviously, it is impossible to completely develop and market a novel 
peptide-loaded polymeric implant formulation within the given time and resource boundaries. 
Therefore, this work represents a proof of principle study, upon which future research and 
formulation development can be built, bringing safer and more efficacious peptide medicines faster 
to the patient. 
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In order to achieve this central goal, different questions are put forward as objectives: 
(1) How can recent analytical advances improve peptide analysis? 
Solid-phase peptide synthesis (SPPS) of therapeutic peptides is known for also producing 
unwanted structurally closely-related peptide impurities. If post-SPPS semi-preparative 
purification steps are not adequately performed, these impurities end up in the final peptide 
product. Furthermore, (semi-)biosynthesized peptides are often a mixture of closely-related 
bioactive compounds. The separations of these complex, multi-compound peptide mixtures 
from each other as well as from unwanted impurities are major analytical challenges for 
traditional liquid chromatography. Moreover, given the wide variety in the available 
analytical columns, differing e.g. in stationary phase chemistry, silanol-endcapping, particle 
type (i.e. fused-core or fully porous), particle size and column length, choosing the best 
suited column to tackle this analytical challenge is cumbersome. Furthermore, even if full 
separation of all peptide-related components is achieved, traditional PDA detection 
techniques will provide virtually no structural information of the unwanted impurities or 
formed degradants. Currently, only the simultaneous analysis of tediously obtained, high-
priced reference standards, can provide some insight and allow for partial identification of 
the impurity profile. 
(2) How can peak area balance problems be solved? 
On its own, peak area balance is recommended by the ICH in the validation procedure of 
stability-indicating methods. Furthermore, during stability studies of finished drug products 
or APIs, demonstrating the presence of peak area balance is a request from the regulatory 
authorities. If peak area imbalances are seen, what options are available to amend this in a 
cost- and time-efficient manner, especially in the early phases of development?  
(3) Are solid-state peptides stable under dry heat conditions? 
Vast amounts of research regarding general peptide stability is available, probing different 
stress influences, including temperature exposure. When looking at this information, the 
answer to our question would be “NO”. However, an in-depth review of the existing 
literature reveals that the vast majority of research was performed with peptides in solution. 
Almost no peptide stability research in their dry state has been performed, suggesting that 
“WE DON’T KNOW” is a more honest answer to our question.  
(4) Where does API loss occur in lab-scale production processes ? 
During drug discovery/development phase, pilot drug formulations produced at a lab-scale 
(e.g. in a hospital pharmacy) are administered to animals, to ascertain drug efficacies and 
adverse reactions (discovery and preclinical trials), as well as to humans in early clinical trials 
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to determine their safety (Phase I clinical trials). To be able to draw valid conclusions and 
guarantee patient safety, these lab-scale formulations must be of sufficient quality, whereby 
the main quality emphasis is given to API dosing. However, if this quality standard is not met, 
resulting in sub-dosed formulations, a corresponding API loss should have occurred 
somewhere within the lab-scale production process, as APIs cannot simply disappear. 
(5) Can a functional peptide-loaded implant be prepared using a hot-melt process method? 
Repeated parenteral peptide administration to treat diseases as diabetes, HIV and cancer can 
in the long-term entail risk of patient non-compliance issues. Extended release formulations 
can reduce the risks of these non-compliances. However, current implant manufacturing 
methods, e.g. solvent evaporation, solvent extraction or coacervation are not first choices 
from an economical point of view, as they are non-continuous by nature, often require 
organic solvents which also raises quality and toxicity concerns, and encompass cost-and 
time-expensive drying steps to remove these solvents. 
(6) What are the most commonly observed related peptide impurities? 
The monitoring of closely-related peptide impurities is critical for marketed peptide drugs. 
However, these impurities also possess the capability of greatly influencing initial 
functionality studies during early drug discovery phases, possibly resulting in erroneous 
conclusions. For peptide drugs, this important quality issue is not yet well-developed, and 
little is known about the possible related impurities by pharmaceutical quality people. 
 
7. THESIS OUTLINE 
As this exploratory research covered different aspects in parallel, the chapters of this thesis are not 
chronologically ordered, but are arranged from analytical considerations and data interpretation, to 
peptide stress testing and implant manufacturing, ending with a more formal regulatory-quality 
overview in line with the DruQuaR tradition. Therefore, each chapter is written and presented so that 
it can be read as a “stand-alone” text, with the introduction giving the specific context of the chapter.  
 
In Chapter II, two independent approaches will be used for the selection of an appropriate stationary 
phase. First the kinetic plot approach, comparing the different columns at different flow rate ranges, 
will be employed. As the optimal kinetic column performance is obtained at its maximal pressure, 
experimental data (retention times and peak capacities) will be transformed by using the length 
elongation factor λ (Pmax/Pexp), thus allowing for the construction of kinetic performance limit (KPL) 
curves, and direct visual and unbiased column comparison. The second, Derringer desirability 
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approach, will rescale six single and multiple chromatographic response values into one overall D-
value per column, which can then be compared. 
In Chapter III, a single quad mass spectrometry detector will be directly coupled to an existing UPLC-
PDA system and integrated into its software platform. A performance comparison between the 
traditional HPLC-PDA methods and newly developed UPLC-PDA/MS methods for QC analysis of 
complex peptide mixtures will be performed, focusing on impurity separation and identification. 
In Chapter IV, the response factors of newly formed degradants in a stress study will be calculated in-
silico and used to correct peak area balance problems, in order to adhere to the requirements made 
by regulatory authorities. Moreover, this chapter tends to provide a valid alternative for the 
elaborate, expensive and time-consuming experimental response factor calculations using isolated 
reference standards. 
One of the main research questions “Do peptides degrade upon exposure to dry heat?” will be 
answered in Chapter V. In this chapter, the solid-state thermal stability of a number of peptides APIs, 
i.e. buserelin acetate, enfuvirtide, C34, SC34EK and casein-related peptides, will be investigated by 
exposing them to elevated temperatures for different time periods. The exposure conditions will be 
deliberately chosen to be hot-melt-related, providing a prediction of peptide stability during hot-melt 
processing. Alternatively, thermal conditions surpassing those of the hot-melt process will also be 
used, deliberately provoking peptide degradation, allowing the construction of a kinetic model. 
Identification of the peptide-related degradation products formed at these elevated temperatures 
will also be provided, together with their possible formation mechanisms. This chapter intends to 
demonstrate – contrary to popular believe – the thermal stability properties of peptides in solid-
state. 
In Chapter VI, the API losses in lab-scale implant preparation and pharmacy-scale capsule 
compounding will be quantified by swabbing the surfaces of used equipment and working areas. The 
determined API losses will be correlated to experimentally determined sub-dosed final drug 
formulations, and the presence of API mass balance will be evaluated. This chapter also intends to 
alert pharmacists of the correlation between their quality of compounding equipment and final API 
dose in the compounded capsules. 
In Chapter VII, the central question “Can peptides be formulated into polymeric implants by hot-melt 
processing?” will be answered by the preparation of a buserelin acetate loaded polymeric implant, as 
a proof of principle. This chapter intends to demonstrate the stability of this model peptide 
immediately after implant manufacturing, as well as under ICH-compliant stability conditions. 
Furthermore, the pharmaceutical functionality of the implant will be demonstrated by in-vitro and in-
vivo release studies. 
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In good DruQuaR tradition, the final 
other thesis chapters as it will present a
observed peptide impurities, together with possible formation mechanisms. This
related chapter underlines the importance of adequate peptide quality control
analytical methods. 
To summarize, a graphical representation of the different aspects investigated in this work is given in 
Figure 3. 
 
Figure 3. Graphical representation of 
  
Chapter VIII is more or less independently constructed from the 
 regulatory-quality literature review of the most commonly 
different research aspects 
 
 
 regulatory quality 
 by using suitable 
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“Strive not to be a success, but rather to be of value”  
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ABSTRACT 
Lipopeptides are currently re-emerging as an interesting subgroup in the peptide research field, 
having historical applications as antibacterial and antifungal agents and new potential applications as 
antiviral, antitumor, immune-modulating and cell-penetrating compounds. However, due to their 
specific structure, chromatographic analysis often requires special buffer systems or the use of 
trifluoroacetic acid, limiting mass spectrometry detection. Therefore, we used a traditional aqueous / 
acetonitrile based gradient system, containing 0.1% (m/V) formic acid, to separate four 
pharmaceutically relevant lipopeptides (polymyxin B1, caspofungin, daptomycin and gramicidin A1), 
which were selected based upon hierarchical cluster analysis and principal component analysis. 
In total, the performance of four different C18 columns, including one UPLC column, were evaluated 
using two parallel approaches. First, a Derringer desirability function was used, whereby six single 
and multiple chromatographic response values were rescaled into one overall D-value per column. 
Using this approach, the YMC Pack Pro C18 column was ranked as the best column for general MS-
compatible lipopeptide separation. Secondly, the kinetic plot approach was used to compare the 
different columns at different flow rate ranges. As the optimal kinetic column performance is 
obtained at its maximal pressure, the length elongation factor λ (Pmax/Pexp) was used to transform the 
obtained experimental data (retention times and peak capacities) and construct kinetic performance 
limit (KPL) curves, allowing a direct visual and unbiased comparison of the selected columns, 
whereby the YMC Triart C18 UPLC and ACE C18 columns performed as best. Finally, differences in 
column performance and the (dis)advantages of both approaches are discussed. 
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CHAPTER II 
LC COLUMN SELECTION: DERRINGER 
DESIRABIITY AND KINETIC PLOTS 
Main focus in this chapter: 
 Explore different column selection approaches for a given analytical separation 
 Compare (dis)advantages of these approaches  
 
1. INTRODUCTION 
As shown in Chapter I, lipopeptides are an increasingly important subgroup of the antibiotic 
peptides, attracting more and more pharmaceutical and biomedical attention. However due to their 
specific structure, in which an acyl chain is coupled to a linear or cyclic (oligo)peptide structure 
resulting in amphiphilic properties, chromatographic analysis often requires the use of special buffer 
systems, e.g. sodium sulphate [1-4] or trifluoroacetic acid [5-8]. These systems are not directly 
compatible with mass spectrometry or can cause quantification problems due to ion suppression [9]. 
As will be shown in Chapter III, this mass spectrometry detection is a must when it come to analyzing 
(lipo)peptides. Therefore, an LC-MS compatible system for general lipopeptide analysis was 
developed, using a formic acid containing water / acetonitrile based gradient. Samples possibly 
containing new, undiscovered, bioactive lipopeptides can be screened by this new (U)HPLC-MS 
method.  
First, we have selected a number of model lipopeptides from a list of 22 pharmaceutical-biomedically 
relevant lipopeptides (Table 1), using their chemical descriptors and applying clustering techniques 
(HCA and PCA). 
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Table 1. Lipopeptide selection 
# Compound Formula Mr
1 
1 Amphomycin C58H91N13O20 1290.42 
2 Anidulafungin C58H73N7O17 1140.24 
3 Arthrofactin C64H111N11O20 1354.63 
4 Caspofungin C52H88N10O15 1093.31 
5 Cilofungin C49H71N7O17 1030.12 
6 Colistin A C53H100N16O13 1169.46 
7 Colistin B C52H98N16O13 1155.43 
8 Dalbavancin C88H100Cl2N10O28 1816.69 
9 Daptomycin C72H101N17O26 1620.67 
10 Echinocandin B C52H81N7O16 1060.24 
11 Gramicidin A1 C99H140N20O17 1882.29 
12 Iturin A2 C48H74N12O14 1043.17 
13 Micafungin C56H71N9O23S 1270.27 
14 MX-2401 C67H101N15O22 1468.61 
15 P3CSS C60H113N3O11S 1084.62 
16 Plipastatin C72H110N12O20 1463.71 
17 Polymyxin B1 C56H98N16O13 1203.48 
18 Ramoplanin A2 C119H154N21O40 2554.07 
19 Surfactin C53H93N7O13 1036.34 
20 Syringomycin E C53H85ClN14O17 1225.78 
21 Teicoplanin A2-2 C88H97ClN12O33 1879.66 
22 Telavancin C80H106Cl2N11O27P 1755.64 
1 Calculated using MarvinSketch software (version 5.4.1.1, ChemAxon Ltd.) 
Bold: selected lipopeptides based upon PCA and HCA 
 
Secondly, and the main focus point of this chapter, was the comparison of 4 different stationary 
phases for the separation of 4 selected lipopeptides by two rational approaches. First, using similar 
chromatographic conditions, the performance was evaluated and ranked using a Derringer 
desirability function, combining six individual chromatographic responses, each given the same 
weight, i.e. asymmetry factor, limit of detection (LoD), time-corrected resolution product, separation 
factor, peak capacity and chromatographic response factor [10]. Secondly, the kinetic plot approach 
is based on the principle that the kinetic optimum of a chromatographic system or column is 
achieved when a preset desired efficiency or peak capacity is reached in the shortest possible time 
frame or alternatively, when a maximum efficiency is reached during a preset time frame. Therefore, 
a plot of the analysis time versus the plate number (isocratic) or peak capacity (gradient) provides the 
most direct way to compare the performance of chromatographic systems with different 
physicochemical properties. As this kinetic optimum is always obtained when the chromatographic 
system is operated at its maximal pressure, the different columns are therefore compared on an 
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unbiased basis, i.e. preventing that one column is tested under less than optimal conditions [11-16]. 
Finally, both approaches are compared. 
 
2. MATERIALS AND METHODS 
2.1 Materials 
Polymyxin B sulphate (Ph. Eur. quality [3]) was bought at Genaxxon BioScience (Ulm, Germany). 
Gramicidin A ( >90% purity) and formic acid (MS grade >98%) were obtained from Sigma Aldrich 
(Bornem, Belgium). Cubicin® (containing 94.6% (m/m) daptomycin - Novartis) and Cancidas® 
(containing 41.7% (m/m) caspofungin – MSD) were purchased from Care4Pharma (Schiphol, The 
Netherlands). Acetonitrile (LC-MS grade) was purchased from Fisher Scientific (Aalst, Belgium). Water 
was purified using an Arium 611 purification system (Sartorius, Gottingen, Germany) yielding ≥ 18.2 
MΩ×cm quality water. YMC Pack Pro C18, YMC Triart C18 HPLC, ACE C18 (all 250 mm × 4.6 mm I.D.; 5 
µm particle size; 120 Å (YMC) and 100 Å (ACE)) and YMC Triart C18 UPLC (100 mm × 2.0 mm I.D.; 1.9 
µm particle size; 120 Å) columns were obtained from Achrom (Machelen, Belgium). 
 
2.2 Lipopeptide clustering 
The molecular structures (given in Supplementary information) of 22 pharmaceutically relevant 
lipopeptides in isomeric SMILES format [17], were imported into MarvinSketch (version 5.4.1.1, 
ChemAxon Ltd.), thus obtaining a two-dimensional peptide model. The selection was based upon (i) 
clinical application as antibacterial agent (e.g. polymyxin B sulphate), antifungal agent (e.g. 
anidulafungin) or adjuvant (e.g. P3CSS) and (ii) upon prior use in biomedical research, i.e. new 
potential APIs (e.g. MX-2401). As some lipopeptides consisted of mixtures of closely related 
compounds (e.g. polymyxin B1, B1-I, B2 and B3), the structures of the main compound (e.g. polymyxin 
B1) were considered in this study. Gramicidin A1, although strictly speaking not a lipopeptide, was 
also included in this set of 22, based upon its similar antibacterial working mechanism (i.e. pore 
formation in bacterial cell wall) and its deviating structure as it does not contain the typical 
conjugated acyl chain present in the other selected lipopeptides, but rather a series of hydrophobic 
amino residues (alanine, valine and leucine).  
Three-dimensional structure optimization was performed using HyperChem 8.0 (Hypercube, 
Gainesville, FL, USA) software. The molecular mechanics force field method using the Polak-Ribière 
conjugate gradient algorithm, with a root mean square (RMS) of 0.1 kcal/(Å × mol) as termination 
condition, was used. Using the 3-D optimized lipopeptide structures, 3224 descriptors were 
calculated using Dragon (version 5.5, Talete), 5 descriptors were calculated using MarvinSketch 
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software (pI and LogD at pH 2.0, 5.5, 7.4 and 10.0) and 7 descriptors were calculated using 
HyperChem software [18]: the solvent accessible Surface Area (i, ii) was computed using both the 
fast approximate method and a more accurate grid algorithm. The lipopeptide Volume (iii) 
calculation also employed this grid algorithm. The calculation of the Hydration Energy (iv), which 
determines the stability of the molecular conformation, was based on the exposed surface area. LogP 
(v) and Refractivity (vi) values were estimated by the Ghose, Pritchett and Crippen approach, 
whereby each atom contributes to the overall hydrophobicity and refractivity, respectively. Finally, 
Polarizability (vii) was calculated based upon different increments associated with the different atom 
types. In total, 3236 descriptors were obtained for each lipopeptide.  
Elimination of constant descriptors, i.e. identical value for all lipopeptides, reduced the number of 
descriptors to 1464. Each descriptor data-set was then transformed into a N (0,1) distribution using 
z-score normalization: 
z =  x − X SD  
where, x is the individual value of a data point, X is the mean and SD is the standard deviation of the 
descriptor data-set. 
Lipopeptide clustering was performed using HCA analysis with SPSS software (SPSS 19, IBM) and PCA 
with SIMCA-P+ software (version 12.0, Umetrics). HCA is used for pattern recognition based on 
similarities between objects according to the Euclidean distance and the result is visualized in a 
dendrogram. Starting from the individual components, branches are built up to form clusters. The 
length of the branches are inversely related to their similarity, thus short branches mean high 
similarity. PCA is a tool for the interpretation of large data tables and visualization of systematic 
trends. In this approach the multidimensional space, characterized by the 1464 descriptor variables, 
is reduced to principal components (PC), which are linear combinations of the original variables, 
whereby the first PC withholds the most variability in the data set. Based on commercial availability, 
a lipopeptide representative for each of the formed clusters was used for further column 
comparison. 
 
2.3 Column selection 
Four different stationary phases were evaluated for lipopeptide separation. The YMC Pack Pro C18 
HPLC column (Vc: 2.125 mL) was selected based on the work of Orwa et al. [2], where this column 
showed the best chromatographic separation of the different polymyxin B sulphate constituents. The 
second and third columns, i.e. YMC Triart C18, have comparable hydrophobicity k’ (amylbenzene) 
value as the YMC Pack Pro C18 column (both approximately 7.0), but have a 20% lower hydrogen 
bonding capacity α (caffeine/benzene) due to a multi-stage endcapping procedure of the residual 
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silanol groups (YMC Pack Pro C18: 0.105 vs. 0.085 for the YMC Triart C18 chemistry) [19]. This 
stationary phase was obtained both in HPLC (Vc: 2.082 mL) and UPLC (Vc: 0.219 mL) compatible 
format, of which the latter, due to lower particle size (1.9 µm), has the additional benefit of its ultra-
fast analysis time. The last column, i.e. ACE C18 (Vc: 1.968 mL) was selected based on a column 
comparison which indicated better peak shape and column efficiency when compared to the YMC-
Pack Pro column for basic compounds, while the hydrophobicity and selectivity are very close to the 
YMC Pack Pro C18 stationary phase [20]. 
 
2.4 Liquid chromatography 
The UPLC apparatus consisted of a Waters Acquity H UPLC Class Quaternary Solvent Manager, a 
Waters Acquity Sample Manager, combined with a Flow Through Needle, and a Waters Acquity Ultra 
Performance LC PDA (500 nL – 10 mm path length analytical flow cell) detector, with Empower 2 
software for data acquisition. Mobile phases consisted of 0.1% (m/V) formic acid in water (A) and 
0.1% (m/V) formic acid in acetonitrile (B). A general linear gradient was implemented running from 
10% B to 90 % B in 25 column volumes (Vc) followed by returning to the initial conditions and re-
equilibration. A lipopeptide mixture sample containing 0.1 mg/mL polymyxin B sulphate, gramicidin 
A, daptomycin and 1.0 mg/mL caspofungin was prepared in H2O / ACN (50:50, V/V) containing 0.1% 
(m/V) formic acid. Higher concentrations exceeded the solubility, yielding a turbid solution. Column 
temperature was set at 40°C ± 5°C and sample compartment at 5°C ± 3°C. The injection volumes for 
HPLC and UPLC column analysis were set at 10 µL and 2 µL, respectively. Absorbance was detected at 
215 nm, using a sampling rate of 20 Hz combined with a detector time constant of 0.1 s. The flow 
rates for the Derringer comparison were set at 1.0 and 0.5 mL/min for the HPLC and UPLC columns, 
respectively. The flow rate settings used in the Kinetic Plot approach are discussed in detail in section 
2.6. As mentioned in section 2.2, only the major constituent of the individual lipopeptide (i.e. 
polymyxin B1 in the polymyxin B sulphate and gramicidin A1 in gramicidin A) was considered, as the 
main objective was to evaluate the separation between structurally different lipopeptides, rather 
than between the closely related ones. 
 
2.5 Derringer desirability - chromatographic response factors 
The lipopeptide chromatographic characteristics were divided into six different response factors, 
containing both single and multiple responses, and are presented in Table 2 [21-23]. As four 
lipopeptides were analyzed on each column, 3 to 4 separate values for certain single responses, i.e. 
separation factor and As, were obtained per column. These separate values of these single responses, 
as well as the multiple responses, were re-expressed as a dimensionless desirability scale (d) using 
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two linear desirability functions, depending whether the desired chromatographic response was to 
be minimized, e.g. LoD, or maximized, e.g. peak capacity. The geometrical mean of the 
aforementioned separate d-values of the single responses was calculated to obtain one average d-
value for the single response per column. Finally, the geometrical mean of the six d-values was 
calculated in order to assess the overall performance (D-value) of each column [10,23], thereby 
appointing equal weights to each of the six response factors. 
 
 Minimized:    dY =  . . . Maximized: dY =  
 .
. . 
 
Desirability function: D =  ∏ d / 
 
In which d is the desirability value, D is the geometric mean of the desirability values, Yi are the 
experimental response value and Ymin and Ymax are the minimal and maximum values within the 
experimental data set. 
 
Table 2. Selected chromatographic response factors and formulas 
 Response factor Formula # 
1
 
1 Asymmetry factor (As)  =  
 .!
2#  4 
2 Limit of detection (LoD) (ng) 
$
% =  
2&
ℎ = 3 4 
3 
Time-corrected resolution product 
(Rs corr) 
)* =  1.18-./ − -. 0 +  0/  
2 )*3455 =  
∏ )*
6.789  
1 
4 Separation factor (S) $ =  -./ −  --. −  - 3 
5 Peak capacity (:;) :; = 1 + 
-<
1
: ∑  0>
 1 
6 
Chromatographic response 
function (CRF) 
?)@ =  A B )*C,CE
>
C
+ FG-< −  )6789H 1 
1 Number of responses obtained per column 
w0.05: peak width at one-twentieth of the peak height 
wh: width of the peak at half-height 
d: distance between the perpendicular dropped from the peak maximum and the leading edge of the peak at one-twentieth of the peak 
height 
H: height of the peak 
h: range of the noise 
tR: retention time of the peak corresponding to the component 
t0: column dead time 
RT max: t0-corrected tR of the last eluting peak, expressed as column volume 
tg: defined gradient run time expressed in column volume 
a: 1 
b: 1 
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2.6 Kinetic plots 
Kinetic performance limit (KPL)-curves were constructed for each column by performing the 
experiments described in section 2.4 at different flow rates, whereby the total gradient time was 
adjusted accordingly, i.e. fixed at 25 Vc, in order to conserve equal gradient steepness. For each 
individual column experiment at a given flow rate, the corresponding peak capacity :I,JI was 
calculated (Table 2). These experimental peak capacities :I,JI, as well as the retention times (TL of 
the last eluting lipopeptide, i.e. gramicidin, were subsequently converted into KPL-data points, (i.e. 
:I,MNO and TL,MNO) using the length elongation factor λ: 
 
λ =  PRSPJI  
where PRS is the maximum allowed column or system pressure and PJI is the maximum pressure 
achieved during the chromatographic analyses. 
 
:I,MNO = 1 + √λ × G:I  − 1H 
TL,MNO =  λ. TL 
To determine the flow rate range to be used within the kinetic plot experiments, the highest flow 
rates, resulting in a still acceptable PJI column pressure were determined for the 4 selected (U)HPCL 
columns. The lowest flow rates were determined in reference to the fixed flow rates used during the 
Derringer column comparison. Thus, the flow rate ranges used for the kinetic plot evaluation of the 
HPLC and UPLC columns were 0.60 – 1.40 mL/min and 0.20 – 0.80 mL/min, respectively, with 7 
different rates per column. Subsequently, each of the 7 obtained data points per column was plotted 
(TL,MNO in function of :I,MNO) to obtain the KPL-curve [11-16]. 
 
3.  RESULTS AND DISCUSSION 
3.1 Lipopeptide clustering 
The resulting dendrogram of the HCA and the results of the PCA, visualized by means of score plots, 
are shown in Figure 1 and 2. The first 4 PCs explained approximately 80% of the structural variability 
within the 22 selected lipopeptides.  
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Figure 1. Dendrogram obtained from hierarchical cluster analysis of 22 lipopeptides.
 
Based on the PCA result (Figure 
to a lesser extent, components 22, 8 and 21 (‘violet’ cluster 5), are very dissimilar to all other 
components which are classified into 3 major clusters (red, green and blue clusters, 1 to 3) and a 4
cluster containing micafungin (13). This can also be observed in the HCA dendrogram (Fig
similar color legend). The major lipopeptide cluster, containing 72% of the originally selected 
lipopeptides, includes compounds adhering to the most strict l
connection of an acyl chain to a linear or cyclic (oligo)peptide structure. As previously mentioned, 
this major cluster can be divided into 4 sub
8 clusters. The other, structurally deviating lipopeptides still contain the connection of an acyl chain 
to a linear or cyclic (oligo)peptide structure, but also include sugar residues (ramoplanin 
18), multiple lipid chains (P3CSS 
structure (cluster 5, peptides 8, 21 and 22) in their structures (Supplementary Data). Gramicidin 
(peptide 11) does not contain the typical conjugated acyl chain present in the other selected 
lipopeptides, but rather a series of hydrophobic amino residues (alanine, valine and leucine).
Y AND KINETIC PLOTS 
2), we can see that peptides 15, 11 and 18 (clusters 6, 7 and 8), and 
ipopeptide definition, 
-clusters, thus classifying the original 22 components into 
– peptide 15) or alternative linkage between acyl chain and peptide 
 
 
 
th 
ure 1, 
i.e. direct 
– peptide 
 
  
Figure 2. Principal component
 
Based on commercial availability, lipopeptide representatives, 
red cluster 1), caspofungin (4, green cluster 2), daptomycin (9, blue cluster 3) and gramicidin A
cluster 6) were selected, thus representing the major lipopeptide cluster as well as one structurally 
different cluster. 
 
3.2 Derringer desirability 
The chromatographic responses, together with their calculated d
presented in Table 3. The chromatograms obtained using the four different columns are depicted in 
Figure 3. 
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Table 3. Chromatographic response values, calculated desirability values (d) and overall desirability (D)
Parameter ACE C18 
As
 
d 
3.783 
0.529 
LoD1 
d 
14.605 
0.725 
Rs corr 
d 
250.96 
0.132 
S 
d 
1.335 
0.428 
: p 
d 
180.400 
0.813 
CRF 
d 
70.182 
0.419 
D 0.441 
1 absolute mass on column (ng) 
 
Figure 3. Typical chromatograms obtained during the Derringer column comparison
0.5 mL/min for the HPLC and UPLC columns, respectively)
indicated by arrows are the selected lipopeptides (left to right: polymyxin B
(9) and gramicidin A1
 
  
Y AND KINETIC PLOTS 
YMC-Pack Pro C18 YMC-Triart C18 HPLC 
1.160 1.912 
0.658 0.262 
56.822 29.381 
0.239 0.248 
1350.88 153.10 
0.905 0.063 
2.188 1.805 
0.807 0.469 
172.931 142.927 
0.735 0.423 
97.984 58.519 
0.849 0.239 
0.644 0.241 
 (flow rates set at 1.0 and 
. The X-axis was fixed at 25 column volumes. Peaks 
1 (17), caspofungin (4), daptomycin 
 (11)); peaks indicated by braces are considered blank peaks.
 
 
YMC-Triart C18 UPLC 
2.343 
0.247 
3.064 
0.991 
69.91 
0.005 
1.574 
0.287 
113.523 
0.118 
47.853 
0.074 
0.120 
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The average lipopeptide asymmetry factor, calculated using the four individual As of the lipopeptides, 
showed large variability (average 81 % RSD) on each of the selected columns, which can be explained 
by the fact that the four lipopeptides were selected based on their structural diversity, resulting in 
different interactions with the stationary phase. The best As results, i.e. closest to 1, for the 4 
lipopeptides were obtained with the YMC Pack Pro C18 column (average As: 1.16, 45% RSD), 
suggesting a more uniform lipopeptide column interaction. Alternatively, the average asymmetry 
factor of the individual lipopeptides on the 4 different columns showed a smaller variability (average 
38 % RSD), which can be explained by the different endcapping procedures/efficiencies leading to 
different amounts of peak tailing. However, Grubbs outlier testing (α: 0.05) showed no outliers in the 
individual lipopeptide asymmetry factors, indicating that the individual lipopeptides interacted in a 
similar way with all of the 4 selected stationary phases. 
The LoD is the smallest amount of substance that is accurately detectable, having a S/N ratio of 3. 
Both the signal or peak height, which can be correlated to the ‘sharpness’ of the peak, and the 
amount of noise determine the LoD value. The average noise value obtained with the 4 columns is 
calculated to be 2.121×10-4 AU (22.03 % RSD). On the other hand, the peak heights of the individual 
lipopeptides were seen to differ between the selected columns (Figure 3). This peak height is directly 
proportionate to the detectors ability of detecting the solute concentration at the maximum of the 
peak (Cmax). As all analyses were performed using the same chromatographic system (incl. tubings, 
injector and detector), any observed peak broadening, resulting in decrease in peak height, can be 
attributed to the analytical column. Moreover, peak areas of the four lipopeptides analyzed on the 
three HPLC columns were found to be similar (%RSD ranging from 1.22 to 8.11). The relationship 
between the Cmax and the column parameters are summarized in following formula [24]: 
CRS =
4
εYπ√2π1 + |A] − 1|
× √NLd/` ×
VC
1 + kc 
 
Derivation of the formula is thoroughly discussed in Supplementary Data. In this formula, the first 
term includes the column porosities (εY, which were found to be similar throughout the 4 columns. 
This term also correct the Gaussian peak profile for the any peak asymmetries, both fronting and 
tailing. As the average asymmetry factors ranged from 1.16 to 3.78, this will have a significant 
influence on the LoD (Table 3). 
The second term incorporates the column efficiency (N) and the column dimensions, i.e. length (L) 
and diameter (d`). On its own, N is influenced by column length (L) and particle size (dp) (N~ Oef. 
When comparing the HPLC and UPLC columns, L is reduced from 250 to 100 mm, and the dI is 
reduced from 5 µm to 1.9 µm, resulting in a near constant 
O
ef ratio of 50000 for both column 
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dimensions (i.e. 
/!  gR
! gR  HPLC ≈
  gR
. gR UPLC). However, the reduction in column 
dimensions, i.e. L (250 to 100 mm) and d` (4.6 to 2.0 mm), will increase the Cmax result and thus the 
peak height.  
The third and final term, links the Cmax to the absolute mass loaded onto the column, i.e. injection 
volume (v and concentration (c, as well as to the retention characteristics (k’). As c is constant, 
the absolute mass loaded onto the HPLC column is 5 times higher than the mass injected onto the 
UPLC column (10 vs. 2 µL v.). However, as the LoD is expressed as absolute mass, the calculations 
already accounted for this difference in absolute mass loaded onto the UPLC column (see 
Supplementary Data). It also takes into account the capacity factor, which does not differ significantly 
throughout the 4 columns (%RSD of the lipopeptide k’ values on the 4 different columns range from 
21 to 50%). 
When summarizing these different LoD influences, i.e. reduction of column length, column diameter 
and peak asymmetry factor, the Triart UPLC peak height will be approximately 11 times higher as the 
peak height obtained using Triart HPLC column when identical quantities (mass) are injected. Indeed, 
the LoD results for the Triart HPLC and UPLC columns, i.e. 29 and 3 ng respectively, demonstrate this 
underlying relationship, as their LoD values differ by approximately a factor 10. 
The high LoD value observed when using the YMC Pack Pro C18 column is caused by an unretained 
fraction of the injected polymyxin B1, causing a smaller retained polymyxin B1 peak (i.e. smaller S 
value), leading to a relative high LoD value for polymyxin, which in turn leads to a higher average LoD 
value for the four lipopeptides, and smaller LoD d-value for the YMC Pack Pro C18 column. The 
presence of polymyxin B1 compounds in the unretained peak was verified using mass spectrometry 
(MS1 and MS2). Different factors (polymyxin B1 concentration, column temperature, gradient 
composition, column batch and sample solvent strength) were varied to investigate their influence 
on this peculiar polymyxin B1 retention pattern. The main cause of this observed dual retention, 
which is influenced by a variety of parameters, is the strength of the sample solvent in relationship to 
the starting strength of the applied gradient. As the sample, dissolved in 50/50 H2O/ACN sample 
solvent, is injected onto the column, two processes occur. (i) A plug containing the strong sample 
solvent will move unretained through the column, and due to its strong solvent strength, above the 
critical value for desorption, will cause the polymyxin B1 to remain in this plug, desorbed from the 
stationary phase. (ii) While moving through the column, there is a diffusion of polymyxin B1 from this 
plug into the mobile phase. In this mobile phase, polymyxin B1 adsorbs to the hydrophobic surface of 
the stationary phase, and remains adsorbed until the concentration of acetonitrile in the gradient 
reaches the critical value necessary to cause sudden desorption from the stationary phase. The 
diffusion process of polymyxin B1 from the plug into the mobile phase, and from there adsorption to 
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the stationary phase, occurs continuously whilst the plug is moving through the column. This 
polymyxin B1 diffusion into the mobile phase occurs throughout the entire column length, resulting in 
polymyxin B1 being retained throughout the entire column length, until the gradient at the right 
solvent strength (i.e. critical value) sweeps away all desorbed polymyxin. 
The resolution (Rs) takes into account three key factors: (i) column efficiency (N), (ii) selectivity (α) 
and (iii) retention factor (k). As mentioned above, N is determined by the column length and particle 
size and as the L/dp ratios between the evaluated HPLC and UPLC columns are constant, N will not 
have an influence on the calculated Rs values. Selectivity (
mn
mo) and retention factors (
pqpr
pr ) are closely 
related and are determined by mobile phase composition, which was equal for all columns 
evaluated, and by stationary phase. All columns are based upon the same main separation principle, 
i.e. reversed-phase C18. Therefore, no major selectivity differences, e.g. different elution orders, were 
observed for the 4 lipopeptides. However, subtle difference in stationary phase chemistries between 
the YMC Pack Pro C18 and the other columns, also reflected in other chromatographic parameters, 
resulted in higher selectivity values (e.g. YMC Pack Pro C18 vs. ACE C18: 1.38 vs. 1.18 for 
α(daptomycin/caspofungin)) and subsequently higher Rs values. The three individual Rs values, 
obtained for each column, are recalculated into the time corrected resolution product (Rs corr), which 
also takes the column dead volume corrected retention time (expressed in column volume) of the 
last eluting lipopeptide in the mixture, i.e. gramicidin A1, into account. This RTmax was similar for all 
columns, i.e. 19.53 Vc (5.69 % RSD). Calculation of the separation factor S, only takes the column 
dead volume corrected TR of the eluting components into account. The YMC Pack Pro column 
performed the best. The average separation factors of the other three columns showed high 
similarity, as was also noticed for Rs corr parameter. 
Peak capacity is determined by the total gradient run time and by the individual peak widths at half 
maximum. The total gradient run time (expressed as column volumes) is equal to 25 for all columns. 
Therefore, the peak capacity, as calculated here, can be correlated with the individual peak widths at 
half maximum. The ACE HPLC column performed best, closely followed by the YMC Pack Pro C18 
column. The chromatographic response factor takes into calculation the three resolution results 
obtained for each column and the retention time of the last eluting peak. The YMC Pack Pro column 
showed the highest CRF value, which is to be expected as the column was also characterized by the 
highest resolution values. The other 3 columns showed a comparable, but statistically significant, 
lower CRF value. 
From the global desirability D-value, the YMC Pack Pro C18 column showed the best overall 
performance in the chromatographic characteristics of pharmaceutically important lipopeptides. 
However, a major drawback of this column was the observation of an unretained fraction of 
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polymyxin B1. The ACE C18 column ranked as second best column and the overall performance of the 
YMC Triart C18 columns, both HPLC and UPLC, were found to be rather similar (Table 3). 
 
3.3 Kinetic plots 
The 4 constructed KPL-curves are depicted in Figure 4. From the extreme TL,MNO points, it can be 
derived that the YMC-Triart C18 UPLC outperforms the 3 others columns in minimal analysis time. Due 
to its nature, i.e. smaller void volume and particle size together with higher maximal pressure limit, 
this UPLC column is able to generate TL,MNO values below 20 min. This TR region is inaccessible by the 
HPLC columns, as the maximal applicable column pressure would be exceeded. 
 
Figure 4. Kinetic plot with      YMC Triart C18 (UPLC; Pmax: 15000 psi) and      
ACE C18;      YMC Pack Pro C18;      YMC Triart C18 (HPLC; Pmax: 4000 psi). 
 
The highest column performance was obtained with the ACE C18 and YMC Pack Pro C18 columns, i.e. 
:p,KPL values of 288 and 284, respectively. As the only variable in the :,p calculation is the peak-width 
at half-height, as Tg is constant, i.e. 25 Vc for each column, one can expect that a UPLC column will 
generally result in smaller, sharper peaks compared to an HPLC column, if the sample amount is 
proportional among both. However, the mean peak width at half-height (expressed in column 
volumes) using the UPLC column is larger than those obtained with the HPLC columns (0.90 vs. 0.56 
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for ACE C18 and YMC Pack Pro C18). Even the elongation factor λ, which is by far the largest for the 
UPLC column (4.0 vs. 2.5 for the ACE C18) cannot compensate for this mean peak width difference, 
thus explaining this observation. 
It should be noted that the fixed dwell volume (or gradient delay volume) of our chromatographic 
system (Vd: 0.55 mL), which in essence corresponds to an unwanted pre-gradient isocratic section, 
will result in a relatively larger contribution the peptide retention factors obtained from UPLC 
analysis (Vc: 0.22 mL), when compared to HPLC analysis (Vc: ~ 2.00 mL). This effect can be seen in 
Figure 3. Peak capacity calculation utilizes total gradient time, which was fixed at 25 Vc, and peak 
widths. Given the previously explained peptide reversed phase retention behavior, this gradient 
delay will have little impact on peptide peak broadening and thus subsequent peak capacities. 
Obviously, the larger UPLC k’ values will translate into higher peptide retention times, and will impact 
its kinetic plot. This effect can be corrected by obtaining an equal Vd/Vc ratio for both HPLC and UPLC 
analysis. This can be experimentally achieved in two ways: (i) introducing a short isocratic hold prior 
to the HPLC gradient settings or (ii) by delaying the UPLC injection [11]. No adaptations to the 
gradient or injection timing were made in this study, as a practical comparison between lipopeptide 
separation performances on the different columns was envisioned. 
 
3.4 Comparison of the Derringer desirability vs. kinetic plot approach 
The KPL-curve depicted in Figure 4 is based on only 3 variable parameters, i.e. TL,MNO, :p,KPL and λ and 
allows a fast and visual interpretation of column performances. Alternatively, the Derringer 
desirability function approach is based on using six chromatographic responses, including the 
experimentally obtained :p, which allows a more exhaustive comparison of the selected columns. 
Moreover, certain chromatographic responses can be emphasized in the Derringer desirability 
approach by assigning certain weight factors. However, the Derringer approach also increases the 
overall data processing and interpretation time. Chromatography of the components can be adjusted 
by fine-tuning either the physical or the chemical column properties. Regarding the comparison of 
chemical properties and the interaction between the analytes and chromatographic system, the 
Derringer desirability function outperforms the Kinetic Plot method. For example, peak tailing is 
related to the chemical properties of the stationary phase, thus providing initial information of the 
column chemistry, which is lacking in the Kinetic Plot approach. Although the retention time of a 
compound on a given column is also related to the column chemistry, the chemical information 
which can be derived from the Derringer desirability approach is superior to the Kinetic Plot 
approach. 
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As commonly known, the column performance can be depicted in a so called Van Deemter curve, 
where the column is characterized by an optimum performance at a given flow rate. The Derringer 
desirability approach compares the columns at a preset, quite often traditionally used flow rates, 
which may not correspond to the individual optimal flow rates, thus introducing bias in the overall D-
value. By using the different flow rates in the Kinetic Plot approach and transforming the obtained 
data using the elongation factor λ, each column is compared unbiased at its kinetic optimum, i.e. at 
Pmax. However, the Kinetic Plot method pushes the columns and the chromatographic system to their 
pressure limits when the peak capacity is examined at the maximal flow rate, thus most likely 
shortening column and device life. 
The Derringer desirability function maximizes or minimizes individual data points into d-values, using 
the overall experimental data set. This relative character does not allow easy introduction of new 
columns into the comparison. However, the relative nature of the Derringer desirability function can 
be avoided by predefining a set of maximal and minimal values for the chromatographic responses. 
This is straightforward for certain responses, e.g. 1.0 as optimal value for As, but other responses are 
ideally as high, e.g. :p, or as low as possible, e.g. LoD. One must then consider the specific purpose of 
the chromatographic method, e.g. stability-indicating method (low LoD) or high-throughput 
separations of complex mixtures (high :p) and define these optimal values to meet these 
requirements upfront. Alternatively, the Kinetic Plot approach is a stand-alone method, allowing 
incorporation of new, untested columns in the plot as the depicted graphs can be obtained 
independent from each other. 
 
4.  CONCLUSIONS 
Four different (U)HPLC columns were compared for the separation of four lipopeptide 
representatives, using a formic acid containing water / acetonitrile gradient. In order to select the 
most appropriate column, first a Derringer desirability function was employed using a combination of 
single (As, LoD, separation factor) and multiple (time corrected resolution product, peak capacity and 
chromatographic response factor) response parameters. The YMC-Pack Pro C18 column was 
characterized by the highest overall D-value, i.e. 0.644, but also showed an unretained polymyxin B1 
fraction. Alternatively, the kinetic plot approach first transforms the retention times of the last 
eluting compound and experimental peak capacities obtained at different flow rates for each column 
into (TL,MNO ; :p,KPL) data points using the elongation factor λ (Pmax/Pexp). These obtained KPL data 
points are then plotted out. This fairly straight forward approach appoints the YMC Triart C18 UPLC 
and ACE C18 as the most appropriate columns for the mass spectrometry-compatible 
chromatographic analysis of lipopeptides.  
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ABSTRACT 
A single quad MS detector was coupled to a UPLC system and implemented in the routine quality 
control and impurity analysis of 4 therapeutic peptides. Bleomycin sulfate, tyrothricin, vancomycin 
HCl and bacitracin were selected given their multi-component drug nature and their structurally 
closely related impurity profiles. The results obtained using this new UPLC-PDA/MS system were 
compared to the results obtained using the traditional pharmacopoeial HPLC-PDA methods. The use 
of sub-2 µm particle (UPLC) technology resulted in better limit of detection values, higher resolution 
separations, resulting in more detected impurities, and shorter overall run times when compared to 
the traditional HPLC columns. Moreover, online coupling of the newly developed single quad MS 
detector, allowed direct peak identification of the main compounds as well as small impurities, 
hereby eliminating the need of costly reference standards. Our results show the enhanced 
performance of the UPLC-MS system and it is expected that this technology platform will soon 
become a standard technique in QC environments. Therefore, seen the increased importance of 
biologic medicines as well, it is highly recommended that the molecular weight information given in 
the European pharmacopoeia is updated, implementing the most recent IUPAC atomic weight data. 
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CHAPTER III 
QC ANALYSIS OF PEPTIDE API 
Main focus in this chapter: 
 Evaluate the implementation of mass spectrometry in routine QC (peptide) analysis 
 Critically evaluate molecular weight information as currently given by the European 
Pharmacopoeia 
 
1. INTRODUCTION 
Over the past few decades, mass spectrometry (MS) has become an essential tool in fundamental 
disease research [1-4]. Mass spectrometry-based proteomics, metabolomics, peptidomics, glycomics, 
phosphoproteomics and lipidomics is used to quantitatively and qualitatively differentiate between 
the proteins, peptides, sugars and lipid structures of patients and healthy volunteers, in order to 
identify new biomarkers or treatment opportunities [5]. Due to the complexity of these human 
samples, as well as the quest to obtain greater sensitivity, a wide variety of high-end mass 
spectrometry instruments have been developed in the past years. An excellent review by Domon et 
al., provides an overview of the performance of the different MS types used in the proteomics field, 
e.g. the triple quads used for quantification and ultra-high resolution Fourier Transform Ion Cyclotron 
Resonance (FT-ICR) used for identification [3]. Mass spectrometry also has its applications in drug 
development and other pharmaceutical aspects, e.g. drug metabolism studies [6,7]. The main 
drawbacks of this high-end MS equipment are the high purchasing and maintenance costs and 
complex operations. They also require highly skilled operating personnel as analysis of various 
components generally requires component-specific method optimization and subsequent data 
interpretation is often complex. 
These drawbacks of the high-end MS equipment have prevented MS to enter routine pharmaceutical 
quality control (QC) environments. In this setting, matrix effects and drug concentrations are 
generally less challenging than in the “omics”-field, resulting in the need for a more downsized, 
lower-end MS equipment. Recently, a number of small, single quadrupole MS detectors that are 
directly compatible with existing QC HPLC/UPLC equipment and software platforms, have been 
developed and introduced into the pharmaceutical setting [8-10]. The availability of these new MS 
detectors has created the potential to bring the pharmaceutical QC to another level. The present 
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work will compare a new UPLC-PDA/MS equipment set-up with the traditional HPLC-PDA set-up as 
listed in the pharmacopoeias for the quality control and impurity profiling of therapeutic peptides. 
 
2. MATERIALS AND METHODS 
2.1 Materials 
Tyrothricin, bacitracin, propionic acid, sodium pentane sulfate, sodium sulfate and triethylamine 
were bought at Sigma Aldrich (Diegem, Belgium), whereas vancomycin HCl was purchased at Bufa 
(Ijsselstein, the Netherlands). These peptides were ordered without explicit pharmacopoeia quality 
requirements to increase the probability of containing related impurities. Bleomycin sulfate was 
obtained from Sanofi Aventis (Brussel, Belgium). HPLC grade acetonitrile, methanol and 
tetrahydrofuran were acquired from Fisher Scientific (Aalst, Belgium), whereas UPLC grade 
acetonitrile, methanol and trifluoroacetic acid were bought from Biosolve (Valkenswaard, The 
Netherlands). Water was purified using an Arium 611 purification system (Sartorius, Gottingen, 
Germany) yielding ≥ 18.2 MΩ×cm quality water. Potassium dihydrogen phosphate and ammonium 
sulfate was purchased at Merck (Overijse, Belgium), whereas dipotassium hydrogen phosphate was 
obtained from Panreac Chimica (Barcelona, Spain). 
 
2.2 Peptide selection 
Three different antimicrobial peptides, i.e. tyrothricin (cyclic polypeptide), vancomycin HCl 
(glycopeptide), bacitracin (cyclic polypeptide) and a chemotherapeutic peptide, bleomycin sulfate 
(glycopeptide), were selected as test compounds, given their complex, multi-component drug nature 
and their closely structurally related impurity profiles. An overview of the selected peptides, as well 
as their major component and structural properties is given in Table 1. 
 
2.3 Sample preparation 
Peptide samples were analyzed according to the European Pharmacopoeia HPLC-PDA methods, as 
well as by newly developed UPLC-PDA/MS methods [11-14]. As the latter comprised MS detection, 
peptide samples were prepared by replacing the buffer components of the sample solutions with 
H2O, whilst maintaining the same concentrations as stipulated in the European Pharmacopoeia. 
Details regarding peptide concentrations and solvents used for the samples are given in Table 1.  
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Table 1. Overview of selected peptides 
Name Major compounds
1
 Formula Molecular weight
2
 Sample solvent
3
 Ph. Eur. concentration
3
 
Bleomycin sulfate 
Bleomycin A2 
Bleomycin B2 
C55H84N17O21S3 
C55H84N20O21S2 
1414.52 
1424.56 
H2O Test solution: 0.5 mg/mL
*
 
Tyrothricin 
Gramicidin A1 
Gramicidin A2 
Gramicidin C1 
Gramicidin C2 
Tyrocidin A 
Tyrocidin B 
Tyrocidin C 
Tyrocidin D 
Tyrocidin E 
C99H140N20O17 
C100H142N20O17 
C97H139N19O18 
C98H141N19O18 
C66H88N13O13 
C68H89N14O13 
C70H90N15O13 
C72H91N16O12 
C66H88N13O12 
1881.07 
1895.09 
1858.05 
1872.07 
1270.66 
1309.67 
1348.68 
1371.70 
1254.67 
15 volumes H2O 
85 volumes MeOH 
Test solution: 1.0 mg/mL 
Reference solution B: 0.02 mg/mL
*
 
Vancomycin HCl Vancomycin HCl C66H75Cl2N9O24 1447.43 
10 volumes THF 
70 volumes ACN 
920 volumes H2O 
Test solution A: 2.0 mg/mL 
Test solution B: 0.08 mg/mL 
Test solution C: 0.002 mg/mL
*
 
Bacitracin 
Bacitracin A 
Bacitracin B1 
Bacitracin B2 
Bacitracin B3 
C66H103N17O16S 
C65H101N17O16S 
C65H101N17O16S 
C65H101N17O16S 
1421.75 
1407.73 
1407.73 
1407.73 
40 volumes ACN 
400 volumes H2O 
520 volumes MeOH 
Test solution: 2.0 mg/mL 
Ref. solution C: 0.01 mg/mL
*
 
1
 As listed in Ph. Eur. monograph 
2
 Monoisotopic molecular weight 
3
 Based upon Ph. Eur. 8.0 monographs, buffer solution substituted with H2O 
*
 For disregard limit purposes 
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2.4 Chromatography 
The HPLC apparatus consisted of a Waters Alliance 2695 separations module and a Waters 2996 
Photodiode array (PDA) detector with Empower 2 software for data acquisition (all Waters, Milford, 
MA, USA). Chromatographic analysis of the 4 selected peptides were performed as stipulated in the 
European Pharmacopoeia [11-14]. Tyrothricin, vancomycin HCl and bleomycin sulfate were analyzed 
with a Lichrospher 100 RP-18 (250 mm × 4 mm I.D. ; 5 µm particle size; Merck) column, whereas 
bacitracin was analyzed with a Hypersil ODS (250 mm × 4 mm I.D.; 5 µm particle size; Thermo 
Scientific) column. A brief overview of the chromatographic conditions are given in Table 2.  
The UPLC equipment consisted of a Waters UPLC quaternary solvent manager, a Waters Acquity 
Sample manager, a Waters Ultra Performance LC PDA a Waters Acquity Isocratic solvent manager 
and a Waters Acquity QDa detector (QDa), which is a compact single quadrupole mass detector 
equipped with an electrospray ionization (ESI) interface. For data acquisition and instrument control, 
the Empower 3 FR 2 software was used. The Acquity UPLC CSH C18 column (100 mm x 2.1 mm I.D.; 
1.7 µm particle size; Waters) was maintained at 40°C [15]. Mobile phase A consisted of a 95/5 
H2O/ACN + 0.1 % trifluoroacetic acid, whilst mobile phase B consisted of 5/95 H2O/ACN + 0.1 % 
trifluoroacetic acid. The peptide analyses used different gradient methods (Table 3). The flow rate 
was set at 0.5 mL/min and the injection volume at 2 µL. A post-column 10/1 PDA/QDa split ratio was 
employed, together with a post-column addition of 40/10/50 H2O/propionic acid/2-propanol at 0.35 
mL/min to the portion going to the QDa. This post-column addition neutralized the TFA ion 
suppression effects [16] and sustained sufficient flow rate to the QDa MS detector. The Waters QDa 
was operated in positive ion mode by applying a voltage of 0.8 kV to the ESI capillary and the cone 
voltage was set at 15 V. The probe temperature was set to 600°C. A full mass spectrum between m/z 
100 and 1250 was acquired at a sampling rate of 2.0 spectra/sec. 
The HPLC and UPLC method were compared based upon (i) the system suitability tests (SST) listed in 
the Ph. Eur., i.e. resolution, peak to valley ratio (p/v), signal to noise ratio (S/N) and asymmetry factor 
(As), (ii) the quality limits of the active pharmaceutical ingredient (API) (iii) the limit of detection 
(LoD), (iv) the number of peaks detected above reporting threshold (reported peaks), (v) the number 
of peaks (tentatively) identified and (vi) the total run time. 
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Table 2: European Pharmacopoeia - chromatographic conditions for selected peptides 
Name MP A MP B 
Run time 
(min) 
Flow rate 
(mL/min) 
Column T 
(°C) 
Injection vol. 
(µL) 
Quant. wavelength 
(nm) 
Bleomycin sulfate MeOH Pentanesulfonate buffer 100 1.2 room 20 254 
Tyrothricin 
75 MeOH 
25 sulfate buffer 
- 60 1.2 60 25 280 
Vancomycin HCl 
70 ACN 
10 THF 
920 triethylamine 
290 ACN 
10 THF 
700 triethylamine 
35 1 room 20 280 
Bacitracin 
40 ACN 
300 H2O 
520 MeOH 
100 phosphate buffer 
- 75 1 room 100 254 
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Table 3. Different gradient systems used for UPLC-PDA/MS analyses. 
Time (min) MP A(%) MP B(%) 
Bleomycin sulfate 
0 100 0 
10 70 30 
12.50 70 30 
14 100 0 
20 100 0 
Tyrothricin 
0 60 40 
10.50 10 90 
11.86 10 90 
12.60 60 40 
16.80 60 40 
Vancomycin HCl 
0 100 0 
10 90 10 
20 70 30 
22 100 0 
30 100 0 
Bacitracin 
0 95 5 
10.50 50 50 
11.86 50 50 
12.60 95 95 
16.80 95 95 
 
3. RESULTS 
Chromatograms obtained from HPLC-PDA and UPLC-PDA/MS analysis of bleomycin sulfate are given 
in Figure 1. Using the HPLC-PDA method, bleomycin A2 and B2 were identified by their high 
normalized peak area (62.79 % and 34.05) [11]. Impurity D (desmethylbleomycin A) was identified by 
its relative retention time (RRT) to Bleomycin A2, i.e. 1.5 to 2.5. Although this HPLC-PDA method 
adheres to the SST (resolution between bleomycin A2 and B2 is higher than 5; peak width at half 
height), the bleomycin B2 amount surpasses the limit stipulated in the European Pharmacopoeia. This 
is a prime example of how using an averagely performing, but SST-conform, HPLC-PDA QC method, 
combined with automatic integration, e.g. no peak deconvolution was used, can result in a false low 
quality assessment of an API. When using the UPLC-PDA/MS method, which resulted in a better 
chromatographic separation of all compounds as evidenced by the reduction in tailing of the major 
  
bleomycin compounds and increased resolution with the present impurities, the bleomycin B
amount was determined to be 29.0%, thus complying with the Ph. Eur. limits. Moreover, using the 
MS detection possibilities, the identity of the bleomycin A
and B2 (m/z values 713.52 and 476.06; z=2, 3) were confirme
listed impurities were identified
and bleomycin A5 (m/z values 720.42 and 480.73; z=2, 3). The identity of desmethylbleomycin A 
(impurity D) was also confirmed (
the UPLC-PDA/MS method was reduced to 20 min, whereas the HPLC
 
Figure 1. Bleomycin sulfate (0.5 mg/mL) HPLC
identification of major compounds and method comparison. The MS
bleomycin A2 and B2, as well as from impurities bleomycin A
 
Chromatograms obtained from HPLC
Figure 2. Due to the complex nature of the tyrothricin sample
gramicidins, formal identification was not possible with the HPLC
of expensive reference standard materials. Alternatively, using the UPLC
A-D (m/z values: 636.01; 655.67; 675.11 and 686.47, respectively; z=2) and gramicidin A
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2 (m/z values 708.08 and 472.44; z=2, 3) 
d. Furthermore two additional Ph. Eur.
 by their mass spectra, i.e. bleomycin acid (m/z
m/z values 701.04; z=2). Finally, it is noted that the total run time of 
-PDA run time was 100 min.
-PDA (top) and UPLC-PDA/MS (bottom) 
1
 spectra of the main compounds 
5 and desmethylbleomycin A are given.
-PDA and UPLC-PDA/MS analysis of tyrothricin are given in 
 that contains different tyrocidins and 
-PDA method wi
-PDA/MS method, tyrocidins 
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2 
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analysis with 
 
thout the purchase 
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(m/z values: 941.65, 948.76 and 930.22, respectively; z=2) were i
spectrum and the presence of K
+
 
Figure 2. Tyrothricin (1 mg/mL) HPLC
major compounds and method comparison. Exemplary MS
 
Chromatograms obtained from HPLC
Figure 3. Identification of vancomycin B using the traditional HPLC
high relative peak area, whereas aglucovancomycin B (Ph. Eur. imp
[17]. Analysis of the same sample using the UPLC
in the separation of more impurity peaks. Moreover, using the MS detection, the majority of these 
impurity peaks could be tentatively identified based upon their MS
performed by Diana et al. (Table 4) [17]. The mass spectra of two vancomycin
which were tentatively identified as a demethylated impurity (peak 3) and aglucovancomycin B (
13), are given in Figure 3. Even though their individual impurity amount, relative to the main 
compound vancomycin B, is well below 1%, 
spectra can be used for immediate identification purposes.
dentified based upon their MS 
-adducts, hereby eliminating the need of costly reference materials.
-PDA (top) and UPLC-PDA/MS (bottom) analysis with identification of 
1
 spectra of main compounds tyrocidin C and 
gramicidin C1 are given. 
-PDA and UPLC-PDA/MS analysis of vancomycin HCl are given in 
-PDA method was based upon its 
urity C) was identified 
-PDA/MS method improved the resolution, resulting 
1
 spectrum and the work 
i.e. 0.1% for peak 3 and 0.3% for peak 13, these mass 
 
 
 
by its RRT 
-related impurities, 
peak 
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Table 4. Identified Vancomycin HCl related impurities 
# RT (min) m/z Identification 
1 1.134 661.24 
Oxidized desvancosaminylvancomycin 
Demethylleucylvancomycin B 
2 5.028 734.78 
Crystalline degradation product (demethylated) 
Deamidated vancomycin B (demethylated) 
N-demethylvancomycin B 
3 5.095 718.40 
Crystalline degradation product (demethylated) 
Deamidated vancomycin B (demethylated) 
4 5.209 725.51 
Oxidized vancomycin B (demethylated) 
Crystalline degradation product major 
Crystalline degradation product minor 
5 5.318 717.77 
Crystalline degradation product (demethylated) 
Deamidated vancomycin B (demethylated) 
N-demethylvancomycin B 
6 5.950 718.47 
Crystalline degradation product (demethylated) 
Deamidated vancomycin B (demethylated) 
7 6.009 724.95 
Crystalline degradation product major 
Crystalline degradation product minor 
8 6.098 725.51 Oxidized vancomycin B (demethylated) 
9 6.302 724.95 
Crystalline degradation product major 
Crystalline degradation product minor 
10 6.369 725.44 Vancomycin B 
11 6.518 725.92 Oxidized vancomycin B (demethylated) 
12 6.707 725.58 Oxidized vancomycin B (demethylated) 
13 12.694 1143.48 Aglucovancomycin B 
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Figure 3. Vancomycin HCl (2 mg/mL) HPLC
major compounds and method comparison. The MS
 
A similar observation was made for analysis of bacitracin by UPLC
identity of the main compounds, as well as tentative identification of major impurity peaks, could be 
performed with previous MS-work done by Govaerts et al. [18]
compound bacitracin A, as well as of two small impurities, 
A) and bacitracin H (1.7% relative to bacitracin A) are given in Figure 4
identification purposes. The total run time of the UPLC
when compared to the HPLC method, 
 
-PDA (top) and UPLC-PDA/MS (bottom) analysis with identification of 
1
 spectra of the main compound Vancomycin B and of two 
exemplary impurity peaks are given. 
-PDA/MS. Confirmation of the 
. The mass spectra of the main 
i.e. bacitracin E (1.5% relative to bacitracin 
, and were positively used for 
-PDA/MS method was also drastically reduced 
i.e. 16.8 min vs. 75 min. 
 
  
Figure 4. Bacitracin (2 mg/mL) HPLC
compounds and method comparison. The MS
 
A comparison between the performances of the traditional HPLC
methods for bleomycin sulfate, vancomycin
tyrothricin components could not be identified using the HPLC
comparison could be made. 
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Figure 5. Relative performance comparison between UPLC
sulfate, vancomycin HCl and bacitracin QC analysis. HPLC
 
4. DISCUSSION 
The advantages of sub-2µm chromatography (UPLC) over traditional HPLC chromatography for 
analysis of pharmaceutical compounds hav
smaller particle size results in improvement of efficiency and optimum velocity, resulting in faster, 
high resolution separations when compared to traditional HPLC column particle sizes, 
Current HPLC-based quality control methods for APIs listed in the European Pharmacopoeia generally 
still utilize these large HPLC particle dimensions. Small variations in particle size are permitted for 
isocratic method, i.e. reduction of 50% in particle size,
allowed with gradient elutions [24]. As a result, the use of sub
convert existing European Pharmacopoeial API quality control methods into faster, more efficient 
sub-2µm methods is currently not allowed without validation. However, newly developed quality 
control methods already use this sub
methods for quetiapine fumarate and nevirapine hemihydrates [25,26]. Moreo
Eur. 8.3 general chapter 2.2.29 Liquid chromatography
Although mass spectrometry is listed as a
the use in the quality control of APIs 
phosphate and determination of the interferon
the newly developed smaller, budget friendly
% 
-PDA/MS and HPLC-PDA methods for bleomycin 
-PDA performance was set at 100%.
e already been extensively documented [19
 whereas no alteration in particle size is 
-2 µm particle size chromatography to 
-2 µm stationary phase as evidenced by the related substance
 will cover sub-2 µm particle technology [27].
n analytical technique in the European Pharmacopoeia [28], 
is currently limited to detection of impurity B of oseltamivir 
 β-1a isoform distribution [29,30]. However, due to 
 and easy to use single quad MS detectors, 
 
 
-23]. The 
i.e. 5-10 µm. 
s 
ver, the revised Ph. 
 
such as the 
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Acquity QDa detector, it is expected that the application of this detection technique will 
exponentially increase. Coupled to HPLC separation, they adequately answer the current shift in QC 
emphasis from API assay towards impurity profiling [31,32]. 
This study has demonstrated the applicability of identifying related impurities in complex peptide API 
samples by using single quad MS detection. The current equipment set-up, using a post-column split, 
coupled with post-column addition of a propionic acid-containing solvent, even permitted the use of 
TFA to improve chromatographic peak shape [33], without compromising the MS detection too 
much. As expected, resolution and limit of detection were improved by the use of sub-2 µm column 
technology and finally the overall run time was significantly reduced, when compared to traditional 
HPLC methods, using 5-10 µm column technologies. 
The molecular weight (Mr) of a compound is a fundamental value, which describes an important 
aspect of a molecule in a quantitative way. In the European Pharmacopoeia, it is given in 
monographs for information only; in other words, it is not part of the mandatory quality 
specifications but the value given should be used, if needed, in the practical analytical tests. The 
value given, Mr, is the isotopic-weighted average: it is calculated from the molecular formula and the 
atomic weights of the constituting atoms, which are dependent on the atomic masses of the isotopes 
of each element and the corresponding mole fractions of these isotopes. However, contrary to 
general belief, the atomic weight (Ar) is not a fixed error-free theoretical value: conceptually, it will 
not only vary with place (deep-sea versus mountain) and time (on a geological time scale), but the 
method used for this Ar determination will also influence the uncertainty accounting for both 
systematic and random errors. Using different normal terrestrial samples and analytical techniques, 
different results are thus obtained by different groups for the Ar values. In all cases, the reference 
value used is Ar (12C) equals 12. The International Union of Pure and Applied Chemistry (IUPAC) 
biennially publishes an updated Table of Standard Atomic Weights, based upon careful evaluation of 
results obtained and an overall statistical evaluation. This evaluation also explicitly includes the 
uncertainty, which is reflected in the number of significant figures. Hence, in its most recent Table of 
Standard Atomic Weights [34], interval values [a ; b] are given for some elements rather than a single 
value corresponding to the best individual estimate [35]. The lowest value a is obtained from the 
lowest experimental value found with a representative terrestrial sample, lowered by its uncertainty 
and rounded to the last certain digit. In the case of carbon, the fifth digit after the decimal point was 
uncertain, hence, its Ar value is reduced to four figures after the decimal point. The IUPAC 
commission may still deviate from the accepted rounding rules and widen the limits in the rounding 
step to ensure that normal terrestrial materials all safely fall within the interval. The interval is thus 
obtained by a so-called type B uncertainty evaluation, and it should not be considered as some 
Gaussian-type of confidence interval; hence, the mid-value of the interval cannot be taken as a best 
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single estimate. As it is impractical to work with interval values in a pharmacopoeial context, even 
though it is more correct, we have moved to abridging the lower a and upper b bounds to fewer 
figures until a equals b. These abridged atomic weights are given in the last column of Table 4. 
 
Table 4. Atomic weights 
Element  Symbol Atomic number Atomic weight 
1
 Atomic weight interval [a ; b] 
2
 Abridged atomic weight 
Carbon C 6 12.0107 (8) [12.0096 ; 12.0116] 12.01 
Hydrogen H 1 1.00794 (7) [1.00784 ; 1.00811] 1.008 
Oxygen O 8 15.9994 (3) [15.99903 ; 15.99977] 16.00 
Nitrogen N 7 14.0067 (2) [14.00643 ; 14.00728] 14.01 
1
 Standard values as from IUPAC (2007) [35]. The uncertainty for given atomic weights is given in parentheses following the last significant 
figure to which it is attributed. 
2
 Standard values as from IUPAC (2011) [34] 
 
While for low molecular weight compounds, this will hardly make a difference, this is by no means so 
for higher molecular weight compounds such as peptides, proteins, oligo/polynucleotides and 
oligo/polysaccharides. The number of these oligo/polycompounds is expected to increase in the 
pharmaceutical field as they are steadily replacing small molecules which, even though they currently 
predominate, are being rapidly phased out. Moreover, the importance of clearly agreeing on Ar 
values and their definition will also increase due to the previously demonstrated added values of 
mass spectrometry detection. Since isotopic distribution and monoisotopic masses are commonly 
used in MS, for current pharmacopoeial monographs, at least an agreed consensus on Ar and hence 
Mr values should be reached and formally communicated. Within the analytical MS community, 
software is often used which will also give the user “an average” molecular mass. In general, these 
types of software are consistent in their results. For example, polymyxin B1 has the molecular 
formula C56H98N16O13 whereas tyrocidin C has the molecular formula C70H90N15O13. The different Mr 
values obtained for both compounds are given in Table 5. We have included all figures and did not 
perform any rounding. 
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Table 5. Polymyxin B1 and tyrocidin C Mr values 
Source 
Polymyxin B1 Tyrocidin C 
Mr Rounded Mr Mr Rounded Mr 
Ph. Eur. [12,36] 1204 1204 1350 1350 
MolE [37] 1203.49416 1203 1349.57790 1350 
Lenntech [38] 1203.47 1203 1349.55 1350 
Environmental chemistry [39] 1203.494 1203 1349.578 1350 
BMRB [40] 1203.479587 1203 1349.559591 1350 
IUPAC (2011) a [34] 
IUPAC (2011) b [34] 
IUPAC (2011) abridged 
1203.39619 
1203.55787 
1203.504 
1203 
1204 
1204 
1349.46114 
1349.64811 
1349.570 
1349 
1350 
1350 
IUPAC (2007) [35] and Exploring 
chemical analysis [41] 
1203.47672 1203 1349.56322 1350 
 
It is thus observed that different Mr values are obtained for polymyxin B1 and tyrocidin C, if we round 
them to the unit (amu), we thus obtain 1203 or 1204 and 1349 or 1350, respectively. Both values 
reflect in some way the uncertainty interval. In case of polymyxin B1, only the IUPAC abridged value 
corresponds to the Ph. Eur. value of 1204, whereas for tyrocidin C all calculations correspond to the 
Ph. Eur. value of 1350. Taking the correct full IUPAC approach, a molecular weight interval of 
[1203.3962 ; 1203.5579] and [1349.4611 ; 1349.6481] is defined for polymyxin B1 and tyrocidin C, 
respectively. As mass spectrometry applications in routine QC analysis are expected to rise in the 
future and the Ph. Eur. represents state-of-the-art science, it is highly recommended that the Ph. Eur. 
aligns the given molecular weights with the most recent IUPAC atomic weight data. 
 
5. CONCLUSION 
A newly developed, single quadrupole MS detector was coupled to an UPLC separation module and 
used in routine quality control analysis of bleomycin sulfate, tyrothricin, vancomycin HCl and 
bacitracin peptide APIs. These results were compared to their pharmacopoeial equivalent, obtained 
with traditional HPLC-PDA methods. UPLC separation resulted in higher resolution and lower limit of 
detection, as well as a significant reduction in run time. Furthermore, the added MS detection 
possibilities render expensive reference materials, often used for identification purposes based upon 
relative retention times, superfluous. Finally, low level related impurities could immediately be 
identified without the need for further experimental steps. Currently, the mass spectrometry 
technique is only sparsely applied in the European Pharmacopoeia. However, given recent technical 
advances, delivering fit for use single quad mass spectrometer detectors to the pharmaceutical field, 
its applications in QC analysis is expected to rise in the near future. Therefore, it is highly 
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recommended that the molecular weight information given in the European pharmacopoeia is 
updated, implementing the most recent IUPAC atomic weight data. 
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CHAPTER IV 
 
PEAK AREA BALANCE 
 
“Failure is simply the opportunity to begin again, 
 this time more intelligently”  
 
Henry Ford 
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Van Gompel J. Relative response factor determination of β-artemether degradants by a dry heat 
stress approach. Journal of Pharmaceutical and Biomedical Analysis 2012; 70: 111–116. 
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ABSTRACT 
Peak area balance is not only an important tool in the verification of newly developed stability-
indicating methods, measuring the method’s capability to detect all formed degradants, but is also a 
regulatory request in stability studies. Forced degradation (stress) testing of the investigated 
compound is recommended as part of the method development and validation. In this study, an in-
silico mathematical approach is used to calculate the average and individual response factors of 
degradants formed during forced degradation experiments, as well as during formal ICH stability 
studies. The calculated response factors can be used to solve peak area balance problems. 
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CHAPTER IV 
PEAK AREA BALANCE 
Main focus in this chapter: 
 Investigate peak area balance in stability and stress studies 
 Implement a mathematical approach for in-silico calculation of response factors 
 
1. INTRODUCTION 
The ICH provides a number of guidelines regarding the stability testing of the active pharmaceutical 
ingredient (API) and drug product [1-6]. These guidelines clearly define storage conditions for the 
determination of long-term and accelerated stability as well as for photostability. Forced degradation 
studies or stress testing of the drug substance is briefly mentioned in the ICH guidelines, as this can 
help in the identification of degradant products and degradation mechanisms, as well as in the 
validation of analytical methods. Forced degradation studies of solid-state API typically involves 
exposure to heat, humidity and light. In addition, in solution-state studies, the API is subjected to 
various pH values, oxidative and reductive environments, all combined with elevated temperatures. 
However, no formal conditions to perform this forced degradation study are provide in the ICH 
guidelines. 
The FDA defines a stability-indicating method as a validated analytical method capable of accurately 
differentiate between the intact drug molecule(s), any possible degradation products and product 
excipients [7]. ICH Q2 provides guidance regarding the validations of these stability-indicating 
methods. If no (known) degradation products are available, the ICH advocates the use of forced 
degradation studies to verify the selectivity of the stability-indicating method [8]. An important 
aspect to evaluate if all API-related degradants are detected by the stability-indicating method is the 
peak area balance. This ratio compares the sum of peak areas found in stressed samples, which 
contain API- and degradant-related peaks, with the API peak area in an unstressed reference sample. 
The relationship between the signal produced by a compound, e.g. peak area, and the quantity or 
concentration of that compound is called the response factor (RF). Generally, it is assumed that API-
related degradants have a similar RF as the parent molecule, i.e. relative response factor (RRF) equals 
approximately 1. If this is the case for all the degradants, a peak area balance of 100% should be 
reached, provided that all formed API-related degradants are detected by the analytical method. 
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During formal ICH-stability studies, the presence of peak area balance is currently a requirement by 
the pharmaceutical regulatory authorities, to support the conclusions. 
In chapter VI, buserelin acetate (pGlu-His-Trp-Ser-Tyr-D-Ser(tBu)-Leu-Arg-Pro-NH-Et) was subjected 
to forced degradation conditions in order to verify the selectivity of a newly developed stability-
indicating method. However, the buserelin acetate peak area balances at the different stress 
conditions were consistently found to be below 100%, ranging from 90% to 60%, under our 
experimental conditions employing UV detection at 220 nm [9]. This peak area balance issue, 
encountered in stability studies and validation of stability-indicating methods, was not only confined 
to peptides, e.g. buserelin acetate, but appeared to be a general pharmaceutical challenge. 
Therefore, we enlarged this study to include a problematic small molecule drug substance, i.e. β-
artemether. This compound is an anti-malarial, semi-synthetically derived from artemisinin. The 
structures of buserelin and β-artemether can be seen in Figure 1. As antimalarials are used in regions 
characterized by relatively high temperatures and humidity (climate zones III and IV, as defined by 
WHO), accurate knowledge regarding accelerated-, intermediate- and long-term stability of β-
artemether is crucial. An intriguing peak area balance problem was encountered when β-artemether-
containing finished drug products (FDP) were stored under ICH-compliant stability conditions. The 
stability samples were characterized by a consistent and disproportional increase in the peak areas of 
β-artemether degradation products, when compared to the peak area decline of β-artemether itself, 
resulting in peak area balances well above 100%, which contrasted the buserelin situation. Proper 
knowledge of the RF of these unknown β-artemether-related degradation compounds is required to 
solve this peak area mass balancing problem [10]. This problem was efficiently approached by short-
term stressing β-artemether in its dry form, as a single compound, under various time, temperature 
and environmental conditions, where all the degradant peaks formed were directly related to β-
artemether. Using a mathematical approach, the corresponding RF of the β-artemether-related 
degradants could be calculated, thus solving the peak area balance problem. 
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Figure 1. Structure of buserelin and β-artemether (left to right) 
 
2. MATERIALS AND METHODS 
2.1 Materials 
Buserelin acetate (European Pharmacopoeia quality) was bought at Hybio Pharmaceutical Co. 
(Shenzhen, China). Acetonitrile (LC-MS grade) was purchased from Fisher Scientific (Aalst, Belgium). 
Water was purified using an Arium 611 purification system (Sartorius, Gottingen, Germany) yielding ≥ 
18.2 MΩ·cm quality water. Monobasic potassium phosphate was bought from Sigma Aldrich 
(Bornem, Belgium), potassium permanganate and zinc powder were obtained from Flandria (Ghent, 
Belgium) and Janssen Chimica (Beerse, Belgium), respectively. β-artemether, drug substance and 
FDP, as well as related compounds, i.e. dihydroartemisinin (DHA), artemisinin, 9,10-
anhydroartemisinin (LEI, Late Eluting Impurity) and α-artemether, were gifts from Dafra Pharma 
(Turnhout, Belgium). β-artemether Synthesis impurities 9-epi-artemisinin and artemisitene were 
purchased from SensaPharm (Wearfield, UK). The degradation compound 2-[4-methyl-2-oxo-3-(3-
oxobutyl)cyclohexyl]propanal (DKA) was obtained from Sigma Tau (Rome, Italy). 
 
2.2 Liquid chromatography 
The UPLC apparatus, used for quantification of buserelin and β-artemether, as well as their related 
degradants, consisted of a Waters Acquity H UPLC Class Quaternary Solvent Manager, a Waters 
Acquity Sample Manager, combined with a Flow Through Needle, and a Waters Acquity Ultra 
Performance LC PDA detector with Empower 2 software for data acquisition (all Waters, Milford, MA, 
USA). Details regarding the stability-indicating buserelin method can be found in Chapter V. An 
Acquity UPLC BEH Shield RP 18 (100 mm × 2.1 mm I.D., 1.7 µm particle size) column (Waters, Zellik, 
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Belgium), thermostated in an oven set at 30 °C, was used for β-artemether assay and degradant 
profiling. The flow rate was set at 0.6 mL/min and a linear gradient was applied (where A = 25 mM 
phosphate buffer, adjusted to pH 2.5 using diluted sodium hydroxide, and B = acetonitrile), running 
from 30 to 75% B from 0 to 12.5 min, followed by returning to the initial conditions and re-
equilibration. The sample compartment was thermostated at 5 °C and UV detection was performed 
at 210 nm. The injection volume used was 1.7 µL. The reporting threshold for the dry heat stressed 
samples (see section 2.3) was set at 1% and 5% peak area relative to unstressed buserelin acetate 
and β-artemether, respectively. 
 
2.3 Dry heat stress samples 
β-artemether and buserelin acetate, in their native dry powder form, were exposed to various high 
temperatures. In addition, the influence of an oxidizing and reductive environment on the β-
artemether dry heat-induced degradation profile was also evaluated by mixing β-artemether (3 
parts) with potassium permanganate and zinc, respectively (1 part), using mortar and pestle, thus 
obtaining two different powder mixtures [11]. The powders were accurately weighed (1 mg buserelin 
acetate and 40 mg β-artemether) and transferred into separate glass vials (12×32 mm, Borosilicate, 
Type 1, Class A glass), which were then incubated in a preheated heating block (Stuart, Stone, United 
Kingdom). Buserelin acetate was exposed to temperatures ranging from 150°C to 180°C, with 
incubation times ranging from 10 to 160 min, whereas the temperature settings for β-artemether 
varied from 125 to 150 °C, with incubation times ranging from 10 to 90 minutes, depending on the β-
artemether powder composition. After incubation, the stressed samples were immediately placed on 
ice, in order to prevent further degradation. Unstressed buserelin acetate and β-artemether samples, 
i.e. not incubated in the heating block, were also stored in ice to guarantee identical treatment. The 
contents of the unstressed and stressed buserelin acetate samples were solubilized using 
appropriate volumes of solvent consisting of 95% H2O and 5% ACN mixture with 0.1% FA to obtain a 
1 mg/mL buserelin acetate solution. The contents of the unstressed and stressed β-artemether vials 
were dissolved with acetonitrile, the resulting solution transferred quantitatively into a 10 mL 
volumetric flask and diluted to volume using acetonitrile. All samples were sonicated (Branson™ 
2510) before UPLC analysis. 
 
2.4 UPLC profiling of degradation impurities 
The degree of degradation was calculated from the residual buserelin acetate and β-artemether peak 
areas after heat stress. Experiments yielding between 10 to 90% degradation were withheld for 
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further calculations, i.e. for the calculation of average and individual relative response factors RRFs of 
the β-artemether-related degradants. Those stress conditions with extreme (i.e. > 90%) or very 
limited (i.e. <10%) degradation were not withheld due to their irrelevance for our problem. Due to 
the huge number of relatively small and/or infrequently observed peaks in the withheld β-
artemether chromatograms, the selection of the β-artemether-related degradants for the calculation 
of their individual RRF was limited to the most important peaks. Details regarding the selection 
criteria can be found in Supplementary information [12]. 
 
2.5 Calculation of average relative response factor degradation products 
The residual buserelin acetate and β-artemether amount present in the stress samples, expressed in 
mass units, was calculated from the peak area in the chromatogram. The total mass-amount of 
formed degradants (= mass amount degradation) was then deduced by subtracting the calculated 
residual buserelin acetate and β-artemether amount from the originally weighed amounts present in 
the stress samples. The average RRF value for each stress condition, i.e. temperature, incubation 
time and environment, is calculated using following formula: 
 
Average RRF per experiment = 
Residual  parent   mg  ×degradation  peak  areas
Residual  parent  peak  area ×mass  amount  degradants   mg  
 
 
2.6 Calculation of individual relative response factor of selected β-artemether 
degradation products 
Selection of experiments and degradant peaks, of which the individual RRF values were calculated, 
was performed as described in Supplementary information [12]. The following model was used to 
calculate the individual response values of the selected degradants in Matlab: 
 
Mass amount degradants (mg) = ∑
AU degradant  i
RF degradant  i
 
 
with AU degradant i the experimentally obtained peak area units and RF degradant i the unknown RF 
expressed in area units per mg. 
 
The mass amount degradants (in mg) is calculated by subtracting the calculated residual β-
artemether amount from the originally weighed β-artemether amount present in the stress samples. 
As the individual RRF values of the most important unidentified degradation peaks are calculated, 
some small degradation peaks and previously identified peaks are ignored. In order to obtain a more 
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precise estimate of the unknown RRF values, a correction is made for these ignored peaks. 
Moreover, an additional correction is made for minor mass losses, due to formation of volatile 
components, e.g. CO2, by comparing the weight before and after dry heat stress (see Supplementary 
Information for more details about these corrections). The calculated individual RF of the degradants 
are transformed to their respective RRF values by dividing with the β-artemether RF, obtained from 
the unstressed samples. 
 
2.7 Real life β-artemether stability samples 
The β-artemether degradant profiles, obtained from the various dry heat stress conditions, are 
compared with the profiles seen in accelerated and long-term ICH stability samples of 
β-artemether FDP. For this, a 80 mg/mL arachis oil stability sample, stored at 40°C / 75 % R.H. for 1 
year, was analyzed using the described UPLC method. The oily formulation for intramuscular 
injection first underwent a sample preparation step in which β-artemether and degradants were 
quantitatively extracted to acetonitrile (recovery: 100.3%). This acetonitrile phase is subsequently 
injected into the UPLC system. 
 
3. RESULTS 
3.1 Average relative response factor degradation products 
The different dry heat stress resulted in buserelin acetate degradation ranging from 20% to 90% and 
in formation of a variety of buserelin-acetate related impurities. The identification of all formed 
buserelin acetate-related degradants is discussed in detail further on in Chapter V. The average RRF 
of buserelin acetate-related degradants, formed under dry heat conditions, was calculated to be 
0.54. 
In total, 21 β-artemether stress experiments yielded between 10% and 90% degradation, in which 17 
different peaks were observed at least once above the reporting threshold of 5%. Figure 2 depicts 
typical UV (210 nm) chromatograms obtained from a dry heat stressed sample (145 °C – 30 min) and 
the unstressed reference sample, both at identical mass concentrations. From visual inspection, it is 
already clear that the average RRF values of the β-artemether degradants will be significantly higher 
than 1. The average RRFs of the β-artemether degradants in the KMnO4, dry heat and zinc stressed 
samples were calculated to be 12.7, 26.4 and 23.6, respectively, with an overall RRF of 21.2. 
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Figure 2. Overlay chromatogram of a dry heat (145 °C – 30 min) stressed sample (red) and unstressed reference 
sample (blue) 
 
3.2 Calculation of individual relative response factor of β-artemether 
degradation products 
When applying the peak selection model, the 9 most prominent peaks are withheld (see degradant 1 
to 9 in Figure 2), whereas the data matrix used for the individual RRF calculations consisted of 21 
experimental results, obtained under different temperature-time-environmental stress conditions. 
This number of degradants correlates well with the typical number given by Baertschi, i.e. an average 
of 8.2 major degradation compounds per drug [13]. 
Within two sets of degradation peaks, i.e. set 1: degradants 2, 4, 6 and 7; set 2: degradants 5 and 8, a 
very high peak area correlation over the 21 experiments (R>0.90) was seen, and were therefore 
combined (degradants 2, 4, 6, 7; degradants 5 and 8), acknowledging that the resulting individual RRF 
value will be an average for each of the two sets of degradants. Applying RF boundaries of 15’000 to 
10’000’000 area units/mg, the model was evaluated by minimizing the sum of residual squares. To 
include the experimental variability, numerical sampling was performed, taking n=1000 randomized 
samples using Gaussian distribution with sigma 1% and within 5% boundaries around the obtained 
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experimental peak-area values. The model estimated (± std dev) RF values are given in Table 1: they 
range between 4.4×104 to 3.8×105 area units/mg, which is much higher than the RF of β-artemether 
(8.9×103 area units/mg), leading to RRF-values as high as 42.4. The results obtained by this approach 
provided a good model fitness with a correlation of 0.81 between the calculated and experimental 
residual mass expressed as β-artemether (Figure 3). 
 
Table 1. Calculated individual RRF values of the major observed β-artemether degradants 
Degradant RF ×10
5
 AU/mg (95% CI) RRF (95% CI) 
# RRT     
1 0.288 0.4399 (0.4357 – 0.4441) 4.94 (4.90 – 4.99) 
2 0.616 3.7771 (3.7652 – 3.7890) 42.44 (42.31 – 42.57) 
3 0.694 1.1717 (1.0785 -1.2649) 13.17 (12.12 – 14.21) 
4 0.802 3.7771 (3.7652 – 3.7890) 42.44 (42.31 – 42.57) 
5 0.826 2.5105 (2.4096 – 2.6114) 28.21 (27.07 – 29.34) 
6 0.842 3.7771 (3.7652 – 3.7890) 42.44 (42.31 – 42.57) 
7 0.867 3.7771 (3.7652 – 3.7890) 42.44 (42.31 – 42.57) 
8 0.935 2.5105 (2.4096 – 2.6114) 28.21 (27.07 – 29.34) 
9 1.264 0.7879 (0.7849 – 0.7909) 8.85 (8.82 – 8.89) 
(1) RF β-artemether: 0.089 ×105 AU/mg 
 
 
Figure 3. Correlation between experimental and model-derived amounts of formed degradants 
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Traditional determination of the RRF of unknown degradants, i.e. using references of these 
degradants, encompass several time- and cost-intensive steps. First, the structural identity of the 
degradant must be determined, which can be accomplished using different strategies, e.g. HPLC 
coupled to MS is most often used to propose a tentative structure. Alternatively and/or 
subsequently, preparative degradant isolation is used for further structural elucidation and/or 
confirmation by spectral techniques, e.g. NMR and IR. Finally, the degradant must be manufactured 
and purified before being injected together with the parent compound into the chromatographic 
system. The RRF of the degradant is then calculated by comparing the chromatographic responses, 
corrected for any concentration differences, of both degradant and parent compound. Alternatively, 
the RRF of the degradant can be derived from the slopes of the peak area – concentration regression 
curves of degradant and parent compound, after injecting a dilution series of both [14-17]. The use 
of alternative, universal detection systems such as refractive index detection (RID), 
chemiluminescent nitrogen detection (CLND), nebulize-based detectors like evaporative light 
scattering detection (ELSD) or charged aerosol detection (CAD) also allow in principle direct 
calculation of the RRF values, without the need for isolation steps. However, these detectors are not 
always available and each of these universal detectors has its own limitations and disadvantages 
compared to UV. RID exhibits a rather low sensitivity and is not only sensitive to temperature and 
flow change, but is also incompatible with gradient elution, which is often used for peptide analysis. 
The absence of nitrogen atoms in the parent structure (e.g. β-artemether) renders the CLND 
technique useless, as the response is directly proportional to the nitrogen content [18-20]. The ELSD 
and CAD techniques record only non- or semi-volatile compounds after evaporation of column 
eluent, often with inherent sensor noise and drift, being sensitive to the mobile phase composition 
[21-23]. 
However, when using our stress approach, an estimation of the RRF of degradants can be obtained, 
without having to perform elaborate, expensive and time consuming experiments. Moreover, the β-
artemether related degradation products are unstable during the MS ionization process, leading to 
characteristic in-source fragments of m/z 163.2, 221.1 and 238.9, without structural differentiation, 
so that identification by LC-MS is far from trivial. We constructed a matrix model in which a series of 
equations, i.e. stress experiments, is used to calculate a series of unknowns, i.e. the response factors 
of the different degradants. The calculated RF values are subsequently transformed into 
corresponding RRF values by dividing these RF values by the RF value of β-artemether. 
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3.3 Real life β-artemether stability samples 
Figure 4 depicts an overlay chromatogram of a dry heat stress β-artemether sample (145°C during 30 
min) and the chromatogram obtained from a 80 mg/mL arachis oil stability sample. From this, it is 
clear that the vast majority of degradants seen in this stability sample were also seen in the dry heat 
stress samples. An overview of all previously identified β-artemether related degradants and 
synthesis impurities, together with their RRF, seen in stability samples of different oily FDP, can be 
found in the Supplementary information [12]. This overview clearly shows that certain β-artemether 
degradants or synthesis impurities are characterized by RRF significantly larger than 1, and none with 
a RRF lower than 1. 
 
 
Figure 4. Overlay chromatogram of a dry heat (145 °C – 30 min) stressed sample (red) and a 80 mg/mL arachis 
oil stability (11 months at 40 °C 75 % R.H.) sample (black) 
 
Accurate knowledge regarding the response factors of formed degradants is vital for peak area 
balancing during stability studies. In general, related degradants have response factors similar to the 
native molecule, i.e. between 0.8 and 1.2 and hence no RRF correction is required [24]. However, this 
is clearly not the case for the β-artemether degradants. Instead of the elaborate isolation of each 
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degradant, or the simultaneous use of universal detectors with their uncertainty of variable response 
[10,18] we have solved this peak area imbalance by using a new stress approach, performed in 
different time (minutes) and temperature (125°C – 150°C) space compared to current 
pharmaceutical stress conditions [25-27]. 
 
4. DISCUSSION 
In this study, it was demonstrated for the first time that β–artemether related degradation products 
have a significantly larger RF, when compared to β–artemether itself. Recently, Stringham et al. 
(2011), reported an RRF range for the synthesis impurity artemisitene, i.e. 37 to 43 [28], which was 
confirmed under our experimental conditions (RRF 40 ± 4). Artemisitene is a synthesis impurity found 
in artemisinin, which is a starting material for β–artemether. Artemisitene is structurally very similar 
to artemisinin, differing in one extra double bond resulting in a conjugation with the keto function, 
giving a hyperchromic shift. Our findings indicate that also degradation products can result in 
significant changes in UV-response factors of the formed degradants, causing regulatory peak area 
balance issues, especially in early development phases.  
Contrary to the findings with β-artemether-related degradants, the average RRF of the buserelin 
acetate-related degradants was found to be 0.54. This is also visualized in Figure 5, depicting an 
overlay chromatogram of stressed and unstressed buserelin. It is immediately apparent that the 
decrease in buserelin peak area is not compensated by a similar increase in degradant peak areas. As 
is shown in Chapter V, the largest degradant peak areas are attributed to degradants formed by 
back-bone peptide bond cleavage. This backbone cleavage will not result in electron rearrangement 
and subsequent hyperchromic shift, as seen for β-artemether degradants. Moreover, given the 
additive nature of Lambert-Beers law, the reduction in functional groups, as the peptide is cleaved 
into smaller fractions, will result in a decreased UV detector response.  
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Figure 5. Overlay chromatogram of a dry heat (165°C – 60 min) stressed sample (red) and unstressed buserelin 
sample (blue) 
 
In our approach, two assumptions were made: (a) peaks below the stress reporting threshold do not 
significantly contribute to the total mass of degradants; (b) all degradation products are separated, 
eluted and UV-absorbing at 220 nm (buserelin) and 210 nm (β-artemether). Furthermore, retention 
of degradation compound on the UPLC system and column is considered to be negligible: (i) semi-
quantitative normal-phase TLC of representative β-artemether dry heat stress samples, according to 
International Pharmacopoeia and United States Pharmacopeia Salmous [29,30], did not result in 
observable spots in the frontline of the TLC; (ii) initial UPLC experiments with extensive gradient 
followed by isocratic elution at high solvent strength, i.e. 95% acetonitrile for 5 minutes, did not 
reveal any strongly retained components; (iii) direct UV comparison at 210 nm of three 
representative stress samples (ranging from 30 to 70% β-artemether degradation) with the β-
artemether unstressed sample revealed similar ratios as obtained by the UPLC method, herein 
described. The average value when comparing the ratios obtained by UPLC vs. the direct UV 
measurement ratios, was calculated to be 96.53%. 
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The ICH guidelines, legally incorporated in e.g. the European Pharmacopoeia, demand qualification 
of impurities when above the qualification threshold (QT) of 0.15% or 1.0 mg, whichever is the 
lowest (maximum daily dose < 2 g), after correction with their corresponding RRF [31]. The in-vitro 
mutagenicity of the β-artemether-related degradants, present in the dry heat stressed samples, was 
evaluated by the AMES test. No mutagenic properties for both β-artemether and its most prominent 
degradants was found [12]. In stability samples of an oily β-artemether finished drug product (FDP) 
(80 mg/mL stored at 30°C / 65% R.H. for 2 years), the DKA assay after RRF correction, was above the 
0.15% qualification threshold, thus requiring a qualification procedure as stipulated by the ICH 
guideline. Other degradation products, e.g. LEI, were initially clearly observed above the 0.15% 
threshold, suggesting the need for similar qualification. However, after correcting the observed peak 
area with the corresponding RRF value, the LEI assay was calculated to be even below the reporting 
threshold (RT). Moreover, the RRF values are also important in designing fractionation and isolation 
experiments by semi-preparative chromatography to estimate the mass quantity of the impurity 
which will be obtained for further spectroscopic characterization. Besides solving the peak area 
balance problem encountered in the stability samples, these two additional aspects, i.e. impurity 
threshold and mass estimation, further underline the importance of this work, in which a fast and 
efficient method is presented allowing accurate estimation of the RRF values of a set of degradation 
products. 
 
5. CONCLUSION 
Until now solving the peak area balance problems in stability and stress studies was a tedious task. 
To resolve this, an in-silico calculation of the average and individual relative response factors of the 
formed degradants was performed. This in-silico RRF calculation approach eliminates the need to 
perform time and cost expensive peak isolation steps. For this, buserelin acetate and β-artemether in 
its native powder form, were subjected to a series of dry stress experiments, using different 
temperature, time and environmental conditions. Under our experimental conditions, an average 
RRF value of 0.54 was calculated for the buserelin acetate-related degradants, whereas for β-
artemether, the average RRF value was 21.2 The individual RRF values of the most prominent β-
artemether degradants ranged between 4.9 and 42.4. These high RRF values can then be used to 
correct the experimental β-artemether stability results, thus achieving a peak area balance of 100%.  
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CHAPTER V 
 
DRY HEAT STABILITY 
EVALUATION OF 
PEPTIDE APIs: KINETICS 
AND DEGRADANT 
PROFILING 
 
“The greater danger for most of us is not that our aim is too high and 
we miss it, but that it is too low and we reach it” 
 
Michelangelo 
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forced degradation of buserelin peptide: kinetics and degradant profiling. International Journal of 
Pharmaceutics 2014; 467: 48-59. 
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ABSTRACT 
The general heat stability of peptide APIs in their solid-states were evaluated by subjecting these 
peptides in to different dry heat stress conditions. The hot-melt processability of casein-derived 
peptides, buserelin acetate, enfuvirtide and C34 was examined by 5 min incubation at 100°c and 
125°C. All investigated peptide APIs were found to be stable at our experimental conditions, 
underlining their hot-melt process capabilities. 
Buserelin acetate is a GnRH agonist peptide drug, comprising a nine amino acid sequence (pGlu-His-
Trp-Ser-Tyr-D-Ser(tBu)-Leu-Arg-Pro-NH-Et) and most commonly known for its application in hormone 
dependent cancer therapy, e.g. prostate cancer. Next to hot-melt-related conditions, buserelin was 
also subjected to more severe dry heat conditions. Different solid state kinetic models were 
statistically evaluated of which the Ginstling-Brounshtein model fitted the data best. Mass 
spectrometric identification of the buserelin-related degradants formed these severe dry heat 
condition was also performed. Based upon the identity of these degradants, different degradation 
hypotheses were raised. First, direct β-elimination of the hydroxyl moiety at the serine residue, 
followed by fragmentation into an amide (pGlu-His-Trp-NH2) and pyruvoyl (pyruvoyl-Tyr-D-Ser(tBu)-
Leu-Arg-Pro-NH-Et) peptide fragments, was postulated. Alternatively, internal esterification due to 
nucleophilic attack of the unprotected serine residue, followed by β-elimination or hydrolysis would 
yield pGlu-His-Trp, pGlu-His-Trp-NH2 and the pyruvoyl peptide fragment. Degradant pGlu-His-Trp-Ser-
Tyr-NH2 is believed to be formed in a similar way. Secondly, direct backbone hydrolysis would yield 
pGlu-His-Trp and Tyr-D-Ser(tBu)-Leu-Arg-Pro-NH-Et peptide fragments. Moreover, the presence of 
Ala-Tyr-D-Ser(tBu)-Leu-Arg-Pro-NH-Et can be explained by hydrolysis of the Trp-Ser peptide bond and 
conversion of the serine moiety to an alanine moiety. Third and finally, isomerisation of 
aforementioned peptide fragments and buserelin itself was also observed. Enfuvirtide and C34 both 
belong to the class of anti-HIV fusion inhibiting peptides, and can be used to treat or prevent HIV-1 
infection. A third anti-HIV peptide, i.e. SC34EK, derived from C34 to further increase its anti-HIV 
activity, was found to be more susceptible to HME-related dry heat conditions. Moreover, 
identification of degradants formed at dry heat stress conditions surpassing those of HME revealed 
backbone cleavage between 5D-6R in both C34 and SC34EK. Moreover, two additional C34-related 
degradants, originating from 16H-17S and 21E-22S backbone cleavage, were also identified. 
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CHAPTER V 
DRY HEAT STABILITY EVALUATION OF 
PEPTIDE APIs: KINETICS AND DEGRADANT 
PROFILING 
Main focus in this chapter: 
 To explore the solid-state heat stability of peptide APIs 
 To evaluate the hot-melt processing capabilities of different peptide APIs 
 To identify formed degradation products and degradation mechanisms 
 
1. INTRODUCTION 
Generally, peptides are considered to be unstable, prone to a variety of degradation pathways, as 
discussed by Manning et al. [1]. However, this consideration is mainly based on stability evaluation of 
peptides in solution, in which the dissolved peptides are traditionally subjected to a variety of stress 
conditions, e.g. enzymes, elevated temperatures, oxidative reagents, extreme pH [2-4]. The limited 
research of the stability of peptides in their solid state focused on the drying process used, most often 
freeze-drying, during which again a variety of degradation mechanisms can take place, e.g. 
deamidation, peptide bond cleavage, oxidation, Maillard reaction, β-elimination and aggregation 
[5,6]. 
In search for more cost effective and efficient production techniques, the pharmaceutical industry has 
a renewed interest towards hot-melt extrusion (HME). HME is a fast and cost-efficient solvent-free 
processing technique with 3 critical aspects toward stability of the active pharmaceutical ingredient 
(API): high temperature exposure during short time periods, mechanical shear stress influence and 
polymer/matrix-API interaction [7,8]. To our knowledge, the evaluation of peptide drugs as HME drug 
candidates is yet to be performed in a structured manner, although some promising preliminary 
results have been obtained [9]. A first and critical aspect which needs to be evaluated is the heat 
exposure to the peptide. Therefore, a number of peptide APIs, i.e. buserelin acetate, enfuvirtide, C34, 
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SC34EK and casein-derived peptides, were exposed in their solid-state to HME-related temperature-
time conditions, in order to evaluate their potential HME process capabilities. Stress conditions 
surpassing HME-related conditions were also used for method verification purposes and construction 
of kinetic model, whilst peptide-related degradants formed at these severe conditions were identified. 
Buserelin is a synthetic GnRH agonist peptide drug, comprising a nine amino acid sequence (pGlu-His-
Trp-Ser-Tyr-D-Ser(tBu)-Leu-Arg-Pro-NH-Et) therapeutically used as an antitumor drug in hormone 
dependent cancers like prostate and breast cancer [10-14]. Continuous receptor stimulation results in 
down regulation of the GnRH receptor and suppression of LH and FSH release and subsequent sex 
hormones [15-17]. Enfuvirtide, synonym T20 (trade name: Fuzeon®), C34 and SC34EK all belong to a 
relatively new class of anti-HIV drugs called the HIV fusion inhibitors. Enfuvirtide and C34 are both 
derived from the C-HR sequence and exert their anti-HIV action by avoiding the formation of the 6-
helix bundle formation within a viral glycoprotein, ultimately blocking the membrane fusion [18-25]. 
The sequences of the three HIV fusion-inhibition peptides are given in Figure 1. Casein-derived 
peptides have recently attracted scientific interest as evidence of antihypertensive, anti-oxidative, 
opioid, immunomodulatory, antimicrobial, anticariogenic and mineral binding properties were shown 
[26-36]. Besides potential pharmaceutical applications, these peptides also have potential to be used 
as functional food additives in the food sector. 
 
Ac-YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF-NH2 
WMEWDREINNYTSLIHSLIEESQNQQEKNEQELL 
WXEWDRKIEEYTKKIEELIKKSQEQQEKNEKELK (X: norleucine) 
Figure 1. Amino acid sequence of enfuvirtide, C34 and SC34EK (top to bottom) 
 
2. MATERIALS AND METHODS 
2.1 Materials 
Buserelin acetate, European Pharmacopoeia (Ph. Eur.) quality, [37] was bought at Hybio 
Pharmaceutical Co. (Shenzhen, China). Enfuvirtide was purchased from HanHong (Shanhai, China) and 
C34 and SC34EK were obtained from Lifetein (Hillsborough, New Jersey, USA). The enzymatic 
(pancreatic) hydrolyzed casein digest was a kind gift from DMV International (Veghel, the 
Netherlands). According to information provided by DMV International, the casein hydrolysate is 
prepared by dissolution of the casein proteins and subsequent addition of the pancreatic enzyme 
mixture, containing trypsin, chymotrypsin, aminopeptidase and carboxypeptidase. The digestion 
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process is terminated by heat inactivation of the enzymes, followed by a filtration step. Finally, the 
peptide mixture is concentrated, dried and packaged. ULC-MS grade acetonitrile (ACN), formic acid 
and methanol (MeOH) was obtained from Biosolve (Valkenswaard, The Netherlands), whereas HPLC 
gradient grade ACN was purchased from Fisher Scientific (Aalst, Belgium) and Romil (Merelbeke, 
Belgium). Water was purified using an Arium 611 purification system (Sartorius, Gottingen, Germany) 
yielding ≥ 18.2 MΩ×cm quality water. 
 
2.2 Liquid chromatography 
Pancreatic hydrolyzed casein digest 
The HPLC apparatus, implemented for casein pancreatic digest quantification, consisted of a Waters 
Alliance 2695 separations module and a Waters 2487 dual wavelength absorbance UV detector with 
Empower 2 software for data acquisition (all Waters, Milford, MA, USA). A HALO Peptide ES-C18 (75 
mm × 3 mm I.D., 2.7 µm particle size, 160 Å) column (Achrom, Machelen, Belgium), thermostated in 
an oven set at 30°C, was used. The flow rate was set at 0.6 mL/min and a linear gradient was applied 
(where A = 0.1% (m/V) formic acid in water and B = 0.1% (m/V) formic acid in MS grade acetonitrile) 
from 95% A to 71% A in 40 min. The chromatographic method also included a rinsing step at 90% B, 
followed by returning to the initial conditions and re-equilibration. Samples were thermostated at 
20°C, injection volume was set at 10 µL and UV detection was performed at 195 nm.  
 
Buserelin acetate 
The UPLC apparatus, implemented for quantification of buserelin acetate and its degradants, 
consisted of a Waters Acquity™ H UPLC Class Quaternary Solvent Manager, a Waters Acquity™ Sample 
Manager, combined with a Flow Through Needle, and a Waters Acquity™ UPLC Photodiode Array 
(PDA) detector with Empower 2 software for data acquisition (all Waters, Milford, MA, USA). An 
Acquity™ UPLC BEH 300 C18 (100 mm × 2.1 mm I.D., 1.7 µm particle size, 300 Å) column, 
thermostated in an oven set at 30°C ± 3°C, was used. The flow rate was set at 0.6 mL/min and a 
gradient was applied (where A = 95% water and 5% ACN with 0.1% FA (m/V), and B = 95% ACN and 5% 
water with 0.1% FA (m/V)), starting with a 1.5 min. isocratic step at 100% A, followed by a linear 
gradient from 100% A to 79% A in 9.5 min. and ending with a isocratic hold for 7 min. The 
chromatographic method also included a rinsing step at 80% B, followed by returning to the initial 
conditions and re-equilibration. The sample compartment was thermostated at 5°C ± 3°C and UV 
detection was performed at 220 nm. The injection volume used was 2 µL. The reporting threshold for 
the dry heat stressed samples was set at 1% peak area relative to unstressed buserelin. 
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The range and linearity of the buserelin acetate UPLC method was verified by injecting 5 increasing 
buserelin concentrations, ranging from 0.01 to 1.00 mg/mL, and evaluating the peak areas. Injection 
repeatability was characterized by sextuplicate injections of 1.00 mg/mL buserelin. The limit of 
detection and quantification was determined by the Ph. Eur. method using the 0.01 mg/mL solution, 
and should be below the applied reporting threshold of 1% relative to the 1 mg/mL buserelin injection 
[38]. Carry-over was tested by following a 1.00 mg/mL injection by a blank injection. EDQM guidelines 
stipulate a carry-over specification limit of <0.05% [39]. The analytical stability of buserelin samples in 
the UPLC autosampler, i.e. at 5°C ± 3°C, is evaluated by comparing the first and last injection of 1 
mg/mL buserelin, previously used for injector repeatability (3 hours). No significant buserelin 
degradation, i.e. no statistically significant decrease in buserelin peak area nor the formation of 
degradation products above the applied reporting threshold, is allowed. 
 
HIV Fusion inhibiting peptides 
The UPLC system as described for buserelin acetate quantification was used for quantification of the 
fusion inhibiting peptides (enfuvirtide, C34 and SC34EK) and combined with an Acquity™ UPLC CSH 
300 C18 (100 mm × 2.1 mm I.D., 1.7 µm particle size, 130 Å) column, thermostated in an oven set at 
40°C ± 3°C. The flow rate was set at 0.5 mL/min and a linear gradient was applied (where A = 95% 
water and 5% ACN with 0.1% FA (m/V), and B = 95% ACN and 5% water with 0.1% FA (m/V)) from 
100% A to 0% A in 10.5 min, followed by a short isocratic hold and re-equilibration to gradient starting 
conditions. The sample compartment was thermostated at 10°C ± 3°C and UV detection was 
performed at 210 nm. The injection volume used was 2 µL. 
 
2.3 Dry heat stress stability evaluation of peptide drug candidates 
Pancreatic hydrolyzed casein digest 
Homogenized casein pancreatic digest was accurately weighed into a 50 mL glass conical flask (Schott 
Duran®, Mainz, Germany), which were incubated in castor oil, heated at 100°C, 140°C and 180°C (± 
3°C) using a Memmert universal oven (Memmert, Schwabach, Germany), for 1, 3 and 5 min. Each 
stress condition was performed in duplicate. After incubation, the heat-treated samples were 
immediately stored in ice, in order to limit further degradation. The stress samples were dissolved in 
appropriate volumes of 95/5 water/ACN, to obtained a 1 mg/mL concentration and sonicated 
(Branson™ 2510). 
The results were compared to an unstressed reference solution of equal concentration. In order to 
assess inter-sample variability, six separate reference solutions were prepared and analyzed. The 
variability between the 6 peak areas, obtained from the 6 separate reference solutions, of each 
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identified peptide was characterized by calculating the 95% confidence intervals around the average 
peak areas, set as 100%. The limit of quantification (LoQ) was defined as the concentration equivalent 
to a signal to noise value of 10. The degradation of the identified peptides was calculated relative to 
the unstressed reference solution. The relative peptide amounts after dry heat stress were compared 
to their relative 95% confidence intervals of the unstressed samples as well as to the 90 – 110% 
interval, which is considered as the specification acceptance limits [37,40]. The overall total error 
between both repeats, throughout the different stress conditions, was also calculated. 
 
Buserelin acetate 
Approximately 1 mg of buserelin acetate was accurately weighed and transferred into separate glass 
vials (12×32 mm, Borosilicate, Type 1, Class A glass), which were then incubated in a preheated 
heating block (Stuart, Stone, United Kingdom, temperature accuracy and temperature uniformity 
within the block both ± 1°C) [41]. For kinetic modeling and degradant identification purposes, the 
temperature settings varied from 150 to 180°C, with incubation times ranging from 10 to 160 minutes, 
thus surpassing typical HME conditions. Furthermore, buserelin acetate was also exposed to HME-
related conditions, i.e. 5 min at 100°C and 125°C. All buserelin acetate dry heat stress experiments 
were performed in duplicate. After incubation, the stressed samples were immediately placed on ice, 
in order to prevent further degradation. Unstressed buserelin samples, i.e. not incubated in the 
heating block, were also stored on ice to guarantee identical treatment. The contents of the 
unstressed and stressed vials were solubilized using appropriate volumes of solvent consisting of 95% 
H2O and 5% ACN mixture with 0.1% FA, and sonicated (Branson™ 2510) to obtain a 1 mg/mL buserelin 
solution. An aliquot was transferred into a HPLC vial and analyzed. The peak areas of buserelin were 
used to determine the solid state degradation kinetics. 
 
HIV fusion inhibiting peptides 
Enfuvirtide, C34 and SC34EK were exposed to HME-related conditions, i.e. 5 min at 100°C and 125°C, 
using the same methodology as described for buserelin acetate. Enfuvirtide, as well as C34 and 
SC34EK, were also exposed to stress levels surpassing HME-related conditions in order to demonstrate 
method selectivity (40 min at 150°C), as well as to identify possibly formed degradants (45 min 160°C). 
After incubation, the stressed samples were immediately placed on ice, in order to prevent further 
degradation. Unstressed samples, i.e. not incubated in the heating block, were also stored on ice to 
guarantee identical treatment. Unstressed and stressed peptides were solubilized using appropriate 
volumes of solvent consisting of 95% H2O and 5% ACN mixture with 1% FA (C34 and SC34EK), and 
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50/50 0.4% NH4OH in H2O/MeOH solvent (enfuvirtide), and sonicated (Branson™ 2510) to obtain a 1.0 
mg/mL peptide solution [42].  
 
2.4 Solid state degradation kinetic of buserelin acetate  
Unlike rate laws in homogeneous kinetics, i.e. dissolved state, which usually depends on the reaction 
order (zero, first, second, third, etc.), reaction kinetics in solid state can depend on other factors such 
as rate of nuclei formation, interface advance, diffusion and/or geometrical shape of the solid particle. 
These additional factors result in several models exclusive for solid state reactions [43]. These 
different models are listed in Table 1: the degradation fraction α, i.e. 
Buserelin unstressed −Buserelin stressed
Buserelin unstressed
 
obtained at a certain temperature, is modeled in function of the degradation rate constant k and time. 
The original buserelin degradation data, i.e. buserelin peak areas, are used to calculate α. Let Yi tj Tl  
be the integrated form of α, i.e. g(α) of the different solid state kinetic models (Table 1), of ith unit at 
time 𝑡𝑗  and stress level 𝑇𝑙  of temperature.  
 
𝑌𝑖 𝑡𝑗  𝑇𝑙 = 𝛩𝑖 𝑇𝑙 𝑡𝑗 + 𝜎𝐵𝐵 𝑡𝑗  + 𝜀𝑖𝑗𝑙          𝑖 = 1,2;  𝑗 = 1, … ,4;   𝑙 = 1, … ,5   (1) 
 
where 𝛩𝑖 𝑇𝑙 ~𝑁(𝑘(𝑇𝑙), 𝜎𝑙
2) is a random variable representing the unit-to-unit variability of the 
product and incorporating the degradation constant k, 𝐵 𝑡𝑗   denotes standard Brownian motion 
representing the within-unit variability, and finally the measurement error 𝜀𝑖𝑗𝑙  is following a normal 
distribution with mean 0 and variance 𝜎𝜀
2. The random effect 𝛩𝑖 𝑇𝑙 , the standard Brownian motion 
𝐵 𝑡𝑗  , and the measurement error εijl  are assumed to be mutually independent. The advantage of 
this degradation model is that it allows the simultaneous consideration of unit-to-unit variability with 
time-dependent error structure and measurement error. In the iDEMO package (integrated 
degradation models) in statistical software R [44], six combinations of variations for a degradation 
model are available (Table 2). 
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Table 1. Solid-state rate expressions for different reaction models and AIC values for best fitting model variation (Mx) 
Model Differential Form 𝒇 𝜶 =
𝟏
𝒌
𝐝𝜶
𝐝𝒕
 Integral form 𝒈 𝜶 = 𝒌𝒕 150.0°C 157.5°C 165.0°C 172.5°C 180°C 
Nucleation models        
Power Law (P2) 2𝛼(1 2 ) 𝛼(1 2 ) -1.54 (M2) 4.29 (M4) 6.04 (M4) 4.36 (M4) 4.33 (M4) 
Power Law (P3) 3𝛼(2 3 ) 𝛼(1 3 ) 3.37 (M4) 7.05 (M4) 8.17 (M4) 7.04 (M4) 7.06 (M4) 
Power Law (P4) 4𝛼(3 4 ) 𝛼(1 4 ) 5.68 (M4) 8.41 (M4) 9.23 (M4) 8.37 (M4) 8.41 (M4) 
Avarami-Erofe’ev (A2) 2(1 − 𝛼)[−ln(1 − 𝛼)](1/2) [−ln(1 − 𝛼)](1/2) -2.76 (M2) 3.43 (M4) 7.32 (M2) 5.70 (M4) 4.78 (M4) 
Avarami-Erofe’ev (A3) 3(1 − 𝛼)[−ln(1 − 𝛼)](2/3) [−ln(1 − 𝛼)](1/3) 3.01 (M4) 6.96 (M4) 9.19 (M4) 7.98 (M4) 7.55 (M4) 
Avarami-Erofe’ev (A4) 4(1 − 𝛼)[−ln(1 − 𝛼)](3/4) [−ln(1 − α)](1/4) 5.53 (M4) 8.47 (M4) 10.03 (M4) 9.10 (M4) 8.84 (M4) 
Prout-Tompkins 𝛼(1 − 𝛼) ln[α/(1 − α)] 20.59 (M4) 11.34 (M4) 2.10 (M4) 7.20 (M4) 9.28 (M4) 
Geometrical Contraction models        
Contracting area (R2) 2(1 − 𝛼)(1/2) [1 − (1 − 𝛼)1/2] -32.12 (M4) -17.95 (M2) -10.82 (M2) -14.10 (M2) -15.30 (M2) 
Contracting volume (R3) 3(1 − 𝛼)(2/3) [1 − (1 − 𝛼)1/3] -40.23 (M4) -26.11 (M2) -17.06 (M2) -20.28 (M2) -21.96 (M4) 
Diffusion models        
1-D diffusion (D1) 1/2𝛼 𝛼2 -28.70 (M4) -23.70 (M4) -13.97 (M4) -20.47 (M2) -21.25 (M4) 
2-D diffusion (D2) [−ln(1 − 𝛼)]−1   1 − 𝛼 ln 1 − 𝛼  + 𝛼 -31.41 (M2) -30.00 (M4) -23.98 (M4) -29.75 (M4) -28.08 (M4) 
3-D diffusion – Jander eqn. (D3) 3 1 − 𝛼 2/3/2(1 − (1 − 𝛼)1/3) [1 − (1 − 𝛼)1/3]2 -46.98 (M2) -36.48 (M4) -46.29 (M4) -52.00 (M4) -41.88 (M4) 
Ginstling-Brounshtein (D4) (𝟑/𝟐((𝟏 − 𝜶)−𝟏/𝟑 − 𝟏) 𝟏 −  𝟐𝜶/𝟑 − (𝟏 − 𝜶)𝟐/𝟑 -52.67 (M2) -48.63 (M4) -47.93 (M4) -53.30 (M4) -49.23 (M4) 
Reaction-order models        
Zero-order (F0) 1 𝛼 -17.78 (M2) -4.97 (M2) -0.82 (M2) -4.07 (M2) -4.41 (M2) 
First – order (F1) (1- 𝛼) −ln(1 − 𝛼) -25.60 (M2) -16.46 (M4) 0.62 (M4) -2.17 (M2) -4.97 (M4) 
Second –order (F2) (1 − 𝛼)2 (1 − 𝛼)−1 − 1 -5.56 (M2) 20.67 (M2) 2.34 (M4) -0.96 (M2) 7.68 (M4) 
Third – order (F3) (1 − 𝛼)3 0.5((1 − 𝛼)−2 − 1) 16.63 (M2) 54.22 (M4) 36.35 (M4) 4.39 (M4) 34.29 (M4) 
Partially adapted from (Khawan and Flanagan, 2006) 
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Table 2. Variation sources incorporated in the different solid-state reaction models  
Model 𝒌(𝑻𝒍) 𝝈𝒍
𝟐 𝝈𝑩
𝟐  𝝈𝜺
𝟐 
𝑀0 v v v v 
𝑀1 v v  v 
𝑀2 v  v  
𝑀3 v v v  
𝑀4 v   v 
𝑀5 v  v v 
 
The maximum likelihood estimates (MLEs) ˆ  for all model variations were calculated at each 
temperature using the iDEMO package where 𝜗 = (𝑘 𝑇𝑙 , 𝜎𝑙 , 𝜎𝐵 , 𝜎𝜀). Let r and L(ˆ |y) be the number 
of parameters of a degradation model and the value of the log-likelihood function, respectively [44]. 
For the 17 degradation models with six different variation sources per model, the Akaike information 
criterion (AIC) as proposed is calculated as AIC=-2 L(ˆ |y) +2r. The degradation model with minimum 
AIC is finally selected, best fitting the observed degradation data [45].  
 
2.5 Peptide degradant identification 
Pancreatic hydrolyzed casein digest 
As the pancreatic hydrolyzed casein digest itself is already a complex mixture of several peptides, the 
first priority was to identify the casein-related individual peptides. The LC-MS apparatus used for this 
identification consisted of a Thermo Spectra System SN4000 interface, a Spectra System SCM 1000 
degasser, a Spectra System P1000XR Pump, a Spectra System AS3000 autosampler set and a Finnigan 
LCQ Classic ion trap mass spectrometer in positive ion mode (all Thermo, San José, CA, USA) equipped 
with a Waters 2487 dual wavelength absorbance UV detector (Waters, Milford, MA, USA). The LC 
settings as described for the assay of casein-related peptides were used whereas ESI was conducted 
using a needle voltage of 4.5 kV. Nitrogen was used as the sheath and auxiliary gas with the heated 
capillary set at 250°C. Positive mode mass spectra were obtained in the range of m/z 300 to 2000. 
The mass spectra obtained from the different HPLC-peaks were correlated with a database containing 
the amino acid sequences of the four different casein protein, i.e. αS1-, αS2-, β-, and κ-casein, using a 
software package (Bioworks Browser 3.3.1), thus resulting in tentative identified amino acid 
sequences. The amino acid sequences were further confirmed by comparing experimentally obtained 
MS² spectra with theoretical MS² spectra obtained from aforementioned tentative peptide amino acid 
sequences. 
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Buserelin acetate 
Buserelin acetate-related degradants were identified by UPLC-ESI-MS/MS (Xevo TQ-S, Waters, 
Milford, MA, USA). The UPLC conditions were identical to those used for buserelin acetate assay. 
Electrospray ionization with a capillary voltage of 3.0 kV, combined with a cone voltage of 60 V and 
source offset of 60 V was used. Nitrogen gas, at a flow rate of 800 l/h and heated to 600°C was used 
as desolvation gas and as cone gas at 150 l/h. Argon, operated at different collision energies for the 
different degradants, was used as collision gas to obtain MS/MS spectra. 
 
HIV fusion inhibiting peptides 
Stressed C34 and SC34EK peptides were analyzed using a nano-Acquity™ UPLC (Waters, Eschborn, 
Germany) coupled to a LTQ Orbitrap XL ETD mass spectrometer, equipped with a nano-ESI source 
(Thermo Fisher Scientific, Bremen, Germany). A 1:1000 dilution of the fusion inhibiting peptide 
solutions was made using 95/5 H2O/ACN + 0.1% FA. From this, 15 μL is mixed with 35 μL of the 
solvent 95/5 water/ACN with 0.1% (m/V) FA. Finally, 10 µL of this peptide solution is injected onto 
the nanoAcquity symmetry C18 trap column (20 mm × 0.180 mm I.D., 5 μm particle size, 100 Å) by 
the autosampler at a flow rate of 10 µL/min. The peptide and its impurities were separated on a 
nanoAcquity UPLC BEH C18 130 column (100 mm × 75 μm I.D., 1.7 μm particle diameter, 130 Å) at 
a flow rate of 400 nL/min. A linear gradient was applied (mobile phase A was 0.1% (m/V) FA in 
water and mobile phase B was 0.1% (m/V) FA in ACN) from 97% A to 62.2% A in 28.5 min. The LC 
method also included a rinsing step at 81% B, followed by returning to the initial conditions and re-
equilibration. The transfer capillary temperature was set to 200°C and tube lens voltage to 120 V. An 
ion spray voltage of 1.5 kV was applied to a PicoTipTM SilicoTipTM on-line nano-ESI emitter (New 
Objective, Berlin, Germany). For precursor ion survey scans the orbitrap resolution was set to 60000 
and the scan was performed from m/z 400-2000. CID spectra were acquired form three most 
abundant ions in each MS scan (isolation width 2, activation Q 0.25, normalized collision energy 35%, 
activation time 30 ms). This method was also used for identity confirmation of the buserelin-related 
degradation products. 
  
CHAPTER V – DRY HEAT STABILITY EVALUATION OF PEPTIDE APIS: KINETICS AND DEGRADANT PROFILING 
 
 
108 
3.  RESULTS AND DISCUSSION 
3.1 Dry heat stability of pancreatic hydrolyzed casein digest 
The individual casein-related peptides present in the casein pancreatic digest were identified using LC-
MS/MS. A detailed overview of the individually identified peptides is given in Table 3. Only peptides 
free of post-translational modification (PTM), e.g. phoshorylation of serine residues, were selected. 
The observed monoisotopic molecular weight of the peptides, originating either from β- or αS1-casein, 
ranges between 576 (HLPLP) and 1373 (TDAPSFSDIPNPI) g/mol. Twelve separate peaks, to which the 
amino acid sequences could be attributed, were considered to be examined in this dry heat stability 
evaluation. A typical baseline-corrected HPLC-UV chromatogram, obtained from unstressed casein 
pancreatic digest, is depicted in Figure 2. 
 
 
Figure 2. Typical baseline-corrected, HPLC-UV chromatogram (195 nm) obtained from unstressed pancreatic 
hydrolyzed casein digest 
 
Given the strong overlap between peptide peak No. 3 (VAPFPE/NVPGEIV) and 4 (LEIVPN/HLPLP), these 
peaks were integrated together. The calculated 95% confidence intervals of the peptide peak areas, 
together with the relative peptide amounts, are given in Table 3. The confidence intervals of only 
three peptides i.e. YPVEP, SDIPNPI and RGPFPI, are marginally wider than the 90 - 100% interval, 
which is considered as the specification acceptance limit. Further investigations revealed normal 
distributions of the 6 individual peptide peak areas (Shapiro-Wilk’s test for normality) and the absence 
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of outliers within the sets of integration results (Grubbs test). The limits of quantification of the 
identified peptides, are presented in Table 3. The peptide represented by the smallest peak, i.e. 
SDIPNPI, has a LoQ value of 46.93%. Thus, in order to accurately quantify the SDIPNPI peptide in a 
stress sample, not more than 53.07% of aforementioned peptide may be degraded, relative to the 
same peptide peak area in a reference sample. 
 
Table 3. Overview of identified casein-related peptides  
# 
Retention time 
(min.) 
Observed mass 
Theoretical 
mass 
Amino acid 
sequence 
95% confidence 
interval (%) 
LoQ ± SEM (%) 
Relative 
amount (%)(1) 
1 10.22 604.15 604.30 YPVEP 89.34-110.16 8.81 ± 2.78 14.85 
2 12.94 652.15 652.40 VLPVPQ 93.70-106.30 3.60 ± 0.59 19.39 
3(2) 15.52 
659.10 
727.15 
659.34 
727.40 
VAPFPE 
NVPGEIV 
95.27-104.73 7.59 ± 1.46 15.58 
4(2) 15.75 
684.14 
576.10 
684.39 
576.35 
LEIVPN 
HLPLP 
95.27-104.73 7.59 ± 1.46 15.58 
5 17.70 755.18 755.39 SDIPNPI 87.48-112.52 46.93 ± 7.26 1.66 
6 19.21 686.34 686.40 RGPFPI 89.98-110.02 10.41 ± 0.91 8.89 
7(2) 20.90 
838.27 
659.18 
838.45 
659.34 
PFPGPIPN 
APFPEV 
93.38-106.62 14.66 ± 2.58 3.39 
8 24.83 1001.28 1001.51 YPFPGPIPN 90.91-109.09 29.89 ± 2.77 3.84 
9 26.21 1025.33 1025.57 VVPPFLQPE 96.64-103.36 14.43 ± 1.15 8.74 
10 27.05 1100.36 1100.58 VYPFPGPIPN 92.66-107.34 11.75 ± 0.94 11.06 
11 28.77 1373.33 1373.66 TDAPSFSDIPNPI 94.90-105.10 8.93 ± 1.37 8.06 
12 29.87 889.25 889.48 VYPFPGPI 95.27-104.73 27.36 ± 2.41 4.55 
(1) Calculated in unstressed sample as: average peptide peak / ∑(average peptide peaks). 
(2) Different [M+H]+ values, corresponding to two different amino acid sequences. 
 
The relative peptide amounts, after dry heat stability evaluation under different conditions, and their 
respective 95% confidence intervals are presented in Figure 3. In general, the peptides remained 
stable up to 3 min. incubation at 180°C. These casein-derived peptides would be eligible for HME 
processing, as can be seen from the excellent stability results seen at HME-related conditions, e.g. 5 
min at 100°C. However, both specification-significant (i.e. below 90%) and statistically significant 
degradation, ranging from 10 to 40%, of all identified peptides was observed in the samples incubated 
at 180°C for 5 min, indicating the selectivity of the HPLC-UV to detect peptide degradation. These 
samples were also characterized by a yellow – brownish discoloration, as opposed to the native white 
color, and a strong odor, indicative for the presence of Maillard reaction products. Seen the lactose 
content of the casein pancreatic digest powder (0.8%), it is possible that a part of the peptide 
degradation can be attributed to the Maillard reaction. In total, 8 of the 12 identified peptide peaks 
contain amino acid residues sensitive to Maillard reaction i.e. arginine (R), lysine (K), asparagine (N) 
and glutamine (Q). Two major new peptide peaks were found in the 3 min. and 5 min. 180°C samples. 
The degradation peaks shouldered the RGPFPI (peak No. 6, RT: 19.19 min.) and VPFPGPI (peak No. 12, 
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RT: 29.83 min.) peaks, and were characterized by [M+H]+ values of 730.25 and 1315.40 g/mol, 
respectively. 
 
 
Figure 3. Dry heat stability evaluation of pancreatic hydrolyzed casein digest – relative peptide amounts. 
Relative peptide amounts outside 95% confidence intervals are indicated in red. 
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Previous dry heat stability studies using casein hydrolysates, focused on phosphorylated peptides, 
whereas in this study only basic peptides, i.e. without post-translational modifications, were 
considered. Meisel et al., investigated the impact of dry heat treatment of casein (170°C for 45, 60 and 
75 min) on phosphoseryl stability [46]. A time dependant decrease of caseinophosphopeptides was 
observed, accompanied by a dephosphorylation and decomposition of serine residues. Furthermore, 
β-elimination of alanine, yielding dehydroalanine, resulted in the formation of lysinoalanine, as is 
illustrated further on in Figure 13. The authors reported the hydrolysis of phosphoseryl to seryl 
residues as the prevailing degradation step. 
 
3.2 Buserelin acetate UPLC-PDA method verification 
The R2 value of the buserelin area vs. concentration curve was 0.9966 (F-value 873.24), with a random 
residual plot, so a sufficient linear relationship is obtained within the 1.00 to 0.01 mg/mL buserelin 
range. During the repeatability evaluation of the UPLC method, the relative standard deviation (%RSD) 
of six successive 1.00 mg/mL buserelin injections was 0.99%, which is slightly higher than the %RSD 
limit of 0.85% as given in the Ph. Eur. [39]. However, as this stability-indicating buserelin UPLC method 
deviates from the formal Ph. Eur. buserelin acetate assay method, the Ph. Eur. RSD limit is not 
applicable to our method. Moreover, the purpose of this UPLC method, i.e. allowing simultaneous 
buserelin assay and identification of all buserelin-related degradants by MS detection, surpasses that 
of the Ph. Eur. method, focusing primarily on synthesis impurities. Therefore, the %RSD value 
obtained with the proposed UPLC method was deemed acceptable for our purposes. The limit of 
detection (LoD) and the limit of quantification (LoQ) (S/N = 3 and 10 according to Ph. Eur., 
respectively) was 0.422 × 10-3 mg/mL and 1.405 × 10-3 mg/mL or 0.14% relative to the 1 mg/mL 
buserelin sample. Injection of a 1.00 mg/mL buserelin sample did not result in peaks in the 
subsequently injected blank solution, indicating there was no carry-over (i.e. < LoD of 0.04% relative 
to 1 mg/mL). The buserelin peak area of the last injection was not statistically significant different 
from the first injection, nor were any buserelin degradants present above LoD. Therefore, the 
analytical stability of the buserelin samples was guaranteed for at least 3 hours in the thermostated 
sample compartment (5°C ± 3°C). A typical chromatogram, obtained after representative dry heat 
stress of buserelin is given in Figure 4, indicating the high selectivity of the UPLC method. 
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Figure 4. Typical UV (210 nm) chromatogram of dry heat stressed buserelin (60 min. at 165°C). Undegraded 
buserelin (°) elutes at 13.71 min. An overview of all positively identified buserelin degradants as well as their 
possible degradation mechanisms. 
 
3.3 Dry heat stability of buserelin acetate: solid state degradation kinetic 
The calculated AIC values for the best fitting model variation, i.e. Mx, for each of the 17 kinetic models 
at the 5 different temperature settings are given in Table 1. Due to the minimum AIC values observed 
at each temperature level, the Ginstling-Brounshtein (D4-M4) kinetic model was found to best fit the 
observed degradation data. Using this Ginstling-Brounshtein (D4-M4) kinetic model, including the 
introduced variation sources, the degradation constants k were obtained from each of the 5 
temperature settings using equation (1). 
By plotting the obtained k values against the inverse of the corresponding absolute temperature, the 
Arrhenius equation allows us to calculate the activation energy (Ea) and frequency factor (A). 
However, one of the conditions to apply this equation is that the physical state of the API under 
investigation remains constant. Starting from 165°C, we observed the formation of a melt, in which 
the powder nature of the buserelin peptide was lost. Therefore, instead of a traditional linear 
relationship a polynomial correlation is obtained (Figure 5).  
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Figure 5. Polynomial correlation between observed degradation constant k and temperature. Residual plot of 
model is given in inset. 
 
The amount of buserelin degradation at typical HME-related conditions, which are less severe than 
the stress conditions used in this study [7,8], were calculated by using the two lowest temperature 
settings, i.e. 150.0 and 157.5°C, at which the physical state of buserelin remained solid (powder). To 
do so, the degradation rate k at the HME-related temperatures (e.g. 100°C and 125°C) were derived 
by linear regression using data obtained from the 150.0°C and 157.5°C stress conditions. Next, the 
extrapolated degradation rate k is inserted into the Ginstling-Brounshtein model, together with the 
exposure time (e.g. 300 s or 5 min), to calculate the degradation fraction α. By using this approach, k 
values of 3.16×10-10 and 1.97×10-5 were extrapolated, which would result into 0.1% and 1.33% 
buserelin degradation when exposed for 5 min to 100°C and 125°C, respectively. Furthermore, In 
order to confirm this approach, the buserelin degradation at these HME-related conditions was 
experimentally determined by performing dry heat experiment at 100°c and 125°c combined with a 5 
min incubation time. No significant buserelin degradation, i.e. below LoD, was found at these HME-
related conditions, hereby experimentally demonstrating the HME capabilities of buserelin acetate. 
 
3.4 Identification of buserelin-related degradants 
Degradants #1-4 (RT 2.50; 2.85; 3.16 and 3.94 min): m/z 452 
Investigation of degradant peaks 1 to 4 revealed similar MS1 spectra. The m/z value of 451.84 was 
identified as the molecular ion for all four peaks, as Na+ and K+ adducts were seen at m/z values of 
473.47 and 489.59, respectively. Structure elucidation of the four degradant peaks was performed by 
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collision induced dissociation (CID), using a collision energy setting of 30 eV and m/z 452.09 as parent 
mass. The resulting fragmentation pattern and interpretation is given in Figure 6. From this, the 
degradant structure pGlu-His-Trp-NH2 was derived, characterized by a calculated monoisotopic mass 
[M+H]+ of 452.20406 [47]. Determination of the m/z value of the parent ion by high resolution MS, i.e. 
452.2037, further confirmed this structure elucidation. The mass spectrometric analysis of these four 
degradation peaks were found to be structurally similar in both MS1 and MS2, but a different 
chromatographic behavior was observed, suggesting the presence of diastereoisomers. 
 
 
Figure 6. Typical MS
2
 fragmentation pattern of degradants 1 to 4 (parent mass: 452.09; collision energy: 30 eV). 
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Degradant #5-7 (RT 4.63; 4.95 and 5.65 min): m/z 453 
Investigation of degradant peaks 5 to 7 revealed similar MS1 spectra. The m/z value of 453.01 was 
identified as the molecular ion for all three peaks. CID was performed on the 3 previously mentioned 
peaks, using a collision energy setting of 35 eV and using m/z 453.14 as parent mass. The resulting 
fragmentation pattern and interpretation is given in Figure 7. Based upon molecular weight, i.e. 453, 
and fragment ions y2 (m/z: 341.92) and z1 (m/z: 187.88), it was concluded that degradants #5-7 were 
characterized by a carboxylic acid end, whereas degradants #1-4 contained an amide group. From this, 
the structure pGlu-His-Trp was derived, characterized by a theoretical monoisotopic mass [M+H]+ of 
453.18808 [47].  
 
 
Figure 7. Typical MS
2
 fragmentation pattern of degradants 5 to 7 (parent mass: 453.14; collision energy: 35 eV). 
 
Degradant #8-11 (RT 6.57; 6.73; 6.95 and 7.23 min): m/z 702 
Upon investigation of degradant peaks 8 to 11, m/z value of 702.25 was identified as the molecular 
ion for all four peaks. CID was performed on aforementioned peaks, using a collision energy setting of 
42 eV and using m/z 701.95 as parent mass. The resulting fragmentation pattern and interpretation is 
given in Figure 8. From this, the structure pGlu-His-Trp-Ser-Tyr-NH2 was derived, characterized by a 
theoretical monoisotopic mass [M+H]+ of 702.29941 [47]. Determination of the m/z value of the 
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parent ion by high resolution MS, i.e. 702.3008, further confirmed this structure elucidation. The mass 
spectrometric analysis of these four degradation peaks were found to be structurally similar in both 
MS1 and MS2, but a different chromatographic behavior was observed, suggesting diastereoisomers. 
 
Figure 8. Typical MS
2
 fragmentation pattern of degradants 8 to 11 (parent mass: 701.95; collision energy: 42 eV). 
 
Degradant #12, 13 and 15 (RT 9.40; 10.02 and 10.74 min): m/z 718 
The m/z value of 717.89 was identified as the molecular ion for all three degradation peaks. 
Furthermore, the corresponding Na+- and K+-adducts were also observed at m/z 740.25 and 756.18, 
respectively. CID was performed, using a collision energy setting of 45 eV and using m/z 718.24 as 
parent mass. The resulting fragmentation pattern and interpretation is given in Figure 9. From this, 
the structure Tyr-Ser(tBu)-Leu-Arg-Pro-NH-Et was derived, characterized by a theoretical 
monoisotopic mass [M+H]+ of 718.46099 [47]. Determination of the m/z value of the parent ion by 
high resolution MS, i.e. 718.46190, further confirmed this structure elucidation. The mass 
spectrometric analysis of these four degradation peaks were found to be structurally similar in both 
MS1 and MS2, but a different chromatographic behavior was observed, suggesting diastereoisomers. 
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Figure 9. Typical MS
2
 fragmentation pattern of degradants 12, 13 and 15 (parent mass: 718.24; collision energy: 
45 eV). 
 
Degradant #14 and 16 (RT 10.64 and 11.17 min): m/z 789 
Investigation of degradant peaks 14 and 16 revealed similar MS1 spectra. The m/z value of 789.07 was 
identified as the molecular ion for both peaks. This m/z value was also observed at RT 9.90, 10.10, 
10.27 and 10.33, however this peaks could not be distinguished from the noise in the depicted UPLC-
UV chromatogram, i.e. below LoD, and were thus not indicated in Figure 4. Collision induced 
fragmentation was performed on the 3 previously mentioned peaks, using a collision energy setting of 
45 eV and using m/z 789.23 as parent mass. The resulting fragmentation pattern is given in Figure 10. 
From this, the structure Ala-Tyr-Ser(tBu)-Leu-Arg-Pro-NH-Et was derived, characterized by a 
theoretical monoisotopic mass [M+H]+ of 789.49810 [47]. Determination of the m/z value of the 
parent ion by high resolution MS, i.e. 789.4995, further confirmed this structure elucidation. The mass 
spectrometric analysis of these two degradation peaks were found to be structurally similar in both 
MS1 and MS2, but a different chromatographic behavior was observed, suggesting diastereoisomers. 
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Figure 10. Typical MS
2
 fragmentation pattern of degradants 14 and 16 (parent mass: 789.23; collision energy: 45 
eV). 
 
Degradant #17-19 (RT 12.70; 12.84 and 13.43 min): m/z 1239 
Investigation of degradant peaks 17 to 19, eluting just before buserelin, revealed similar MS1 spectra. 
The m/z value of 1239.12 was identified as the molecular ion for all three peaks, which corresponds to 
the m/z value of single charged buserelin. Two-fold charged peptide degradants were observed at m/z 
619.56 and the single charged Na+ and K+-adduct were also identified at m/z values 1261.61 (+22) and 
1276.56 (+38). Collision induced fragmentation was performed on the 3 previously mentioned peaks, 
using a collision energy setting of 60 eV and using m/z 1239.30 as parent mass. The resulting 
fragmentation pattern is given in Figure 11. From this, the structure buserelin pGlu-His-Trp-Ser-Tyr-
Ser(tBu)-Leu-Arg-Pro-NH-Et was derived, characterized by a theoretical monoisotopic mass [M+H]+ of 
1239.66325 [47]. Determination of the m/z value of the parent ion by high resolution MS, i.e. 
1239.665, further confirmed this structure elucidation. Again, the mass spectrometric analysis of 
these three degradation peaks were found to be structurally similar in MS1, MS2 and high resolution 
MS to buserelin, but a different chromatographic behavior was observed, suggesting 
diastereoisomers. 
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Figure 11. Typical MS
2
 fragmentation pattern of degradants 17 to 19 (parent mass: 1239.30; collision energy: 60 
eV). 
 
Degradant #20 (RT 14.00 min): m/z 788 
Investigation of degradant peak 20 revealed m/z value of 788.03 as the molecular ion. Collision 
induced fragmentation was performed using a collision energy setting of 40 eV and using m/z 788.11 
as parent mass. The resulting fragmentation pattern and interpretation is given in Figure 12. When 
comparing the fragmentation pattern of degradant 788 with the fragmentation pattern of degradants 
12, 13 and 15 (m/z 718), we can conclude that the 4 carboxyterminal amino acids of both degradant 
m/z 718 and m/z 788 are identical, i.e. Ser(tBu)-Leu-Arg-Pro-NH-Et. On the other hand, the m/z values 
of the amino terminal fragments reveal a mass difference of 70 Da, which can only be added to the 
first amino acid residue, i.e. tyrosine. Based upon the high resolution MS mass data of both m/z 718 
and m/z 788 peaks, i.e. 718.462 and 788.4673, a precise mass difference of 70.0053 Da was 
calculated. The elementary formula of this addition was calculated, using following assumptions: (i) 
the added mass is related to addition of carbon (C), oxygen (O), hydrogen (H) and nitrogen (N), as no 
other atoms are present in the buserelin sample; (ii) number of C, N and O atoms ranges from 0 to 4; 
(iii) number of H atoms range from 0 to 10; (iv) mono-isotopic masses were used in the calculations. 
From this calculation it was found that a net addition of C3H2O2 (mono isotopic: 70.00547) best fitted 
the calculated mass difference of 70.0053, which can be attributed to a pyruvate group.  
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Figure 12. Typical MS
2
 fragmentation pattern of degradants 20 (parent mass: 788.11; collision energy: 40 eV). 
 
In Table 4, a literature overview of previously observed buserelin degradants is given, as well as the 
implemented stress conditions [38,48-50]. As can be observed in Table 3, buserelin was dissolved in 
different buffers. The stress conditions included enzymatic degradation, i.e. incubation with rat kidney 
membrane, as well as forced degradation, i.e. heating of the buserelin buffer solution for prolonged 
time periods. Two of the currently observed degradants, i.e. pGlu-His-Trp (degradants 5 to 7) and Tyr-
Ser(tBu)-Leu-Arg-Pro-NH-Et (degradants 12, 13 and 15) were previously observed. Degradant pGlu-
His-Trp was observed after in-vitro incubation with rat kidney membrane fraction [48,50] as well as 
after forced heat degradation at pH 5 [49]. For this, 1000 µg/mL buserelin in 25 mM acetate buffer at 
pH 5 was incubated for 720 hrs at 80°C. This degradant, i.e. composed out of the first three amino-
terminal amino acids, was also seen for other gonadorelin analogues, e.g. gonadorelin, goserelin and 
triptorelin, of which the first three amino acid residues were different, but had the same fourth amino 
acid residue, i.e. serine. Strickley et al. demonstrated a degradation mechanism catalyzed by the 
hydroxyl moiety of serine in aqueous solution [51]. Motto et al. also identified cleavage of Trp-Ser and 
Glu-His peptide bonds as a predominant degradation mechanism in aqueous solution (pH 6.5) at 25, 
37 and 80°C using Luteinizing Hormone-Releasing Hormone (LH-RH; Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-
Pro-Gly-NH2) [52]. Moreover, isomerisation of serine and histidine residues was found to be a second 
route of degradation, which was also observed by Hoitink et al. at pH 5 and 9 [49]. Epimerization of 
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serine is known to occur through a carbanion intermediate, in which a relatively stable 6-membered 
intermediate with a hydrogen bridge is proposed for serine isomerisation. The tertiary butylated 
serine in position 6 cannot form this intermediate and is therefore unable to isomerize. One of the 
observed degradants in this study, i.e. pGlu-His-Trp (degradant # 5-7; m/z 453), contains a histidine 
residue in position 2. However, 3 different degradants with the same mass were seen in the 
chromatogram, which suggests the presence of multiple isomers. So, the previous reported 
isomerization of L-histidine alone could not explain this observation. However, exposure to our dry 
heat conditions might results in additional isomerisation of different amino acid residues. Wu et al. 
demonstrated a spontaneous, i.e. solvent- and catalyst-free, isomerisation of pyroglutamic acid when 
heated above its melting temperature of around 162°C [53]. Degradant #12, 13 and 15 (m/z 718 with 
proposed structure Tyr-Ser(tBu)-Leu-Arg-Pro-NH-Et) was previously reported by Kertscher et al. after 
an in-vitro degradation study of buserelin using rat kidney membrane fraction [50]. We found that the 
peptide bonds Trp-Ser, Tyr-Ser and Ser-Tyr were the most prominent cleavage sites under our dry 
heat stress conditions. Although degradant # 15 (m/z: 718) did not contain a free serine or histidine 
amino acid residue, two additional small peaks, i.e. degradants # 12 and 13, were seen during the MS 
analysis suggesting diastereoisomers.  
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Table 4. Literature overview of known buserelin degradation products. 
Name Structure Stress conditions Ref. 
Buserelin pGlu-His-Trp-Ser-Tyr-D-Ser(tBu)-Leu-Arg-Pro-NHEt API [38] 
[2-D-Histidine] Buserelin 
(specified impurity A) 
pGlu-D-His-Trp-Ser-Tyr-D-Ser(tBu)-Leu-Arg-Pro-NHEt - [38] 
[4-D-Serine] Buserelin 
(specified impurity B) 
pGlu-His-Trp-D-Ser-Tyr-D-Ser(tBu)-Leu-Arg-Pro-NHEt 25 mM borate buffer (pH 9) + heated at 70°C for 24 – 48 h [38,49] 
Buserelin-(3-9)-peptide 
(specified impurity C) 
Trp-Ser-Tyr-D-Ser(tBu)-Leu-Arg-Pro-NHEt 20 mM Tris HCl / 100 mM NaCl (pH 7.4) + rat kidney membrane fraction [38,50] 
[5-D-Tyrosine] Buserelin 
(specified impurity D) 
pGlu-His-Trp-Ser-D-Tyr-D-Ser(tBu)-Leu-Arg-Pro-NHEt - [38] 
[1-(5-oxo-D-proline)] 
Buserelin (specified impurity E) 
D-pGlu-His-Trp-Ser-Tyr-D-Ser(tBu)-Leu-Arg-Pro-NHEt - [38] 
Ser Ser 20 mM Tris HCl / 100 mM NaCl (pH 7.4) + rat kidney membrane fraction [48,50] 
Trp Trp 20 mM Tris HCl / 100 mM NaCl (pH 7.4) + rat kidney membrane fraction [48,50] 
Tyr Tyr 20 mM Tris HCl / 100 mM NaCl (pH 7.4) + rat kidney membrane fraction [50] 
B1-2 pGlu-His 20 mM Tris HCl / 100 mM NaCl (pH 7.4) + rat kidney membrane fraction [48,50] 
B1-3 pGlu-His-Trp 
20 mM Tris HCl / 100 mM NaCl (pH 7.4) + rat kidney membrane fraction 
25 mM acetate buffer (pH 5) + heated at 80°C for 720 h 
[48-50] 
B1-4 pGlu-His-Trp-Ser 20 mM Tris HCl / 100 mM NaCl (pH 7.4) + rat kidney membrane fraction [48,50] 
B3-4 Trp-Ser 20 mM Tris HCl / 100 mM NaCl (pH 7.4) + rat kidney membrane fraction [50] 
B4-9 Ser-Tyr-D-Ser(tBu)-Leu-Arg-Pro-NHEt 
20 mM Tris HCl / 100 mM NaCl (pH 7.4) + rat kidney membrane fraction 
25 mM acetate buffer (pH 5) + heated at 80°C for 720 h 
[49,50] 
B5-9 Tyr-D-Ser(tBu)-Leu-Arg-Pro-NHEt 20 mM Tris HCl / 100 mM NaCl (pH 7.4) + rat kidney membrane fraction [48,50] 
B6-9 D-Ser(tBu)-Leu-Arg-Pro-NHEt 20 mM Tris HCl / 100 mM NaCl (pH 7.4) + rat kidney membrane fraction [48,50] 
B1-9 (-tBu) pGlu-His-Trp-Ser-Tyr-D-Ser-Leu-Arg-Pro-NHEt 0.01M perchloric acid (pH 2) + heated at 70°C for 24 – 48 h [49] 
B1*-9 (-tBu) 
pGlu*-His-Trp-Ser-Tyr-D-Ser-Leu-Arg-Pro-NHEt 
(*hydrolysis of pGlu ring) 
0.01M perchloric acid (pH 2) + heated at 70°C for 24 – 48 h [49] 
B2-9 (-tBu) His-Trp-Ser-Tyr-D-Ser-Leu-Arg-Pro-NHEt 0.01M perchloric acid (pH 2) + heated at 70°C for 24 – 48 h [49] 
cB1-2 
Cyclo-(His-Trp) 
(DKP – diketopiperazine) 
25 mM acetate buffer (pH 5) + heated at 80°C for 720 h [49] 
cBD1-2 
Cyclo-(D-His-Trp) 
(DKP – diketopiperazine) 
25 mM acetate buffer (pH 5) + heated at 80°C for 720 h [49] 
B4-9 D-Ser-Tyr-D-Ser(tBu)-Leu-Arg-Pro-NHEt 25 mM acetate buffer (pH 5) + heated at 80°C for 720 h [49] 
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Degradants # 1-4 (m/z 452, pGlu-His-Trp-NH2) and degradant #20 (m/z 788, pyruvoyl-Tyr-Ser(tBu)-
Leu-Arg-Pro-NH-Et) are among the first buserelin degradants to be formed, e.g. at relatively low 
stress conditions of 40 min incubation at 150°C. Different possible mechanistic hypotheses for the 
formation of both degradants are given in Figure 13. The first hypothesis starts with the β-
elimination of the hydroxyl moiety of serine, resulting in the formation of a dehydroalanine group. 
This dehydroalanine intermediate is then hydrolyzed into the amide degradants #1-4 (i.e. pGlu-His-
Trp-NH2) and pyruvoyl degradant #20 (i.e. pyruvoyl-Tyr-Ser(tBu)-Leu-Arg-Pro-NH-Et) [6,54]. An 
alternative hypothesis involves internal esterification, initiated by nucleophilic attack of the serine 
hydroxyl moiety on the carbonyl moiety of the Trp-Ser peptide bond. The ester intermediate is 
degraded further, yielding degradants #5-7 (m/z 453, pGlu-His-Trp) and degradant #20 (m/z 788, 
pyruvoyl-Tyr-Ser(tBu)-Leu-Arg-Pro-NH-Et). The formation of the latter involves the release of 
ammonia, which can react with degradants #5-7, forming degradants #1-4 (m/z 452, pGlu-His-Trp-
NH2) [55]. Other mechanisms can also lead to the same degradants. Removal of the tertiary butyl 
group results in a second free serine moiety, which can degrade in similar ways, possibly yielding 
degradants #8-11 (m/z 702, pGlu-His-Trp-Ser-Tyr-NH2). No intermediate with two free serine residues 
was observed. Further isomerisation degradants of pGlu-His-Trp-NH2, pGlu-His-Trp and pGlu-His-Trp-
Ser-Tyr-NH2, most likely due to pGlu and His isomerisation, were positively identified. 
 
 
Figure 13. Possible degradation mechanisms for degradants #1–4, #5–7 and #20. 
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The origin of degradant #14 and 16 (m/z 789, Ala-Tyr-Ser(tBu)-Leu-Arg-Pro-NH-Et) is currently 
unclear. Different degradation pathways can be hypothesized (i) hydrolysis of Trp and Ser peptide 
bond and (ii) conversion of serine moiety to an alanine moiety, i.e. removal of the serine hydroxyl 
group. In-vivo posttranslational conversion from an L-serine residue to D-alanine was observed in 
lantibiotic antimicrobial peptides. It was postulated that L-serine is first converted to dehydroalanine, 
as shown in the β-elimination scheme (Figure 13), which is then further enzymatically reduced to D-
alanine by the LtnJ enzyme [56,57]. It is clear that in our experiments, no enzyme was used to 
catalyze this reaction, but the applied high temperatures can possibly replace this catalysis-effect. 
Furthermore, special attention was given to degraded histidine residues, as histidine is sensitive to 
oxidative degradation, but no such degradants were identified [58,59]. 
A global schematic overview of all identified buserelin degradation products is given in Figure 4. The 
predominant degradation pathways were hypothesized to be chemical cleavage of peptide 
backbones, rather than oxidative processes. 
 
3.5 Dry heat stability of HIV fusion inhibiting peptides 
The HIV fusion inhibiting peptides enfuvirtide and C34, exposed to hot-melt proces related condition, 
i.e. 5 min incubation at 100°C and 125°C, did not result in observable degradation as evidenced by 
similar peak areas and the absence of newly formed degradation peaks (Figure 14 and 15). In turn, 
the main peak areas of both enfuvirtide and C34 were significantly reduced, i.e. approximately 40%, 
after 40 min incubation at 150°C, demonstrating the selectivity of the UPLC-PDA method to detect 
enfuvirtide and C34 degradation. These results clearly demonstrate the possibilities of processing the 
HIV fusion inhibiting peptides enfuvirtide and C34 by hot-melt processing. 
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Figure 14. Overlay chromatograms obtained from unstressed enfuvirtide (black), enfuvirtide 5 min 100°C 
(orange) and enfuvirtide 5 min 125°C (red). A magnification of the baseline is given in the insert. 
 
Figure 15. Overlay chromatograms obtained from unstressed C34 (black), C34 5 min 100°C (orange) and C34 5 
min 125°C (red). 
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Alternatively SC34EK, derived from C34 and designed to have an increased α-helicity resulting in 
increased anti-HIV activity, already showed some degradation, i.e. 9%, after 5 min incubation at 
100°C, which further increased to 40% after 5 min incubation at 125°C and 80% after 40 min 
incubation at 150°C (Figure 16). Although the SC34EK fusion inhibiting peptide is clearly more 
susceptible to dry heat-related degradation when compared to enfuvirtide and C34, HME processing 
can still be possible. This would require a rational polymer choice, optimization of the experimental 
HME settings and possible use of excipients e.g. plasticizers, to reduce the amount of thermal stress, 
i.e. absolute temperature and time duration, subjected to the SC34EK peptide, in order to keep 
peptide degradation to a minimum. 
 
 
Figure 16. Overlay chromatograms obtained from unstressed SC34EK (black), SC34EK 5 min 100°C (orange) and 
SC34EK 5 min 125°C (red). 
 
3.6 Identification of HIV fusion inhibiting peptides-related degradants 
The total ion chromatograms (TIC) obtained from unstressed SC34EK and SC34EK stressed at 
conditions surpassing HME, i.e. 5 and 45 min at 160°C, were compared. To distinguish between 
newly formed degradation products and peptide-related impurities which were already present, the 
base peak intensities of the peaks in the heat stressed peptides were compared with their 
corresponding intensities in the unstressed sample. When the intensity is higher in the heat stressed 
peptides, the peak was considered as degradation product. Using this approach, the peak eluting at 
26.81 min (RRT: 0.78) was identified as a degradation product (Figure 17).  
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Figure 17. Total ion chromatogram obtained from SC34EK incubated at 160°C for 5 min. 
Undegraded SC34EK elutes at 34.39 min. 
 
From its MS1 spectrum, a monoisotopic molecular weight of 3646.00 was calculated, which 
corresponds to a mass loss of 729.38 Da, relative to the SC34EK molecular weight. Based on this data, 
the SC34EK-related degradant sequence was determined to be RKIEEYTKKIEELIKKSQEQQEKNEKELK 
and confirmed by collision induced fragmentation (Figure 18). This degradant was formed by peptide 
bond cleavage between the amino acid aspartate (5D) and arginine (6R), of which the former residue 
is known to cause non-enzymatic bond cleavage in through an imide formation [60,61]. 
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Figure 18. Typical MS
2
 fragmentation pattern of SC34EK-related degradant RKIEEYTKKIEELIKKSQEQQEKNEKELK 
(RRT: 0.78, parent mass: 913.01; collision energy: 35) 
 
C34 was also subjected to identical stress conditions, surpassing those of HME, and the same 
approach was used to identify C34-related degradation products. The TIC obtained from the 5 min 
160°C C34 sample is given in Figure 19. Under these stress conditions, three C34-related degradation 
products were identified, eluting at 20.14 min (RRT: 0.54), 26.40 min (RRT: 0.71) and 34.26 min (RRT: 
0.82). Based upon the MS1 spectrum, a monoisotopic molecular weight of 1526.76 Da was calculated 
for the first degradant. This corresponds to a sequence of SQNQQEKNEQELL, which was confirmed by 
collision induced fragmentation (Figure 20).  
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Figure 19. Total ion chromatogram obtained from C34 incubated at 160°C for 5 min. 
Undegraded C34 elutes at 37.28 min. 
 
 
Figure 20. Typical MS
2
 fragmentation pattern of C34-related degradant SQNQQEKNEQELL 
(RRT: 0.54, parent mass: 794.40; collision energy: 35) 
 
The second C34-related degradant was identified as SLIEESQNQQEKNEQELL, of which the MS² 
fragmentation pattern is given in Figure 21. The third C34-related degradant was identified as 
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REINNYTSLIHSLIEESQNQQEKNEQELL, the result of peptide bond cleavage between 5D and 6R, as was 
also observed with the SC34EK peptide. 
 
 
 
Figure 21. Typical MS
2
 fragmentation pattern of C34-related degradant SLIEESQNQQEKNEQELL 
(RRT: 0.71, parent mass: 1080.53; collision energy: 35) 
 
Summarizing, following dry heat-related C34 and SC34EK degradation products were identified: 
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4.  CONCLUSIONS 
The dry heat stability of different peptide APIs was evaluated by dry heat exposure. Dry heat 
conditions mimicking hot-melt process conditions, i.e. 5 min at 100°C and 125°C, were used to 
evaluate their potential for hot-melt processing. Several casein-derived peptides, of which certain 
peptides have antihypertensive, opioid or immunomodulatory activities, were found to be stable at 
these HME-related conditions. All evaluated casein-derived peptides remained stable up to 3 min 
incubation at 180°C, whereas they were all significantly degraded after 5 min incubation at 180°C. 
Buserelin acetate (pGlu-His-Trp-Ser-Tyr-D-Ser(tBu)-Leu-Arg-Pro-NH-Et), a gonadotropin-releasing 
hormone agonist used in the long-term treatment of prostate cancer, was also stable at these hot-
melt-related conditions Moreover, subjecting buserelin to more severe dry heat stress conditions, 
allowed for the identification of formed degradants, and further elucidation of degradation 
mechanisms. Furthermore, different solid state kinetic models were statistically evaluated of which 
the Ginstling-Brounshtein model fitted the data best. Mass spectrometric analysis of the buserelin-
related degradants demonstrated three different degradation mechanisms. First, β-elimination of the 
hydroxyl moiety at the serine residue, followed by fragmentation into an amide (pGlu-His-Trp-NH2) 
and pyruvoyl (pyruvoyl-Tyr-Ser(tBu)-Leu-Arg-Pro-NH-Et) peptide fragment was observed. Degradant 
pGlu-His-Trp-Ser-Tyr-NH2 is believed to be formed in a similar way. Secondly, backbone hydrolysis 
was observed yielding pGlu-His-Trp and Tyr-Ser(tBu)-Leu-Arg-Pro-NH-Et peptide fragments. 
Moreover, the presence of Ala-Tyr-Ser(tBu)-Leu-Arg-Pro-NH-Et can be explained by subsequent 
hydrolysis of Trp-Ser peptide bond and conversion of the serine moiety to a alanine moiety. Finally, 
isomerisation of aforementioned peptide fragments and buserelin itself was also observed. 
Two anti-HIV fusion inhibiting peptides, C34 and enfuvirtide were undegraded after incubation at 
hot-melt-related conditions, whereas a third, SC34EK, showed some degree of degradation. 
Degradant identification revealed backbone cleavage between 5D-6R in both C34 and SC34EK. 
Moreover, two additional C34-related degradants, originating from 16H-17S and 21E-22S backbone 
cleavage, were also identified. 
The evaluation of a first critical aspect for peptide APIs hot-melt processing, i.e. short-term high 
temperature exposure, thus resulted in promising results as the majority of the evaluated peptide 
APIs remained stable under the hot-melt-related conditions. Based on these results, and contrary to 
general belief, peptide hot-melt-processing is feasible, and will be further explored in Chapter VII.  
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ABSTRACT 
Loss of active pharmaceutical ingredient (API) powder during lab-scale implant manufacturing as well 
as during pharmacy-scale capsule compounding can lead to under-dosed finished drug products and 
can potentially decrease the beneficiary therapeutic effects for the patient or affect the outcome of 
initial animal or clinical trials. The amount and location of API was experimentally determined using 
an API mass balance approach. An overall API mass balance between 97% and 103% was seen for all 
investigated manufacturing processes. Swabbing of the different compounding equipment and 
working areas indicated the mortar surface as the largest API loss location. An agate mortar 
accounted for the least amount of API loss, whereas an extensively used porcelain mortar accounted 
for the highest amount of API loss: optical microscopy and roughness (Ra) determination by 
profilometry of the different mortar surfaces revealed a significant influence of the mortar surface 
wear and tear on the observed API loss. 
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CHAPTER VI 
API MASS BALANCE IN LAB- AND 
PHARMACY-SCALE PREPARATIONS 
Main focus in this chapter: 
 Quantify the different API loss steps during lab- and pharmacy-scale preparation 
 Give recommendations to reduce expected API loss 
 
1. INTRODUCTION 
During initial drug discovery or early development phases, including preclinical animal and Phase I 
clinical trials, small batches of medicine formulations are mostly manually prepared in a GLP/GMP- 
laboratory setting (e.g. university hospitals). Therefore, it is essential that these formulations are of 
adequate quality, most importantly to ensure the patient’s safety, but also to make unbiased 
conclusions regarding the medicine’s functionality. In chapter VII, the lab-scale processing of a pilot 
buserelin acetate-loaded (20% m/m) poly(ethylene-vinyl acetate) (pEVA) formulation is described. 
When assaying the final polymeric implant form, a consistent and significant buserelin acetate loss 
was observed. 
On the other hand, marketed drug formulations are generally manufactured industrially. The reasons 
for the popularity of industrially produced medicines are the low costs, the high production speed, 
the complexity of the new drug formulations and the high quality requirements [1-6]. A disadvantage 
of these industrial drug preparations is that this approach limits individualized medication, resulting 
in a “one size fits all”-strategy. A more personalized medication program is allowed through 
pharmaceutical compounding, i.e. the preparation of drug formulations by the pharmacist, which 
continues to play an important role in today’s health care system. Some patient groups suffer from 
rare orphan diseases, requiring a personalized medicines approach, whereas in geriatrics 
polypharmacy, i.e. simultaneous use of five or more drugs to treat a variety of diseases, is often a 
problem. Here, pharmaceutical compounding is used to optimize these drug combinations, as well as 
their dosage levels, to best suit the need of the individual. Moreover, administration of custom 
compounded formulations in the pediatric and neonatal field are also common. Therefore, 
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pharmaceutical compounding is still one of the pillar stone in the education of pharmacists, to ensure 
that a safe and high-quality drug product can be delivered to the patient [7-9]. Capsules remain a 
popular dosage form in pharmaceutical compounding because of its stability, the high dosage 
accuracy, fast drug release and ease of swallowing. However, API content analyses of 
pharmaceutically compounded capsules often reveal under-dosed preparations [10-14].  
Up till now, no studies were conducted to quantify the API losses during lab-scale and pharmacy 
compounded manufacturing processes. This chapter aims to answer this question and will do so by 
individually assaying equipment surfaces for residual API, thus experimentally determining the API 
loss location, as well as the API content in the final drug formulation. For the latter, a lab-scale 
buserelin acetate-loaded (20% m/m) pEVA implant and 5 different pharmacy-scale capsule 
preparations were prepared. 
 
2. MATERIALS AND METHODS 
2.1 Materials 
Buserelin acetate (European Pharmacopoeia quality) was bought at Hybio Pharmaceutical Co. 
(Shenzhen, China). Poly(ethylene-vinyl acetate) (33% vinyl acetate) polymer was purchased from 
Celanese (Edmonton, Canada). Hydrocortisone, triamcinolone, dexamethasone and dexamethasone 
trituration (10% m/m) were all obtained from Fagron (Waregem, Belgium). Excipient diluent B, 
containing 99.5% mannitol and 0.5% anhydrous colloidal siliciumdioxide, was also purchased from 
Fagron. Acetonitrile and methanol (MeOH) were obtained from Fisher Scientific (Aalst, Belgium). 
Water was purified using an Arium 611 purification system (Sartorius, Gottingen, Germany) yielding ≥ 
18.2 MΩ×cm quality water. K2HPO4 was obtained from Panreac Quimica (Barcelona, Spain) and 
NaH2PO4 from Merck (Overijse, Belgium). An Acquity UPLC BEH C18 (50 × 2.1 mm I.D.; 1.7 µm particle 
size; 130 Å) and suitable guard column were purchased from Waters (Zellik, Belgium), whereas a 
HALO C18 column was obtained from Achrom (Machelen, Belgium). 
The agate mortar was from Specac (Kent, United Kingdom). The new, averagely worn and extensively 
worn porcelain mortars were acquired from Avignon Ceramic (Avignon, France) and HCT (Germany). 
Plastic and metal capsulation devices were obtained from Stefarm BVBA (Bertem, Belgium). The 
flexible plastic (PVC) card was a kind gift from ACA Pharma (Waregem, Belgium), whereas the 
porcelain pestle was bought at Omega Pharma (Nazareth, Belgium). Coni-snap ivory gelatin-based 
capsules No. 2 were purchased from Feton N.V. International (Brussel, Belgium). 
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2.2 Chromatography 
The HPLC-UV apparatus used for buserelin acetate quantification consisted of a Waters Alliance 2695 
separations module and a Waters 2487 dual λ absorbance detector with Empower 2 software for 
data acquisition (all Waters, Milford, MA, USA). The HALO C18 column (50 mm × 4.6 mm I.D.; 2.7 µm 
particle size, 90Å) was thermostated in an oven set at 40°C (± 3°C), whereas the autosampler 
temperature was set at 5°C (± 3°C) and UV detection was performed at 220 nm. The flow rate and 
injection volume were set at 0.6 mL/min and 10 µL, respectively, and a gradient was applied (where 
A = 95% water and 5% acetonitrile with 0.1% (m/V) formic acid, and B = 95% acetonitrile and 5% 
water with 0.1% (m/V) formic acid), starting with a 1.0 min. isocratic hold at 90% A, followed by a 
linear gradient from 90% A to 75% A in 3.0 min. and ending with a isocratic hold for 1 min, followed 
by returning to the initial conditions and re-equilibration. 
The UHPLC apparatus consisted of a Waters Acquity H UPLC Class Quaternary Solvent Manager, a 
Waters Acquity Sample Manager, combined with a Flow Through Needle, and a Waters Acquity Ultra 
Performance LC PDA (500 nL – 10 mm path length analytical flow cell) detector with Empower 2 
software for data acquisition. An isocratic flow consisting of 65 parts of H2O and 35 parts of 
acetonitrile was implemented for hydrocortisone and triamcinolone assay. For dexamethasone 
assay, the water fraction was substituted by a 10 mM phosphate buffer (set at pH 4). The flow rate 
was set at 0.5 mL/min for all analyses. Column and sample compartment were thermostated at 30°C 
(± 3°C) and 10°C (± 3°C), respectively. The injection volume was set at 2 µL and UV-detection was 
performed at 240 nm. 
 
2.3 Lab-scale implant preparation 
The preparation process of a 100 mg weighing pEVA polymeric implant, loaded with 20% m/m 
buserelin acetate is described in full detail in Chapter VII. In short, appropriate amounts of buserelin 
acetate and pEVA were weighed in a weighing boat and mixed in an agate mortar, using an agate 
pestle and plastic card, until a homogenous powder was obtained. Of this mixture, approximately 
100 mg is transferred into a glass vial, which is incubated at elevated temperature, hereby melting 
the polymer and incorporating the buserelin acetate. 
 
2.4 Pharmacy-scale capsule preparations 
In total, five different capsule preparations were pharmaceutically compounded: (i, ii) 10 and 20 mg 
hydrocortisone capsules, (iii) 4 mg triamcinolone capsules and (iv, v) 0.25 mg dexamethasone 
capsules, using a 10% m/m self-made (SMT) or commercial trituration (CT). All capsule preparations 
were compounded according to guidelines provided by the Therapeutic Magistral Formulary, a 
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Belgian reference book for compounded preparations, drafted by a sub-committee of the Belgian 
Pharmacopoeia Commission and published by the Federal Agency for Medicines and Health 
Products. It is an official document and is required to be present in Belgian pharmacies by Royal 
Decree of 26 March 2003 [15]. All capsule compounding was performed utilizing an averagely worn 
porcelain mortar and plastic capsulation device, unless otherwise specified. Plastic card and pestle 
were the same for all preparations. 
  
Self-made dexamethasone (10% m/m) trituration 
500 mg (x) of dexamethasone, 50 mg (y) of riboflavine and 100 mg (z) of diluent B excipient were 
accurately weighed into plastic weighing boats. The remaining amount of diluent B needed to obtain 
a 10% (m/m) dexamethasone trituration was calculated (5000 – x – y - z mg) and weighed into a 
plastic weighing boat. The 100 mg diluent B was transferred into a mortar, together with the 50 mg 
of the coloring agent riboflavine. Both powders were homogenized using pestle until a uniform 
powder color is obtained. Next, the dexamethasone powder (API) was added and mixed with 
aforementioned homogenized powder, until re-obtaining a uniform color. The remaining diluent B 
was then added in small steps to the mortar powder content and thoroughly mixed after each 
addition. The content of the mortar is transferred into a dark glass recipient. The weight difference 
between the full and empty glass recipient corresponds to the powder amount of 10% (m/m) 
dexamethasone trituration. 
 
Capsule compounding 
The required amount of API or dexamethasone trituration, and 1 g of excipient diluent B, were 
separately weighed into a weighing boat. Both powders were homogenized using mortar and pestle. 
Next, the powder mixture was transferred into a measuring cylinder, without densifying the powder. 
Diluent B excipient was added until the required volume for filling 20 No. 2 capsules is reached (0.37 
mL per capsule or 7.4 mL for 20 capsules). The content of the measuring cylinder was transferred 
into the aforementioned mortar and mixed until homogeneous. Finally, the powder mixture was 
distributed uniformly into 20 No. 2 capsules using a capsulation device and plastic card. 
 
Mortar influence 
The influence of the mortar material, i.e. agate (i) vs. porcelain, and the mortar usage grade, i.e. 
unused (ii), averagely worn (iii) and extensively worn (iv) porcelain mortars, were evaluated by 
preparing 10 mg and 20 mg hydrocortisone capsules using aforementioned four mortars. Identical 
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pestle and plastic card were used and each preparation was compounded by the same person, in 
order to limit additional variability.  
 
Capsulation device influence 
The influence of the capsulation device material, i.e. plastic (i) vs. metal (ii) was evaluated by 
preparing 10 mg and 20 mg hydrocortisone capsules and 0.25 mg dexamethasone capsules, using 
aforementioned capsulation devices. 
 
2.5 Sample preparation 
Lab-scale prepared implants 
Prepared implants were weighed and transferred into a 50 mL Erlenmeyer flask. The pEVA polymer 
was dissolved by adding 5 mL of chloroform and shaken until fully dissolved. Buserelin acetate was 
extracted by adding 6 mL of 0.1% formic acid H2O, followed by gently shaking the Erlenmeyer flask. 
Next, the entire solvent mixture was transferred into a glass test tube and centrifuged for 1 min at 
1000 rpm, after which the water fraction was transferred into a 25.0 mL volumetric flask. This liquid-
liquid extraction procedure was repeated an additional three time, i.e. four separate extraction steps 
in total. Finally, the 25.0 mL volumetric flask was diluted to volume using 0.1% formic acid H2O. 
Verification results of this liquid-liquid extraction method are given in Chapter VII. 
 
Pharmacy-scale compounded capsules 
Ten individual capsules, containing the API powder mixture, were weighed and carefully opened. The 
bulk powder of the capsules was transferred into an appropriate volumetric flask, depending on the 
API dosage of the capsule preparation. The emptied capsules were closed, as some residual powder 
is still present in the capsules, and were again weighed. The bulk powder mixture was dissolved using 
MeOH, sonicated and diluted to volume. The obtained solution was centrifuged at 3220 × g for 5 min 
at 22°C. An appropriate dilution of the MeOH supernatant was made using H2O and volumetric 
pipettes, resulting in 50/50 (v/v) H2O/MeOH sample solvent for hydrocortisone and triamcinolone 
and 70/30 (v/v) H2O/MeOH sample solvent for dexamethasone.  
In order to quantify the API content in the residual capsule powder, the emptied capsules were re-
opened and the two capsule parts carefully transferred into 10 mL volumetric flasks. MeOH was 
added and solutions were sonicated for 5 min to dissolve the residual powder. Appropriate dilutions 
were made using H2O and volumetric pipettes, resulting in 50/50 (v/v) H2O/MeOH sample solvent for 
hydrocortisone and triamcinolone and 70/30 (v/v) H2O/MeOH sample solvent for dexamethasone.  
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The volumetric flasks containing the cotton swabs were diluted to volume using MeOH and sonicated 
for 5 min to dissolve the cotton-adsorbed API powder. Appropriate dilutions were made using H2O 
and volumetric pipettes, resulting in 50/50 (v/v) H2O/MeOH sample solvent for hydrocortisone and 
triamcinolone and 70/30 (v/v) H2O/MeOH sample solvent for dexamethasone. 
Aliquots of all sample solutions were transferred into glass HPLC vials and analyzed (see Section 2.2) 
 
Swabbing of work area and equipment surfaces 
In order to trace potential buserelin acetate losses during the lab-scale preparation process, the 
surfaces of the various compounding equipment and working areas were repeatedly swabbed for the 
presence of buserelin acetate, using cotton wetted with H2O with 0.1% formic acid. After wet 
swabbing, the equipment and surfaces were dried using dry cotton swabs. The swabs of the different 
surfaces were transferred into separate volumetric flasks, allowing individual buserelin acetate 
quantification. Appropriate flask volumes were selected based upon the expected buserelin amount 
and specific swab area. Following surfaces were swabbed: (i) plastic card, (ii) desk and spoon, (iii) 
mortar surface, (iv) pestle, (v) residual glass vial and (vi) weighing boat. Besides these swabs, the 
buserelin acetate content of the implant itself was determined using the aforementioned extraction 
procedure. 
After filling the powder mixture into the pharmacy-scale prepared capsules, the various 
compounding equipment and working area were repeatedly swabbed for the presence of API, using 
cotton wetted with MeOH. In total, eight different equipment areas were swabbed: (i) weighing boat 
used to transfer API, (ii) measuring cylinder to ensure the presence of sufficient powder volume for 
homogeneous distribution into the capsules, (iii) funnel to transfer powder mixture into measuring 
cylinder, (iv) mortar, (v) pestle and (vi) plastic card used to obtain a homogeneous powder mixture, 
(vii) capsulation device to fill powder mixture into the capsules and (viii) the working area on which 
all powder manipulations were performed. The swabs of the different areas were transferred into 
separate volumetric flasks, allowing individual API quantification. Appropriate flask volumes were 
selected based upon the API dosage, i.e. total API amount present in powder mixture, and specific 
swab area. 
 
Reference solution 
Appropriate reference solutions were prepared at 100%, 90% and 80% of the theoretical label claims, 
i.e. corresponding to 50, 45 and 40 µg/mL hydrocortisone and triamcinolone solutions in 50/50 (v/v) 
H2O/MeOH and 30, 27 and 24 µg/mL dexamethasone solutions in 70/30 (v/v) H2O/MeOH. Similar 
references were prepared for buserelin acetate. Subsequently, two 10-fold dilutions to 10%, 9% and 
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8% reference solutions and 1%, 0.9% and 0.8% reference solutions were made using premixed 50/50 
(v/v) or 70/30 (v/v) MeOH/H2O, respectively. 
 
2.6 API mass balance calculation 
By using the %API mass balance (%MB), the experimentally determined API amounts within the final 
drug formulation, as well as from the different swabbed areas, are compared to the API amount 
originally weighed: 
 
%API mass balance: 
API amount experimental (mg)
 API amount weighed (mg)
× 100 
 
This approach allows to chart where the API loss mainly occurs. When the individual %API mass 
balances are summarized, a theoretical result of 100% is expected. The ICH defines mass balance as 
the adding together the all individual assay values to see how closely these correspond to initial 
value, with due consideration of the margin of analytical error [16]. However, no fixed range for 
acceptable mass balance results are provided by the ICH. Therefore due to aforementioned analytical 
errors, e.g. dilution errors, chromatographic variability, a %MB ranging from 97% to 103% is deemed 
acceptable. 
 
2.7 Mortar surface characterization: optical microscopy and profilometry 
Visual inspection of the mortar surface was performed using a stereomicroscope (StereoDiscovery 
V12, C. Zeiss MicroImaging GmbH, Göttingen, Germany), equipped with a PlanApo S lens (1x, FWD 60 
mm). Images of the different mortar surface areas were recorded using 8x, 32x and 100x 
magnification. Surface roughness measurements were performed using profilometry based on 
interferometry (Wyko NT3300 Profiling System, Veeco Metrology Group). The equipment scanned a 
surface of 1.2 x 0.92 mm (with a image resolution of 1.65 µm/pixel) combined with a height 
resolution of 6 nm. The high curvature of the mortar surface impeded an adequate focusing of the 
profilometer. Therefore, the mortar surface was replicated by applying a liquid polymer resin 
(RepliSet, Struers) which - after hardening - mimics all imperfections on the surface, effectively 
obtaining a negative duplicate of the surface. The resin was manually applied onto the actual mortar 
surface (area of 1 to 2 cm²), using non-sticking paper to avoid the incorporation of air bubbles. The 
thickness of the resin layer was 3 to 4 mm. After drying for 20 minutes, the resin was removed from 
the actual surface and was ready for analysis. The results of this profilometric analysis was a 3D-plot, 
comprising a 1.2 × 0.9 mm surface area (X and Y-axis), where the Z-axis (color code) depicted the 
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measured distance between surface area and equipment, which is a measurement for the surface 
roughness. Six line scans in both X- and Y-directions were derived to visualize the measured distance 
differences in function of the X- and Y-distance. From each line scan, the surface roughness Ra was 
calculated as the arithmetic average of the absolute distance measurements. 
 
2.8 Overview of assay data derived from compounded capsules 
Assay results and production charts of different compounded capsule preparations dating back to 
2006 were obtained from the Ghent University Hospital as well as from an additional Belgian 
pharmacy study. An overview of the 17 median assay values is given in Figure 1. In the overall data 
set, 17 different APIs were present, totaling 1922 assay results. 
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Figure 1. Boxplots depicting the assay data sets of 17 pharmaceutically compounded molecules. The top and 
bottom of the box depict the first (Q1) and third (Q3) quartile. The band inside the box corresponds with the 
median assay value (Q2). Top and bottom whiskers represent 1.5 times the interquartile range (IQR). Circles 
show mild outliers (i.e. outside bottom or top whisker but inside Q1 - 3×IQR or Q3 + 3×IQR range), whereas 
stars correspond to extreme outliers (i.e. outside Q1 - 3×IQR or Q3 + 3×IQR range). Boxplots with median assay 
values above 95% are indicated in green, the ones below 95% are indicated in red. The number of batches is 
given between brackets. 
 
From this, a large difference within the median assay data set can be seen, possibly indicating a 
molecule-specific influence on the median assay value. This was investigated further by calculating 
molecular descriptors of the 17 different molecules, and correlating them to the historical assay data 
[17]. 
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3. RESULTS AND DISCUSSION 
API mass balance results 
The API mass balance recorded during lab-scale buserelin acetate-loaded implant preparation is 
given in Table 1. An overall buserelin acetate mass balance result of 97.06% was obtained, which lies 
within the preset 97 - 103% interval, ensuring that valid conclusions can be drawn from these results. 
As can be seen from these results, a significant portion of the buserelin acetate, i.e. approximately 
25%, was not incorporated in the final implant. 
 
Table 1. API mass balance during lab-scale buserelin acetate implant preparation 
Description Recovered buserelin acetate (mg) % buserelin mass balance
1 
Weighing boat 0.05 0.24 
Mortar 2.86 13.09 
Pestle 0.61 2.81 
Card 1.07 4.92 
Desk and spoon 0.36 1.64 
Residual vial 0.41 1.87 
Implant 15.81 72.48 
Total 21.18 97.06 
1 % buserelin mass balance: 
𝑎𝑚𝑜𝑢𝑛𝑡  𝑏𝑢𝑠  𝑟𝑒𝑐𝑜𝑣𝑒𝑟𝑒𝑑  (𝑚𝑔 )
 𝑖𝑛𝑖𝑡𝑖𝑎𝑙  𝑤𝑒𝑖𝑔 ℎ𝑒𝑑  𝑎𝑚𝑜𝑢𝑛𝑡  𝑏𝑢𝑠  (𝑚𝑔 )
× 100. Initial weighed amount buserelin i.e. 21.82 mg  
 
The %API mass balance results of the 5 pharmacy-scale capsule preparations and 10% (m/m) 
dexamethasone trituration are given in Table 2. Again, the calculated API mass balance lies between 
97% and 103%. The API amount present in the 5 capsule preparations, i.e. sum of bulk and residual 
capsule powder, varies between 90.8% (DEX 0.25 SMT) and 96.6% (TRI 4 mg). These results confirm 
that, for certain preparations, significant API loss occurs during the pharmaceutical compounding of 
capsules. It is interesting to note that on average 1.1% (%RSD: 14.2) of the API powder remains 
adsorbed to the capsule wall after emptying: in the pediatric, neonate or geriatric setting, capsules 
are often opened and have their content mixed with food or drinks to enable patient compliance. 
This procedure will thus contribute to a small but statistically significant API loss. 
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Table 2. API mass balance during pharmacy-scale capsule preparation 
 Description HC 10 mg HC 20 mg TRI 4 mg 
DEX trit.  
(10 % m/m) 
DEX 0.25 mg 
(SMT) 
DEX 0.25 mg 
(CT) 
1 Weighing boat 0.42 0.16 0.24 0.15 0.98 1.24 
2 Measuring cylinder 0.30 0.12 0.54 - 0.32 0.25 
3 Funnel - 0.01 0.01 - 0.01 0.03 
4 Mortar 6.98 4.97 2.31 2.17 3.80 2.99 
5 Pestle * * 0.98 1.22 1.09 0.86 
6 Plastic card * * 0.24 0.39 0.13 0.33 
7 Capsulation device 0.51 0.47 0.70 - 0.37 0.22 
8 Desk 0.02 0.06 0.03 0.33 0.03 0.04 
9 
Bulk powder (caps. 
/trit.) 
90.01 90.48 95.64 98.45 89.91 91.12 
10 
Residual powder 
(caps.) 
1.28 1.17 1.00 - 0.89 1.20 
 
∑% API mass 
balance 
99.52 97.44 101.68 102.72 97.54 98.27 
* included in sample 4, i.e. analyzed together with mortar 
- not used during experiments 
 
Swabbing of the different equipment and working areas enables to pinpoint exactly where this API 
loss occurs. From Table 1 and 2, it is clear that the majority of API loss, in both lab-scale implant 
prepared and pharmacy-scale capsule compounding, occurs at the surface of the mortar, pestle and 
plastic card. On average 77% (%RSD: 10.1) of the API loss in capsules and 85% of the buserelin loss 
observed in the implant can be traced back to this specific equipment. These three surfaces were 
examined separately during the triamcinolone and dexamethasone capsule preparations. From these 
results, it was seen that the mortar accounted for 50.8% (%RSD: 10.5) of the total API loss. Therefore, 
the influence of the mortar surface in pharmacy-scale compounding was examined further. Similar 
API loss conclusions can be drawn from the dexamethasone trituration results, where the mortar 
accounts for the majority of the observed API loss.  
 
Mortar influence 
The %API mass balance results derived from the plastic card, pestle and mortar swabs for the 10 mg 
and 20 mg hydrocortisone capsule preparation are depicted in Figure 2. The %API mass balance 
recovered from the pestle and plastic card are similar for all 8 preparations, i.e. ranging from 0.7% to 
1.7%.  
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Figure 2. Influence of mortar material and surface wear and tear on API loss. 
 
When examining the influence of the mortar material, it is immediately apparent that API loss at the 
agate mortar is minimal, even smaller than the loss at pestle and plastic card. Less API was lost using 
the agate mortar, when compared to the different porcelain mortars. This was expected as agate is a 
much harder and denser material than the relatively porous porcelain, minimizing sample loss and 
potential cross contamination. These material characteristics render agate mortars the first choice 
when preparing KBr tablets for infrared analyses. However, the production costs for agate mortars 
are significantly higher than for porcelain mortars, which are still most often used during 
pharmaceutical compounding. 
The influence of the porcelain mortar’s usage grade on the API loss in those mortars is also clear. The 
extensively used porcelain mortar accounts for approximately 3 to 4 times the amount of API loss 
when compared to an unused porcelain mortar, and is as high as 5.2%. Multiple pharmaceutical 
preparations, sometimes involving relatively hard powders or crystals, can result in physical 
deformation, i.e. scratch formation of the relatively soft porcelain surface, in which the API particles 
can become adsorbed. This is clearly visible from the microscopic images (100×) in Figure 2, which 
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depicts the difference in formed scratches between agate and porcelain material as well as between 
the different wear and tear stages of a porcelain mortar. 
Profilometry allows for the quantification of this wear and tear of the different surface areas of the 
mortars. For this, a negative duplicate of the surface imperfections was made by applying a polymer 
resin and the distance between the equipment and polymer surface was measured. A two 
dimensional color coded topographical image of each scanned mortar surface, with height 
measurements ranging from blue to red (normalized per surface), is given in Figure 2. The arithmetic 
average of these absolute distance measurements, i.e. Ra value, was calculated to express the surface 
roughness. Six independent line scans, were derived from each scanned surface, thus obtaining 6 Ra 
values per mortar surface (Figure 2). As can be seen from Figure 3, the average Ra value of the mortar 
surface is correlated with the experimentally determined %API loss in these mortars, demonstrating 
the relationship between surface roughness due to wear and tear and the delivered quality of 
pharmaceutically compounded capsules. Therefore, regularly exchanging old, used mortars by new 
porcelain mortars is recommended to all pharmacists in order to keep the API mortar-loss at a 
minimum. A future perspective is the development of a simple, easy to use mortar surface 
characterization test and to set quantitative thresholds for the mortar to ensure acceptable API 
losses. Alternatively, API overdosing in the powder mixture, to compensate for the API loss during 
compounding, is already employed for certain preparations, e.g. 0.25 mg dexamethasone capsules 
[15]. 
 
Figure 3. Correlation mortar surface Ra and API loss. Average Ra (n=6) and %API loss (n=2) ± 95% confidence 
intervals. 
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Capsulation device influence 
The capsulation device material can influence the API loss in 3 ways: (i) API loss via adhesion at the 
capsulation device surface, (ii) API loss due to electrostatic repulsion between API and capsulation 
device, quantified by the amount of API recovered on the surface of the bench used to prepare the 
capsules, (iii) influencing the residual API amount present at the capsule wall after capsule emptying 
by attraction or repulsion forces between the capsulation device and API-excipient mixture whilst in 
the capsulation device. The %API loss at the capsulation device surface, for hydrocortisone (10 mg 
and 20 mg) and 0.25 mg dexamethasone preparations are given in Figure 4.  
 
Figure 4. Influence of capsulation device material on API loss. Average %API loss and 95% confidence level 
error bars indicated for hydrocortisone preparations (10 and 20 mg). 
The hydrocortisone loss using the metal capsulation device is approximately half of the loss using the 
plastic capsulation device and statistically significant at the 95% level. For the dexamethasone 
preparation, no significant influence of the capsulation device material was seen, indicating also a 
molecule-specific effect. However, although the metal material has beneficiary effects on the 
observed hydrocortisone loss at the capsulation device, the API loss occurring prior to capsulation, 
i.e. mortar, pestle, plastic card and weighing boat, still account for the vast majority of the overall API 
loss, rendering the contribution of the capsulation device small. 
No statistical significant difference was seen in the API amounts recovered from the residual capsule 
powders prepared by the different capsulation devices. Moreover, API loss at the desk, due to 
potential repulsion forces, was also found to be negligible and not statistically significant, as could 
also be seen from Table 2. The API loss at the desk is mainly caused by human error, and thus 
dependent on the skill and training level of the pharmacist.  
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Legal and pharmaceutical care considerations 
In drug discovery phase, pilot formulations prepared at lab-scale can be used to evaluate initial drug 
efficacy in animal trials. In order to obtain valid results from these initial experiments, the quality of 
the pilot drug formulation is of the utmost importance, and these should thus be prepared according 
to the GMP/GLP guidelines. Moreover, pilot drug formulations, prepared in lab or in hospitals, and 
used for Phase I clinical trials should also legally adhere to these GMP/GLP guidelines [18]. The 
importance of the formulation quality is further underlined here as the clinical trial application form 
contains a section in which the quality of the investigational medicinal product must be shown. 
As from April 2013, the general monograph ‘Pharmaceutical Preparations’, first published in the 
European Pharmacopoeia 7.7, was implemented [6]. This monograph is a reference source for active 
substances, excipients and dosage forms which are used in the preparation of unlicensed 
pharmaceutical preparations, i.e. pharmaceutical compounding, to meet specific needs of a specific 
patient or patient group. Moreover, as it is included in the European Pharmacopoeia, this monograph 
has a legally binding character and must be adhered to by all pharmaceutical professionals who 
manufacture compounded drug products. As demonstrated in this study, the assay value of 
pharmaceutically compounded capsules is greatly influenced by specific aspects of the production 
process, i.e. the mortar surface roughness, and by intrinsic API chemical properties, i.e. drug 
substance properties.  
Delivery of sub-standard compounded drugs adversely affects not only financial and ecological goals, 
but also the pharmaceutical care objective to improve the patient’s quality of life. The European 
Directorate for the Quality of Medicines & Healthcare recently published different reported cases in 
which this primary objective could not be reached [19]. The responsibility of this failure varied 
between the doctor (prescribing errors), pharmacist (dispensing/administrative errors) and patient 
(non-adherence with treatment regimen). In 2009, James et al. reviewed the incidence and causes of 
dispensing errors in community and hospital pharmacies, and identified a multitude of dispensing 
errors, including drug under-dosing [20]. The primary causes for these dispensing errors were 
attributed to high workload, interruptions and inadequate lighting. An in depth investigation toward 
the compounding process, as discussed in this manuscript was not yet performed. Therefore, it is in 
the patient’s health interest that the considerations raised in this study regarding the compounding 
process and API properties must be implemented by community and hospital pharmacies to ensure 
the delivery of compounded preparation with adequate quality attributes and subsequent 
pharmaceutical patient care. 
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4. CONCLUSIONS 
To draw valid conclusions from animal experiments or Phase I clinical trials and to ensure the safety 
of the patient, the drug formulations used during these initial drug development phases must be of 
adequate quality. Contrary to marketed drug formulations which are industrially produced, these 
investigational drug formulations are often manually prepared in a GLP/GMP-laboratory setting. In 
this study, the cause of under-dosed buserelin acetate-loaded polymeric implants was investigated. 
The largest peptide loss could be traced back to the mortar surface, whereas total peptide loss during 
the lab-scale preparation process was calculated to be 25%. Similar findings were made with 
pharmacy-scale compounded capsules. The largest API loss during hydrocortisone, triamcinolone and 
dexamethasone capsule preparation was also seen at the mortar surface, followed by pestle and 
plastic card. Subsequently, the influence of mortar surface was investigated separately, using two 
hydrocortisone capsule preparations. This revealed a significant influence of the mortar wear. First, 
lower API amounts were lost in agate mortars when compared to the relatively porous porcelain 
mortars. Second, the use of extensively worn porcelain mortars resulted in higher API losses, up to 3 
to 4 times the amount when compared to a new porcelain mortar, which is due to physical scratch 
formation in the porcelain surface. This was confirmed by visualizing the mortar surface by optical 
microscopy and determining the Ra roughness by profilometry. Furthermore, a statistically significant 
influence of the capsulation device material was also demonstrated. However, this API loss on the 
capsulation device only accounts for 10% of the API loss observed in the mortar. 
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CHAPTER VII 
 
HOT-MELT 
PREPARATION OF A 
NON-BIODEGRADABLE 
PEPTIDE IMPLANT: 
A PROOF OF PRINCIPLE 
 
“Live as if you were to die tomorrow, learn as if you were to live forever”  
 
Mahatma Gandhi 
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D’Hondt M, Verbeken M, Verbeke F, Wuytens P, Skirtach A, De Spiegeleer B. Hot-melt manufacturing 
of a non-biodegradable peptide implant: a proof of principle study; in preparation. 
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ABSTRACT 
Due to its excellent thermal stability properties in dry form, buserelin acetate was found to be a 
prime candidate for hot-melt processing into a polymeric implant. The feasibility of hot-melt 
processing was assessed by developing a non-biodegradable poly(ethylene-vinyl acetate) (33% VA) 
implant loaded with 20 % (m/m) buserelin acetate. As was predicted from previous dry heat stability 
testing, no significant buserelin acetate-related degradation products were formed during this hot-
melt preparation. Cross sectional implant characterization by Raman microscopy showed the solid 
dispersion distribution of the buserelin acetate powder in the polymeric matrix. The in-vitro buserelin 
acetate release from the implant was assessed in PBS and found to diffusion-controlled, releasing on 
average 5 µg of buserelin acetate daily, after observation of an initial burst release. The stability of 
buserelin acetate in the polymeric matrix was evaluated for 3 months under ICH stability conditions 
(5°C, 25°C/60% R.H. and 40°C/75% R.H.). Given the consistent buserelin acetate assay values, 
combined with the absence of degradation products, chemical peptide stability was demonstrated. 
Moreover, similar in-vitro release profiles were obtained, demonstrating the functional stability of 
the peptide implant. Finally, the in-vivo functionality of the hot-melt produced implant was 
demonstrated by sub-dermal implantation in mice. Buserelin acetate concentrations in plasma, 
kidney and liver obtained 1 day post-implantation also reflected the initial buserelin acetate burst 
release, before leveling out as observed 8 and 30 days post-implantation. These results clearly 
indicate the feasibility of non-biodegradable peptide loaded implants using hot-melt production 
method and may act as a proof of principle concept for further innovation in peptide medicines. 
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CHAPTER VII 
HOT-MELT PREPARATION OF A NON-
BIODEGRADABLE PEPTIDE IMPLANT: 
A PROOF OF PRINCIPLE 
Main focus in this chapter: 
 Explore the feasibility of a peptide-loaded polymeric implant produced by a hot-melt technique 
 Evaluate peptide stability after implant preparation and under ICH stability conditions 
 Demonstrate the functionality of the newly produced peptide-polymer formulation 
 
1. INTRODUCTION 
Buserelin acetate (pGlu-His-Trp-Ser-Tyr-D-Ser(tBu)-Leu-Arg-Pro-NH-Et) is part of a therapeutic class 
known as the gonadotropin-releasing hormone (GnRH) agonists, affecting the hypothalamic-pituitary-
gonadal axis. The seven different, currently marketed GnRH agonists (buserelin, leuproreline, 
goserelin, histrelin, deslorelin, nafarelin and triptorelin) are all derived from the natural GnRH 
decapeptide (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-CONH2) [1,2]. Buserelin has therapeutic 
applications as an antitumor agent in hormone dependent cancers, e.g. prostate and breast cancer [3-
7]. Continuous stimulation of the GnRH receptor located in the anterior pituitary, results in down- 
regulation through internalization of the GnRH receptor, suppression of the luteinizing hormone (LH) 
and follicle-stimulating hormone (FSH) release and subsequent sex hormones [8-10]. Furthermore, it 
is also used in the treatment of endometriosis and uterine fibroids, which are both estrogen 
dependent diseases [11-13]. At lower dosage, buserelin can be used in assisted reproduction [14]. The 
structure of buserelin is given in Table 1. 
Administration of this therapeutic family is mainly done by nasal administration, e.g. Suprefact® 
(buserelin acetate) or by subcutaneous injection, e.g. SupreCur® (buserelin acetate). Long-term 
treatment options for palliative prostate cancer treatment, typically given every 3 months, use 
biodegradable peptide-loaded implants, e.g. Zoladex® (goserelin acetate) and Leuproreline Sandoz® 
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(leuproreline acetate). These implant are constructed of biodegradable poly (D,L-lactide-co-glycolide) 
(PLGA) and poly(L-lactide) (PLA) polymers, respectively [15,16]. Recently, a non-biodegradable implant 
formulation (Vantas®), containing 50 mg of histrelin acetate, was marketed [17]. It comprises a 
cylindrical implant (35 mm length, 3 mm diameter), comprising a inner histrelin acetate (50 mg) drug 
core, surrounded by a non-biodegradable hydrogel (2-hydroxyethyl methacrylate) reservoir, designed 
for daily release of 50 µg of histrelin acetate. This non-biodegradable formulation has a treatment 
duration of 1 year, hereby limiting repeated drug administration. Moreover, this non-biodegradable 
implant can be removed at any time to stop the therapy, which is not always possible with the 
biodegradable formulations. 
 
Table 1: Overview of buserelin and goserelin properties 
 Buserelin (API) Goserelin (IS) 
Structure 
Sequence 
  
Pyr-His-Trp-Ser-Tyr-D-Ser(tBu)-Leu-Arg-Pro-NHEt 
(acetate salt) 
Pyr-His-Trp-Ser-Tyr-D-Ser(tBu)-Leu-Arg-Pro-Azagly-NH2 
(acetate salt) 
Chemical 
formula 
C60H86N16O13 C59H84N18O14 
Physicochemical properties 
Mono-
isotopic MW 
1238.65 1268.64 
pI 9.6 9.6 
H2O 
solubility  
Sparingly soluble Soluble 
 
As demonstrated in Chapter V, buserelin acetate possesses adequate thermal stability properties in its 
dry powder state, opening perspectives for the solvent-free, hot-melt processing of this drug into 
polymeric formulations [18]. As a proof of principle, a buserelin acetate-loaded polymeric implant 
formulation will be produced using this hot-melt method. Poly(ethylene-vinyl acetate) (pEVA) is 
ideally suited for the manufacturing of non-biodegradable implants, as it is not water soluble and has 
suitable melt characteristics. The melt temperature of this co-polymer depends on the ethylene-vinyl 
acetate ratio. As the percentage vinyl acetate (VA) increases, the melting temperature of the polymer 
decreases [19]. The melting temperature of polymers containing 40% to 9% vinyl acetate content 
ranges between 43°C and 99°C, respectively. Moreover, pEVA has already been extensively used in 
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various medical formulations, e.g. films, stent coatings, implant devices and vaginal rings [20-26]. In 
this proof of principle study, a pEVA polymer with 33% VA was selected, due to its low melt 
temperature of 60 °C [27]. Previous work has shown that daily subcutaneous administration of 50 µg 
buserelin acetate was able to completely suppress testosterone production [28]. Therefore, in this 
proof of principle study, a buserelin acetate drug load of 20% (m/m) was chosen, theoretically 
allowing for a year round daily release of 50 µg buserelin acetate. The influence of the hot-melt 
production method on the buserelin acetate stability will be investigated as well as the ICH 
accelerated stability of the implant formulation. Buserelin acetate release from the produced implant 
will be verified in-vitro as well as in-vivo. 
 
2. MATERIALS AND METHODS 
2.1 Materials 
Buserelin acetate and goserelin acetate European Pharmacopoeia (Ph. Eur.) quality were bought at 
Hybio Pharmaceutical Co. (Shenzhen, China) and EDQM (Strasbourg, France), respectively. UHPLC 
grade acetonitrile, methanol, water, formic acid and trifluoroacetic acid were obtained from BioSolve 
(Valkenswaard, The Netherlands), whereas HPLC gradient grade acetonitrile and chloroform was 
purchased from Fisher Scientific (Aalst, Belgium). Water was purified using an Arium 611 purification 
system (Sartorius, Gottingen, Germany) yielding ≥ 18.2 MΩ×cm quality water. Phosphate buffered 
saline (PBS) sachets to prepare 0.01 M solution were purchased from Sigma Aldrich (Diegem, 
Belgium). Poly(ethylene-vinylacetate) (33% vinyl acetate) polymer was obtained from Celanese 
(Edmonton, Canada). Acquity UPLC BEH 300 C18, UPLC CSH C18 and suitable guard column were 
purchased from Waters (Zellik, Belgium), whereas HALO C18 column was obtained from Achrom 
(Machelen, Belgium). 
 
2.2 Implant preparation 
The preparation process of a 100 mg weighing pEVA polymeric implant, loaded with 20% (m/m) 
buserelin acetate began by weighing approximately 88 mg of pEVA and 22 mg of buserelin acetate in a 
weighing boat whilst noting down their exact weights. The powders were transferred into an agate 
mortar and grinded using an agate pestle and plastic card until a homogenous powder was obtained. 
Approximately, but accurately, 100 mg of the buserelin acetate-pEVA mixture was transferred into a 
glass vial (12×32 mm, Borosilicate, Type 1, Class A glass). The heating block (Stuart, Stone, United 
Kingdom, temperature accuracy and temperature uniformity within the block both ± 1°C) was 
preheated at 100°C and the vial was incubated for 4 min. After incubation, the vial was removed and 
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allowed to cool for 30 sec after which the hot buserelin acetate-pEVA mixture was removed from the 
vial using spoon and tweezers. A piece of aluminum foil (0.015 mm, Strobbe, Gent, Belgium) was 
placed on the heating block on which the buserelin acetate-pEVA hot mixture was placed and shaped 
into a cylindrical shape using a small metal block for approximately 30 sec. Finally, the aluminum foil 
was removed from the heating block, the cylindrical implant cooled at room temperature and 
removed from the aluminum foil. 
 
2.3 Buserelin acetate assay in implant 
Sample preparation of buserelin acetate-pEVA implants 
Accurately weighed produced implants or aliquots thereof, were transferred into a 50 mL Erlenmeyer 
flask. The pEVA polymer was dissolved by adding 5 mL of chloroform and shaken until fully dissolved. 
Buserelin acetate was extracted by adding 6 mL of 0.1% formic acid H2O, followed by gently shaking 
the Erlenmeyer flask. Next, the entire solvent mixture was transferred into a glass test tube and 
centrifuged for 1 min at 1000 rpm, after which the water fraction was transferred into a 25.0 mL 
volumetric flask. This liquid-liquid extraction procedure was repeated an additional three time, i.e. 
four separate extraction steps in total. Finally, the 25.0 mL volumetric flask was diluted to volume 
using 0.1% formic acid H2O. Accuracy and precision of the extraction method was verified by means of 
spiking pEVA polymer with buserelin acetate, whilst the amount of un-extracted buserelin acetate was 
verified by means of an additional 5th liquid-liquid extraction step. 
 
Buserelin acetate assay: rapid RP-fused-core-UV 
The HPLC-UV apparatus consisted of a Waters Alliance 2695 separations module and a Waters 2487 
dual λ absorbance detector with Empower 2 software for data acquisition (all Waters, Milford, MA, 
USA). The HALO C18 column (50 mm × 4.6 mm I.D.; 2.7 µm particle size, 90Å) was thermostated in an 
oven set at 40°C ± 3°C, whereas the autosampler temperature was set at 5°C ± 3°C and UV detection 
was performed at 220 nm. The flow rate and injection volume were set at 0.6 mL/min and 10 µL, 
respectively, and a gradient was applied (where A = 95% water and 5% acetonitrile with 0.1% (m/V) 
formic acid, and B = 95% acetonitrile and 5% water with 0.1% (m/V) formic acid), starting with a 1.0 
min isocratic hold at 90% A, followed by a linear gradient from 90% A to 75% A in 3.0 min and ending 
with a isocratic hold for 1 min, followed by returning to the initial conditions and re-equilibration. The 
method was verified for repeatability (sextuplicate injection of 0.1 mg/mL buserelin acetate [29]), 
linearity (ranging from 0.1 mg/mL to 0.001 mg/mL buserelin acetate) and limit of detection. This 
method was used for buserelin acetate assay in implants, and in-vitro dissolution samples. 
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Buserelin acetate stability: stability-indicating RP-UHPLC-PDA 
The UPLC apparatus, implemented for quantification of buserelin-related degradants, consisted of a 
Waters Acquity H UPLC Class Quaternary Solvent Manager, a Waters Acquity Sample Manager, 
combined with a Flow Through Needle, and a Waters Acquity Ultra Performance LC PDA detector with 
Empower 2 software for data acquisition (all Waters, Milford, MA, USA). An Acquity UPLC BEH 300 
C18 (100 mm × 2.1 mm I.D., 1.7 µm particle size) column, thermostated in an oven set at 30°C ± 3°C, 
was used. The flow rate was set at 0.6 mL/min and a gradient was applied (where A = 95% water and 
5% acetonitrile with 0.1% formic acid (m/V), and B = 95% acetonitrile and 5% water with 0.1% formic 
acid (m/V)), starting with a 1.5 min isocratic step at 100% A, followed by a linear gradient from 100% A 
to 79% A in 9.5 min and ending with a isocratic hold for 7 min. The chromatographic method also 
included a rinsing step at 80% B, followed by returning to the initial conditions and re-equilibration. 
The sample compartment was thermostated at 5°C ± 3°C and UV detection was performed at 220 nm. 
The injection volume used was 2 µL. The reporting threshold for the dry heat stressed samples (see 
section 2.3) was set at 1% peak area relative to unstressed buserelin. Method verification results can 
be found in previous published work [18]. 
 
2.4 Implant stability 
The stability of buserelin acetate in the produced implants was ascertained at 25°C/60% R.H. (long-
term) and 40°C/75% R.H. (accelerated), as specified by ICH guidelines [30], whereas control samples 
were stored at 5°C. The accelerated stability samples were analyzed monthly, up to 3 months 
incubation, whereas long-term stability samples were analyzed after 3 months, each in triplicate. 
Buserelin acetate assay and impurity content were analyzed using aforementioned methods. 
 
2.5 Buserelin acetate release from implant 
In-vitro dissolution 
The in-vitro dissolution study was performed using HPLC vials (12×32 mm, Borosilicate, Type 1, Class A 
glass). After determining the buserelin acetate content, the implants (n=2) were placed into the glass 
vials and submerged with 1.8 mL of 0.01M PBS. The implants were incubated at 37°C, using an 
Eppendorf Thermomixer Comfort (VWR, Leuven, Belgium), whilst shaking planetary at 300 rpm. At 
defined time points, the entire dissolution medium was refreshed and the amount of buserelin 
acetate release in the PBS medium quantified, using the rapid fused-core-UV method. A potential 
initial burst phenomenon was tracked by frequent sampling during the first two days of the study, i.e. 
sampling after 0.5, 1, 2, 4, 8, 24, 32 and 48 hours. After this, sampling frequency was reduced to 
approximately once a day. Furthermore, the in-vitro buserelin acetate release of implants stored for 
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three months at 5°C, 25°C/60% R.H. (long-term stability) and 40°C/75% R.H. (accelerated stability) was 
also evaluated. 
Different mechanistic mathematical models can be employed to described drug release from 
polymeric implants. The quantitative drug release from a cylindrical monolithic implant is described 
using a formula derived from Fick’s second law of diffusion [31,32]. This formula assumes (i) that the 
initial drug concentration is below drug solubility in the matrix (solid solution) (ii) axial as well as radial 
mass transfers, (iii) perfect sink conditions, (iv) an initially homogenous drug distribution in the matrix 
and (v) a negligible mass transfer resistance due to unstirred boundary layers at the polymeric surface. 
 
𝑀𝑡
𝑀∞
= 1 −
32
𝜋2
·  
1
𝑞𝑛
2
∞
𝑛=1
· 𝑒𝑥𝑝  −
𝑞𝑛
2
𝑅2
· 𝐷 · 𝑡 ·  
1
(2 · 𝑝 + 1)2
· 𝑒𝑥𝑝  
(2 · 𝑝 + 1)2 · 𝜋2
𝐻2
· 𝐷 · 𝑡 
∞
𝑝=0
 
 
Here, Mt is the cumulative drug amount released at time t, M∞ is the drug quantity released at time 
infinity, i.e. total initial drug load drug. D is the diffusion coefficient of the drug within the matrix, qn 
are function roots and radius and height of the cylindrical implant are R and H. 
Alternatively, when initial drug concentration exceeds the drug solubility in the polymeric matrix, a 
solid dispersion is formed. Higuchi published following formula: [31,33]: 
 
𝑀𝑡
𝐴
=  𝐷(2𝐶0 − 𝐶𝑠)𝐶𝑠𝑡 
 
Where Mt is the cumulative drug amount released at time t, A is the surface area, D is drug diffusion 
coefficient in the matrix and C0 and Cs are the initial drug concentration and drug solubility in the 
matrix, respectively. This formula assumes (i) formation of a solid dispersions, (ii) matrix geometry of a 
thin film, (iii) drug particles are much smaller than the thickness of the polymer formulation, (iv) 
carrier materials does not swell or dissolve, (v) drug diffusion is constant, i.e. not time- or place-
dependant and (vi) perfect sink conditions are maintained. 
 
Simplified models can also be used to fit the in-vitro release data, i.e. the Higuchi and Korsmeyer-
Peppas models [34-37]. The Higuchi models drug release as a diffusion process based upon Fick’s law: 
 
Mt = kH × t
1/2 
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Where Mt is the cumulative drug amount released at time t (days) and kH is the Higuchi dissolution 
constant, which essentially corresponds to 𝐴 𝐷(2𝐶0 − 𝐶𝑠)𝐶𝑠, when the formulation is a solid 
dispersion. 
Alternatively, the Korsmeyer-Peppas model described the drug release as follows: 
 
Mt
M∞
= k × tn  
 
Where Mt is the cumulative drug amount released at time t, M∞ is the drug quantity released at time 
infinity, i.e. total initial drug load, k is a kinetic constant and n is the release exponent. The value of n is 
used to determine the drug release mechanism and is related to the geometrical shape of the implant. 
For cylindrical devices undergoing diffusion controlled drug release, n is equal to 0.45, whereas larger 
n values indicate non-Fickian drug release. Drug release from porous systems can result in n values < 
0.45, resulting from a combination of Fickian diffusion and diffusion through water filled pores.  
 
In-vivo dissolution  
In order to determine the in-vivo buserelin acetate release, the implant was implanted sub-dermally in 
the neck of female BALB/c mice (T0). The mice were anesthetized approximately 15 min before 
surgery by inhalation of 2.5% isoflurane with 30% oxygen and 70% medical air. The neck region of the 
mice was shaved and disinfected with iodine. A small incision was made between the two shoulder 
blades and a distal pocket was created by blunt forceps followed by implantation of the polymeric 
device and closing the incision with 5.0 Vicryl suture and a droplet of tissue glue. At defined time 
points, i.e. 1, 8 and 30 days post-implantation, the mice were anesthetized by isoflurane 
administration, directly followed by blood collection in heparine-coated tubes by cardiac puncture. 
Plasma was prepared by centrifuging at 3500 rpm for 10 min (Rotafix 32a) and frozen at -80°C until 
analysis. After the blood sampling, the animals were euthanatized by cervical dislocation and their 
implants removed. Kidneys and livers were harvested and frozen at -80°C until analysis. The study 
design was approved by the Animal Experiment Committee (BTX0013). 
 
Buserelin acetate assay in biological matrices: bio-analytic SPE-RP-UHPLC-
MS/MS method 
Solid-phase extraction (SPE) of buserelin acetate from the harvested biological matrices, i.e. (i) mice 
plasma, (ii) mice kidney homogenate and (iii) mice liver homogenate, was performed using Oasis 
Weak Cation Exchange (WCX) µElution plates, combined with a Waters positive pressure manifold, 
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designed to move liquids through the WCX µElution plates. Goserelin acetate was selected as an 
internal standard (IS), due to its close structural resemblance to buserelin acetate (Table 1). 
The chemistry of the WCX µElution plates is based upon a water-wettable Hydrophilic-Lipophilic 
Balance (HLB) poly(divinylbenzene-co-N-vinylpyrrolidone) copolymer, which is modified with surface-
bound carboxylic acid groups, thus providing a dual retention mode, i.e. RP and ion-exchange 
retention mechanisms. Settings of the positive pressure manifold are given between brackets [38]. 
The SPE columns were first conditioned and equilibrated using 200 µL MeOH and H2O (10 sec, 30 psi), 
respectively. 200 µL acidified, aqueous sample was loaded (30 sec, 10 psi), using the RP interaction to 
retain the buserelin and goserelin peptides. The first wash step, involving 200 µL of 5% NH4OH in H2O 
(10 sec, 30 psi), ionizes the carboxylic acid groups of the SPE column, creating an additional ion 
interaction between these carboxylate residues and the positively charged basic amino acid residues 
of buserelin and goserelin, i.e. arginine (pKa 12.5) and to lesser extent histidine (pKa 6.10). Moreover, 
unretained hydrophilic contaminants are washed away at this point. The second wash step, using 200 
µL of 80/20 H2O/ACN solution (10 sec, 30 psi), eliminates hydrophobic contaminants. Finally, the 
peptides are eluted from the SPE columns by adding in twofold 25 µL 40/60 H2O/ACN + 1% TFA (30 
sec, 10 psi). The elution solvent, totaling 50 µL, was captured in a polypropylene 96 well plate, further 
diluted with 50 µL H2O, protected from the environment by a polypropylene cap mat and sonicated. 
This solution was analyzed using a Waters Acquity UPLC H-class Bio, equipped with a Xevo Triple 
Quad-S MS detector, of which the operational settings are given in Table 2. 
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Table 2: Bio-analytic RP-UPLC-MS/MS method 
Chromatography inlet 
Column + guard 
Acquity UPLC CSH C18 (2.1mm x 100 mm, 1.7 µm particle size, 130 Å)  
with suitable guard column 
Flow 0.5 mL/min 
Injection volume 10 µL 
Needle wash 45:45:10 H2O:ACN:DMSO + 0.1% FA Post injection: 20 s 
Column oven temperature 40°C ± 4°C 
Sample temperature 10°C ± 3°C 
Mobile phase A: 0.1% FA in 90:5:5 H2O:ACN:DMSO B: 0.1% FA in 5:5:90 H2O:ACN:DMSO 
Gradient program 
 
Time (min) Mobile phase A (%) Mobile phase B (%) 
0 
2.5 
2.75 
5 
85 
60 
85 
85 
15 
40 
15 
35 
Run time 5 min 
MS tuning conditions 
Capillary voltage 2.80 kV 
Cone voltage 30V 
Source offset 50.0 V 
Source temperature 150 °C 
Desolvation gas flow (N2) 1000 l/h 
Desolvation temperature 500 °C 
Cone gas flow 150 l/h 
Collision gas flow (Ar) 0.23 mL/min 
Nebuliser 7.00 bar 
Method events: 
0  2.75 min: MS 
2.755 min: divert valve to waste 
MRM 
Buserelin: 620.38592.39; CE: 16V (loss of tBu) 
Goserelin: 635.34607.37; CE: 16V (loss of tBu) 
 
Sample preparation 
Stock solutions containing 500 ng/mL goserelin acetate (IS) and different buserelin acetate 
concentrations, i.e. 500, 50 and 5 ng/mL, were prepared for SPE-RP-UPLC-MS/MS method verification 
purposes. Details regarding the sample preparation process are given in Table 3. All pre-SPE sample 
preparations were performed in glass HPLC vials. The buserelin acetate recovery was evaluated by 
comparing pre- and post-SPE spiked water samples (A and B). Matrix effects were evaluated by 
comparing post-SPE spiked water and plasma samples (B and C). Linearity of the method was 
evaluated by pre-spiking plasma with various buserelin acetate concentrations (500-50-5 ng/mL), 
whilst keeping the goserelin acetate (IS) concentration constant at 500 ng/mL (D). 
Mice plasma samples were prepared by mixing 180 µL plasma, 20 µL goserelin acetate (IS; 500 ng/mL) 
and 200 µL of 4% H3PO4 in a glass HPLC vial. The sample was vortexed and SPE processed. Harvested 
kidneys and liver were defrosted, weighed and transferred into glass test tubes, to which 1 mL and 2 
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mL, respectively, of a 50 ng/mL goserelin acetate IS solution was added. The kidney and liver were 
homogenized using a mixer (VDI12, VWR). The resulting solution was centrifuged during 1 min at 3000 
rpm and 200 µL of supernatant was mixed with 200 µL 4% H3PO4 in a glass HPLC vial. The sample was 
vortexed and SPE processed. 
 
Table 3. SPE sample preparation overview 
 A. Pre-spiked H2O B. Post-spiked H2O C. Post-spiked plasma D. Pre-spiked plasma 
P
re
-S
P
E 
180 µL H2O 180 µL H2O 180 µL plasma 180 µL plasma 
20 µL stock: 
500 ng/mL bus. ac./gos. ac. 
20 µL H2O 20 µL H2O 
20 µL stock: 
 500-50-5 ng/mL bus. ac. 
500 ng/mL gos. ac. 
200 µL 4% H3PO4
1 200 µL 4% H3PO4
1 200 µL 4% H3PO4
1 200 µL 4% H3PO4
1 
SPE 
200 µL sample 200 µL sample 200 µL sample 200 µL sample 
Wash steps Wash steps Wash steps Wash steps 
P
o
st
-
SP
E 
50 µL eluate 50 µL eluate 50 µL eluate 50 µL eluate 
50 µL H2O 
50 µL stock: 
100 ng/mL bus. ac./gos. ac. 
50 µL stock: 
 100 ng/mL bus. ac./gos. ac. 
50 µL H2O 
1 disrupt peptide-protein binding 
 
2.6 Confocal Raman spectroscopy 
In order to characterize the buserelin acetate distribution in the pEVA matrix, the cross section of the 
implant was investigated by Raman spectroscopy. Raman spectra were acquired using a commercial 
confocal Raman microscope (WITec Alpha300R). A 785 nm excitation wavelength (Toptica XTRA 785 
diode laser) was chosen to reduce auto-fluorescence and sample heating due to absorption. The laser 
energy on the sample was approximately 150-200 mW. Reference spectra of a blank pEVA implant, i.e. 
no buserelin acetate present, and buserelin acetate powder were acquired using a 5 sec integration 
time and averaged over 10 spectra. From this, the Raman signal was found to be selective for the 
presence of pEVA (1305 cm-1) and buserelin acetate (1550 cm-1). For further cross sectional analysis, 
the 1550 cm-1 (± 15 cm-1) and 1305 cm-1(± 25 cm-1) spectral bands were integrated, to respectively 
quantify the buserelin acetate and pEVA polymer. These values were then normalized by following 
formula: 
Buserelin acetate: 
S1550 cm−1
S1305 cm−1 + S1550 cm−1
 
 
For further cross sectional analyses, Raman spectra were acquired with an integration time of 1 sec. 
For the high-resolution area scans, a 100x/0.9 NA air objective (Zeiss EC Epiplan-NEOFLUAR) was used 
to focus light on the sample. A 25 µm by 25 µm area was scanned in 75×75 pixels. The line scans were 
acquired through a 10x/0.3NA (Nikon CFI Plan Fluor 10x), with a line length of approximately 2500 µm 
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sampled by 1500 points. The large cross section maps were made with a 4x/0.13NA objective 
(NikonCFI Plan Fluor 4x), with 800×5 pixels in a 2700 µm by 100 µm area. The scattered light was 
collected through a multimode fiber-based confocal pinhole (100 µm) and directed to a spectrometer 
equipped with a cooled CCD camera at -60°C (Witec UHTS 300). 
 
3. RESULTS AND DISCUSSION 
3.1 Buserelin acetate recovery 
The average buserelin acetate recovery from the spiked pEVA polymer is given in Table 4, as well as 
the amount of un-extracted buserelin acetate. During method development, the method accuracy 
was calculated to be 103.05%, whereas the method precision was determined to be 0.66% RSD (n=3). 
From an additional 4th liquid-liquid extraction step, a residual un-extracted buserelin acetate amount 
of 0.09% was deduced, which was considered to negligible. However, when applying this sample 
extraction method to the produced buserelin acetate-pEVA implants, only 73.87% of the buserelin 
acetate was recovered (0.67% RSD, n=3). Furthermore, based upon an additional 4th liquid-liquid 
extraction step, an un-extracted residual buserelin acetate amount of 2.9% was detected. Therefore, 
the final extraction procedure was adjusted to contain 4 independent liquid-liquid extraction steps. 
After this adjustment, the residual buserelin acetate determined using a 5th additional liquid-liquid 
extraction step was found to be negligible, i.e. 0.20%, hereby validating the finale extraction 
procedure. 
As shown in Chapter VI, 25.3% of the buserelin acetate is lost during the preparation process, resulting 
in under-dosed implants. Given this information, the experimentally determined buserelin acetate 
assays and recovery values were corrected for this observed production process-related API loss. The 
corrected buserelin acetate assay and recovery values are given between brackets in Table 4. The 
corrected buserelin acetate recoveries and the amount of un-extracted buserelin acetate, account for 
a total buserelin acetate recovery of approximately 100%. Therefore, it can be concluded that the low 
buserelin acetate recovery is directly linked to API loss during the preparation process, rather than 
degradation-related. This was further confirmed, as the samples were analyzed using the stability-
indicating RP-UHPLC-PDA method and no significant degradants were found. Obviously, these findings 
further underlines the capabilities of processing buserelin acetate using our hot-melt preparation 
method.   
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Table 4. Buserelin acetate recovery from spiked pEVA and buserelin acetate-loaded implants. 
 # 
Buserelin acetate 
(mg)
1
 
Buserelin acetate 
recovered (mg)
3
 
Recovery (%)
3
 Un-extracted buserelin (%)
2
 
Sp
ik
ed
 1 18.70 19.14 102.37 0.07 
2 19.18 19.90 103.74 0.07 
3 18.76 19.33 103.04 0.12 
 Average 103.05 0.09 
 %RSD 0.66 33.93 
Im
p
la
n
t 1 19.51 14.47 (19.38) 74.18 (99.31) 3.34 
2 19.71 14.45 (19.35) 73.30 (98.13) 1.99 
3 20.19 14.97 (20.04) 74.13 (99.24) 3.22 
 Average 73.87 (98.90) 2.85 
 %RSD 0.67 26.20 
1 Buserelin acetate weighed (spiked pEVA samples) or calculated as:𝑖𝑚𝑝𝑙𝑎𝑛𝑡 𝑤𝑒𝑖𝑔ℎ𝑡 (𝑚𝑔) ×
𝐵𝑢𝑠𝑒𝑟𝑒𝑙𝑖𝑛  𝑎𝑐 .(𝑚𝑔 )
𝐵𝑢𝑠𝑒𝑟𝑒𝑙𝑖𝑛  𝑎𝑐 . 𝑚𝑔  + 𝑝𝐸𝑉𝐴  (𝑚𝑔 )
 (implant) 
2 Calculated from additional 4th extraction step during method development 
3 Values between brackets were corrected for observed API loss (see Chapter VI) 
 
3.2 Implant homogeneity 
Repeatability of the RP-fused-core-UV method, evaluated by sextuplicate 0.1 mg/mL buserelin acetate 
injection, resulted in a 0.31% RSD value, which is below the 0.85% threshold as stipulated in the 
European Pharmacopoeia for assay method [29]. The R² value of the buserelin acetate area versus 
concentration curve was 0.9999 (F value: 225816), with a random residual plot, thus obtaining a 
sufficient linear relationship within the 0.1 – 0.001 mg/mL buserelin acetate range. The limit of 
detection was 9.92 ×10-6 mg/mL .  
The buserelin acetate concentration distribution throughout the produced implants was verified by 
dividing implants (n=3) into 5 separate sections and quantifying the buserelin acetate concentration of 
each individual section. As can be seen from Figure 1, a small longitudinal buserelin acetate 
concentration gradient can be seen in some implants, most likely due to the manual implant 
preparation process, whereas in others no clear trend was observed. Importantly, the buserelin 
acetate amount present in the produced implants can be extrapolated from two extremity aliquots, 
i.e. small implant sections taken from the left and right side of the implant. The ratio between the 
extrapolated buserelin acetate amount in the implant and the experimental determined buserelin 
acetate amount in the same implant was calculated to be 100.20% (1.36% RSD; n=3). 
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Figure 1. Buserelin acetate homogeneity in produced implants. 
 
3.3 Implant stability 
The buserelin acetate stability results, obtained with the RP-fused-core method, are depicted in Figure 
2. The buserelin acetate concentrations of each individual implant, at the different stability conditions 
and time points, were subsequently re-expressed relatively to the average buserelin acetate 
concentration (% m/m) obtained at T0M. Simultaneously to the buserelin acetate assay, the stability 
samples were also analyzed using the stability-indicating RP-UHPLC-PDA method. As mentioned 
before, no significant buserelin acetate degradation was observed at T0M (reporting threshold of 1%), 
confirming the hot-melt process capabilities of buserelin acetate. Moreover, no significant buserelin 
acetate degradation was observed at the different stability storage conditions, which is supportive of 
the (short-term) buserelin acetate stability in the pEVA matrix. Some variability can be seen in the 
buserelin acetate assay values derived at the different storage conditions and time points. Given the 
verification results for the rapid RP-fused-core-UV and buserelin acetate extraction, this variability is 
attributed to the manual nature of the implant preparation process, combined with previously 
observed API losses occurring during the preparation process. 
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Figure 2. Buserelin acetate stability in the produced implants at 5°C (blue), long-term stability conditions 
(25°C/60% R.H. – green) and accelerated conditions (40°C/75% R.H. – red). Individual buserelin acetate 
concentrations (% m/m) were re-expressed relative to the average buserelin acetate concentration observed at T0M. 
 
3.4 Buserelin acetate release from implant 
In-vitro dissolution 
The cumulative buserelin acetate release curves, obtained from two implants are given in Figure 3. 
The initial buserelin acetate concentrations in both implants, i.e. 15.84% (m/m) and 17.85% (m/m) for 
implants A and B respectively, were derived from two aliquots taken from the left and right side of the 
implants. As can be seen from Figure 3, large quantities of buserelin acetate are released during the 
first hours of dissolution testing, i.e. 561 µg and 759 µg during the first 48 h for implant A and B, 
respectively. The in-vitro dissolution data obtained after the initial burst release, i.e. post-48 hrs, were 
modeled using the Higuchi and Korsmeyer-Peppas (n=0.45) equations. Given the high correlation 
values, i.e. R² >0.99 for both models and both release profiles, the buserelin acetate release from the 
cylindrical pEVA matrix is found to be diffusion controlled. Buserelin acetate release from implant A 
and B in steady state conditions, i.e. post-48 h to end of in-vitro study, was calculated to be 5.38 and 
5.23 µg/day, respectively. 
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Figure 3. In-vitro buserelin acetate cumulative release curves. In-vitro dissolution testing of Implant A stopped 
after 40 days. 
 
Moreover, the in-vitro release profiles obtained from implant stored at different storage conditions 
for 3 months, i.e. 5°C, 25°C/60% R.H. (long-term stability) and 40°C/75% R.H. (accelerated stability), 
are given in Figure 4. 
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Figure 4. In-vitro buserelin acetate cumulative release curves obtained from implants stored 
at 5°C (blue; 17.36% m/m bus. ac.), 25°C/60% R.H. (green; 17.84% m/m bus. ac.) and 40°C/75% R.H. (red; 
18.49% m/m bus. ac.) 
 
A summary of the in-vitro release data is given in Table 5. A similar initial buserelin acetate burst 
release is was also observed with the stability implants, accumulating for 693.17 µg (5°C), 768.47 µg 
(25°C/60% R.H.) and 499.99 µg (40°C/75% R.H.) within the first 48 h. Following this initial burst effect, 
the daily buserelin acetate releases data were calculated from the available data, i.e. 48 – 120h, and 
found to be 12.01 µg, 8.11 µg and 8.14 µg, for the implants stored at 5°C, 25°C and 40°C, respectively. 
Evaluation of the release data showed high correlation values, i.e. R² >0.99, for both Higuchi and 
Korsmeyer-Peppas (n=0.45) models, similar to the T0M in-vitro release data. Based on the available 
data and assuming similar prepared implants, no statistically significant influence of temperature and 
humidity was observed for the buserelin acetate release from the stability implants. By using similar 
time intervals to calculate the short-term buserelin acetate release of the T0M implants, small, but 
statistically significant differences were found at the 95% significance level between implant B and the 
implants stored at 25°C/60% R.H. and 40°C/75% R.H. However, no statistically significant differences 
were found when compared to the T0M implant A. 
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Table 5. Summary of in-vitro buserelin release results  
Implant Bus ac. (% m/m) 
Cum. bus ac. release 
<48h (µg) 
Short-term release 
(µg/day)
1
 
T0M - A 15.84 561.37 10.51 (7.48 – 13.55) 
T0M - B 17.85 759.29 15.22 (12.30 – 18.14) 
T3M - 5°C 17.36 693.17 12.01 (7.53 – 16.49) 
T3M - 25°C/60%R.H. 17.84 768.47 8.11 (4.86 – 11.36) 
T3M - 40°C/75%R.H. 18.49 499.99 8.14 (6.29 – 9.99) 
1 95% CI given between brackets 
 
Bio-analytic SPE-RP-UHPLC-MS/MS method verification results 
The recovery value determines the loss during the sample preparation process and subsequent SPE 
processing. It is determined by comparing the response of pre- and post-spiked H2O samples (Table 3, 
A and B). High recovery values were obtained for both buserelin acetate and goserelin acetate 
individually, i.e. >85%. Moreover, the buserelin acetate recovery, using goserelin acetate as IS, was 
calculated to be 94.19% (5.06% RSD; n=3). In order to determine the buserelin acetate loss steps in 
the SPE process, the loading step and both washing steps were collected and analyzed. The average 
buserelin acetate losses were quantified to be 1.17% (load step), 0.20% (wash 1, 5% NH4OH) and 
0.68% (wash 2, 80:20 H2O:ACN), and were thus found to be negligible. 
The matrix effect determines the loss or gain in signal due to the presence of a (biological) matrix. On 
average, matrix suppression was seen for both buserelin acetate (-39.72%, n=3) and goserelin acetate 
(-43.96%, n=3) individually, determined at one experimental condition. However, the buserelin 
acetate recovery, calculated using goserelin acetate as IS, derived from post-spiked plasma and H2O 
samples (Table 3, B and C) was calculated to be 107.03% (%RSD 3.50, n=3). The use of goserelin 
acetate as internal standard thus compensates for the observed matrix effect. A linear relationship 
between the buserelin acetate concentration ranging from 5 to 500 ng/mL, each concentration 
performed in duplicate, and the obtained buserelin acetate/goserelin acetate peak area ratios was 
observed (R²: 0.9995; F-value: 7471).  
 
In-vivo release 
The buserelin acetate concentrations in the mouse plasma, kidney and liver samples, collected at 
three different post-implantation times points, are given in Figure 5. Each time point was performed 
in triplicate. As can be seen from Figure 5, high buserelin acetate concentrations are present one day 
after implantation in each of the three biological matrices. This observation is consistent with the 
observed in-vitro dissolution burst effects in the first 24 hrs. At 30 days post-implantation, buserelin 
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acetate levels drop to a concentration of 4 ng/mL in plasma, 0.1 ng/mg in kidney homogenate and 
0.04 ng/mL in liver homogenate. 
 
Figure 5. In-vivo buserelin acetate release results. Blue spheres: individual data points (n=3), 
black crosses: averages (top to bottom: plasma, kidney and liver concentrations). 
 
3.5 Confocal Raman microscopy 
The reference Raman spectra of buserelin acetate powder and a blank pEVA implant are given in 
Figure 6 (A and B). Selective Raman signals were observed at 1550 cm-1 (buserelin acetate) and 1305 
cm-1 (pEVA). This selective buserelin acetate Raman signal corresponds to the Amide II bond signal, 
whereas the pEVA signal is attributed to CH2 deformation, which is part of the polymer backbone. 
Using these two signals, the buserelin acetate signal was normalized, resulting in a 0 – 1 range. Three 
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line-scans were recorded of the cross section of a produced buserelin acetate loaded pEVA implant, 
and the normalized Raman values are given in section C of Figure 6. As reference, the normalized 
buserelin acetate signal obtained from a line scan of a blank pEVA polymer implant is also given. 
When comparing both, it is obvious that the buserelin acetate in the polymeric matrix is distributed in 
a heterogeneous manner, i.e. solid dispersion [39]. The dispersion nature of buserelin acetate in the 
polymeric matrix is clearly visual from the high-resolution scans, which show small pockets of 
buserelin acetate (yellow) surrounded by the polymeric matrix (black). 
 
 
Figure 6. Reference spectra of buserelin acetate powder (A) and a blank pEVA implant (B). Selective Raman 
signals were observed at 1550 cm
-1
 (buserelin acetate) and 1305 cm
-1
 (pEVA). (C) Normalized signals of 
buserelin acetate-loaded implant (3 line-scans) and of blank pEVA implant (1 line-scan). (D) High resolution scan 
of buserelin acetate-loaded implant. 
  
CHAPTER VII – HOT-MELT PREPARATION OF A NON-BIODEGRADABLE PEPTIDE IMPLANT: A PROOF OF PRINCIPLE 
 
 
176 
4. DISCUSSION 
The dry heat experimental results performed at hot-melt-related conditions using buserelin acetate in 
Chapter V were confirmed: no significant peptide degradation products (reporting threshold 1%) were 
found after implant preparation [18]. In-vitro and in-vivo buserelin acetate release from the pEVA 
matrix revealed the presence of an initial burst release. Generally, burst release of the drug is 
unwanted as this initial high drug release may lead to local or systemic toxicity [40]. Moreover, the 
burst release will reduce the effective lifetime of the implant, as this initial drug fraction is essentially 
wasted, and will thus have therapeutic as well as economical consequences. An excellent review 
explaining the mechanisms behind the burst release in matrix-controlled drug delivery systems was 
made by Huang et al. [41]. For matrix systems, one possible hypothesis explaining the observed burst 
involves the preparation process, where a fraction of the initial drug load becomes trapped on the 
surface of the polymer matrix. When the implant comes into contact with the release medium, this 
drug fraction is immediately released. Alternatively, as pEVA forms a porous polymeric matrix, 
buserelin acetate which is immediately adjacent to a porous channel will be released into the medium 
much faster, compared to buserelin acetate which first has to diffuse through the pEVA polymer.  
Our results clearly demonstrate the feasibility of preparing non-biodegradable polymeric implants 
loaded with a therapeutic peptide, e.g. buserelin acetate, using a hot-melt production method. Raman 
microscopy showed a heterogeneous distribution of the buserelin acetate in the polymeric matrix. 
The hot-melt production technique did not result in significant peptide degradation and buserelin 
acetate stability in the polymeric matrix was demonstrated up to three months storage at 40°C, 75% 
R.H. After a burst effect was seen during the first 48 h, in-vitro peptide release from the implant was 
diffusion-controlled. Peptide release from the polymeric device, sub-dermally implanted into mice, 
was also seen up to 30 days post-implantation, as evidenced from the buserelin acetate levels found 
in plasma, kidney and liver. Although a case-by- case evaluation of the thermal stability properties of 
the peptide will be required, these results open up new opportunities of processing therapeutic 
peptides using hot-melt techniques. 
 
5. CONCLUSION 
A non-biodegradable poly(ethylene-vinyl acetate) (33% VA) implant, loaded with 20 % (m/m) 
buserelin acetate, was produced using a hot-melt preparation method. No significant buserelin 
acetate-related degradation products were formed during this hot-melt preparation under our 
experimental conditions. The buserelin acetate distribution in the polymeric matrix was found to be a 
solid dispersion. In-vitro buserelin acetate release from the implant to phosphate buffered saline 
CHAPTER VII – HOT-MELT PREPARATION OF A NON-BIODEGRADABLE PEPTIDE IMPLANT: A PROOF OF PRINCIPLE 
  
 
177 
solution was found to be diffusion-controlled, releasing on average 5 µg of buserelin acetate daily. An 
initial burst release of buserelin was seen in the first 48 h. The stability of the therapeutic peptide in 
the polymeric matrix was evaluated during 3 months under ICH stability conditions (5°C, 25°C/60% 
R.H. and 40°C/75% R.H.). The buserelin acetate assay value remained stable throughout the different 
stability conditions and no significant buserelin acetate-related degradants were found. Moreover, 
similar in-vitro release profiles were obtained, demonstrating chemical and functional stability of the 
peptide implant. Finally, the in-vivo functionality of the hot-melt produced implant was demonstrated 
by sub-dermal implantation in mice. Buserelin acetate concentrations in plasma, kidney and liver 
obtained 1 day post-implantation also reflected the initial buserelin acetate burst release observed in-
vitro, before leveling out at 8 and 30 days post-implantation. These results clearly indicate the 
feasibility of non-biodegradable peptide loaded implants using a hot-melt process technique and may 
act as a proof of principle concept for further innovation in peptide medicines. 
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ABSTRACT 
In good DruQuaR tradition, this last chapter was constructed more or less independently from 
previous thesis chapters and focused on a key regulatory quality aspect. This chapter will provide a 
structured literature overview of the most commonly observed peptide-related impurities in peptide 
medicines, encompassing the active pharmaceutical ingredients (API or drug substance) as well as 
the finished drug products. Not only is control of these peptide-related impurities and degradants 
critical for the already approved and clinically used peptide-drugs, these impurities also possess the 
capability of greatly influencing initial functionality studies during early drug discovery phases, 
possibly resulting in erroneous conclusions. 
The first group of peptide-related impurities are SPPS-related: deletion and insertion of amino acids 
are related to inefficient Fmoc-deprotection and excess use of amino acid reagents, respectively. 
Fmoc-deprotection can cause racemisation of amino acid residues and thus diastereomeric 
impurities. Inefficient deprotection of amino acid side chains results into peptide-protection adducts. 
Furthermore, unprotected side chains can react with a variety of reagents used in the synthesis. 
Oxidation of amino acid side chains and dimeric-to-oligomeric impurities were also observed. 
Unwanted peptide counter ions such as trifluoroacetate, originating from the SPPS itself or from 
additional purification treatments, may also be present in the final peptide product. Contamination 
of the desired peptide product by other unrelated peptides was also seen, pointing out the lack of 
appropriate GMP. The second impurity group result from typical peptide degradation mechanisms 
such as β-elimination, diketopiperazine, pyroglutamate and succinimide formation. These SPPS- and 
degradation-related impurity types can also found in the finished peptide drug products, which can 
additionally contain a third group of related impurities, i.e. the API-excipient degradation products. 
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CHAPTER VII 
RELATED IMPURITIES IN PEPTIDE 
MEDICINES 
Main focus in this chapter: 
 Provide a literature review of the most commonly observed peptide impurities and degradants 
 
1. INTRODUCTION 
This last chapter should be viewed more or less independently from the previously presented work. 
As is the tradition in the DruQuaR laboratory, this chapter contains a literature review focusing on a 
selected regulatory aspect. Here, the impurity profile of peptide active pharmaceutical ingredients 
(API) and finished drug products (FDP) was reviewed. Quality control of peptide APIs prior to FDP 
manufacturing is a necessity. Currently, the pharmacopoeias such as the European Pharmacopoeia 
(Ph. Eur.) contain a number of general and peptide API specific monographs to which the quality of 
the peptide API material must legally adhere to. Moreover, general chapters in the Ph. Eur. - on its 
own not legally mandatory - become legally binding when referenced to from a general or API 
specific monograph [1]. A critical review regarding peptide pharmacopoeial API monographs has 
been performed by Vergote et al. [2]. A general lay-out for peptide drug monographs was proposed 
and was suggested to consist of appearance, solubility information, identification by LC-UV 
supplemented by a mass spectrometry (MS) detection technique, related peptides by LC-UV 
(including higher molecular weight derivatives), residual solvents (water, acetic acid, others), residual 
reagents, inorganic impurities (such as catalysts), microbiological quality attributes and assay by LC-
UV. Peptide-related substances in chemically synthesized peptide APIs are expected to adhere to 
thresholds of reporting (0.1%), identification (0.5%) and qualification (1.0%). The European 
Pharmacopoeia reflect the current pharmaceutical quality level for a given marketed drug. Given 
their multistep manufacturing process resulting in higher impurity amounts, the general reporting, 
identification and qualification thresholds for peptide impurities were set higher than the 
corresponding thresholds for organic impurities present in the small organic molecule APIs. 
Moreover, it is currently perceived that impurities of peptides are of a lesser toxicological concern 
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compared to related impurities of traditional, small molecules. Furthermore, individual impurities 
should primarily focus on synthesis impurities such as diastereoisomeric and deamidated peptides. 
The total related impurities level should not pass 5%. 
Good Manufacturing Practices (GMP) provides guidelines regarding the manufacturing of APIs and 
FDP, whether it be traditional small organic molecules or peptides [3]. The API guide covers APIs that 
are manufactured by chemical synthesis, extraction, cell culture/fermentation, by recovery from 
natural sources, or by any combination of these processes. Specific guidance for APIs manufactured 
by cell culture/fermentation, i.e. biotechnological products, and advanced therapeutic medicinal 
products (ATMPs) is also available. However, no specific guidance for synthetic peptides is provided. 
Moreover, a rationale must be designed and documented for the point at which GMP production of 
the API begins. For synthetic processes, this is known as the point at which "API starting materials" 
are entered into the process. Starting materials are defined as a raw material, an intermediate or an 
API that is used in the production of an API and is incorporated as a significant structural fragment 
into the structure of the API [4]. However, for synthetic peptides, these API starting materials are not 
specifically and explicitly defined. A number of principles are generally used in the consideration of 
the API starting material: the API starting material must (i) have sufficient propinquity from the API, 
i.e. generally at least 3 synthesis steps removed from the final API, excluding purifications, (ii) be an 
essential structural element of the API, (iii) be not too structurally complex, (iv) preferably be a 
widely commercially available material, i.e. not a new or unique material, (v) be a well defined, stable 
chemical and (vi) have a well defined impurity profile, as well as impurity limits for both related 
impurities as others such as residual solvents [5]. Considering this rationale, the individually Fmoc-
protected amino acids can be considered as API starting materials for the solid-phase peptide 
synthesis (SPPS) of synthetic peptide API material. Starting material (SM) related impurities have the 
potential to react in the SPPS process and thus be incorporated as impurities in the final product. 
Such SM-related impurities can include (i) free amino acids or amino acid derivates, (ii) amino acid 
contaminants, i.e. other amino acids than the desired amino acid, (iii) incorrect enantiomers, (iv) 
dipeptides or oligopeptides and (v) β-alanine containing contaminants. Moreover, a (toxicity) risk 
assessment of the starting materials, taking into account different batches and suppliers as these 
might have different impurity profiles, must be performed. This requires validated analytical 
methods capable of detecting all possible impurities and degradants present in the starting materials. 
The quantitative carry-over and purging of these impurities/degradants throughout the API synthesis 
process and eventually towards the patient is a critical part in the control strategy and risk 
assessment, which can be demonstrated by means of spiking experiments. Unrelated impurities such 
as reagents and solvents used in the manufacturing process are unlikely to be incorporated in the 
final peptide product, due to purification and isolation steps within the synthesis process, and are 
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therefore considered to be non-critical. An exception to this are the reagents and solvents used in 
these final purification and isolation steps. Moreover, if the final manufacturing steps include 
lyophilization or evaporation, any impurities can be upconcentrated in the final peptide product. 
Therefore, the quality attributes of the solvents and reagents used during the final manufacturing 
steps should be taken into account. However, applicants will also be expected to provide information 
regarding the origin of the Fmoc-protected amino acids, i.e. (human) hair, animal, plant, 
fermentation, to ascertain the risk from Bovine Spongiform Encephalopathy (BSE) and Transmissible 
Spongiform Encephalopathies (TSE) [4]. 
Both Pharmaceutical Development guidance and Process Analytical Technologies (PAT) acknowledge 
that the final product quality should be built in the manufacturing process, rather than tested once 
manufacturing is complete [6,7]. The principle of Quality by Design (QbD) uses the understanding of 
the manufacturing process to define the design spaces, in which critical process parameters are 
identified and controlled based upon risk assessment, thus effectively designing the final product 
quality into the manufacturing process [8]. PAT is an important tool for the application of QbD as it 
continuously monitors the manufacturing process through measurements of critical quality 
attributes of raw and intermittent materials, with the goal of ensuring adequate final product quality 
[9]. Currently, the QbD concepts are not consistently implemented in the manufacturing process of 
peptide APIs, thus offering the peptide manufacturers the opportunity of further optimizing their 
manufacturing process. In order to aid in the implementation of these QbD principles, this chapter 
will provide a structured overview of the most commonly observed related impurities in peptide 
medicines, encompassing the active pharmaceutical ingredients (API or drug substance) as well as 
the finished drug products. These impurities originate from SPPS, intrinsic peptide degradation 
mechanisms and peptide-excipient interaction. Moreover, the formation of these impurities will also 
be discussed, as well as ways to reduce their formation, thus effectively building-in the desired 
peptide quality. Not only is control of these peptide-related impurities critical for the manufacturing 
of already approved and clinically used peptide-drugs, these impurities also possess the capability of 
greatly influencing initial functionality studies during drug discovery phase, possibly resulting in false 
positive results, thus demonstrating the functional importance of peptide impurity control [10]. 
 
2. PEPTIDE SYNTHESIS 
Depending on the peptide size, i.e. number of amino acid residues, different peptide production 
techniques can be used. Recombinant DNA techniques are generally applied for the synthesis of large 
peptides, e.g. insulin, calcitonin and glucagon, whilst enzymatic synthesis is restricted to synthesis of 
peptides typically containing less than 10 amino acid residues, e.g. LVVH-7, VV-hemorphin-7 and 
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glutathione [11]. However, chemical synthesis remains the gold standard for the production of most 
peptides, ranging from 5 to 50 amino acid residues. This synthesis process was originally performed 
in solution, but became increasingly popular after introduction of the solid-phase peptide synthesis 
(SPPS) mode by Merrifield, and continues to be further improved [12,13]. These chemical synthesis 
techniques have been thoroughly discussed in other papers, but a short summary is given here, as its 
understanding is critical for the evaluation of possible synthesis-related impurities. 
Generally, in SPPS, amino acids are linked to each other during individual coupling steps, thus 
constructing the desired peptide sequence. This occurs while the carboxylic end of the sequence is 
covalently attached to a solid support matrix. The solid support is a synthetic polymer derivatised 
with functional groups such as hydroxyl groups (–OH) through linkers. These groups can easily react 
with the carboxyl group of a N-α-protected amino acid, hereby establishing a covalent bond to the 
resin. The transient protection of the amino group and permanent protection of the side chain group 
of the incoming amino acid is necessary to avoid undesired reactions, e.g. the nucleophilic N-
terminus of the added amino acid should not react with the carboxyl carbon of the same amino acid 
during the coupling reaction. The next step in the SPPS process is the removal of the transient 
protecting group of the resin-coupled amino acid providing a free α-NH2 end, followed by coupling of 
the next N-α-protected amino acid in the presence of activators. Through these deprotections and 
coupling steps, accompanied with the necessary washing steps to remove reagents and byproducts, 
the desired peptide sequence is synthesized from C-terminal to N-terminal end. At the end of the 
SPPS process, a strong acid is added to cleave the bond between the C-terminal amino acid and the 
polymer support, thereby also dissolving the peptide in the reaction medium. This final reaction step 
can be combined with the removal of permanent side chain protecting groups [11,14]. 
The SPPS originally developed by Merrifield in 1963 used tert-butyloxycarbonyl (t-Boc) as transient 
(N-α-) protecting group and benzyl (Bzl) as permanent (side chain) protecting group [13]. After 
removal of the transient protecting group by addition of trifluoroacetic acid (TFA), the positively 
charged amine that is generated is neutralized with a base, e.g. triethylamine, before coupling to the 
next incoming t-Boc protected amino acid. At the end of the synthesis, the last Boc-group, the 
permanent (side chain) protecting groups and carboxy-terminal link with the resin are removed by 
acidolysis with hydrofluoric acid (HF). Both the transient and permanent protecting groups, as well as 
the peptide-resin bond are acid labile. So certain peptide chains will be cleaved from the resin during 
each synthesis step and lost in the following washing step. Moreover, due to the loss of the side 
chain protecting groups, undesired products will be formed as well. In a search for more suitable 
protecting groups, the 9-fluorenylmethoxycarbonyl group (Fmoc) was introduced by Carpino and Han 
in 1972 as a transient protecting group [15]. Fmoc derivates are acid-stable but sensitive to mild 
base, e.g. piperidine. The advantages of the Fmoc strategy compared to the t-Boc strategy are 
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obvious. In this orthogonal strategy, the acid labile protecting groups on the side chains (e.g. tBu) and 
the peptide-resin link remain unaffected during each base-catalyzed deprotecting step. Depending 
on the amino acid residue, different permanent side-chain protecting groups can be used [11,16,17]. 
Tertiary butyl (tBu), trityl and t-Boc are among the most often used permanent protection groups. 
Currently, Fmoc-based SPPS is the most often used technique to produce synthetic peptides and its 
general mechanism is given in Figure 1 and discussed further below. 
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Figure 1. Schematic overview of Fmoc solid-phase peptide synthesis (SPPS), including related impurity 
formation. 
(Adapted from Benoiton NL, Chemistry of peptide synthesis. Boca Raton, Taylor & Francis, 2006) 
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2.1 Linkage to resin 
As discussed earlier, Fmoc SPPS involves assembly of a peptide chain that is anchored to a 
polystyrene resin through a linker, usually an ester bond. This ester is more sensitive to acids by 
electron-donating groups such as alkoxy, phenyl, alkoxyphenyl and halogens. The nature of the C-
terminus of the target peptide determines the peptide-linker bond. For the synthesis of a peptide 
with a free C-terminus, a 2-chlorotrityl chloride resin can be used. This is a polystyrene resin with a 
trityl-based linker. The 2-chlorotrityl chloride resin reacts very efficiently with Fmoc–amino acid 
anions of the first added amino acid. Any unreacted chlorotrityl groups are capped by conversion to 
methoxy groups by reaction with methanol. The linker bond is sensitive to a weak acid, which is 
generally combined with nucleophiles in a cleaving solution. For synthesizing amidated C-termini, the 
Rink amide resin is used. This has a 2,4-dimethoxy-substituted benzhydrylamine linker affixed to the 
polystyrene matrix through an ether linkage. The carboxamido–methyl bonds, anchoring the peptide 
chains, have been rendered sensitive to TFA by the methoxy groups. The linker is presented as the 
Fmoc derivative, so the amino group has to be deprotected for synthesis before the first amino acid 
can be added [14,17].  
 
2.2 Transient deprotection 
The Fmoc protecting group is removed before each amino acid coupling by a base-induced β-
elimination. The C-9 hydrogen atom on the Fmoc group is activated by the aromaticity of the rings. 
Abstraction of this proton by the piperidine is followed by a rearrangement of electrons leading to 
removal of the leaving group, the carboxamido anion, with generation of CO2 and dibenzofulvene. 
The latter molecule has an exocyclic double bond, which reacts with the nucleophilic piperidine 
[14,17]. 
 
2.3 Activation and amino acid coupling 
The Fmoc protected amino acid is linked with its carboxylic group to the free amino function of the 
last amino acid in the growing peptide chain. The nucleophilic amine attacks the electrophonic 
carbonyl group to form an amide bond. This reaction is a nucleophilic acyl substitution reaction as a 
nucleophile (the amine) replaces the substituent (the OH group) that was attached to the carbonyl 
group in the reactant and leaves the molecule. This reaction only occurs when activating the amino 
acids by transforming them into esters, anhydrides or acyl halides that easily react with an amine to 
form an amide plus an alcohol, carboxylate or halide respectively. In this way, the esterification of 
the Fmoc protected amino acid, where the OH group is replaced by a good leaving group, also 
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increases the electrophilicity of the carbonyl group. [14,17]. However, this activation step is 
associated with the formation of racemization impurities. 
Uronium salts such as O-Benzotriazole-N,N,N’,N’-tetramethyluroniumhexafluorophosphate (HBTU) 
are commonly used to form activated esters, surpassing the carbodiimides, e.g. 
diisopropylcarbodiimide (DIC). HBTU converts the Fmoc amino acid into the active benzotriazole 
ester (OBt) in the presence of a base. The base generates the carboxylate of the amino acid that can 
attack the reagent. The bases used for binding these protons are usually tertiary amines that are very 
suitable because they are very weak nucleophiles that do not compete for the electrophiles. This 
gives the acyloxycarbenium intermediate that is converted to the benzotriazole ester while 
tetramethylurea is liberated, which is miscible with polar solvents. The activated ester can be easily 
substituted by the amine function with OBt as a leaving anion [14,17].  
 
2.4 Resin cleavage 
In this final step, the peptide is cleaved from the resin and the permanent side chain protecting 
groups are removed by acidolysis. The removal of the permanent protecting groups by acidolysis 
involves protonation, followed by spontaneous rupture of the formed cation. Trityl, tert-butyl and 
arylsulfonylium ions but also the resin-bound species are left as cations. By adding TFA, they are 
trapped. The cation-trifluoroacetate produced is an alkylating agent and has a tendency to attack 
nucleophilic centers on the side chains of the peptide, e.g. hydroxyl groups on tyrosine, serine and 
threonine, resulting in unwanted impurities. For this reason, one or more nucleophiles are added to 
the acid to trap the generated cations. These scavengers are bases that are weak enough not to be 
protonated by the acid, and usually include thiol compounds, e.g. 1,2-ethanedithiol, 2-
mercaptoethanol, phenol compounds, e.g. anisol, p-cresol, and water. Also trialkylsilanes derivatives 
such as triisopropylsilane (TIS) show good efficacy in trapping tert-butyl, trityl, and arylsulfonyl 
carbocations [14,17]. 
Alternatively to conventional heating, microwave-assisted SPPS introduces energy into the synthesis 
mixture, resulting in acceleration of the reaction. The applied electromagnetic energy is converted 
into thermal energy due to dielectric polarization, resulting in reduced reaction time and increased 
synthesis yield as well as purity [18,19]. 
 
2.5 Fermentation 
Beside solid-phase synthesis, some peptides can also be derived from microorganisms by means of 
fermentation. These peptides are secondary metabolites produced by bacteria or fungi and generally 
belong to the antibiotic drug class. On an industrial scale the source microorganism is cultivated in 
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large bioreactors containing the optimal growth-medium to ensure maximum yield. Once this 
process is complete, the metabolites are extracted and purified [20]. Examples of antibiotic peptides 
obtained by fermentation are: daptomycin, which is marketed in the USA under the trade name 
Cubicin®, and fusafungine, a mixture of enniatins used to treat upper respiratory infections 
(Locabiotal®) [21,22].  
 
3. ANALYTICAL METHODS FOR PEPTIDE IMPURITY/DEGRADANT 
PROFILING 
3.1 Pharmacopoeial methods 
Peptide API monographs are given in different pharmacopoeias, often containing a suitable analytical 
method for the determination of related substances [1,2,9]. The majority of these methods are 
traditional HPLC-UV methods, using octadecylsilyl (C18) silica stationary phases with a variety of 
dimensions, i.e. difference in column length, diameter, pore size. The Ph. Eur. methods are relatively 
strict, as only minor changes are permitted to isocratic methods, e.g. column length and internal 
diameter dimension may vary ±70% and ±25%, respectively. The particle size can be reduced by as 
much of 50%, but no increase is permitted [42]. The same variations are allowed by the United States 
Pharmacopeia (USP) [24]. However, in both pharmacopoeias, the fundamental chemical nature of 
the stationary phase, e.g. C18, may not be modified [23,24]. Monographs may also contain an 
additional section on oligomerization products, where size exclusion chromatography (SEC) methods 
are used, e.g. insulin monograph [25]. Identification of the peptide and of the related impurities are 
based upon relative retention times and use of standard references. 
The USP also provides traditional HPLC-UV methods for ‘related compounds’ and ‘chromatographic 
purity’. The majority of these methods are based upon the use of octadecylsilyl (C18) silica stationary 
phases (L1). However, other column chemistries are also used, e.g. octylsilane C8 (L7) for human 
glucagon, irregular or spherical totally porous silica gel having a chemically bonded, strongly acidic 
cation-exchange coating (L9) for calcitonin and a strong cation exchange resin made of porous silica 
with sulfopropyl groups (L52) for aprotinin [24]. As in the Ph. Eur., identification of the related 
substances is based upon relative retention times. However, the identification test in USP for certain 
peptide APIs, e.g. desmopressin and gonadorelin acetate, uses mass spectrometry detection, which is 
currently not included in the Ph. Eur. A critical assessment of the peptide monographs, as well as 
suggestions for further improvements were made by Vergote et al. [21]. The major potential 
improvement for these peptide monographs is the inclusion of MS-based detection techniques, 
which is expected to be introduced in the near future, as suitable, easy-to-use and economically 
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affordable MS equipment like the single quadrupole detector will become available for Quality 
Control purposes [26].  
 
3.2 Methods used in drug discovery, research and development 
UHPLC and fused-core chromatography 
Ultra High Performance Liquid Chromatography (UHPLC) can be seen as an evolution of traditional 
HPLC. UHPLC uses smaller fully porous particle sizes, typically sub-2 µm in diameter, which 
significantly reduces the Height Equivalent to a Theoretical Plate (HETP) and results in higher 
efficiency and flatter Van Deemter curve. However, this decrease in particle size also results into an 
increase in back pressure, which was overcome with the development of newer chromatographic 
equipment. The major advantages of this technique are improved sensitivity and resolution, 
combined with significant reduction in analysis time and solvent consumption [27]. Several UHPLC 
peptide assays have already been reported in the literature, mostly focusing on peptide stability in 
different matrices [27-30]. Furthermore, stability indicating methods, focusing on peptide degradants 
or impurities are also reported [31-34]. Depending on the objective, i.e. assay or stability-indicating 
method, peptide concentration and matrix complexity, UHPLC is coupled to PDA or MS detection. 
Alternatively, (U)HPLC chromatography with fused-core particles uses particles with a solid, inert 
core and a thin porous outer shell, i.e. superficially porous particles (SPP). With superficially porous 
particles, larger solutes can move rapidly in and out of the thin porous shell, resulting in reduced 
band broadening at higher mobile phase velocities for greater separation speeds. These SPP sizes 
range from 1.3 µm to 5 µm, in which the porous shell is usually around 0.5 µm thick. High efficient 
separations, similar to UHPLC separations with sub-2 µm fully porous particles, are obtained with 2.7 
µm SPP at relatively low back pressure. Given the low back pressure, these chromatographic 
separations can still be performed with conventional HPLC instruments. Various fused-core 
chromatographic methods, coupled to PDA or MS detection, for peptide assay and peptide stability 
determination have already been published [35-41]. Given permitted variations in particle size 
dimension in the Ph. Eur. and USP, columns with 2.7 µm SPP technology are typically allowed to be 
used in pharmacopoeial peptide analysis, giving this SPP technology a major advantage over the sub-
2 µm UHPLC technology which falls outside the permitted pharmacopoeial method adaptations, thus 
requiring formal variation-activities. 
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3.3 Supercritical fluid chromatography 
Supercritical fluid chromatography (SFC) uses a low viscosity and highly diffusing mobile phase, 
mostly CO2 in a supercritical state, resulting in lower pressure along a packed chromatographic 
column, thus allowing the use of higher flow rates when compared to traditional HPLC. Moreover, 
SFC is seen as a green technology since it requires a smaller amount of organic solvent compared to 
other liquid chromatography techniques. This is especially appealing for preparative-scale 
chromatography since less time and energy are required to remove solvent and isolate the analyte. 
Traditionally, use of relatively non-polar CO2 has limited the SFC applications to separations of non-
polar and low-polar compounds. In order to expand the application range to more polar compounds 
such as peptides, several strategies have been employed: (i) use of relatively polar fluids, e.g. NH3, 
SO2, (ii) use of a polar modifier in CO2 and (iii) addition of a highly polar or ionic component to the 
modifier, e.g. TFA or dichloroacetic acid. Furthermore, given the high volatile nature of the mobile 
phases, SFC technology is extremely compatible with MS detection. Tognarelli et al. reported 
chromatographic separation of five peptides, ranging in molecular weights from 238.2 to 1046.2, by 
SFC in less than 12 min, compared with 50 min using HPLC [42]. Patel et al. used SFC to separate 
water-soluble isomeric peptides, whereas Zheng et al. demonstrated SFC/MS separation of peptides 
up to 40 amino acids in length, comprising acid and basic residues [43-45]. An alternative for these 
aforementioned chromatographic peptide separation techniques is capillary electrophoresis (CE) 
[46]. Here, samples are placed in an electrolyte solution and separation is achieved under the 
influence of an electric field. Given their nature, peptides and proteins are ideally suited for capillary 
electrophoresis separation. Further information regarding CE separation of peptides can be found in 
the extensive review by Kašička et al. and will not be discussed in further details in this chapter [47]. 
 
3.4 Spectroscopic techniques 
Circular dichroism (CD) is considered as one of the most valuable technique for examining the 
structure of peptides and proteins in solution. CD refers to the differential absorption of counter-
clockwise (left-handed, L) and other clockwise (right-handed, R) circularly polarized light. From this, 
complementary structural information can be obtained from a number of spectral regions. In 
peptides, the chromophores of interest include the peptide bond (absorption below 240 nm) which is 
used to determine secondary structure, aromatic amino acid side chains (absorption in the range 260 
to 320 nm) and disulphide bonds (weak broad absorption bands centered around 260 nm) [48]. The 
advantages of CD are multiple as it is a non-destructive, fast and simple technique, consuming small 
sample quantities. Alternatively, Fourier Transform Infrared (FT-IR) measures the absorption of 
energy by vibrating chemical bonds (primarily stretching and bending motions). In order to 
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characterize the secondary structure of peptides and proteins, the different wavenumbers at which 
the amide peptide bonds show absorption can be used. Nine characteristic IR absorption bands for 
the amide bond in peptides and proteins are obtained. These are called Amide A, B and I-VII in order 
of decreasing frequency. The amide bands I (80% C=O stretch, near 1650 cm-1), II (60% N–H bend and 
40% C–N stretch, near 1550 cm-1), and III (40% C–N stretch, 30% N–H bend, near 1300 cm-1) are 
generally employed to study peptide and protein structure [49]. As both CD and IR techniques are of 
spectroscopic nature following Lambert-Beer’s law, signals arising from low concentrated impurities 
will be added to the larger signal obtained from the parent peptide. Therefore, in order to fully 
exploit for example CD as an peptide impurity profiling technique, the use of a well characterised 
peptide reference standard is required or separation/isolation of the impurity from the parent 
peptide, which can be achieved by online coupling of CD detection to HPLC [50]. 
The β-amyloid peptide, comprising 42 amino acid residues, of healthy individuals and patients 
suffering from Hereditary Cerebral Hemorrhage with amyloidosis-Dutch-type were compared by 
Fabian et al. by FT-IR and CD [51]. The Dutch-type β-amyloid peptide differs in one amino acid, i.e. 
mutation of Glu to Gln, resulting in an altered secondary structure when present in membrane 
mimicking solvents: the mutant Dutch-type β-amyloid peptide, containing the Gln residue, showed a 
significantly higher β-sheet content observed by analysis of the amide I region (1700-1600 cm-1). This 
amide I region is extremely useful for this secondary structure analysis as different hydrogen bond 
patterns give rise to shifts in C=O stretching frequencies. Alternatively, the intensity of the CD signals 
obtained at 208 nm was used to estimate the α-helix content of both peptides and confirmed the FT-
IR results. Furthermore, changes in pH were less effective in eliminating the β-sheet conformation for 
the mutant peptide, suggesting that its conformation is energetically favored, compared to the 
human–type. This β-sheet plays an important role in fibril formation, which is associated with 
Alzheimer’s disease. Insulin fibrillation at 60°C, induced by vortexing, was examined by Loksztejn et 
al. using CD measurements over the course of time. The gradual transition of the native 
predominantly α-helical structure into aggregated β-sheets was determined by the decreasing 
double minima at 208 and 222 nm and the appearance of a single minimum at 216 nm [52]. Using 
both FT-IR and CD, Banerjee et al. found that a small nine residue peptide interferes with the 
fibrillation of insulin. The peptide stabilized the native-like secondary structure of insulin, hereby 
delaying the formation of the fibril nucleus [53]. 
Cell penetrating peptides (CPPs), generally described as short amphipathic or purely cationic peptides 
of less than 30 amino acids which possess a positive net charge, are able to penetrate biological 
membranes and transfer covalently or non-covalently attached bioactive cargoes into cells [54]. A 
conformational analysis by CD of 10 well-known CPPs (including Tat, R9, penetratin) in different 
media, highlighted that these CPPs are random coils in water, but they become structured or partially 
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structured in small unilamellar vesicles prepared from negatively charged phospholipids. Neutral 
(zwitterionic) phospholipids or a mixture of phospholipids, sphingomyelin and cholesterol (40/40/20) 
did not induce formation of an α-helix or β-sheet. Many hydrophobic CPPs appear insensitive to 
sequence scrambling. This suggests that amino acid composition and their surroundings, i.e. 
membrane mimicking solvents, drive the cell-uptake of these peptides, rather than the actual 
primary sequence [55,56]. 
Alpha-helical peptides, such as enfuvirtide and C34, are derived from a 36 amino acid region of the 
carboxyl-terminal heptad repeat (C-HR) of gp41, an HIV-1 transmembrane envelope glycoprotein, 
which plays a central role in the fusion of HIV-1 with host cells. Enfuvirtide and C34 prevent the 
formation of a 6-helical bundle, which is comprised of a trimer of dimers formed from the amino-
terminal heptad repeat (N-HR) and the C-HR in an antiparallel orientation. Six-helix formation by 
physiological gp41 enables host cell and virus membranes to contact and fuse, enabling the virus 
entry into the cells. Therefore, inhibition of the formation of this 6-helical bundle prevents fusion of 
HIV-1 and targeted host cell membranes. The interaction between the fusion inhibiting peptides, e.g. 
C34 and SC34EK, and the N36 peptide, representing the N-HR of the HIV-1 gp41 surface protein, was 
studied by circular dichroism in function of temperature. The authors found a strong correlation 
between the in-vitro anti-HIV-1 activities of these peptides and their thermal stability, determined by 
CD measurement, of the 6-helical bundles that are formed with these peptides [57,58]. This 
peptide/protein temperature denaturation experiment, using the sole peptide/protein or in 
combination with its target receptor can be used as a fundamental quality attribute as it results in a 
numerical Tm value, which can be correlated with its biological function. At this time, the 
pharmacopoeial analysis of peptide/proteins only focuses on primary structures through peptide 
mapping, thus neglecting secondary and higher structures. Pharmacopoeial inclusion of denaturation 
experiments, e.g. by CD detection, will not only provide this higher structural information, but also 
allow for the determination of a numerical functional quality attribute, i.e. a Tm value, which can then 
be compared to a Tm specification acceptance range. 
Optical Rotation Dispersion (ORD) measures the ability of a sample to rotate linear polarized light, in 
function of the wavelength [59]. This technique, closely related to CD, was very popular in the past 
for the conformational analysis of peptides and proteins, but is now largely surpassed by more 
advanced techniques, such as CD [60-62]. Vibrational circular dichroism (VCD) can be viewed as a 
combination of the CD and IR approaches, utilizing the bandshape variability of CD and the frequency 
resolution of IR. This technique can be used for both quantitative and qualitative analyses of peptides 
and proteins [63,64]. Alternatively, two-dimensional IR (2D-IR) can also be used, as shown by the 
review of Kim et al. [65]. 
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Raman spectroscopy relies on inelastic scattering (Raman scattering) of monochromatic laser light, in 
the visible, near infrared or near ultraviolet range. The light interacts with molecular vibrations, 
phonons or other excitations in the system, resulting in the energy of the laser photons being shifted 
up or down. The shift in energy gives information about the vibrational modes in the system, 
providing similar but complementary information to IR absorption spectroscopy. The presence of 
specific side-chain marker bands for the cysteine sulfhydryl group (2500-2600 cm-1) and methionine 
sulfoxide (1010 and 704 cm-1, corresponding to S=O and C-S stretch) can be used as selective markers 
for peptide/protein oxidation [66]. Traditional Raman as well as more advanced Raman techniques 
such as Surface-Enhanced Raman (SER), resonance Raman and transient UV Raman have been used 
to study various conformational peptide aspects [67-70].  
 
3.5 NMR 
Nuclear Magnetic Resonance (NMR) spectroscopy measures the absorption of electromagnetic 
radiation of a specific frequency by an atomic nucleus that is placed in a strong magnetic field. In 
2002, Prof. Wüthrich was awarded the Nobel Price in Chemistry for his involvement in the 
development of this technique, which can provide unique information about peptide structure, 
dynamics, hydration and folding in the solution state [2,71-74]. Therefore, the Ph. Eur. utilizes NMR 
for identity confirmation based on profile comparison versus a reference NMR spectrum, e.g. 
buserelin and goserelin. Furthermore, online HPLC coupling of NMR detection permits peptide 
impurity profiling [74]. However, due to the structural complexity of most peptides, especially those 
larger than 15 amino acids, 1H and 13C NMR spectra are full of partially overlapping signals that can 
only be assigned by means of two-dimensional techniques, i.e. 2D-COSY (2D Correlated 
spectroscopy) and 2D-TOCSY (2D Total Correlation Spectroscopy). In general, as NMR is a time 
consuming technique and the peptides are in solution, special attention must be paid to possible 
degradation and aggregation. 
 
 
4. IMPURITY CLASSES 
Structurally related impurities present in peptide drug substances can have significant consequences 
on its functional biological function. Hemopressin, a nonamer peptide (PVNFKLLSH) derived from the 
α1 chain of hemoglobin, is an antagonist of the cannabinoid-1 receptor and exhibits antinociceptive 
activity. Gomes et al. identified two hemopressin-related impurity peptides, i.e. VDPVNFKLLSH and 
RVDPVNFKLLSH which interestingly were found to be agonists of the receptor [75]. This functionality 
influence of the peptide impurity is sometimes missed in the early phases of pharmaceutical R&D, 
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especially as usually crude peptide mixtures, containing different types and levels of impurities, are 
used in functionality experiments, e.g. receptor binding or tissue organ baths. Alternatively, as 
mentioned earlier, physical aggregation of insulin monomers, will lead to a insulin fibrillation, which 
in turn will result in a lower functionality response [52,53]. An overview of the different peptide 
impurity classes is presented below. 
 
4.1 Amino acid deletion 
Incomplete removal of the transient protecting group of the resin-bound amino acid or insufficient 
activation of the incoming amino acid building block can result into an inefficient SPPS coupling step. 
In turn, this will result into peptide chains missing one or more desired amino acid residues. 
Truncated peptide impurities, missing one or more desired amino acid residues at either the N- or C-
terminal end are also classified as deletion impurities and originate from overdried resin beads, 
causing the peptide to precipitate [76]. Furthermore, N-terminal truncated peptides can also arise 
from (an) inefficient coupling step(s), as discussed above, whereas C-terminal truncated peptides are 
the result of incomplete coupling of the first amino acid to the resin (Figure 1). Sanz-Nebot et al. 
examined the impurity profiles of crude grade carbetocin, eledoisin, leuprolide, goserelin and 
triptorelin peptides [77-83]. A number of deletion impurities were identified and selected examples 
are listed in Table 1. Identification of this class of impurities is done by attributing the mass 
difference between the observed impurity and the parent peptide to a deletion of a certain amino 
acid residue, i.e. amino acid molecular mass minus H2O. 
Taichrib et al. identified a number of peptide impurities present in the synthetic peptide hormone 
tetracosactide (SYSMEHFRWGKPVGKKRRPVKVYP, TCS) [84]. TCS (Synacthen®) is a synthetic analogue 
of the human adrenocorticotropic hormone (ACTH) clinically used as a diagnostic agent and contains 
the first 24 amino acid residues of ACTH, which is composed out of 39 amino acid residues. In order 
to check for the presence of N- and C-terminal truncated TCS-peptide impurities, the theoretical 
mass of these impurities were calculated. The actual presence of truncated impurities in the TCS 
sample was verified by RP-C18 chromatography and capillary electrophoresis coupled with MS 
detection and ion extraction data treatment, using the theoretical impurity masses. The authors 
reported the presence of all N- and C-terminal truncated impurities down to a size of seven amino 
acids, i.e. presence of 1-23 TCS to 1-8 TCS and 2-24 TCS to 18-24 TCS. 
De Beukelaar et al. screened for the presence of T-cells directed against the onconeural HuD protein 
by stimulating peripheral blood cells of individuals with 15-amino acid peptides spanning the HuD 
protein sequence [85]. During initial screening, three different peptides with a purity of 
approximately 70% elicited a positive T-cell response. However, peptide batches with higher purity 
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levels failed to reproduce these initial results. Therefore, MALDI-FT-MS was used to compare the 
impurity profiles of the different peptides batches. FT-MS analysis of the first two peptides, i.e. 
RIITSRILVDQVTGV and EQLFSQYGRIITSRI, revealed the presence of one major impurity type, 
characterised by deletion of the adjacent amino acids “IT”. The impurity profile of the third 15-mer 
peptide, i.e. GFVTMTNYDEAAMAI, is more complicated as more impurities were seen. Table 1 lists 13 
observed peptide-related impurities. Ten impurities were characterised by deletion of one amino 
acid residue, of which the majority occurred within the peptide sequence. The three other impurities 
were missing two amino acid residues, of which two impurities comprised adjacent amino acid 
deletions. Finally, the impurities characterised by deletion of the N-terminal G and GF residues can 
be classified as truncated impurities rather than internal deletions. No further efforts were made to 
pinpoint the impurity eliciting the immunological response. De Spiegeleer et al. performed a quality 
study evaluating obestatin peptides of different origin obtained from different peptide 
manufacturers [10]. Several peptide-related impurities were identified using HPLC-MS and are 
summarized in Table 1. Again, the majority of the impurities seen here are the result of deletion of 
one or more amino acid residues, but also a deletion of 5 amino acid residues was observed. Litowski 
et al. identified several amino acid deletion impurities of a semipure 21-mer peptide, Ac-
KISALKEKISALKEKISALKE-NH2, using HPLC/Cation Exchange Chromatography (SCX), i.e. a lysine 
deletion (mass difference -128), a lysine deletion combined with a side chain acetylation, a double 
lysine deletion and a double lysine deletion combined with acetylation [86]. While performing quality 
control on quorum sensing peptides, Verbeke et al. identified a large number of deletion impurities, 
often combined with other impurity types, e.g. oxidation of cysteine residues to cystines [34]. 
Selected examples of identified impurities, together with the relative mass difference towards the 
parent peptide, are listed in Table 1. 
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Table 1. Overview of identified peptide impurities 
Peptide MW
1
 AA deletion AA insertion Inc. removal PG Ox./Red. Racem. Side/end chain react. 
Tyr(OMe)-Ile-Gln-Asn-Cys-
Pro-Leu-Gly-NH2 
CO-CH2-CH2-CH2 link 
between Y and C 
(Carbetocin) 
988.2 -128.2 (-Gln) +114.1 (+Asn) 
-25.9 
(Fmoc-Ile-Gln-Asn-Cys-Pro-
Leu-Gly-NH2) 
+16.0 (Cys11 sulfoxide) 
+32.0 (Cys11 sulfone) 
+48.0 (Cys11 sulfonate) 
-128.2+16.0 
(-Gln+ Cys11 sulfoxide) 
yes - 
Pyr-Pro-Ser-Lys-Asp-Ala-
Phe-Ile-Gly-Leu-Met-NH2 
(Eledoisin) 
1188.2 
-97.1 (-Pro) 
-111.1 (-Pyr) 
-87.1 (-Ser) 
-128.2 (-Lys) 
+128.2 (+Lys) 
+56.0 (+tBu) 
 
+16.0 (Met11 sulfoxide) 
+128.8+16 (+Lys+ Met11 
sulfoxide) 
yes - 
Pyr-His-Trp-Ser-Tyr-D-Leu-
Leu-Arg-Pro-NHEt 
(Leuprolide) 
1209.4 
-87.1 (-Ser) 
-156.2 (-Arg) 
+186.2 (+Trp) 
+156.2 (+Arg) 
+137.1 (+His) 
+56.0 (+tBu) 
+126.0 (+2×tBu) 
+111.1 
(Fmoc-His-Trp-Ser-Tyr-D-Leu-
Leu-Arg-Pro-NHEt) 
+2.0 (Reduced Trp3) 
+16.0 (Hydroxy-Trp) 
yes 
+126.0 
(subst. guanidine) 
Pyr-His-Trp-Ser-Tyr-D-
(tBu)Ser-Leu-Arg-Pro-AzGly-
NH2 
(Goserelin) 
 
1269.4 
 
-111.1 (-Pyr) 
-97.1 (-Pro) 
-137.1 (-His) 
-58.0 (-AzGly) 
-43.0 
(Acyl-hydrazine) 
+156.2 (+Arg) 
+163.2 (+Tyr) 
+163.2 (+Tyr) 
+97.1 (+Pro) 
+137.1 (+His) 
+113.2 (+Leu) 
+113.2 (+Leu) 
+(97.1-87.1) (+Pro-
Ser) 
- - yes 
+15.0 (Arg amination) 
-42+111.1 
(Gos(Orn)+Pyr) 
-42+248.2 
(Gos(Orn)+His+Pyr) 
-42+434.4 
(Gos(Orn)+Trp+His+Pyr) 
-42+521.5 
(Gos(Orn)+Ser+Trp+His+Pyr) 
-42+684.7 
(Gos(Orn)+Tyr+Ser+Trp+His+Pyr) 
-42+827.8 
(Gos(Orn)+Ser(tBu)+Tyr+Ser+Trp+His+
Pyr) 
Pyr-His-Trp-Ser-Tyr-D-Trp-
Leu-Arg-Pro-Gly-NH2 
(Triptorelin) 
 
1311.5 
-111.1+97.1 
(-Pyr+Pro) 
+137.1 (+His) 
+163.2 (+Tyr) 
+56.0 (+tBu) - yes 
+15.0 (Arg amination) 
+1.0 (deamidation) 
Ser-Tyr-Ser-Met-Glu-His-
Phe-Arg-Trp-Gly-Lys-Pro-
Val-Gly-Lys-Lys-Arg-Arg-
Pro-Val-Lys-Val-Tyr-Pro 
(Tetracosactide) 
2933.4 Different truncations 
+381.5 
(+Tyr-Ser-Met) 
+468.5 
(+Ser-Tyr-Ser-Met) 
+57.0 (+Gly) 
+56.0 (+tBu) 
+100.0 (tBoc-TCS) 
+16.0 (TCS sulfoxide) - +42.0 (Ac-TCS) 
Arg-Ile-Ile-Thr-Ser-Arg-Ile-
Leu-Val-Asp-Gln- 
1670.0 -214.3 (-Ile-Thr) - - - - - 
Val-Thr-Gly-Val 
(HuD peptide) 
       
1 MW: average molecular weight  
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Table 1. Overview of identified peptide impurities (continued) 
Peptide MW
1
 AA deletion AA insertion Inc. removal PG Ox./Red. Racem. Side/end chain react. 
Glu-Gln-Leu-Phe-Ser-Gln-
Tyr-Gly-Arg-Ile-Ile-Thr-Ser-
Arg-Ile 
(HuD peptide) 
1811.7 -214.3 (-Ile-Thr) - - - - - 
Gly-Phe-Val-Thr-Met-Thr-
Asn-Tyr-Asp-Glu-Ala-Ala-
Met-Ala-Ile 
(HuD peptide) 
1633.7 
-57.0 (-Gly) 
-147.2 (-Phe) 
-99.2 (-Val) 
-131.2 (-Met) 
-101.1 (-Thr2) 
-114.1 (-Asn) 
-115.1 (-Asp) 
-71.1 (-Ala1) 
-71.1 (-Ala2) 
-113.2 (-Ile) 
-204.2 (-Gly-Phe) 
-246.4 (-Phe-Val) 
-156.2 (-Val-Gly) 
- - -  - 
Phe-Asn-Ala-Pro-Phe-Asn-
Ile-Gly-Ile-Lys-Leu-Ala-Gly-
Ala-Gln-Ser-Leu-Gln-His-Gly-
Gln-Thr-Leu-NH2 
(bovine obestatin) 
2423.3 -114.1 (-Asn6) - - - - - 
Phe-Asn-Ala-Pro-Phe-Asp-
Val-Gly-Ile-Lys-Leu-Ser-Gly-
Pro-Gln-Tyr-His-Gln-His-Gly-
Gln-Ala-Leu-NH2 
(canine obestatin) 
2522.3 - - - - - +1.0 (deamidation) 
Phe-Asn-Ala-Pro-Phe-Asp-
Val-Gly-Ile-Lys-Leu-Ser-Gly-
Val-Gln-Tyr-Gln-Gln-His-Ser-
Gln-Ala-Leu-NH2 
(human obestatin) 
2545.3 
-229.2 (-Asn2-Asp6) 
-115.1 (-Asp6) 
-512.6 
(-Asp-Val-Gly-Lys) 
- - - - - 
Phe-Asn-Ala-Pro-Phe-Asp-
Val-Gly-Ile-Lys-Leu-Ser-Gly-
Ala-Gln-Tyr-Gln-Gln-His-Gly-
Arg-Ala-Leu-NH2 
(mouse obestatin) 
2515.3 - - - - - +1.0 (deamidation) 
        
1 MW: average molecular weight 
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Table 1. Overview of identified peptide impurities (continued) 
Peptide MW
1
 AA deletion AA insertion Inc. removal PG Ox./Red. Racem. Side/end chain react. 
Phe-Asn-Ala-Pro-Phe-Asn-
Ile-Gly-Ile-Lys-Leu-Ser-Gly-
Ala-Gln-Ser-Leu-Gln-His-Gly-
Gln-Thr-Leu-NH2 
(ovine obestatin) 
2439.3 -114.1 (-Asn6) - - - - - 
Ac-Lys-Ile-Ser-Ala-Leu-Lys-
Glu-Lys-Ile-Ser-Ala-Leu-Lys-
Glu-Lys-Ile-Ser-Ala-Leu-Lys-
Glu-NH2 
(-) 
2368.0 
 
-128.2 (-Lys) 
+42-128.2 (-Lys, Ac) 
-256.4 (-Lys-Lys) 
+42-256.4 (-Lys-Lys, 
Ac) 
- - - - 
+42.0 (Ser3 Ac) 
+42.0 (Ser10/7 Ac) 
Phe-Arg-Ser-Leu-Phe-Trp-
Gly-Asn-His-Ser-Gln 
(INSL6[151-161]) 
1378.6 
 
- - 
+106.0 (+Anisole/p-cresol) 
+56.0 (+tBu) 
+188.2 (Trp adduct) 
+243.0 (+Trityl) 
- - - 
Asn-Asn-Trp-Asn-Asn 
(Q19) 
660.6 - - - - - +1.0 (deamidation) 
Ser-Asn-Leu-Val-Glu-Cys-
Val-Phe-Ser-Leu-Phe-Lys-
Lys-Cys-Asn 
(Q76) 
1731.1 -87.1 (-Ser1) - - - -  
Asn-Asn-Trp-Gly-Asn 
(Q153) 
603.6 -57.0 (-Gly4) - - - - +1.0 (deamidation) 
Cys-Val-Phe-Ser-Leu-Phe-
Lys-Lys-Cys-Asn 
(Q25) 
1188.5 
-103.2 (-Cys1) 
-202.4 (-Cys1-Val2) 
-101.2 
(-Val2+cystine) 
-130.2 
(-Lys7+Cystine) 
- - - - - 
Asp-Leu-Arg-Asn-Ile-Phe-
Leu-Lys-Ile-Lys-Phe-Lys-Lys-
Lys 
(Q31) 
1791.3 
-115.1 (-Asp1) 
-156.2 (-Arg4) 
- - - - - 
GluSerArgLeuProLysIleLeuLe
uAspPheLeuPheLeArgLysLys 
(Q53) 
2116.6 
-156.2 (-Arg15) 
-495.6 
(-Glu1-Arg4-Leu5-Pro6) 
- - - - - 
Ser-Ile-Asn-Ser-Gln-Ile-Gly-
Lys-Ala-Thr-Ser-Asn-Leu-Val-
Glu-Cys-Val-Phe-Ser-Leu-
Phe-Lys-Lys-Cys-Asn 
(Q75) 
2731.2 
-473.6 
(-Lys22-Lys23-Cys24-
Asn25) 
+57.0 (Gly) - - - - 
1 MW: average molecular weight  
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Table 1. Overview of identified peptide impurities (continued) 
Peptide MW
1
 AA deletion AA insertion Inc. removal PG Ox./Red. Racem. Side/end chain react. 
Lys-Ser-Ser-Ala-Tyr-Ser-Leu-
Gln-Met-Gly-Ala-Thr-Ala-Ile-
Lys-Gln-Val-Lys-Lys-Leu-Phe-
Lys-Lys-Trp-Gly-Trp 
(Q125) 
2985.6 - +106.2 (Gly10+Tyr) - - - - 
Leu-Pro-Phe-Glu-Phe 
(Q134) 
651.7 - - +14.0 (methylation Glu) - - - 
1 MW: average molecular weight 
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4.2 Amino acid insertion 
During the coupling step in SPPS, an excess of Fmoc-protected amino acids is used to ensure the 
maximum coupling efficiency. However, this abundance can result into insertion of an additional 
amino acid into the desired peptide sequence, if not all reagents are properly washed away. Besides 
formation of a peptide bond with the resin-bound peptide chain, the activated incoming amino acid 
can also acylate an amide group of this resin-bound peptide chain (Figure 1). During the next 
coupling step, transient deprotection will remove the Fmoc protecting group of this acylated amino 
acid, providing a free, reactive amine. This will further react with the carbonyl moiety of the peptide 
bond, effectively inserting the amino acid into the peptide sequence [87]. This amino acid insertion is 
facilitated if the peptide bond where the acylation occurs is easily accessible, i.e. absence of a bulky 
side chain in the adjacent amino acid residues. Sanz-Nebot et al. examined the impurity profiles of 
crude grade carbetocin, eledoisin, leuprolide, goserelin and triptorelin [77-83]. A number of insertion 
impurities were identified, but the location of insertion was not further clarified (Table 1). As was the 
case for deletion impurities, identification of these insertion impurities is done by attributing the 
mass difference between the observed impurity and the parent peptide to insertion of a certain 
amino acid residue, i.e. amino acid molecular mass minus H2O. De Spiegeleer et al. reported 
observation of an obestatin-related peptide impurity characterised by a mass increase of +137.1, 
corresponding to incorporation of an additional histidine residue into the desired peptide sequence 
[10]. Taichrib et al. also reported two tetracosactide (TCS)-related impurities characterised by a 
higher mass due to incorporation of additional amino acids. The authors deduced the sequences to 
be TCS+YMS (mass increase: 381 Da) and TCS+SYSM (mass increase: 468 Da). A truncated TCS 
impurity peptide, combined with insertion of an additional Gly residue was also reported [84]. 
Verbeke et al. also identified a number of insertion impurities, e.g. insertion of Gly residue [34]. 
A different amino acid insertion mechanism was - independently from each other – observed by 
Obkircher et al. and Isidro-Llobet et al. Both authors observed the formation of unexpected amino 
acid impurities, i.e. Fmoc-β-Ala and Fmoc-β-Ala-AA, during the preparation of Fmoc-protected amino 
acids when using N-9-Fluorenylmethoxycarbonyloxy succinimide (Fmoc-OSu) as a protecting agent 
[87,88]. The explanation for the formation of these impurities is given in Figure 2 and involves the 
presence of two nucleophiles, i.e. -OH and -OSu. The β-Ala structure is formed through a Lossen 
rearrangement after the nucleophilic attack -OH on one of the carbonyl moieties present in Fmoc-
OSu. Finally, this results in the formation of the β-Ala amino acid residue, which subsequently can be 
Fmoc-protected by an additional equivalent of Fmoc-OSu, thus forming the Fmoc-β-Ala impurity. 
Alternatively, nucleophilic attack of -OSu results in formation of a β-Ala-succinimide ester, which in 
turn can be Fmoc-protected and finally react with an unprotected amino acid, forming an Fmoc-β-Ala 
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AA impurity. HPLC analysis of Fmoc-OSu, showing no impurities, indicated that impurity formation 
occurred during preparation of the API starting materials. The same impurity type was also seen after 
H-tBu-Gly and H-β-cyclopropyl-Ala synthesis, and required extensive recrystallization to reduce the 
impurity amount to approximately 0.5%, but unfortunately dramatically reducing the desired peptide 
yield from 99% to 43%. In order to avoid or reduce the formation of these impurities, Fmoc-OSu was 
replaced with the less reactive Fmoc-2-mercaptobenzothiazole (Fmoc-2-MBT) or the Fmoc-OSu 
concentration reduced. 
The presence of this Fmoc-β-Ala-AA impurity type in the Fmoc-protected amino acids, which are used 
as API starting materials in peptide synthesis, resulted in unwanted peptide impurities as was 
reported by Hlebowicz et al. [89]. While chemically synthesizing a non-disclosed peptide API, 
characterised by three Ala residues, an impurity at levels above 0.1% was observed using RP-HPLC. 
Using electrospray ionization-mass spectrometry, the molecular weight of this impurity was 
determined to be 71 Da higher than the desired peptide mass. This mass addition, which was located 
immediately prior to the second Ala residue by MS², indicated the incorporation of an additional Ala 
residue. Chiral amino acid analysis excluded the presence of an additional D-Ala isomer. Other 
suspected impurities such as incorporation of additional L-Ala, sarcosine (N-methyl-glycine) or β-Ala 
residues were synthesized and analyzed using the same RP-HPLC method. By retention time 
comparison, the nature of the impurity was identified as the inclusion of an additional β-Ala residue. 
Moreover, the origin of this impurity could be traced back to the Fmoc-Ala starting material, which 
contained approximately 0.3% of the Fmoc-β-Ala-Ala impurity. However, the provided quality 
certificate did not indicate this, as only the purity specification of >99% and optical purity 
specification of <0.5% were given. This is an example how related impurities in the API starting 
material, having similar structures as the desired starting material, can be carried over towards the 
final peptide drug. To avoid this, appropriate attention is to be paid to the impurity profiles of the 
peptide API starting materials, i.e. Fmoc-protected amino acids, requiring validated analytical 
methods. 
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Figure 2. Synthesis of peptide API starting materials: mechanism for the formation of Fmoc-β-Ala-OH and 
Fmoc-β-Ala-AA-OH impurities. 
 
4.3 Incomplete removal of protecting groups 
Incomplete removal of permanent protecting groups after SPPS will result into protection groups 
covalently attached to peptide sequences. Covalently attached (tBu) peptide impurities, 
characterised by a relative mass increase of +56 Da were reported by Sanz-Nebot et al. [77-83]. The 
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authors also reported impurities with the transient Fmoc-protecting group still attached at the 
amino-terminus (Table 1). The tBu adduct impurity was also seen when analyzing TCS, as well as a di-
tert-butyl dicarbonate (tBoc)-TCS adduct, characterised by mass increase +100 Da [84]. Verbeke et al. 
identified impurities, characterised by methylation of a glutamic acid residue (Table 1) [53]. 
When performing tissue-organ bath experiments using isolated guinea pig longitudinal smooth 
muscle, Verbeken et al. reported a functional activity for peptide FRSLFWGNHSQ (70% purity, i.e. 
crude grade SPPS prepared) of which the sequence is derived from the insulin-like peptide 6 
(INSL6[151–161]) [90]. However, confirmatory experiments with high purity peptide material (95%) 
did no longer induce a functional tissue response, indicating that the parent peptide itself is not 
responsible for the observed activity. HPLC-ESI-MS impurity analysis of the crude peptide material 
revealed the presence of significant impurity levels above the applied reporting threshold of 0.5%. 
The major impurity peak observed in one of the crude material batches was characterised by m/z of 
1484.64, which is a mass shift of +106 relative to the parent peptide (m/z 1378.6). In the MS/MS 
spectrum obtained from m/z 743.08, i.e. [M+2H]2+, the original b1–b5- and y1–y5-fragment ions of the 
parent peptide were detected. On the other hand, the +106 Da mass shift, corresponding to the mass 
of anisole/p-cresol, was observed for b6–b10 and y6–y10 fragment ions, relative to the parent peptide 
b- and y-fragment ions (Figure 3A). From this, it was concluded that the major impurity is an 
anisole/p-cresol adduct of the INSL6[151–161] peptide with the anisole/p-cresol group attached to 
Trp at position 6. The origin of this impurity is most likely the incomplete removal of the anisole/p-
cresol protecting group. Another major impurity of a different batch was characterised by a m/z 
value of 1434.6, a mass shift of +56 Da compared with the parent peptide monoisotopic mass. 
MS/MS analysis revealed a tBu modification of the Ser residue at position 3 (Figure 3B). Tertiary butyl 
was confirmed by the peptide manufacturer to be used during peptide synthesis as a protecting 
group for Ser residues. Yet another batch of crude peptide material contained two major impurities, 
characterised by monoisotopic masses of m/z 1566.68 and 1620.48, respectively. MS/MS results for 
m/z 1566.68 demonstrated the peptide structure to be a synthesis impurity, of the INSL6[151–161] 
parent peptide, with addition of tryptophanyl to the Trp residue at position 6, resulting in the 
observed mass increase of +188.18 Da. The mass shift of +243 of the impurity characterised by m/z 
1620.56 was demonstrated by MS and MS/MS to result from incorporation of a trityl group at the 
Asn residue at position 8 of the parent peptide sequence (Figure 3C).  
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Figure 3. (A) Typical MS and MS/MS spectra (on m/z 743.08 selected precursor ion) for the anisole/p-cresol 
derivative in the crude INSL6[151–161] material batch 1. (B) Typical MS and MS/MS spectra (on m/z 717.99 
selected precursor ion) for the tBu derivative in crude INSL6[151–161] material batch 2. (C) Typical MS and 
MS/MS spectra (on m/z784.08 and 810.95 selected precursor ions) for the major impurity peak observed in 
crude INSL6[151–161] material batch 3. 
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4.4 Oxidation/reduction 
Certain amino acid residues tend to experience oxidations or reductions during the SPPS procedure. 
Impurities caused by oxidation of cysteine and methionine residues have been found in carbetocin 
and eledoisin crude mixtures, respectively (Table 1). These impurities show mass differences of 16, 
32 and 48 Da relative to the parent peptide, depending on the oxidation stage, i.e. sulfoxide, sulfone 
and sulfonic acid, respectively. Taichrib et al. reported a sulfoxide impurity of tetracosactide, 
characterised by a mass increase of +16 [84]. Finally, oxidation of two cysteine residues to cystine 
(mass difference -2) will result into cyclization of the peptide. Verbeke et al. reported this oxidation 
impurity type, which often also contained additional deleted amino acid residues [34] (Table 1). 
Histidine and lysine are also prone to oxidation, forming 2-oxo-histidine and aminoadipic acid, 
respectively [91,92]. The oxidized impurities are formed by prolonged exposure to light and air 
during storage. On the other hand, the side chain of tryptophan is quite reactive in acidic conditions, 
and it can undergo oxidations resulting in hydroxy-Trp, kynurenine, 3-hydroxy-kynurenine, N-
formylkynurenine and hydroxyl-N-formylkynurenine as well as undergo reduction [79,91]. A 
summary of the oxidized and reduced amino acid residues can be found in Figure 4. Similar to 
oxidative stress caused by reactive oxygen species (ROS) in physiological processes, chemical 
oxidative stress in peptides and proteins caused by ROS cannot be excluded. ROS include radical 
species such as superoxide (O2
. -), hydroxyl (OH.), peroxyl (RO2
. ), alkoxyl (RO.) and hydroperoxyl 
(HO2
. ), and nonradical species such as hydrogen peroxide (H2O2), hypochlorous acid (HOCl), ozone 
(O3), singlet oxygen (
1O2) and peroxynitrite (ONOO
-) [93]. 
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Figure 4. Amino acid oxidation/reduction-related impurities. 
 
4.5 Diastereoisomerization 
The incidence of amino acid racemization has been widely investigated for many amino protected 
amino acid residues. Racemisation mechanisms are typically classified into two main types: direct 
enolization and oxazolone (azalactone) formation, which are both base-catalyzed mechanisms [94-
98]. In the case of Fmoc-protected amino acid residues, direct enolization during the coupling step is 
the suggested mechanism. Here, a carbanion is generated due to proton abstraction catalyzed by the 
tertiary amine. Depending on the side chain R, this carbanion can be stabilized, e.g. resonance effect 
observed during phenylglycine racemisation, facilitating the process [99]. This carbanion is then 
protonated from both sides of the plane, resulting in racemisation (Figure 5). Elsawy et al. reported 
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racemisation of a phenylglycine (Phg) residue during conventional and microwave-assisted Fmoc 
SPPS of AVPPhgY-NH2. Optical purity of the Fmoc-Phg-OH starting material was checked, and 
confirmed the formation of the chiral impurity during amino acid coupling steps [100]. An alternative 
peptide synthesis route, using the activated carboxylic end (usually acyl halide activation) of the 
peptide, can also result into racemisation through an oxazolone intermediate (Figure 5). To avoid 
this, peptides are usually synthesised from C- to N-terminus, combined with carboxylic activation of 
the unbound amino acid, rather than the growing peptide chain (Figure 1) [101].  
 
 
Figure 5. Racemization during SPPS coupling step. 
 
Finder et al. observed a faster aggregation rate of recombinant amyloid β-peptide (Aβ1-42) when 
compared to its synthetic counterpart [102]. In order to identify the differences between 
recombinant and synthetic Aβ1-42, the synthetic peptide was subjected to preparative RP-HPLC 
isolation under conditions identical with those used for the purification of the recombinant peptide. 
RP-HPLC analysis of the individual amino acids showed that 1.01%, 0.14% and 0.10% of the histidine, 
arginine, methionine amino acid residues in the synthetic peptide was in the D-configuration, relative 
to the diastereoisomeric-free recombinant Aβ1–42. Histidine is indeed known for a minor, but 
significant tendency of racemisation during peptide synthesis [103]. As three histidines, one 
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methionine, and one arginine are contained in the Aβ1–42 sequence, this adds up to approximately 
3.5% of diastereomeric Aβ1–42 impurities, containing at least one D-amino acid residue, within the 
synthetic Aβ1–42 peptide material. Moreover, these diastereoisomer peptide impurities resulted in 
altered aggregation kinetics of the synthetic Aβ1–42 peptide when compared to the all-L 
recombinant Aβ1–42 peptide, hereby proving that even small amount of stereoisomeric impurities, 
by as little as a single amino acid, can greatly influence the biological function of the parent peptide. 
Furthermore, conventional RP-HPLC is not always capable of separating these diastereoisomeric 
impurities from the all-L form, rendering detecting of these impurities difficult. Sanz-Nebot et al. also 
reported diastereoisomeric impurities for carbetocin, eledoisin, leuprolide, goserelin and triptorelin 
peptides but did not pinpoint the racemisation location [77-83]. 
 
4.6 Side- and end-chain impurities 
Sanz-Nebot et al. identified a number impurities arising from side- and end-chain reactivity. In the 
case of the crude peptide mixtures studied, the most relevant observed side-chain reactions have 
been aminations in the side chain of arginine, resulting in a primary amine, characterised by a mass 
difference of +15. Moreover, side chain reaction of the histidine residue in leuprolide with the amino 
acid activator DIC, lead to substituted guanidines with a mass difference of 126 Da (Figure 6). Before 
the SPPS of goserelin is completed by amidation, the goserelin acid precursor is cleaved from the 
resin, and under normal conditions amidated to form the desired goserelin API. However, this acid 
precursor was involved in a unwanted side-reaction with the dimethylformamide reagent used in the 
SPPS process, to form a dimethylamide (-N(Me)2 derivative of the acid precursor (mass difference: 
+28). The authors also reported the modification of the arginine side chain into an ornithine (Orn) 
residue. This ornithine residue has an unprotected amino group, thus allowing for the coupling of 
additional amino acid residues. In each of the following coupling steps, the amino acid can be linked 
to the main peptide backbone (wanted), or to the side chain of ornithine (unwanted). Up to six 
goserelin-related impurities due to this ornithine side chain reactivity were reported (Table 1) [80]. 
The authors also observed a triptorelin deamidation product, characterised by a mass increase of 1 
Da as a consequence of the -CONH2 to –COOH conversion. This deamidation impurity type was also 
reported by De Spiegeleer et al. for canine and mouse obestatin and by Lai et al. [10,104]. 
Litowski et al. observed two single side chain acetylated peptide impurities, characterised by a mass 
difference of +42, in a semi-pure 21-mer peptide (sequence Ac-KISALKEKISALKEKISALKE-NH2) by RP-
HPLC and Cation Exchange Chromatography (SCX) [86]. The acetylation location was determined to 
be at Ser 3 and at the Ser 10 or Ser 17 residues. Similar acetylated TCS impurity was also reported by 
Taichrib et al., but the acetylation site was not determined [84].  
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Figure 6. Side chain reactivity. 
 
4.7 Dimers 
Different aggregation or self-association mechanisms can lead to high molecular weight peptide 
impurities. Peptide aggregates are classified into covalent (chemical) and non-covalent (physical) 
interaction products, with the extent of their formation dependent on a wide variety of 
environmental factors. Covalent aggregates are typically formed from two or more monomers by 
CHAPTER VIII – RELATED IMPURITIES IN PEPTIDE MEDICINES 
 
 
   213 
disulfide bonds or oxidation of tyrosine to dityrosine. These covalent impurity types are thus in fact 
oxidation impurities (Section 4.4). Non-covalent aggregates are usually the result of weaker 
hydrophobic and electrostatic interactions. It is apparent that the molecular weight of a covalent 
dimer differ from the non-covalent type, i.e. two times molecular weight minus 2 (e.g. disulfide bond 
or tyrosine oxidation) vs. two times molecular weight, respectively. Moreover, a non-covalent 
aggregation impurity is usually in equilibrium with its native monomeric peptide. This equilibrium can 
be influenced by changes in peptide concentration or changes in solvent (e.g. pH), which can be used 
to deduce whether the aggregation is a true impurity or if it is the result of analytical sample 
preparation [105,106]. 
De Spiegeleer et al. identified an impurity related to human obestatin, a 23-amino acid peptide, with 
molecular masses twice that of the parent peptide and with a relative retention time of 
approximately 1.8 relative to the parent peptide, when using a standard RP-HPLC-MS impurity 
profiling protocol [10]. The identity of these high-molecular-weight impurities was unequivocally 
proven to be obestatin dimers, by size-exclusion chromatography coupled to MS detection, as shown 
for human obestatin (Figure 7). 
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Figure 7. Size exclusion chromatography LC–UV/MS analysis of human obestatin: (left) chromatogram showing 
dimeric and monomeric obestatin at 11.5 and 12.9 min, respectively (middle) mass spectra of dimeric obestatin 
with calculated monoisotopic molecular mass of 5104.3 Da; and (right) mass spectra of monomeric obestatin 
with calculated monoisotopic molecular mass of 2546.1 Da. 
 
4.8 Peptide counter ions 
TFA is used in the final stage of SPPS as well as during further peptide RPLC purification steps. As a 
result, TFA will be present in the final peptide product. Whilst performing an infrared absorption 
study of the peptide dynorphin A-(1–13), Surewicz et al. noticed the presence of a strong absorption 
band with a maximum centered at 1673 cm−1 [107]. This band was completely eliminated after 
chromatographic purification of the dynorphin A-(1–13) peptide, suggesting that the above band 
originates from organic counter ions or other impurities. The authors investigated if residual TFA was 
responsible for this strong absorption band as TFA will interact with positively charged amino acid 
side chains. Infrared analysis of sodium trifluoroacetate indeed showed a single strong band at 1673 
cm−1, arising from the asymmetric COO− stretching vibration of the TFA ion. Other authors also 
reported the presence of this absorption band, which not only interferes with the peptide’s amide I 
band, but can also distort the peptide conformation [108-116]. Andrushcenko et al. reported an 
optimal hydrochloric acid concentration of 2 to 10 mM, followed by lyophilization, to remove all TFA 
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impurities, without modification to the peptide secondary structure [117]. Finally, De Spiegeleer et 
al. also reported the detection of peptide counter-ions, e.g. TFA, during RP-HPLC-DAD impurity 
profiling of obstatin peptides [10]. Although TFA salts can sometimes be tolerated during earlier drug 
discovery (R&D) phase, peptide APIs are generally manufactured as acetate salts, which can be 
achieved by an additional salt switching step [118]. 
 
4.9 Structurally unrelated contamination 
Currier et al. described a contamination of individual peptides derived from the human 
immunodeficiency virus (HIV-1) with a commonly used peptide derived human cytomegalovirus 
(HCMV) [119]. The desired Gag 114 peptide (sequence: PTAPPMESLGMGEEI) was contaminated with 
the HCMV-NV9 peptide (sequence: NLVPMVATV) and it was proven that the contamination came 
directly from the manufacturer after comparison with in-house manufactured Gag 114 (Figure 8). 
The desired peptide and the contaminant have a totally different sequence, illustrating that this 
impurity is a contamination, and not formed during the desired peptide synthesis. However, 
although the sequences are different, a similar chromatographic behavior is observed, rendering 
classic HPLC-based QC and purification of the Gag 114 peptide from the contaminant difficult. 
Importantly, this small amount of approximately 1% of unrelated peptide contaminant caused a false 
positive result for the Gag 114 peptide, demonstrating the importance of adequate peptide quality 
control prior to experimental use. De Graaf et al. also reported contamination of HuD peptides (each 
15 amino acid residues long) with an unrelated, immunogenic peptide derived from cytomegalovirus 
(sequence: AIAEESDEEEAIVAY), again resulting in false positive results for the investigated peptides 
[120]. Brezar et al. reported false positive immunogenic stimulation due to a contaminant (sequence 
VYLKTNVFL) present in peptide PIA7-21 (sequence: CTSICSLYQLENYCN) [121]. This contaminant went 
undetected in several quality routine control analyses (MS detection). After a new SPPS batch of the 
PIA7-21 peptide did not reproduce the initial results, the original PIA7-21 peptide underwent HPLC 
fractionation. Each fraction was concentrated 10-fold and tested for an immunogenic response. Only 
one fraction provoked a response and was identified to be VYLKTNVFL using mass spectrometry. 
Jones et al. also described false positive results due to an HIV-1 Gag peptide contamination of 15-mer 
peptides derived from Human Endogenous Retrovirus [122]. Moreover, specific guidance for the 
development, production and control of synthetic peptide vaccines are given by various regulatory 
authorities such as WHO. De Spiegeleer et al. reported delivery of an ovalbumine-derived peptide 
instead of the desired obestatin peptide, probably due to a complete mix-up at the peptide 
manufacturer. However, both peptides showed similar RP-HPLC chromatographic behavior, 
rendering detection of this mix-up only possible by using MS detection [10]. 
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Figure 8. LC–MS analysis of the suspect contaminated Gag 114 peptide from manufacturer A (A–C) and the in-
house-resynthesized Gag 114 peptide (D–F). (A and D) UV traces of HPLC. High peptide purity is evident. The 
selected ion mode with mass filter adjusted to the calculated theoretical mass of the Gag 114 peptide (1559.80 
[M+H]
+
) is shown for each peptide (B and E). The desired product is clearly present in both profiles. The 
selected ion mode with mass filter adjusted to the calculated theoretical mass of the HCMV-HCMV-NV9 
peptide (944.18 [M+H]
+
) is shown (C and F). A signal corresponding the exact theoretical molecular weight 
(MW) of HCMV-NV9 is present in the outsourced Gag 114 peptide. Note the different scales on the y axis. 
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4.10 Miscellaneous 
Singh et al. used Fmoc protected L-cysteine-acetamidomethyl (Acm) as starting material for the SPPS 
synthesis of the cysteine(Acm)-containing tripeptide Ac-Phe-Dap(Boc)-Cys(Acm), designed to be a 
bifunctional VII B metals (e.g. Technetium and Rhenium) chelator radiopharmaceutical [123]. 
However, during cleavage of the tripeptide from the resin using TFA, unwanted deprotection of the 
Cys residue was observed, thus obtaining a free thiol functional group. This reactive thiol functional 
group formed an ethanedithioladduct (Δmass: +92) with the ethanedithiol (EDT) scavenger as well as 
a disulfide dimer (Figure 9). Identification of these impurities was performed using HPLC-ESI-MS. 
These impurity amounts could be reduced by using triisopropylsilane as scavenger in the absence of 
H2O. 
Breslav et al. performed a p-benzoylphenylalanine (Bpa) scan of a tridecapeptide, i.e. Saccharomyces 
cerevisiae α-factor, in order to define the binding site with a G-protein coupled receptor [124]. Two 
of these analogues, with Bpa in position 1 and 3 respectively, were manufactured using Fmoc SPPS, 
and cleaved from the resin using ethanedithiol as scavenger. Besides the desired peptide, one 
impurity characterised by a 76 Da mass increase was observed using RP-HPLC-MS. Further sulfur and 
spectral analysis revealed the presence of a dithioketal group replacing the diarylketone group of Bpa 
(Figure 9). Replacing the ethanedithiol with dithiothreitol as scavenger did not result in impurity 
formation. Sieber et al. reported similar dithioketal formation between tryptophan residues and the 
ethanedithiol scavenger [125]. 
Wang et al. characterised the impurities of a dimeric antitumor peptide, CU201, with sequence 
SUIM-(D-Arg-Arg-Pro-Hyp-Gly-Igl-Serd-Igl-Oic-Arg)2, where SUIM = suberimidyl; Hyp = trans-4-
hydroxyproline; Igl = α-(2-indanyl)-glycine; Oic = octahydroindole-2-carboxylic acid [126]. Figure 10 
shows the presence of 3 impurities in the CU201 peptide. The appearance of the mass spectrum of 
impurity MA is almost identical to that of CU201, with ions at m/z 1407.7, 939.2, and 704.8. 
Therefore, the identity of this impurity was first suspected to be a diastereoisomer of the large 
peptide CU201. However, careful examination of MS zoom scan data showed that the multiply 
charged ions for impurity MA were slightly but consistently higher than those for CU201. The average 
molecular masses calculated from multiple runs and multiple charge state ions of these two 
components are 2812.25 for CU201, and 2813.26 for impurity MA. It became apparent that the 
molecular mass of MA is approximately 1 mass unit higher than the mass of CU201 and it seemed 
plausible that one of the NH groups in CU201 has been replaced by an oxygen atom in impurity MA. 
High resolution LC-TOF/MS and NRM analysis confirmed that one of the two amidinyl=NH groups in 
the suberimidate residue was replaced by an oxygen atom, explaining the +1 mass difference. The DA 
impurity has a set of multiply charged ions that correspond to 2 mass units higher than that of 
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CU201, whereby both amidinyl =NH groups in the suberimidate residue were replaced by oxygen 
atoms. Impurity C was the result of hydrolysis between Arg and suberimidate residues. Finally, Sanz-
Nebot et al. reported linear impurities found in the crude carbetocin sample originating from an 
inefficient cyclization of the molecule [82]. 
 
 
Figure 9. Miscellaneous impurity formation. 
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Figure 10. TIC chromatogram (top panel) of CU201 lot −C/3, 0.5 mg/mL in ACN/H2O (1:1) with 0.1% formic acid, 
fresh. The mass spectra of CU201 and impurities C, MA and DA are displayed under the chromatogram. 
 
 
5. INTRINSIC PEPTIDE MIXTURES 
Some peptide drugs consist of multiple active compounds, i.e. intrinsic peptide mixtures (also termed 
peptide complexes), which is not unusual for antibiotic drugs. An important consideration here is 
that each compound should have its own contributing activity, making the drug mixture acceptable 
for registration and marketing. If one or more components, however, have no activity or even 
antagonist activity, these should then be considered as impurities. Moreover, the ratio in which 
these different active ingredients are present in such a mixture, might vary depending on the drug 
product, but should at all times be consistent within a considered drug product as this links the 
clinical outcome with the quality of the batches. 
A typical example is the antibiotic fusafungine, containing a mixture of cyclic hexadepsipeptide 
enniatins, which is marketed under the trade name Locabiotal® and used to treat upper respiratory 
infections [22]. A representative total ion chromatogram is shown in Figure 11, indicating the 
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presence of at least 7 different enniatin (ENN) isomers. The UHPLC-MS conditions used to obtain 
these data are given in Table 2. The mixture was characterised as followed: 43% ENN B, 31% ENN B1, 
15% ENN A1, 4% ENN D, 3% ENN A, 3% ENN E and 1% ENN C or F. UV spectral data (not shown here) 
confirmed a similar pattern. 
 
Table 2. Fusafungine (Locabiotal® )UHPLC-MS conditions 
Chromatography inlet 
Column + guard Acquity UPLC CSH C18 130Å 150 mm x 2.1 mm x 1.7 µm 
Flow 0.6 mL/min 
Injection volume 10 µL  
Needle wash 
DMSO:isopropanol:ACN 
10:10:80 (V/V/V) 
Pre: 0s 
Post: 6s 
Oven temperature 45°C  
Sample temperature 25 °C  
Mobile phase A: 0.1% FA + 0.1% isopropanol in H2O B: 0.1% FA + 0.1% isopropanol in ACN 
Isocratic 30 % 70 % 
Run time 7 min 
MS tuning conditions 
Capillary voltage 3.50 kV 
Cone voltage 50 V 
Source offset 60 
Source temperature 150 °C 
Desolvation gas flow 1000 L/h 
Desolvation temperature 600 °C 
Cone gas flow 150 L/h 
Collision gas flow 0.19 mL/min 
Nebuliser 7 bar 
Calibration link Quantitative 
MS method: multiple reaction monitoring (MRM) 
Compound Parent (m/z) Daughters (m/z) Collision energy (V) 
ENN B 639.91 
196.08 25 
527.26 22 
ENN D and B1 653.99 
196.09 23 
541.05 21 
ENN E and A1 668.07 
209.99 24 
555.29 21 
ENN C or F and A 682.47 
209.93 26 
555.01 23 
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Figure 11. Total ion chromatogram (TIC) of fusafungine (Locabiotal®). 
 
6. DEGRADATION PRODUCTS 
A number of peptide impurities arising from degradation, e.g. during storage, rather than being 
strictly synthesis-related, are reported here. 
 
6.1 β-elimination 
Constantino et al. proposed a hydroxide ion catalyzed β-elimination of the carbon-sulfur bond in 
cysteine, which would result into two new residues, i.e. dehydroalanine and thiocysteine [127]. 
Dehydroalanine would react with lysine to form a lysinoalanine cross-link leading to insulin 
dimerization, whereas thiocysteine would further degrade into thiol-containing products, e.g. 
hydrosulfide ions. Indeed, the authors demonstrated a 5-fold increase of free thiol groups after 
incubation of insulin at 50°C / 96% R.H. Alternatively, dehydroalanine can undergo hydrolysis, 
yielding the N-terminal amidated peptide product and a C-terminal peptide fragment beginning with 
a pyruvoyl group [104]. This degradation mechanism was also observed during the short term, high 
temperature stressing of buserelin in its solid state, as illustrated in Chapter V [31]. This entire 
degradation pathway is summarized in Figure 12. 
During microwave-assisted SPPS of C-terminal cysteine peptides, β-elimination of the C-terminal 
cysteine residues can also occur, forming a dehydroalanine intermediate which reacts with the 
deprotecting base piperidine, to form a 3-(1-piperidinyl)-alanine residue [128]. To avoid this, Ni et al. 
ENN A 
ENN C or F 
ENN A1 
ENN E 
ENN B1 
ENN D 
ENN B 
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introduced an Fmoc-based SPPS using an aryl-hydrazine linker for synthesis of C-terminal cysteine 
peptides [129]. β-elimination can also occur at serine and threonine residues, effectively removing 
the hydroxyl moiety, of which the dehydroalanine moiety can further degrade as mentioned above 
[130]. 
 
Figure 12. Dehydroalanine formation through a β-elimination mechanism. 
 
6.2 Diketopiperazine, pyroglutamate and Aspartimide/succinimide formation 
Diketopiperazine formation can take place during SPPS and during peptide storage. It is sequence 
dependent and occurs if Pro or Gly residues are at position 1 or 2. The reaction involves a 
nucleophilic attack of the N-terminal nitrogen on the amide carbonyl between the second and third 
amino acid, which leads to the cleavage of the first two amino acids in the form of a diketopiperazine 
(Figure 13). Good accessibility to this amide carbonyl, i.e. absence of a bulky side chain at position 
three as is the case for Gly residues, will facilitate the reaction. Different strategies to avoid this 
reaction during SPPS have been developed [131,132]. On the other hand, pyroglutamic acid 
formation is almost inevitable if Gln is the N-terminal amino acid residue. This is an analogous 
reaction where the N-terminal nitrogen attacks the side chain carbonyl carbon of Gln to form a 
pyroglutamic acid peptide analog, characterised by a mass decrease of 17, similar to deamidation 
[133]. This conversion also occurs when Asn is the N-terminal residue (Figure 13) [134]. 
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Figure 13. Diketopiperazine (A), pyroglutamate (B) and succinimidyl (C) degradation mechanisms. 
 
Internal Asp and Asn residues are prone to aspartimide/succinimide formation, especially when a 
non-bulky side chain amino acid is C-terminally adjacent to the Asp/Asn residue, reducing steric 
interference, e.g. Gly, Ala and Ser. Both the semantics “aspartimide” and “succinimide” terms are 
used to describe the same reaction, i.e. formation of a five-membered succinimide ring by 
nucleophilic attack of the C-terminal amide bond nitrogen on the γ-carbonyl of the Asn or Asp 
residue. The ring formation is favored by mildly acidic conditions and is unstable under physiological 
and alkaline conditions, also undergoing racemisation. Subsequently, racemisation and hydrolysis of 
the succinimide ring gives rise to a mixture of L-Asp, D-Asp, L-isoaspartate and D-isoaspartate, thus 
resulting in deamidation and racemisation of the original Asn residue (mass difference +1) or 
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isomerisation and racemisation of the original Asp residue to isoaspartate [135-139]. Moreover, 
succinimide impurities as such have also been identified in porcine somatotropin and during a 
stability study of recombinant human parathyroid hormone [140,141]. This aspartamide/succinimide 
formation can also occur during SPPS of Asn or Asp containing peptides. Besides the aforementioned 
degradation mechanisms of the succinimide ring, i.e. racemisation and hydrolysis, a nucleophilic 
attack of piperidine or methanol, both used during SPPS, will result in α- or β-piperidide and α- or β-
methyl ester peptides, respectively [142]. Michels et al. proposed addition of 5% formic acid to the 
piperidine to avoid the aspartimide formation during SPPS [143]. Presence of Asn residues can also 
induce peptide bond cleavage between this Asn residue and its C-terminal adjacent residue. Here, 
the amide nitrogen of the Asn side chain attacks the peptide bond carbonyl group, resulting in 
release of the carboxyl-side peptide and formation of a C-terminal succinimide on the original N-
terminal peptide. Both succinimide-mediated Asn deamidation and peptide bond cleavage can occur 
simultaneously, with deamidation usually being the dominant reaction. Only when proline is 
adjacently present, which has no deprotonable peptide bond nitrogen and can thus not initiate 
succinimide formation, bond cleavage is the only degradation route [144,145]. 
 
6.3 Peptide-excipient interaction in FDP 
The influence and interaction between excipient and APIs in FDP has already been reviewed for the 
classic small organic molecules and proteins. In general, four different interaction mechanisms can be 
distinguished: (i) direct interaction between excipients and API, resulting in a covalent bond 
formation between the excipient and API molecule. Typical examples are the Maillard reaction 
between the side chain amino groups of lysine and arginine in proteins and reducing sugars, ester 
formation, transesterification, amide formation and Michael’s addition. (ii) indirect interaction, 
where the excipient acts as a catalyst increasing degradation rate of the API without forming a 
covalent bond. (iii) excipients with ionizable functional groups can act as pH modifiers and impact the 
formulation pH, potentially accelerating degradation. (iv) finally, API interactions with excipient 
impurities such as peroxides, aldehydes, acids and metals must also be considered [146-149]. 
Examples are given by D’Hondt et al. reporting a covalent bond formation between salmon calcitonin 
and a carbomer polymer, and Houchin et al., reporting an acylation reaction between peptides and 
the Poly(lactide-co-glycolide) (PLGA) polymer [150,151]. 
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7. CONCLUSIONS 
Peptide impurities are not only a constant concern in the GMP manufacturing of peptide drugs 
during the drug development phase and clinical use, but should also be considered as possible 
confounders during the initial drug discovery phase. Therefore, it is crucial to verify the quality of 
peptide products, often manufactured using solid-phase peptide synthesis, before biological 
experimental use and it is highly recommended to repeat the biological experiments with a second 
peptide batch, obtained from another source. Commonly observed peptide-related impurities are 
solid-phase peptide synthesis-related: deletion and insertion of amino acids are related to inefficient 
Fmoc-deprotection and excess use of amino acid reagents, respectively. Fmoc-deprotection can 
cause racemisation of amino acid residues and thus diastereomeric impurities. Inefficient 
deprotection of amino acid side chains results into peptide-protection adducts. Furthermore, 
unprotected side chains can react with a variety of reagents. Oxidation of amino acid side chains, due 
to prolonged exposure to air is also a possibility. Dimeric impurities were also found. Peptide counter 
ions, usually trifluoroacetic acid, are often present in the final peptide product, originating from the 
SPPS itself, or from additional purification treatments. Contamination of the desired peptide product 
by other unrelated peptides was also seen, pointing out the lack of appropriate GMP. Secondly, 
peptide impurities resulting from intrinsic peptide degradation such as β-elimination, 
diketopiperazine, pyroglutamate and succinimide formation are also discussed, as well as peptide-
related impurities formed by peptide-excipient interaction in the finished drug product. 
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SUMMARY & GENERAL CONCLUSIONS 
All working in the pharmaceutical field should continuously strive to meet patient demands: the 
patient wants fast access to safe and efficacious drug formulations. The work presented in this thesis 
relies on different analytical approaches and considerations to help meeting each of these 
fundamental patient demands. 
 
Peptides are an increasingly explored group of molecules, with medicinal properties due to their 
ability to treat a variety of diseases, as well as functional food and cosmetic applications. However, 
they are also accompanied by a labile thermal stability profile, rendering them susceptible to a series 
of degradation mechanisms. Unfortunately, the current knowledge about peptide thermal stability is 
mostly derived from in-solution data, but is generally broadened to solid-state as well, hereby 
excluding peptide APIs from certain processing techniques involving their exposure in solid-state to 
high temperatures like hot-melt extrusion. Given their high potencies, requiring only small doses to 
obtain a therapeutic effect, and the frequent observed extended duration of disease treatment (e.g. 
osteoporosis, diabetes type-II, cancer, HIV), peptides are often suitable candidates for implant 
formulations. Therefore, the general aim of this research was to explore the feasibility of hot-melt 
processing peptide APIs into polymeric implants. Therefore, the current knowledge about peptide 
stability was broadened to include solid-state thermal stability.  
 
Peptide analysis requires adequate analytical techniques, capable of assaying the main peptide as 
well as the related impurities, including the formed degradation products. Liquid chromatography 
(U(H)PLC) was the analytical method of choice of which the analytical column is considered the most 
important component, the heart, of this technique. However, choosing a suitable analytical column 
can be cumbersome and is often not rationalized, potentially resulting in a sub-optimal column 
selection. In Chapter II, a Derringer desirability approach and the construction of kinetic plots were 
used to rationally select the most appropriate analytical column to solve the challenge of peptide 
analysis. 
 
The analytical detectors, the eyes and ears of liquid chromatography, are used to quantify the 
different peptide components as they are eluted from the column. As described in Chapter III, a 
single quad mass spectrometry detector coupled to an UPLC-PDA system was implemented in the 
routine quality control of peptide APIs and its performance compared to traditional pharmacopoeial 
HPLC-PDA methods. The full integration of this single quad MS detector into existing QC systems 
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allowed for direct peak identification of the main compounds as well as related impurities. As it is 
inevitable that this technology platform will soon become a standard analytical technique in QC 
environments, the molecular weight information given in the European Pharmacopoeia should be 
updated, implementing the most recent IUPAC atomic weight data. 
 
Based on these analytical considerations and advances, stability indicating analytical methods were 
developed to probe solid-sate peptide stability under thermal stress (Chapter V). The peak area 
balance, comparing the sum of peak areas found in stressed samples with the API peak area in an 
unstressed reference sample, was used during method verification. Interestingly, the peptide peak 
area balances were consistently found to be below 100%. Moreover, this peak area balance issue 
was not only confined to peptides, e.g. buserelin acetate, but appeared to be a general 
pharmaceutical challenge, also arising during formal ICH-stability studies of small molecules. 
Therefore, in Chapter IV, an in-silico mathematical approach is proposed to calculate the average and 
individual response factors of degradants formed during experimental stress or stability studies, thus 
eliminating the direct need to isolate, identify and characterize these degradants. 
 
In Chapter V, a first critical aspect towards the feasibility of peptide hot-melt processing was 
examined by exposing solid-state peptide APIs to short-term dry heat conditions. The majority of the 
evaluated peptide APIs, including anti-cancer (buserelin acetate) and anti-HIV (enfuvirtide and C34) 
therapeutics, remained stable at our hot-melt-related conditions, hereby debunking the resilient 
myth that peptides in general are unstable at elevated temperatures. Obviously, these results greatly 
encouraged the exploration of peptide hot-melt feasibility. 
Furthermore, by increasing the dry heat stress conditions dramatically, hereby widely exceeding hot-
melt-related conditions, formed peptide-related degradants were identified and different 
degradation mechanisms proposed. By including this solid-state peptide stability data, the general 
knowledge regarding peptide stability is broadened. 
 
In Chapter VI, API losses occurring in pharmaceutical preparation processes at lab- and pharmacy-
scale, resulting in under-dosed drug formulations, were traced. For this, the different compounding 
and working area surfaces, as well as the final drug formulations were assayed, from which an API 
mass balance was derived, i.e. all weighed API was experimentally recovered. This study indicated 
that the majority of API loss occurred in the mortar and was directly proportional with the roughness 
of the mortar surface. Although the quality of the compounding equipment is often overlooked in 
the preparation of drug formulations, be it at lab- or pharmacy-scale, this chapter shows its direct 
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impact on the quality of final drug formulations as used in drug discovery and preclinical or early 
clinical phases of drug development. 
 
Given the highly encouraging solid-state stability results obtained with different peptide APIs, a 
peptide-loaded implant was hot-melt prepared in Chapter VII. In this proof of principle set-up, a non-
biodegradable poly(ethylene-vinyl acetate) polymer was loaded with 20% (m/m) buserelin acetate, 
and hot-melt processed into an implant. No significant buserelin acetate degradation was observed 
under our experimental conditions, confirming the previous dry heat stress results. Moreover, 
buserelin acetate remained stable in the polymeric matrix during a 3 month ICH-stability study (5°C, 
25°C/60% R.H. and 40°C/75% R.H.). Furthermore, the implant’s initial functionality was evaluated by 
in-vivo and in-vitro release studies. An in-vitro steady-state daily release of 5 µg buserelin acetate 
was seen, after an initial burst stage. These findings were confirmed in-vivo, given the high buserelin 
acetate concentrations found in mice plasma, kidney and liver, 1 day post-implantation, before 
leveling out at 30 days post-implantation. 
 
Last, Chapter VIII provides a structured regulatory-quality overview of the most commonly observed 
peptide-related impurities in peptide medicines, encompassing the active pharmaceutical ingredients 
(or drug substance) as well as the finished drug products. Not only is control of these peptide-related 
impurities and degradants critical for the already approved and clinically used peptide medicines, 
these impurities also possess the capability of greatly influencing initial functionality studies during 
early drug discovery phases, possibly resulting in erroneous conclusions. 
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The relationship between the different chapters of this doctoral thesis and the fundamental patient 
demands is graphically shown in Figure 1. 
 
 
Figure 1. Overview of the different thesis chapters and their relationship to the patient. 
(A) Analytical considerations were provided to speed up initial drug discovery phases by presenting approaches 
to rationalize the analytical column selection as well as to cost- and time efficiently calculate response factors 
of degradants. (B) A literature review of the most common peptide-related impurities and implementation of 
recent analytical techniques to detect these were given, and should result into safer, high quality peptide 
medicines. (C) A new, hot-melt based approach to incorporate peptides into implants should stimulate further 
innovation towards more efficacious medicines. 
 
Based on the results obtained during this study, our main research question, i.e. “Can peptides be 
processed at elevated temperatures?”, could be answered: YES, a functional polymeric 
poly(ethylene-vinyl acetate) implant loaded with 20% (m/m) buserelin acetate was hot-melt 
prepared. Moreover, other questions, i.e. “Do peptides degrade upon exposure to dry heat and if so, 
which degradants are formed?”, were also answered. A number of peptide APIs, including anti-
cancer and anti-HIV peptide therapeutics, were found to be sufficiently stable at our hot-melt-related 
conditions. Peptide degradation, required for regulatory quality purposes (e.g. method validation), 
could be obtained by dramatically increasing the thermal stress conditions to which the different 
peptide APIs were exposed. As we expect that future regulatory emphasis will be given to peptide-
related impurities derived from synthesis or degradation, a global overview of these impurities was 
made. Moreover, this study was performed using state of the art analytical methods and equipment, 
and we are expecting and looking forward to their general implementation in the quality evaluation 
of peptide medicines from early discovery, research and development to post-marketing phases. 
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Even though these results clearly indicate the feasibility of preparing non-biodegradable peptide-
loaded implants using a hot-melt production technique, this is only the first step. We hope that this 
proof of principle study may inspire further innovation in peptide medicines, but recognize that even 
more questions remain unanswered and are awaiting further investigation, i.a.: “What is the 
influence of shear stress on peptide stability during hot-melt extrusion?”. We already investigated 
the temperature and excipient interaction influence on the peptide stability during the hot-melt 
production. However, the manufacturing of peptide-loaded implants on an industrial scale using hot-
melt extrusion, will subject the peptide APIs to a third stress factor, i.e. shear forces. Moreover, for 
larger peptides, not only the primary structure, but also the secondary structure may be influenced 
by the applied heat and shear stress. Therefore, an in-depth investigation of the amount and 
reversibility of potential peptide denaturation caused by this production method is highly wanted. 
Further optimization of the peptide release from the implants is also an interesting developmental 
aspect. The intrinsic drug release rates can be further optimized by using different existing or 
recently developed polymers or mixtures thereof, whilst not losing sight of their thermal processing 
characteristics. Moreover, this formulation optimization can also incorporate the existing and/or new 
mathematical models for drug release. Furthermore, the use of a rate controlling membrane can also 
reduce the observed burst effect and can simultaneously be used to fine-tune the prolonged steady-
state release of the peptide therapeutic. 
Further exploration of the peptide heat stability should be envisioned, to further widen the 
knowledge regarding solid-state peptide stability. Ideally, this should cover the entire peptide drug 
space, even including peptides in various clinical trial phases, thus probing the solid-state stability of 
different peptide types, e.g. glycopeptides, lipopeptides, nucleopeptides, as well as polymer-linked 
or PEGylated peptides. In turn, this data pool could be further explored to establish a QSPR 
(quantitative structure property relationship) model, linking the solid-state thermal stability of 
peptides to particular properties, e.g. certain amino acid sequences or secondary structure 
properties. The stability of newly discovered bioactive peptides and thus their potential for hot-melt 
processing, could then be predicted from this solid-state QSPR model. Moreover, research has linked 
high Tm values of proteins to the presence of certain amino acids sequences, by comparing 
corresponding proteins in hyperthermophilic and mesophilic microorganisms. It would be interesting 
to compare this solution QSPR model with our solid-state QSPR model. 
Furthermore, the exploration of different polymer types, grades and mixtures, focusing on their 
required hot-melt extrusion conditions, to construct a similar polymeric QSPR model would also be 
interesting. Based upon this model, the development of newer polymers could be stimulated. 
Moreover, by combining the structural properties of both peptides and polymers, the possibility of 
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modeling their compatibility in-silico, e.g. determining peptide dissolution in and diffusion through 
polymer matrix, could be envisioned. In turn, this in-silico calculated peptide-polymer compatibility 
data could then be used to predict the peptide release rate from the polymer. 
 
 
 
By having laid down some of the foundations, we hope that our research will open up new 
formulations for peptide APIs, ultimately leading to high quality peptide medicines, to the benefit of 
the patients.  
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“De man met een nieuw idee is een dwaas, 
tot het idee een succes blijkt te zijn.” 
 
  Mark Twain 
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SAMENVATTING & ALGEMENE CONCLUSIES 
Iedereen werkzaam in de farmaceutische sector zou voortdurend moet streven om de patiënteisen 
te vervullen: de patiënt wil een snelle toegang tot veilige geneesmiddelen, welke van hoge efficaciteit 
zijn. Het in dit proefschrift gepresenteerde werk baseert zich op verschillende analytische 
benaderingen en overwegingen om aan elk van deze fundamentele patiënteisen te helpen voldoen. 
 
Gezien hun vermogen om een verscheidenheid aan ziekten te behandelen, zijn peptiden een steeds 
vaker onderzochte groep van moleculen, en hebben zij ook functionele toepassingen in de voedsel 
en cosmetica sector. Ze gaan echter met een labiel thermisch stabiliteitsprofiel gepaard, waardoor ze 
gevoelig zijn aan verschillende degradatie mechanismen. Deze huidige hitte stabiliteitskennis werd 
grotendeels afgeleid van data bekomen met peptiden in oplossing, maar deze wordt alsook 
veralgemeend tot peptiden in vaste toestand, waardoor peptiden uitgesloten worden van bepaalde 
verwerkingstechnieken waarbij zij in vaste toestand blootgesteld worden aan hoge temperaturen, 
zoals bv. hot-melt extrusie. Gezien hun hoge potentie, waarbij slechts kleine hoeveelheden nodig zijn 
om een therapeutisch effect te verkrijgen, en frequent langere therapieduur (bijvoorbeeld 
osteoporose, diabetes type II, kanker, HIV), zijn peptiden dikwijls geschikte kandidaten voor 
implantaat formulatie. De algemene doelstelling van dit onderzoek was dan ook om na te gaan of het 
haalbaar is om peptiden via een smelt techniek in polymeer implantaten te formuleren. Hiervoor werd 
de huidige peptide stabiliteitskennis uitgebreid met hitte stabiliteitsdata in vaste toestand.  
 
Peptide analyse vereist geschikte analytische technieken, die het gehalte van het peptide alsook van 
de gerelateerde onzuiverheden, waaronder afbraakproducten, kunnen bepalen. 
Vloeistofchromatografie (U(H)PLC) werd als analytische techniek geselecteerd, waarbij de analytische 
kolom beschouwd kan worden als de belangrijkste component, het hart, van deze techniek. In 
Hoofdstuk II werd via toepassing van de Derringer desirability functie en kinetische grafieken, de 
keuze van de meest geschikte analytische kolom voor een bepaalde peptide analyse gerationaliseerd. 
 
De analytische detectoren, de ogen en oren van vloeistofchromatografie, worden gebruikt om de 
verschillende peptide componenten te kwantificeren wanneer zij van de kolom elueren. Zoals 
beschreven in hoofdstuk III, werd een single quadrupool massaspectrometrie detector gekoppeld 
aan een UPLC-PDA systeem gebruikt voor de routine kwaliteitscontrole van peptide activa. De 
prestaties van dit systeem werden vergeleken met de prestaties bekomen met traditionele 
Farmacopee HPLC-PDA methoden. De volledige integratie van deze single quadrupool MS detector in 
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bestaande kwaliteitscontrole systemen laat directe piekidentificatie toe van de belangrijkste 
verbindingen alsook van de gerelateerde onzuiverheden. Gezien het onvermijdelijk lijkt dat deze 
technologie binnenkort zal uitgroeien tot een standaard analytische techniek in kwaliteitscontrole, 
dient de informatie betreffende moleculaire gewichten zoals momenteel weergegeven in de 
Europese Farmacopee bijgewerkt te worden in overeenstemming met de meest recente IUPAC 
atoomgewicht gegevens. 
Op basis van deze analytische overwegingen en innovaties werden stabiliteitsindicerende  
analytische methoden ontwikkeld om de peptide stabiliteit in vaste toestand onder hitte stress 
(hoofdstuk V) te evalueren. De piekoppervlakte balans, waarbij de som van de piekoppervlakken 
teruggevonden in gestreste stalen wordt vergeleken met de piekoppervlakte van het activa in een 
niet-gestrest referentiestaal, werd gebruikt tijdens de methode verificatie hiervan. Opvallend was dat 
deze piekoppervlakte ratio steeds kleiner was dan 100%. Bovendien waren deze piekoppervlakte 
balans problemen niet enkel beperkt tot peptiden, bv. busereline acetaat, maar bleek dit een 
algemene farmaceutische probleem te zijn die ook ontstaat tijdens formele ICH stabiliteitsstudies van 
kleine moleculen. Daarom wordt in hoofdstuk IV een in-silico wiskundige benadering voorgesteld om 
de gemiddelde en individuele responsfactoren van de afbraakproducten gevormd tijdens stress- of 
stabiliteitsstudies te berekenen, waardoor het isoleren, identificeren en karakteriseren van deze 
afbraakproducten overbodig wordt. 
 
In hoofdstuk V wordt een eerste kritisch aspect van peptide smelt verwerking onderzocht door 
peptiden in vaste toestand kortstondig bloot te stellen aan droge hitte. De meerderheid van de 
onderzochte peptide activa, waaronder anti-kanker (busereline acetaat) en anti-HIV (enfuvirtide en 
C34) geneesmiddelen,  bleven stabiel onder onze smeltgerelateerde temperaturen. Hierbij werd dus 
de hardnekkige mythe ontkracht dat peptiden in het algemeen onstabiel zijn bij verhoogde 
temperaturen. Uiteraard moedigden deze resultaten de verdere exploratie van peptide 
smeltverwerking sterk aan. 
Door het dramatisch verhogen van de droge hitte omstandigheden, ruimschoots hoger dan de 
smeltgerelateerde temperaturen, werden gevormde peptide-gerelateerde afbraakproducten 
geïdentificeerd en verschillende degradatie mechanismen voorgesteld. Door opname van deze 
peptide stabiliteitsgegevens in vaste toestand, wordt de algemene kennis over peptide stabiliteit 
verruimd. 
 
In hoofdstuk VI werden activa verliezen gekwantificeerd tijdens magistrale bereidingen op lab- en 
apotheekschaal welke kunnen resulteren in onder gedoseerde geneesmiddelen. De activa 
hoeveelheden aanwezig op de verschillende gereedschap- en werkoppervlakken, alsook in het 
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uiteindelijk geneesmiddel, werden bepaald. Deze data werd gebruikt om de activa massa balans te 
berekenen door deze experimentele gehaltebepalingen te vergelijken met de oorspronkelijk 
afgewogen hoeveelheid activa. Uit dit onderzoek bleek dat het activa verlies zich voornamelijk in de 
mortier voordoet. Bovendien was dit verlies recht evenredig was met de ruwheid van het 
mortieroppervlak. Dit hoofdstuk toont de directe invloed van - de vaak over het hoofd gezien -
gereedschapskwaliteit op de uiteindelijke geneesmiddel aan, zoals deze gebruikt worden tijdens de 
ontwikkeling van nieuwe geneesmiddelen in ontwikkeling, preklinische of klinische fasen. 
 
Gezien de zeer bemoedigende stabiliteitsresultaten verkregen met de verschillende peptide activa in 
vaste toestand, werd in hoofdstuk VII een peptide implantaat bereid via een smelt techniek. Tijdens 
deze “proof of principle” studie werd niet-biologisch afbreekbaar polyethyleen vinylacetaat polymeer 
gemengd met busereline acetaat (20% m/m) en via een smelt techniek verwerkt in een implantaat. 
Er werd geen significante busereline acetaat degradatie waargenomen onder onze experimentele 
omstandigheden, waardoor de eerder bekomen droge hitte resultaten hier dus bevestigd werden. 
Bovendien bleef busereline acetaat stabiel in de polymeer matrix tijdens een 3 maand durende ICH  
stabiliteitsstudie (5°C, 25°C/60% R.V. en 40°C/75% R.V.). Daarnaast werd de initiële implantaat 
functionaliteit via in-vivo en in-vitro vrijgave studies onderzocht. Na een initiële “burst” vrijgave fase 
werd een dagelijkse in-vitro “steady state” afgifte van 5 µg busereline acetaat waargenomen. Deze 
bevindingen werden in-vivo bevestigd, gezien de hoge busereline acetaat concentraties in muis 
plasma, nieren en lever, 1 dag post-implantatie, waar deze na 30 dagen post-implantatie 
stabiliseerden. 
 
Finaal werd in hoofdstuk VIII een gestructureerd, regulatoir kwaliteitsoverzicht geven van de meest 
voorkomende peptide-gerelateerde onzuiverheden in peptide geneesmiddelen, zowel van het actief 
bestanddeel als van het finale geneesmiddel. De controle van deze peptide-gerelateerde 
onzuiverheden en afbraakproducten is niet alleen van cruciaal belang voor de reeds goedgekeurde 
en klinisch gebruikte peptide geneesmiddelen. De onzuiverheden kunnen ook initiële 
functionaliteitsstudies tijdens de ontdekkingsfase sterk te beïnvloeden, en dus verkeerde conclusies 
veroorzaken. 
  
SAMENVATTING & ALGEMENE CONCLUSIES 
  
 
248 
De relatie tussen de verschillende hoofdstukken van dit proefschrift en de patiënteisen wordt 
grafisch weergegeven in figuur 1. 
 
 
Figuur 1. Overzicht van de verschillende hoofdstukken en hun relatie tot de patiënt. 
(A) Rationalisatie van de analytische kolom keuze en ontwikkeling van een kost- en tijdsefficiënte methode om 
de respons factoren van afbraakproducten te berekenen moet de ontdekkingsfase van geneesmiddelen 
versnellen. (B) Een literatuursoverzicht van de meest voorkomende peptide-gerelateerde onzuiverheden en de 
implementatie van recent ontwikkelde analytische technieken om deze op te sporen, moet resulteren in 
veiligere, hoog kwalitatieve peptide medicijnen. (C) Een nieuwe smelt-gerelateerde manier om peptiden in 
implantaten te verwerken moet de verdere innovatie naar geneesmiddelen van hoge efficaciteit stimuleren. 
 
Op basis van de verworven studieresultaten kon onze belangrijkste onderzoeksvraag, i.e. "Kunnen 
peptiden verwerkt worden bij hoge temperaturen?", beantwoord worden: JA, een functioneel 
polyethyleen vinylacetaat polymeer implantaat beladen met 20% (m/m) busereline acetaat werd 
bereid via een smelt techniek. Daarnaast werden ook andere vragen zoals  "Degraderen peptiden bij 
blootstelling aan droge hitte en zo ja, welke afbraakproducten worden gevormd?" beantwoord. Een 
aantal peptide activa, waaronder anti-kanker en anti-HIV-peptide therapeutica, werden voldoende 
stabiel bevonden onder onze smelt gerelateerde omstandigheden. Peptide afbraak, nodig voor 
regulatoire kwaliteitsdoeleinden (bijvoorbeeld methode validatie), kon verkregen worden door de 
droge hitte condities waaraan de verschillende peptide activa blootgesteld werden dramatisch te 
verhogen. Gezien we verwachten dat de toekomstige regulatoire wetgeving de nadruk zal leggen op 
peptide-gerelateerde onzuiverheden afkomstig van synthese of degradatie, werd een globaal 
overzicht van deze onzuiverheden opgesteld. Bovendien werd deze studie uitgevoerd met behulp 
van state of the art analytische methoden en apparatuur, waarvan we hun algemene toepassing in 
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de kwaliteitscontrole van peptide geneesmiddelen verwachten, tijdens de ontdekkings-, 
ontwikkelings- and post-goedkeuringsfase. 
 
 
 
Hoewel deze resultaten duidelijk de haalbaarheid aantoont om niet-biologisch afbreekbare 
implantaten beladen met peptide te bereiden met behulp van een smelt productietechniek, is dit 
slechts de eerste stap. Wij hopen dat deze “proof of principle” studie een inspiratiebron mag zijn 
voor verdere innovatie in peptide geneesmiddelen, maar erkennen dat er nog vele vragen 
onbeantwoord en in afwachting blijven van verder onderzoek, waaronder: "Wat is de invloed van 
shear stress op de peptide stabiliteit tijdens hot-melt extrusie?". Met behulp van onze smelt techniek 
onderzochten we reeds de invloed van temperatuur en excipient interactie op de peptide stabiliteit. 
Echter, tijdens de industriële productie van peptide beladen implantaten via hot-melt extrusie wordt 
het peptide onderworpen aan een derde stressfactor, namelijk shear stress. Bovendien kan bij 
grotere peptiden niet alleen de primaire structuur maar ook de secundaire structuur beïnvloed 
worden door de toegepaste hitte en shear omstandigheden. Daarom is een diepgaand onderzoek 
vereist waarin wordt nagegaan wat de hoeveelheid en omkeerbaarheid van potentiële peptide 
denaturatie is, veroorzaakt door deze productiemethode. 
Verdere optimalisatie van de peptide vrijgave uit de implantaten is ook een interessant 
ontwikkelingsaspect. De intrinsieke hoeveelheid aan geneesmiddelvrijgave kan verder 
geoptimaliseerd worden door gebruik te maken van verscheidene bestaande en recent ontwikkelde 
polymeren of mengsels hiervan, waarbij hun thermische verwerkingseigenschappen niet uit het oog 
verloren mag worden. Daarnaast kan deze formulatie optimalisatie ook bestaande en/of nieuwe 
wiskundige geneesmiddelvrijgave modellen incorporeren. Bovendien kan door gebruik te maken van 
een snelheidscontrolerend membraan het waargenomen “burst” vrijgave effect gereduceerd worden 
en tezelfdertijd gebruikt worden voor het verdere afstemmen van de verlengde “steady state” 
vrijgave van het peptide geneesmiddel. 
Verder verkenning van de peptide hitte stabiliteit moet ook beoogd worden, opdat de 
stabiliteitskennis van peptiden in vaste toestand verder verbreed zou worden. Idealiter omvat dit de 
gehele peptide ruimte, inclusief peptiden in verschillende klinische fasen alsook verschillende 
peptide types, bv. glycopeptiden, lipopeptiden, nucleopeptiden, evenals polymeer-gekoppelde of 
gePEGyleerde peptiden. Op zijn beurt kan deze informatie dan verder gebruikt worden om een QSPR 
(kwantitatieve structuur eigenschap relatie) model op te stellen, die de hitte stabiliteit van peptiden 
in vaste toestand aan bepaalde eigenschappen verbindt, zoals bv. aminozuur sequenties of 
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secundaire structuur eigenschappen. Uit dit QSPR model kan vervolgens de stabiliteit van recent 
ontdekte, biologisch actieve peptiden voorspeld worden en hieruit hun potentieel voor smelt 
verwerking bepaald worden. Bovendien heeft onderzoek hoge Tm waarden van eiwitten gecorreleerd 
met de aanwezigheid van bepaalde aminozuren sequenties door vergelijking van overeenkomstige 
eiwitten in hyperthermofiele en mesofiele micro-organismen. Het zou interessant zijn om dit QSPR 
model met ons vaste fase QSPR model te vergelijken. 
Bovendien zou de verdere exploratie van verschillende polymeersoorten, -kwaliteiten en -mengsels, 
met de nadruk op hun vereiste hot-melt extrusie verwerkingscondities ook interessant zijn met oog 
om een soortgelijk polymeer QSPR model te construeren. Met behulp van dit model kan vervolgens 
de ontwikkeling van nieuwere polymeren gestimuleerd worden. Door combinatie van de structurele 
eigenschappen van de peptiden en polymeren, zou hun compatibiliteit in-silico gemodelleerd kunnen 
worden, wat bv. het voorspellen van peptide oplosbaarheid in en diffusie doorheen de 
polymeermatrix zou mogelijk maken. Op zijn beurt kan deze in-silico berekende peptide-polymeer 
verenigbaarheid vervolgens gebruikt worden om het peptide vrijgavesnelheid uit het polymeer te 
voorspellen. 
 
 
 
Door enkele fundamentele basisprincipes aangetoond te hebben, hopen we dat ons onderzoek 
perspectieven zal openen naar nieuwe peptide formulaties toe, wat uiteindelijk zal leiden tot een 
hoog kwalitatieve peptide geneesmiddelen, wat uiteindelijk in het voordeel van de patiënten speelt. 
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“The scientist is not a person who gives the right answers, he's one who asks 
the right questions.” 
 
Claude Lévi-Strauss 
 
 
 
CURRICULUM VITAE 
  
 
252 
  
    CURRICULUM VITAE   
  
 
253 
CURRICULUM VITAE 
MATTHIAS D’HONDT 
PERSONALIA 
Surname: D’Hondt 
First name: Matthias 
Nationality: Belgian 
Place & date of birth: Gent, 5 March 1986 
 
Private address: Driesstraat 26 
  9890 Gavere 
 
Professional address: Drug Quality & Registration (DruQuaR) laboratory 
  Department of Pharmaceutical Analysis 
  Faculty of Pharmaceutical Sciences 
  Ghent University 
  Ottergemsesteenweg 460 
  9000 Ghent 
  Belgium 
Phone:  (+32) 9 264 80 99 
E-mail:  Matthias.dhondt@UGent.be 
URL:  http://www.ugent.be/DruQuaR 
 
EDUCATION 
1998 – 2004: Science-Maths (8 hrs) high school at Sint-Bernarduscollege, Oudenaarde 
2004 – 2009: Master of Science in Drug Development at Ghent University 
2010:  ‘Molecular simulations of biosystems and in-silico screening’ at Ghent 
University 
 
CURRICULUM VITAE 
  
 
254 
PROFESSIONAL EXPERIENCE 
August 2009 – present: Staff scientist at DruQuaR, Ghent University 
  Supporting master theses and practical courses, as well as 
industrial servicing activities. 
   
January 2012 – present: Quality Assurance manager at DruQuaR, Ghent University 
 
PUBLICATIONS IN JOURNALS WITH PEER REVIEW 
PUBLISHED AND/OR ACCEPTED 
D’Hondt M, Van Dorpe S, Mehuys E, Deforce D, De Spiegeleer B. Quality analysis of salmon calcitonin 
in a polymeric bioadhesive pharmaceutical formulation: Sample preparation optimization by DOE. 
Journal of Pharmaceutical and Biomedical Analysis 2010; 53, 939-945. 
 
Ravelingien M, Mullens S, Luytens J, D’Hondt M, Boonen J, De Spiegeleer B, Coenye T, Vervaet C,  
Remon JP. Vancomycin release from poly(D,L-lactic acid) spray-coated hydroxyapatite fibers. 
European Journal of Pharmaceutics and Biopharmaceutics 2010; 76: 366–370. 
 
D’Hondt M, Demaré W, Van Dorpe S, Wynendaele E, Burvenich C, Peremans K, De Spiegeleer B. Dry 
heat stress stability evaluation of a casein peptide mixture. Food Chemistry 2011; 128: 114-122. 
 
D’Hondt M, Vangheluwe E, Van Dorpe S, Boonen J, Bauters T, Pelfrene B, Vandenbroucke J, Robays 
H, De Spiegeleer B. Stability of extemporaneously prepared cytarabine, methotrexate and 
methylprednisolone sodium succinate. American Journal of Health-System Pharmacy 2012; 69: 232–
240. 
 
De Spiegeleer B, D’Hondt M. Molecular weights under discussion? Pharmeuropa 2012; 24 (April): 1-3. 
 
De Spiegeleer B, D’Hondt M, Vangheluwe E, Vandercruyssen K, De Spiegeleer B, Jansen H, Koijen I, 
Van Gompel J. Relative response factor determination of β-artemether degradants by a dry heat 
stress approach. Journal of Pharmaceutical and Biomedical Analysis 2012; 70: 111–116. 
 
Wynendaele E, Bronselaer A, Nielandt J, D’Hondt M, Stalmans S, Bracke N, Verbeke F, Van De Wiele 
C, De Tré G, De Spiegeleer B. Quorumpeps database: chemical space, microbial origin and 
functionality of quorum-sensing peptides. Nucleic Acids Research 2013; 41: D655-D659. 
 
D’Hondt M, Gevaert B, Stalmans S, Van Dorpe S, Wynendaele E, Peremans K, Burvenich C, De 
Spiegeleer B. Reversed-phase fused-core HPLC modeling of peptides. Journal of Pharmaceutical 
Analysis 2013; 3: 93–101. 
 
    CURRICULUM VITAE   
  
 
255 
Boonen J, D’Hondt M, Veryser L, Peremans K, Burvenich C, De Spiegeleer B. A critical quality 
parameter in quantitative fused-core chromatography: the injection volume. Journal of 
Pharmaceutical Analysis 2013; 3: 330-334. 
 
Vandercruyssen K, D’Hondt M, Vergote V, Jansen H, Burvenich C, De Spiegeleer B. LC-UV/MS quality 
analytics of paediatric artemether formulations. Journal of Pharmaceutical analysis 2014; 4: 37-52. 
 
Suleman S, Vandercruyssen K, Wynendaele E, D’Hondt M, Bracke N, Duchateau L, Burvenich C, 
Peremans K, De Spiegeleer B. A rapid stability-indicating, fused-core HPLC method for simultaneous 
determination of β-artemether and lumefantrine in anti-malarial fixed dose combination products. 
Malaria Journal 2013; 12: 1-11. 
 
Pieters S, Vander Heyden Y, Roger J-M, D’Hondt M, Hansen L, Palagos B, De Spiegeleer B, Remon JP, 
Vervaet C, De Beer T. Raman spectroscopy and multivariate analysis for the rapid discrimination 
between native-like and non-native states in freeze-dried protein formulations. European Journal of 
Pharmaceutics and Biopharmaceutics 2013; 85: 263-271. 
 
Stalmans S, Wynendaele E, Bracke N, Gevaert B, D’Hondt M, Peremans K, Burvenich C, De Spiegeleer 
B. Chemical-Functional Diversity in Cell-Penetrating Peptides. Plos One 2013; 8: e71752. 
 
D’Hondt M, Verbeke F, Stalmans S, Gevaert B, Wynendaele E, De Spiegeleer B. Derringer desirability 
and kinetic plot LC-column comparison approach for MS-compatible lipopeptide analysis. Journal of 
Pharmaceutical Analysis 2014; 4: 173-182. 
 
Bracke N, Wynendaele E, D’Hondt M, Haselberg R, Somsen GW, Pauwels E, Van de Wiele C, De 
Spiegeleer B. Analytical characterization of NOTA-modified somatropins. Journal of Pharmaceutical 
and Biomedical Analysis 2014; 96: 1-9. 
 
D’Hondt M, Wynendaele E, Vandercruyssen K, Bauters T, Vandenbroucke J, Mullens S, Vervaet C, 
Remon JP, De Spiegeleer B. Investigation of active pharmaceutical ingredient loss in pharmaceutical 
compounding of capsules. Journal of Pharmaceutical and Biomedical Analysis 2014; 96: 68-76. 
 
D’Hondt M, Fedorova M, Peng C-Y, Gevaert B, Taevernier L, Hoffmann R, De Spiegeleer B. Dry heat 
forced degradation of buserelin peptide: kinetics and degradant profiling. International Journal of 
Pharmaceutics 2014; 467: 48-59. 
 
Pieters S, Roger J-M, De Beer T, D’Hondt M, De Spiegeleer B, Vander Heyden Y. Raman model 
development for the protein conformational state classification in different freeze-dried 
formulations. Analytica Chimica Acta 2014; 825: 42-50. 
 
D’Hondt M, Bracke N, Taevernier L, Gevaert B, Verbeke F, Wynendaele E, De Spiegeleer B. Related 
impurities in peptide medicines. Journal of Pharmaceutical and Biomedical Analysis 2014; 101: 2-30. 
 
CURRICULUM VITAE 
  
 
256 
Taevernier L, Wynendaele E, D’Hondt M, De Spiegeleer B. Analytical quality-by-design approach for 
sample treatment of BSA-containing solutions. Journal of Pharmaceutical Analysis 2014; DOI: 
10.1016/j.jpha.2014.06.001. 
 
Stalmans S, Willems M, Adriaens E, Remon JP, D’Hondt M, De Spiegeleer B. Flatworm models in 
pharmacological research: The importance of compound stability testing. Regulatory Toxicology and 
Pharmacology 2014; 70: 149-154. 
 
Taevernier L, Veryser L, Vandercruyssen K, D’Hondt M, Vansteelandt S, De Saeger S, De Spiegeleer B. 
UHPLC-MS/MS method for the determination of the cyclic depsipeptide mycotoxins beauvericin and 
enniatins in in-vitro transdermal experiments. Journal of Pharmaceutical and Biomedical Analysis 
2014; 100: 50-57. 
 
Suleman S, Gemechu Z, Habtewold D, Zeleke M, Duchateau L, Levecke B, Vercruysse J, D’Hondt M, 
Wynendaele E, De Spiegeleer B. Quality of medicines commonly used in the treatment of soil 
transmitted helminthes (STH) and giardia in Ethiopia: a nationwide survey. Plos Neglected Tropical 
Diseases 2014; 8: e3345. 
 
Bracke N, Barhdadi S, Wynendaele E, Gevaert B, D’Hondt M, De Spiegeleer B. Surface Acoustic Wave 
biosensor as a functional quality method in pharmaceutics. Sensors and Actuators B: Chemical 2014; 
doi:10.1016/j.snb.2014.12.092. 
 
Wynendaele E, Verbeke F, D’Hondt M, Hendrix A, Van De Wiele C, Burvenich C, Peremans K, De 
Wever O, Bracke M, De Spiegeleer B. Crosstalk between the microbiome and cancer cells by quorum 
sensing peptides. Peptides 2014; doi:10.1016/j.peptides.2014.12.009. 
 
Wynendaele E, Verbeke F, Braet S, D’Hondt M, De Spiegeleer B. Quality evaluation of synthetic 
quorum sensing peptides used in R&D. Journal of Pharmaceutical Analysis 2014. 
 
 
SUBMITTED 
D’Hondt M, Gevaert B, De Spiegeleer B. Implementation of a single quad MS detector in routine QC 
analysis of peptide drugs. 2014. 
 
De Spiegeleer B, Verbeke F, D’Hondt M, Hendrix A, Van De Wiele C, Burvenich C, Peremans K, De 
Wever O, Bracke M, Wynendaele E. Quorum sensing peptides promote angiogenesis and invasion of 
breast cancer cells. 2014. 
 
Suleman S, Verheust Y, Dumoulin A, Wynendaele E, D’Hondt M, Vandercruyssen K, Veryser L, 
Duchateau L, De Spiegeleer B.  Gas chromatographic method for the determination of lumefantrine 
in anti-malarial finished pharmaceutical products. 2014. 
 
    CURRICULUM VITAE   
  
 
257 
Wynendaele E, Verbeke F, D’Hondt M, Hendrix A, Van De Wiele C, Burvenich C, De Wever O, Bracke 
M, De Spiegeleer B. In vitro cell medium and human plasma stability, Caco-2 permeability and toxicity 
of quorum sensing peptides. 2014. 
 
Yao H, Vancoillie J, D’Hondt M, Wynendaele E, Bracke N, De Spiegeleer B. An analytical quality-by-
design (aQbD) approach for L-asparaginase activity. 2014. 
 
IN PREPARATION 
D’Hondt M, Verbeken M, Verbeke F, Wuytens P, Skirtach A, De Spiegeleer B. Hot-melt manufacturing 
of a non-biodegradable peptide implant: a proof of principle study. 
 
Gevaert B, Stalmans S, Wynendaele E, Taevernier L, Bracke N, D’Hondt M, De Spiegeleer B. 
Functional chemical characterization of the peptide-drug space. 
 
Gevaert B, Wynendaele E, Stalmans S, Bracke N, D’Hondt M, Maes K, Smolders I, Van Eeckhaut A, De 
Spiegeleer B. Blood-brain barrier characteristics of four neuromedin peptides. 
 
Gevaert B, D’Hondt M, Bracke N, Yao H, Wynendaele E, Vissers H, de Cecco M, Claereboudt J, De 
Spiegeleer B. Peptide profiling of internet obtained cerebrolysin using LC-ESI ion trap and ion 
mobility-QTOF mass spectrometry. 
 
Suleman S, D’Hondt M, Duchateau L, De Spiegeleer B. Quality-by-Design principles applied in the 
establishment of a Pharmaceutical Quality Control Laboratory in a resource-limited settings.  
CURRICULUM VITAE 
  
 
258 
PRESENTATIONS AT (INTER)NATIONAL CONFERENCES 
D’Hondt M, Van Dorpe S, De Spiegeleer B. Stability indicating method development for low level 
calcitonin, 10th Flemish Youth Conference of Chemistry, 1-2 March 2010, Blankenberge, Belgium. 
Oral presentation 
 
D’Hondt M, Demaré W, De Spiegeleer B. Heat stability of a casein hydrolysate peptide mixture, 
Scientific Afternoon of Faculty of Pharmaceutical Sciences, 12 May 2010, Gent, Belgium. 
Poster presentation 
 
De Spiegeleer B, Van Dorpe S, Boonen J, D’Hondt M, Wynendaele E, Verbeken M. Functional quality 
of pharmaceutical drugs. Knowledge for growth, 5 May 2011, Ghent, Belgium. 
Poster presentation 
 
D’Hondt M, Vangheluwe E, Lemeire N, Bauters T, Pelfrene B, Vandenbroucke J, Robays H, De 
Spiegeleer B. Short-term storage stability of triple IT solution, 15th forum of Pharmaceutical Sciences, 
12-13 May 2011, Spa, Belgium. 
Oral presentation 
 
D’Hondt M, Vangheluwe E, Lemeire N, Bauters T, Pelfrene B, Vandenbroucke J, Robays H, De 
Spiegeleer B. Fused-core HPLC method development implemented in a short-term stability study of 
triple IT solution. Scientific Afternoon of Faculty of Pharmaceutical Sciences, 26 May 2011, Ghent, 
Belgium. 
Poster presentation 
 
D’Hondt M, Wynendaele E, Bauters T, Vandenbroucke J, Robays H, De Spiegeleer B. Influence of 
variability in starting materials quality on stability of finished drug products : a quality-by-design 
factor and response, 13th International symposium on Oncology Pharmacy Practice, 9-11 May 2012, 
Melbourne, Australia.  
Poster presentation 
 
Sultan S, Vandercruyssen K, D’Hondt M, De Spiegeleer B. A rapid stability-indicating fused-core HPLC 
method for β-artemether and lumefantrine antimalarial combination products, Scientific afternoon 
of Faculty of Pharmaceutical Sciences, 16 May 2012, Ghent, Belgium. 
Poster presentation 
 
D’Hondt M, De Spiegeleer B. Dry heat stress of model peptide: buserelin. Scientific afternoon of 
Faculty of Pharmaceutical Sciences, 16 May 2012, Ghent, Belgium. 
Poster presentation 
 
De Spiegeleer B, D’Hondt M, Stalmans S, Wynendaele E, Van Dorpe S. Blood-brain barrier modelling 
of bioactive peptides, 13th symposium on Bioactive peptides, 7-10 June 2012, Naples, Italy. 
Oral presentation 
 
    CURRICULUM VITAE   
  
 
259 
Stalmans S, D’Hondt M, Wynendaele E, Bracke N, De Spiegeleer B. Exploring the Brainpeps database, 
15th International symposium on Signal Transduction in the Blood-Brain Barriers, 13-16 September 
2012, Potsdam, Germany. 
Poster presentation 
 
D’Hondt M, Boonen J, De Spiegeleer B. Stability applications in food, cosmoceutical and pharma. 
Toward smaller particles in HPLC: fused-core and UPLC, 16 November 2012, Ghent, Belgium. 
Oral presentation 
 
D’Hondt M, Peng C-Y, Hoffmann R, De Spiegeleer B. Buserelin: a solid state peptide degradation 
kinetic and mechanistic study, Belgian-Dutch Biopharmaceutical Society, 18 December 2013, Ghent, 
Belgium. 
Poster presentation 
 
Yao H, D’Hondt M, Benoit Y, Bauters T, De Spiegeleer B. Analytical QBD development of 
pharmacopeial monograph for the anticancer drug asparaginase, Belgian-Dutch Biopharmaceutical 
Society, 18 December 2013, Ghent, Belgium. 
Poster presentation 
 
Yao H, D’Hondt M, Benoit Y, Bauters T, De Spiegeleer B. Phamacopeial characterization of 
asparaginase, Oncopoint, 6 Februari 2014, Ghent, Belgium. 
Oral presentation 
 
Wynendaele E, Verbeke F, D’Hondt M, Hendrix A, Van De Wiele C, Burvenich C, Peremans K, De 
Wever O, Bracke M, De Spiegeleer B. Crosstalk between mammalian cells and the microbiome 
through quorum sensing peptides, influencing cancer metastasis, 14th Naples workshop on Bioactive 
Peptides, 12-14 June 2014, Naples, Italy. 
Oral presentation 
 
D’Hondt M, Bart De Spiegeleer. Synthesis and degradation impurities in peptide drugs, Drug Analysis 
2014, 22-25 June 2014, Liege, Belgium. 
Oral presentation 
 
D’Hondt M, Peng C-Y, Hoffmann R, De Spiegeleer B. Solid-state heat stability of peptides: kinetics and 
mechanisms,33rd European Peptide Symposium, 31 August – 5 September 2014, Sofia, Bulgary. 
Poster presentation 
 
Gevaert B, Wynendaele E, Verbeken M, D’Hondt M, Stalmans S, Peremans K, Burvenich C, Delesalle 
C, De Spiegeleer B. Exploration of the peptide drug space, 33rd European Peptide Symposium, 31 
August – 5 September 2014, Sofia, Bulgaria. 
Poster presentation 
 
Wynendaele E, Verbeke F, D’Hondt M, Hendrix A, Van De Wiele C, Burvenich C, Peremans K, De 
Wever O, Bracke M, De Spiegeleer B. How does the human microbiome affect cancer outcome?, 1st 
Peptides in Paris Symposium, 5-8 October 2014, Paris, France. 
Oral presentation 
 
CURRICULUM VITAE 
  
 
260 
Wynendaele E, Verbeke F, D’Hondt M, Hendrix A, Van De Wiele C, Burvenich C, Peremans K, De 
Wever O, Bracke M, De Spiegeleer B. Quorum sensing peptides: missing link between microbiome 
and health, 2nd World Congress on Targeting Microbiota, 16-17 October 2014, Paris, France. 
Poster presentation 
 
D’Hondt M, Bracke N, De Spiegeleer B. The moving boundaries in starting materials: from small 
molecules to biopharma and ATMPs, Topra, 11th Annual Symposium, 13-15 October 2014, Brussels, 
Belgium. 
Poster presentation 
 
RESEARCH VISIT 
7 September – 20 September 2013:  Jimma University Laboratory of Drug Quality 
(JuLaDQ), Jimma, Ethiopia: 
  Supporting the construction and implementation of 
the quality system. 
 
7 October – 11 October 2013:  Université de Kinshasa, Lacokin laboratory, Lacomeda 
laboratory, Kinshasa, Democratic Republic of the 
Congo: 
   A series of technical laboratory visits aiming to 
reinforce the capabilities of local drug quality control 
laboratories in Kinshasa.  
 
 
SUPPLEMENTARY INFORMATION 
  
 
261 
 
 
 
SUPPLEMENTARY 
INFORMATION 
 
 
 
 
 
 
 
 
 
 
 
SUPPLEMENTARY INFORMATION 
  
 
262 
. 
SUPPLEMENTARY INFORMATION 
  
 
263 
  
SI CHAPTER II: LC COLUMN SELECTION: DERRINGER DESIRABILITY 
AND KINETIC PLOTS 
S1.1 Lipopeptide structures 
Selected lipopeptide representatives are marked in bold. 
The lipopeptide name, structure, chemical formule and three descriptor values are given: 
 Mr: Average molecular weight 
 LogP: Octanol-water partition coefficient calculated according to Ghose-Crippen-Pritchett  
 Sv: Sum of atomic van der Waals volumes 
 
 
 
 
 
 
 
 
 
3. Arthrofactin 
 
Formula: C64H111N11O20 
Mr: 1354.63 Da 
LogP: 3.244 
Sv: 115.06 Å
3 
 
  
4. Caspofungin 
 
Formula: C52H88N10O15 
Mr: 1093.31 Da 
LogP: -2.274 
Sv: 92.93 Å
3 
 
  
1. Amphomycin 
 
Formula: C58H91N13O20 
Mr: 1290.42 Da 
LogP: -1.777 
Sv: 104.47 Å
3 
 
2. Anidulafungin 
 
Formula: C58H73N7O17 
Mr: 1140.24 Da 
LogP: 0.257 
Sv: 93.38 Å
3 
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5. Cilofungin 
 
Formula: C49H71N7O17 
Mr: 1030.12 Da 
LogP: -1.411 
Sv: 83.79 Å
3 
 
  
6. Colistin A 
 
Formula: C53H100N16O13 
Mr: 1169.46 Da 
LogP: -5.522 
Sv: 100.66 Å
3 
 
  8. Dalbavancin 
 
Formula: C88H100Cl2N10O28 
Mr: 1816.69 Da 
LogP: 5.297 
Sv: 141.17 Å
3 
7. Colistin B 
 
Formula: C52H98N16O13 
Mr: 1155.43 Da 
LogP: -5.979 
Sv: 99.06 Å
3 
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9. Daptomycin 
 
Formula: C72H101N17O26 
Mr: 1620.67 Da 
LogP: -3.917 
Sv: 127.31 Å
3 
 
  
10. Echinocandin B 
 
Formula: C52H81N7O16 
Mr: 1060.24 Da 
LogP: 0.409 
Sv: 89.26 Å
3 
 
 
11. Gramicidin A1 
 
Formula: C99H140N20O17 
Mr: 1882.29 Da 
LogP: 8.867 
Sv: 163.44 Å
3 
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13. Micafungin 
 
Formula: C56H71N9O23S 
Mr: 1270.27 Da 
LogP: -2.819 
Sv: 96.34 Å
3 
 
  
12. Iturin A2 
 
Formula: C48H74N12O14 
Mr: 1043.17 Da 
LogP: -2.077 
Sv: 85.62 Å
3 
 
  
14. MX-2401 
 
Formula: C67H101N15O22 
Mr: 1468.61 Da 
LogP: -1.491 
Sv: 118.87 Å
3 
 
  
15. P3CSS 
 
Formula: C60H113N3O11S 
Mr: 1084.62 Da 
LogP: 16.711 
Sv: 102.58 Å
3 
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16. Plipastatin 
 
Formula: C72H110N12O20 
Mr: 1463.71 Da 
LogP: 3.614 
Sv: 123.45 Å
3 
 
  
17. Polymyxin B1 
 
Formula: C56H98N16O13 
Mr: 1203.48 Da 
LogP: -5.198 
Sv: 103.06 Å
3 
 
  
18. Ramoplanin A2 
 
Formula: C119H154N21O40 
Mr: 2554.07 Da 
LogP: -3.242 
Sv: 201.1 Å
3 
 
  
19 Surfactin 
 
Formula: C53H93N7O13 
Mr: 1036.34 Da 
LogP: 7.571 
Sv: 92.32 Å
3 
 
  
20. Syringomycin E 
 
Formula: C53H85ClN14O17 
Mr: 1225.78 Da 
LogP: -3.389 
Sv: 97.84 Å
3 
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21. Teicoplanin A2 
 
Formula: C88H97ClN12O33 
Mr: 1879.66 Da 
LogP: 1.924 
Sv: 142.14 Å
3 
 
  
22. Telavancin 
 
Formula: Ca80H106Cl2N11O27P 
Mr: 1755.64 Da 
LogP: 2.317 
Sv: 136.33 Å
3 
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S1.2 Relationship between LoD and column parameters. 
The derivation of the formula presented in the main text is given in detail below (based upon Karger 
et al. 1974). 
The limit of detection (LoD) is calculated using the peak height (h) and the height of the noise (h/2). 
From this the S/N ratio is calculated and the injected mass corresponding to a S/N=3 is derived. 
Detection of the peak will depend on the detectors ability of sensing the concentration at the peak 
maximum, i.e. Cmax. 
The relationship between Cmax and the column parameters is summarized in following formula: 
𝐶𝑚𝑎𝑥 =
4
𝜀𝑡𝜋 2𝜋 1 +  𝐴𝑠 − 1  
×
 𝑁
𝐿𝑑𝑐
2 ×
𝑉0𝐶0
(1 + 𝑘 ′)
 
 
Derivation of this formula was to a large extent described by Karger et al. and is given below for 
completeness: 
 
The relationship between Cmax and the mass injected onto the column (m) is derived from the 
Gaussian peak profile (concentration (y) versus volume (x)) with peak area m and N=VR
2/σ2: 
𝐶𝑚𝑎𝑥 =
𝑚 ×  𝑁
𝑉𝑅 ×  2𝜋 ×  1 +  𝐴𝑠 − 1  
 
m: mass of injected solute 
N: number of theoretical plates 
VR: retention volume in mL 
Factor  2𝜋: Gaussian peak profile, which is then (approximately by triangle approximation) 
corrected for asymmetry by As (=
𝑤0.05
2𝑑
) 
 
𝑚 = 𝐶0 × 𝑉0 
C0: sample concentration 
V0: injected sample volume 
𝐶𝑚𝑎𝑥 =
𝐶0 × 𝑉0 ×  𝑁
𝑉𝑅 ×  2𝜋 ×  1 +  𝐴𝑠 − 1  
 
 
𝑉𝑅 = 𝐹 × 𝑡𝑅 = 𝜀𝑡 × 𝜋 × 𝑟
2 × 𝑁 × 𝐻 × (1 + 𝑘 ′) 
F: volumetric flow rate 
tR: retention time 
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𝜀𝑡 : total cross-sectional fraction of the mobile phase (inter- and intraparticle), i.e. column void 
volume: column void volume / empty column volume: F×t0/π×r
2×L = 4×F×t0/π×dc
2×L 
r: column radius and r=dc/2 (dc: column diameter) 
H: height equivalent to a theoretical plate and N×H=L 
k’: capacity factor and tR/t0 = k’+1 
 
𝐶𝑚𝑎𝑥 =
𝐶0 × 𝑉0 ×  𝑁
 2𝜋 ×  1 +  𝐴𝑠 − 1  × 𝜀𝑡 × 𝜋 × 𝑟2 × 𝑁 × 𝐻 × (1 + 𝑘 ′)
 
 
 
𝐶𝑚𝑎𝑥 =
𝐶0 × 𝑉0 ×  𝑁
 2𝜋 ×  1 +  𝐴𝑠 − 1  × 𝜀𝑡 × 𝜋 × 𝑟2 × 𝐿 × (1 + 𝑘 ′)
 
 
𝐶𝑚𝑎𝑥 =
4 × 𝐶0 × 𝑉0 ×  𝑁
 2𝜋 ×  1 +  𝐴𝑠 − 1  × 𝜀𝑡 × 𝜋 × 𝑑𝑐
2 × 𝐿 × (1 + 𝑘 ′)
 
 
𝐶𝑚𝑎𝑥 =
4
𝜀𝑡𝜋 2𝜋 1 +  𝐴𝑠 − 1  
×
 𝑁
𝐿𝑑𝑐
2 ×
𝑉0𝐶0
(1 + 𝑘 ′)
 
 
LOD comparison between UPLC and HPLC Triart column. 
The LOD was expressed as the amount of lipopeptide injected, m expressed in ng , which 
corresponds to a S/N ratio of 3. This amount was calculated from following formula: 
𝐿𝑂𝐷 =
𝑚
𝑆/𝑁
× 3 
In the previous section, it was demonstrated that the signal (S) will depend on the detector ability of 
sensing the concentration at the peak maximum, i.e. Cmax. Moreover, the noise level was found to be 
similar for all 4 columns (average: 2.121×10-4 AU (22.03 % RSD)), and can thus be considered a 
constant. The LOD formula can be re-expressed as: 
 
𝐿𝑂𝐷~
𝑚
4
𝜀𝑡𝜋 2𝜋 1 +  𝐴𝑠 − 1  
×
 𝑁
𝐿𝑑𝑐
2 ×
𝑉0𝐶0
(1 + 𝑘 ′)
 
 
The injected lipopeptide mass (m) equals the product of the injection volume (V0) and the 
lipopeptide concentration (C0). 
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𝐿𝑂𝐷~
1
4
𝜀𝑡𝜋 2𝜋 1 +  𝐴𝑠 − 1  
×
 𝑁
𝐿𝑑𝑐
2 ×
1
(1 + 𝑘 ′)
× 3 
 
When comparing the UPLC and HPLC Triart columns, only column length (L), column diameter (dc) 
and the asymmetry factor (As) were significantly different: 
 
𝐿𝑂𝐷𝐻𝑃𝐿𝐶
𝐿𝑂𝐷𝑈𝑃𝐿𝐶
~
 𝐿 × 𝑑𝑐
2 ×  1 +  𝐴𝑠 − 1   𝐻𝑃𝐿𝐶
 𝐿 × 𝑑𝑐
2 ×  1 +  𝐴𝑠 − 1   𝑈𝑃𝐿𝐶
 
 
𝐿𝑂𝐷𝐻𝑃𝐿𝐶
𝐿𝑂𝐷𝑈𝑃𝐿𝐶
~
 250 × 4.62 ×  1 +  1.912− 1   
𝐻𝑃𝐿𝐶
 100 × 2.02 ×  1 +  2.343− 1   
𝑈𝑃𝐿𝐶
~
10114
937
~10.79 
 
From this, it can be seen that the LOD value of the HPLC Triart column is calculated to be 
approximately 11-fold higher, when compared to the UPLC Triart column. This ratio was also 
observed in our experimentally determined LOD values, i.e., 29 ng vs. 3 ng. 
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SI CHAPTER IV: PEAK AREA BALANCE 
S2.1 Peak selection criteria for (R)RF calculation of β-artemether-related 
degradants 
1. The degree of β-artemether degradation was calculated from the residual β-artemether peak 
area after heat stress (see section 2.3). 
2. Experiments yielding between 10 to 90% β-artemether degradation were withheld for 
further calculations, i.e. for the calculation of average and individual relative response factors 
(RRF) of the β-artemether degradants. Those stress conditions with extreme (i.e. > 90%) or 
very limited (i.e. <10%) degradation were not withheld as these are considered as too 
extreme values to be useful (due to i.a. analytical consideration) or to be pharmaceutically 
relevant. 
3. A “stress reporting threshold” of 5% was used: smaller peaks are considered as not 
important because: 
 The question of the “stress reporting threshold” in these stress-studies is rather an efficiency 
issue, and is not directly related to our approach-principle: if more smaller peaks are also 
included, then more experiments will be required (mathematics). Moreover, in such relative 
harsh stress conditions, completely different from pharmaceutically accepted solution stress-
studies and even further away from ICH-accelerated studies, these small degradation peaks 
are completely unrelated with the ICH thresholds which are evidently much lower. 
 Although this “stress reporting threshold” seems high, it is an area-based threshold and one 
should keep in mind that the RRF values of the β-artemether degradants are significantly 
higher than 1. 
4. No significant mass loss is assumed during the calculation of the average RRF value. It is 
noted that if mass loss would have occurred, then the calculated average RRF is 
underestimated versus the real RRF. 
5. All experimental data is listed in a data matrix, i.e. β-artemether amount present before 
stress, β-artemether amount present after stress (the difference is equal to the amount of 
degradants formed) and the peak areas of the observed degradation peaks 
 
This data set is then used to calculate the average relative response factor of the β-artemether 
degradants for each experiment. 
Further calculations to determine the RRF value of the most prominent β-artemether degradants 
were performed as follows: 
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6. Known, already identified and available β-artemether degradation products (see Table 1) 
which were formed during the stress experiment were identified based on their relative 
retention  times. The individual RRF values of these degradants were already previously 
determined (either by the current authors or by other research groups). This allows us to 
take these peaks out of the equations. This was done by transforming their corresponding 
peak areas into a degradation mass amount (expressed as β-artemether), using their known 
RRF. This mass was then subtracted from the ‘formed degradant mass’, thus effectively taken 
them out the equations by performing aforementioned mass correction. 
7. Due to the huge number of relatively small and/or infrequently observed peaks still 
remaining, the selection of the most prominent β-artemether degradants for the calculation 
of their individual RRF was based on two quantitative factors, i.e. occurrence of 
aforementioned β-artemether degradants throughout the stress experiments and the 
average peak area of aforementioned β-artemether degradants. The peak selection model, 
taking both factors into account, is presented in Figure 1. 
 
 
Figure 1. peak selection model 
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8. These small degradation peaks were also “eliminated” similar as in point 6. However, as no 
individual RRF values were available for these small, unknown degradation peaks, we used 
the average RRF value, previously calculated from the corresponding experiment in which 
the small peak was taken out of the equation. 
9. Finally, a mass correction was also made for the formation of volatile components, e.g. CO2. 
This was done by weighing the powder mixture and vial before and after stress. The mass 
difference was also subtracted from the degradant mass amount. The average observed 
mass loss was 8.4% (Std dev: 4.4%), throughout the various experimental conditions. 
 
The resulting data set is then used for the calculations of the individual RRF values, using the model 
presented in section 2.6. 
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Table 1. Identified β-artemether related degradants and synthesis impurities  
# CHEMICAL NAME STRUCTURE RRF
(1)
 
1 
α-Artemether 
(3R,5aS,6R,8aS,10R,12R,12aR)-
Decahydro-10-methoxy-3,6,9-
trimethyl-3,12-epoxy-12H-pyrano[4.3-
j]-1,2-benzodioxepin 
[C16H26O5, 298.37] 
 
1.03 
2 
Artemisinin 
(3R,5aS,6R,8aS,9R,12S,12aR)-
octahydro-3,6,9-trimethyl-3,12-epoxy-
12H-pyrano[4,3-j]-1,2-benzodioxepin-
10(3H)-one 
[C15H22O5, 282.33] 
 
1.10 
3 
β-Artemether 
(3R,5aS,6R,8aS,9R,10S,12R,12aR)-
Decahydro-10-methoxy-3,6,9-
trimethyl-3,12-epoxy-12H-pyrano 4,3-
j-1,2-benzodioxepin 
[C16H26O5, 298.37] 
 
1.0 
4 
9-epi-artemisinin 
(1R,5R,12S)-1,5,9-trimethyl-11, 
14,15,16-tetraoxatetracyclo-
hexadecan-10-one 
C15H22O5; 282.33 
 
1.37 
5 
Artemisitene 
3,12-Epoxy-12H-pyrano[4,3-j]-1,2-
benzodioxepin-10(3H)-one,octahydro-
3,6-dimethyl-9-methylene-
,(3R,5aS,6R,8aS,12S,12aR) 
C15H20O5; 280.13 
 
37.52 
(1): λdet: 210 nm 
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Table 1. Identified β-artemether related degradants and synthesis impurities (continued) 
# CHEMICAL NAME STRUCTURE RRF
(1)
 
6 
Deoxyartemisinin 
(1R,9R)-1,5,9-trimethyl-11,14,15-
trioxatetracyclo-pentadecan-10-one 
[C15H22O4, 266,33] 
 
n.a
 
7 
α-Dihydroartemisinin 
3R,5aS,6R,8aS,10S,12R,12aR)-
Decahydro-10-hydroxy-3,6,9-trimethyl-
3,12-epoxy-12H-pyrano[4.3-j]-1,2-
benzodioxepin 
[C15H24O5, 284.35] 
 
1.08 
8 
β-Dihydroartemisinin 
3R,5aS,6R,8aS,10S,12R,12aR)-
Decahydro-10-hydroxy-3,6,9-trimethyl-
3,12-epoxy-12H-pyrano[4.3-j]-1,2-
benzodioxepin 
[C15H24O5, 284.35] 
 
1.08 
9 
Diketo aldehyde
 
2-[4-methyl-2-oxo-3-(3-
oxobutyl)cyclohexyl]propanal 
[C14H22O3, 238.32] 
 
3.41 
10 
Furano acetate 
(3aS,4R,6aS,7R,8S,10R,10aR)-8-
methoxy-4,7-dimethyloctahydro-2H-
furo[3,2-i][2]benzopyran-10-yl acetate 
[C16H26O5, 298.37] 
 
n.a. 
(1): λdet: 210 nm 
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Table 1. Identified β-artemether related degradants and synthesis impurities (continued) 
# CHEMICAL NAME STRUCTURE RRF
(1)
 
11 
Late eluting impurity (LEI) 
(9,10-anhydro-10-deoxoartemisinin) 
(9,10-anhydroartemisinin) 
[C15H22O4, 266.33] 
 
21.30 
(1): λdet: 210 nm 
 
 
  
 
  
 
  
